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Abstract 
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Abstract 
Herpes Simplex Virus (HSV) type 1 and 2 cause lifelong, latent infection with recurrences. 
Serious complications can occur and no vaccine is available. Natural killer (NK) cells play a 
role in the interface between innate and adaptive immunity, and in the antiviral response. 
Nonetheless, NK cells have been largely overlooked in designing vaccine candidates. 
Previously, NK cells were activated by a TLR2 agonist, Pam2Cys, conjugated to an HSV 
gD peptide: Pam2Cys-30-5, and stimulated CD4+T cells in the absence of other antigen-
presenting cells. Human NK cells are comprised of functionally diverse subsets. 
CD56dimCD16+ are the predominant subset in circulation, >95%, and CD56brightCD16-/dim are 
<5%. They have been characterised as highly cytolytic or as potent cytokine producers, 
respectively. The selective responses of CD56bright NK cells to the cytokines IL-15, IL-2 and 
IL-7 were compared to enrich this subset in culture. IL-7 selectively enhanced CD56bright 
survival and proliferation, and perforin expression was not increased. IL-7 CD56bright NK 
cells expressed similar immune function genes as CD56bright NK cells. CD56bright and 
CD56dim NK cell responses to Pam2Cys-30-5 were investigated. Both subsets were activated 
by Pam2Cys-30-5, indicated by expression of CD69 and cytokines. The CD56dim subset 
produced higher concentrations of cytokines, whilst significant upregulation of HLA-DR 
was exclusive to the CD56bright subset. CD16 was significantly downregulated on CD56dim 
NK cells, and both shedding and internalisation were detected as mechanisms. Soluble 
factors produced by both NK cell subsets induced increased expression of maturation 
markers CD83 and CD80 on monocyte-derived dendritic cells (MDDCs). Finally, normal 
foreskin and an initial penile herpes lesion biopsy were examined for NK cells. CLA was 
expressed on CD16- NK cells in normal foreskin, indicating a regular turnover of these cells. 
In infected tissue the majority of NK cells were CD16+. NK cells may play a role in innate 
control of initial genital HSV infection and should be considered in vaccine development. 
Furthermore, understanding the mechanism of NK cell responses to TLR2 agonists will 
provide insight into their use as vaccine adjuvants. 
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Chapter 1: Introduction 
1.1 Herpes Simplex Virus 
1.1.1 Virology and infection cycle 
Herpes Simplex Virus (HSV) type 1 and 2 are classified into the family 
herpesviridae and subfamily alphaherpesvirinae, along with Varicella Zoster Virus 
(VZV). They are characterised by containing linear double-stranded DNA surrounded by 
an icosahedral capsid, a layer of tegument proteins and an envelope containing 
glycoprotein spikes (Kucera, 1979) (Figure 1.1). HSV1 or 2 initially infects oral or 
genital mucosa and replicates in stratified squamous epithelium where it induces cells to 
fuse, forming multinucleated giant cells that cause blistering (Bosnjak et al., 2005a, 
Gupta et al., 2007, Cunningham et al., 2006a). HSV enters host cells by different 
mechanisms depending on the cell-type. HSV enters epithelial keratinocytes by a low pH 
endocytic pathway, whereas it enters neurons via pH-independent fusion (Nicola et al., 
2005). In either mechanism, entry requires the involvement of the HSV envelope 
glycoproteins gB, gC and gD and the gH-gL heterodimer (Nicola et al., 2005). Initially, 
cellular proteoglycans such as heparin sulphate bind to gC, followed by interactions 
between other receptors and gD. Identified receptors for HSV1 include Herpes Virus 
Entry Mediator (HVEM/HveA), nectin-1 (HveC) and nectin-2 (HveB). Fusion between 
viral and cellular membranes is mediated by gB and also requires gH-gL (Everett, 2014, 
Garner, 2003).  
 		
Figure 1.1. HSV Structure. Herpes 
Simplex Virus is a herpesvirus 
characterised by a lipid envelope 
containing glycoproteins gB to gL, a 
tegument layer, and an icosahedral 
capsid containing double-stranded 
DNA (Cunningham and Mikloska, 
2001). 
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Once released into the cytoplasm, viral capsids are transported along microtubules 
to the microtubule-organising centre, and from there, to the nuclear envelope. Viral DNA 
enters the nucleus, where replication and transcription takes place. Viral “immediate-
early”, “early” and “late” mRNAs are transported to the cytoplasm, where they are 
translated to viral proteins. The immediate-early viral proteins return to the nucleus and 
activate transcription of “early” genes. Early viral proteins return to the nucleus and 
function primarily in DNA replication and synthesis. DNA replication and recombination 
form the template for “late” viral genes. Late viral proteins are structural proteins and 
other proteins needed for assembly and egress of the virus. Some late viral proteins return 
to the nucleus and form the nucleocapsid into which newly replicated viral DNA is 
packaged. DNA-containing nucleocapsids bud through both nuclear membranes by a 
process of “primary” envelopment and de-envelopment, the nucleocapsid is then released 
into the cytoplasm and transported to the late Golgi-endosome compartment. They 
acquire an envelope containing viral membrane proteins and the complete tegument layer 
(secondary envelopment). The fully assembled virus buds into a vesicle, is transported to 
the host plasma membrane and is released by exocytosis to infect neighbouring cells 
(Flint, 2004). 
During initial exposure, HSV infects mucosal epithelial cells such as 
keratinocytes as the primary portal of entry and spread. After primary infection, HSV 
virions enter the axon terminals of sensory nerves that innervate the superficial dermis 
(Nicola et al., 2005). HSV travels by retrograde axonal transport to establish lifelong 
latent infection in the neuronal cell body, forming a reservoir for periodic reactivation 
(Bosnjak et al., 2005a, Neumann et al., 2003, Aurelian, 2004, Cunningham et al., 2006a, 
Nicola et al., 2005). Reactivation of latent virus and anterograde axonal transport to the 
original infecting dermatome results in asymptomatic viral shedding or recurrent herpes 
simplex lesions (Bosnjak et al., 2005a). Specific conditions can trigger reactivation of 
latent HSV such as local trauma from surgery or UV light, or systemic stimuli such as 
immunosuppression or fever. However, usually no precipitating factors can be identified 
(Gupta et al., 2007).  
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1.1.2  Epidemiology 
 HSV1 and 2 are pervasive human pathogens, affecting both urban and remote 
populations worldwide (Jones and Cunningham, 2004, Gupta et al., 2007). Infections are 
lifelong with intermittent clinical and subclinical (asymptomatic) viral reactivation and 
shedding from mucosal surfaces (Gupta et al., 2007). Prevalence of infection varies 
markedly by country, region within country and population subgroup (Smith and 
Robinson, 2002). HSV2 is estimated to affect over 16% of the global population aged 15-
49 (Looker et al., 2008, Hofstetter et al., 2014). However, in sub-Saharan Africa HSV2 
seroprevalence is among the highest in the world, reaching greater than 80% in women 
and men aged over 35 (Smith and Robinson, 2002).  HSV1 seroprevalence is over 80-
90% in many countries (Hofstetter et al., 2014). In Australia, a population based study of 
HSV1 and 2 seroprevalence found that 12% of adults had HSV2 and 76% had HSV1, 
although there were significant differences by age group, sex and Indigenous status 
(Cunningham et al., 2006b). 
1.1.3  Disease pathogenesis 
  Infection with HSV can cause several diseases. HSV1 mainly causes oral or facial 
lesions commonly called “cold sores” and is acquired during childhood via nonsexual 
contact (Smith and Robinson, 2002). Genital Herpes is one of the most common sexually 
transmitted diseases (Cunningham et al., 2006a). Worldwide, HSV has been isolated from 
50-80% of genital ulcer disease cases (Hofstetter et al., 2014). HSV2 is the primary cause 
(Smith and Robinson, 2002), although HSV1 is causing an increasing proportion of 
Genital Herpes, particularly among adolescents (Roberts et al., 2003, Cunningham et al., 
2006a). This probably occurs due to a delay in acquisition of oral HSV1 infection, 
resulting in susceptibility to genital HSV1 at initiation of sexual activity. An increase in 
oral sex in young adults is also a likely contributing factor (Gupta et al., 2007, Roberts et 
al., 2003). Primary infection is characterised by bilateral clusters of erythematous papules 
and vesicles on the external genitalia (Figure 1.2). Over 2-3 weeks, 75% of patients have 
new lesions and existing lesions progress to pustules and coalesce into ulcers before 
crusting and healing (Gupta et al., 2007). Of individuals with genital HSV infection, 
about 20% have symptomatic disease that they recognise as Genital Herpes, 60% have 
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lesions that they do not recognise as Genital Herpes without appropriate training, and the 
remaining 20% lack any sign or symptom of Genital Herpes and are truly asymptomatic 
(Dwyer and Cunningham, 2002, Koutsky  et al., 1992). 
 
         
Figure 1.2.  Genital Herpes. Characteristic herpetic lesions present on the external 
genitalia in Genital Herpes disease (Gupta et al., 2007). 
 
1.1.4  Health burden and disease complications 
 While most recurrent herpes infections are self-contained, the disease can have 
significant complications and psychological impact, so there is a significant global health 
burden. In the USA, medical costs associated with HSV2 are estimated at $541 million, 
making it the third most costly STI after Human Immunodeficiency Virus (HIV) and 
Human Papillomavirus (HPV) (Johnston et al., 2014).  
HSV1 can infect the corneal tissues of the eye, leading to herpes keratitis, which 
results in visual impairment or blindness (Everett, 2014). HSV is thought to be the 
leading cause of infectious blindness in developed nations, but the burden of vision loss 
associated with the virus remains uncertain (Farooq and Shukla, 2012). Herpes simplex 
encephalitis is the most common cause of sporadic fatal encephalitis in the USA with an 
estimated frequency of 1 in 250,000 to 1 in 500,000 persons per year (Levitz, 1998, 
Whitley, 1990). A study reviewed rates of hospitalisation for patients with encephalitis in 
New South Wales, Australia, from 1990-2007. Encephalitis was the primary diagnosis for 
5,926 hospital admissions with an average annual hospitalisation rate of 5.2 per 100,000 
population. The most common known aetiology was HSV1, in 12.9% of cases (Huppatz 
et al., 2009).  
Another serious complication of Genital Herpes is neonatal herpes, where infected 
mothers transmit the virus to their infant during delivery. Neonatal herpes can result in 
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substantially less frequently (about once a year) than 
does HSV-2.69,70 In the absence of antiviral therapy, the 
median recurrence rate after the fi rst episode of HSV-2 
infection is about four recurrences a year, with about 
40% of patients having at least six recurrences and 
20% having more than ten recurrences in the fi rst year, 
underscoring the need for type-specifi c diagnosis.71 In 
most individuals, disease activity and HSV shedding is 
highest in the fi rst 6–12 months after HSV infection but 
can persist for years.62,72,73 Third, immunosuppressed 
hosts often have a longer duration and more severe 
symptoms and a higher frequency of reactivations than 
do immunocompetent people.3,74 
First clinical episode 
Although asymptomatic and atypical presentation is 
most frequent, the classic clinical presentation of primary 
HSV-1 or HSV-2 genital infection is characterised by 
Figure 2: Epidemiology and pathogenesis of mucocutaneous HSV Infection 
During initial infection, HSV enters through breaks in the skin or mucosa; it then attaches to and enters epithelial cells and begins replicating. It is taken up by free 
sensory nerve endings found at the dermis, and the nucleocapsid containing the viral genome is transported by retrograde axonal fl ow to the nucleus in the sensory 
ganglion. Skin manifestations include vesicular lesions on an erythematous base. Lesions lead to the focal destruction of the epithelial layer and a widespread 
infi ltrate of infl ammatory cells develops in the surrounding rim and in the underlying dermal layer.128 Only 10–30% of new infections are symptomatic. After recovery 
from the initial infection, the virus remains latent in the sensory ganglion for the life of the host. Periodically, the virus reactivates from the latent state and travels 
back down the sensory nerves to the skin or mucosal surface. Viral shedding can occur either in the presence of lesions (clinical reactivation) or with very mild or no 
symptoms (subclinical reactivation). Shedding from mucosal surfaces leads to transmission to other sexual partners and in some cases HSV can be transmitted from 
mother to infant at delivery. Neonatal image by Kathey Mohan. Histopathology slide by Timothy Berger. Genital images by Michael Remington.
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disseminated infection, skin and eye disease, and complications in the nervous system 
(Gupta et al., 2007). Without treatment, 80% of infants die, and even those who survive 
often have cognitive impairment (Looker et al., 2008). The estimated rate of occurrence 
of neonatal HSV disease in the USA is approximately 1 in 3,200 deliveries and an 
estimated 1,500 cases of neonatal HSV infection per year (Thompson and Whitley, 2011).  
The greatest public health impact of HSV2 infection is its role in exacerbating the 
HIV1 epidemic. HSV2 infection is associated with a three-fold increased risk of HIV 
acquisition (Freeman et al., 2006). This risk increases up to eight-fold if the exposure 
occurs soon after HSV2 acquisition (Johnston et al., 2014).  It has also been estimated 
that the proportion of new HIV1 infections attributable to HSV2 could be up to 35-48% 
in some regions of sub-Saharan Africa (Freeman et al., 2007). Mucosal disruption caused 
by HSV genital ulcers favours HIV acquisition, providing a portal of entry which 
contains an infiltrate of CD4+T cells and macrophages, the target cells of HIV (Gupta et 
al., 2007).  In HIV1 and HSV2 co-infected individuals, HIV1 is consistently detected in 
genital ulcers caused by HSV2 (Schacker et al., 1998). Individuals with genital ulcers are 
at increased risk of transmitting HIV1 (Gray et al., 2001, Johnston et al., 2014). 
Since HSV1 and 2 infections cause a significant global health burden, 
understanding the host immune response to infection and how the virus evades effective 
control and elimination by the host are critical for the development of more effective 
therapies and vaccines that control, and ultimately prevent infection. 
1.2 Immune response to HSV 
1.2.1  Innate immune response 
A. Overview 
The immune response to HSV involves both innate and adaptive immunity 
(summarised in Figure 1.3). The innate immune system is the first line of defence against 
invading pathogens and possesses two main functions: To limit further infection by 
preventing the spread of microorganisms to neighbouring cells, and to initiate the Cellular 
and Humoral-mediated responses of the adaptive immune system (Chan et al., 2011). 
Detection of HSV infection occurs initially within infected epithelial cells. Viral 
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pathogen-associated molecular patterns (PAMPs) are detected by pattern recognition 
receptors (PRRs) within infected cells (Egan et al., 2013). PRRs include Toll-like 
receptors (TLRs), Retinoic acid-inducible gene 1 (RIG-I) like receptors (RLRs), 
Nucleotide-binding oligomerisation domain (NOD)-like receptors (NLRs) and C-type 
lectin receptors (CLRs) (Guo and Zhang, 2012, Carty et al., 2014). 
B. Toll-like receptors 
TLRs include the cell surface TLRs: TLR1, TLR2, TLR4, TLR5 and TLR6, and 
the intracellular endosomal TLRs: TLR3, TLR7/8 and TLR9 (Ma and He, 2014). The 
endosomal TLRs are particularly important for triggering responses to viral infection. 
TLR3 recognises double-stranded (ds) RNA, TLR7/8 recognise single-stranded (ss) RNA, 
and TLR9 recognises cytosine-phosphoguanine (CpG) DNA (Beutler et al., 2003). TLRs 
at the cell surface also recognise viruses, in addition to bacteria, fungi and parasites. 
TLR2 recognises microbial lipopeptides, peptidoglycan (PGN) and lipoteichoic acid 
(LTA) (Aderem and Ulevitch, 2000). In particular, the TLR2 heterodimers TLR1/2 and 
TLR2/6 recognise triacylated and diacylated lipopeptides respectively. TLR4 recognises 
lipopolysaccharide (LPS) and TLR5 recognises flagellin (Beutler et al., 2003, Lester and 
Li, 2014). The pattern of TLR expression varies across cell types, with 
haematopoietically-derived cells such as macrophages and dendritic cells expressing 
nearly all TLRs (Ma and He, 2014). TLRs are expressed on epithelial cells in HSV-
targeted oral, ocular and genital mucosa (Herbst-Kralovetz and Pyles, 2006), as well as 
on monocytes, B cells, neutrophils, natural killer cells and neuronal cells (Tadema et al., 
2011, Hornung et al., 2002, Chalifour et al., 2004, Guo and Zhang, 2012, Zhou et al., 
2009). In particular, HSV is recognised by TLR3 (Zhang et al., 2007b, Boivin et al., 2008, 
Zhou et al., 2009) as well as TLR9 and TLR2 (Ma and He, 2014, Sato et al., 2006, 
Sorensen et al., 2008). 
C. Type I Interferon 
Following recognition of their respective PAMPs, TLRs signal through MyD88-
dependent or independent pathways, which both result in the activation of interferon 
regulatory factors (IRFs) that mediate the production and secretion of Type I Interferons 
(IFN), which are crucial to the antiviral response (Chan et al., 2011). The Type I IFNs 
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expressed in humans include IFN-α (of which multiple subtypes have been identified), 
IFN-β, IFN-ε, IFN-ω, and IFN-κ, although the roles of IFN-α and IFN-β are best 
characterised (Takaoka and Yanai, 2006, Chan et al., 2011). Although there are several 
members and subtypes in the Type I IFN cytokine family, they all signal through the 
same receptor, IFNAR (Hertzog and Williams, 2013). Type I IFNs induce expression of 
antiviral genes known as IFN stimulated genes, (ISGs), which are directly involved in 
inhibiting viral replication and promoting the degradation of viral mRNA (Chan et al., 
2011). Type I IFNs also activate multiple immune cell types to respond to HSV infection 
including neutrophils, macrophages, natural killer cells and dendritic cells, which are 
essential effectors of the innate immune response (Takaoka and Yanai, 2006). 
D. Macrophages and Neutrophils 
Macrophages are cells of the mononuclear phagocyte system found in tissues 
throughout the body. In these tissues, monocytes differentiate into macrophages with 
characteristics of the tissue environment or are seeded early in life as resident 
macrophages. These include Kupffer cells in the liver, alveolar and interstitial lung 
macrophages, microglia in the brain, osteoclasts in bone, as well as skin-resident 
macrophages (Ellermann-Eriksen, 2005). Their major functions are phagocytosis of dead 
or dying cells, antigen presentation, and the production of proinflammatory cytokines 
(Ellermann-Eriksen, 2005, Egan et al., 2013). In early studies of recurrent herpes lesions, 
macrophages were prominent at early stages of lesions (Cunningham et al., 1985, Schiffer 
and Corey, 2013).  
Neutrophils are a type of granulocyte also called a polymorphonuclear (PMN) 
leukocyte, due to having a variably shaped nucleus that is lobed into three segments. 
Neutrophils are attracted to the site of HSV infection and secrete the antiviral cytokine 
Tumour Necrosis Factor (TNF, also known as TNF-α), which can induce apoptosis in 
infected epithelial cells. Neutrophils also phagocytose necrotic and apoptotic epithelial 
cells (Egan et al., 2013). 
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E. Natural killer cells 
 Natural killer (NK) cells are an innate lymphocyte involved in cytokine 
production and the killing of virally infected cells. Activated NK cells mediate antiviral 
activity by inducing apoptosis of virally infected cells through release of perforin and 
granzyme B, and are an important source of the Type II IFN, IFN-γ (Chan et al., 2011). 
IFN-γ activates the inducible nitric oxide synthase (iNOS), which catalyses the oxidation 
of L-arginine to L-citrulline and nitric oxide in epithelial cells, macrophages and DCs. 
The downstream products subsequently interfere with viral replication by reacting with 
nucleic acids and proteins (Bogdan, 2001, Chan et al., 2011). NK cells have been 
observed in recurrent herpes lesions. Early studies by Cunningham et al. found low 
numbers of NK cells at the site of lesions (Cunningham et al., 1985). More recently, 
studies using more selective NK cell markers, including previous studies from our own 
laboratory (Donaghy et al., 2009, Kim et al., 2012), have observed local enrichment of 
NK cells at the site of lesions in patients with recurrent genital HSV2 (Koelle et al., 1998, 
Zhu et al., 2007).  
In recent years it has become apparent that NK cells form part of a broader 
network of innate lymphocytes referred to as Innate Lymphoid Cells (ILCs) (Eberl et al., 
2015). NK cells are a type of ILC1, characterised by the expression of the transcription 
factor T-bet and the production of IFN-γ, however there are other ILC1s that are non-
cytolytic (Seillet and Belz, 2016). Of the ILC1 subset, only NK cells have so far been 
detected in healthy skin, often in small numbers that are then increased in inflammatory 
conditions (Heath and Carbone, 2013). It will be interesting to see whether investigations 
in the coming years determine if other subsets of ILCs have a role in the immune 
response to HSV. NK cells will be discussed in further detail in section 1.4. 
F. Dendritic cells 
Dendritic cells (DCs) are referred to as professional antigen-presenting cells, with 
a unique ability to induce primary immune responses, critical for the initiation of antigen-
specific adaptive responses (Fujii et al., 2004, Banchereau et al., 2000). DCs have been 
categorised into 4 types ontogenetically: myeloid or “classical” DCs (cDCs), with 
precursor cDCs (pre-cDCs) that develop into subtype 1 (cDC1) also known as CD141+ or 
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XCR1+ DCs, or subtype 2 (cDC2) also known as CD1c+ DCs. A separate lineage of DCs 
are plasmacytoid DCs (pDCs) (Guilliams et al., 2014). Like macrophages, DCs are also 
found in different anatomical locations including: epidermal Langerhans cells (LCs), 
dermal DCs, germinal-centre DCs, thymic DCs, liver DCs and blood DCs (Banchereau et 
al., 2000). Immature DCs are very efficient at antigen capture and can use several 
mechanisms, including macropinocytosis, receptor-mediated endocytosis via CLRs or 
Fcγ receptors, and phagocytosis of cell fragments, viruses, bacteria, mycobacteria and 
intracellular parasites (Banchereau et al., 2000).  
Exogenous soluble and particulate antigens are targeted to the Major 
Histocompatibility (MHC) class II antigen presentation pathway. Antigens delivered to 
late endosomes by phagocytosis, pinocytosis or endocytosis are processed by cathepsins 
into peptides. High affinity peptides are loaded onto MHC class II molecules by the 
chaperone HLA-DM, which is regulated by HLA-DO. The MHC class II-peptide 
complexes are transported to the cell surface for recognition by CD4+T cells. In humans, 
the MHC Class II molecules are HLA-DR, HLA-DQ and HLA-DP (Blum et al., 2013). 
Endogenous antigens, derived from the translation of either self or foreign (e.g. viral) 
RNA, are cleaved into peptides in the cytosol, and targeted to the MHC class I antigen 
presentation pathway. Peptides are translocated to the endoplasmic reticulum (ER) by the 
transporter associated with antigen processing (TAP). In the ER, peptides undergo 
trimming by aminopeptidases and then high affinity peptides are loaded onto MHC class 
I molecules by a tapasin-mediated process. The MHC class I-peptide complexes then 
transit to the cell surface for recognition by CD8+T cells. In humans, the MHC class I 
molecules are HLA-A, HLA-B and HLA-C (Blum et al., 2013). DCs are also able to 
target exogenous proteins normally targeted to the MHC class II pathway to the MHC 
class I pathway by translocation into the cytosol from endosomes or phagosomes, a 
process referred to a “cross-presentation”. This is particularly important for initiating a 
primary response by naïve CD8+T cells, which is termed “cross-priming” (Blum et al., 
2013).  
In conjunction with antigen uptake and processing, DCs also undergo a process of 
maturation, characterised by the loss of endocytic/phagocytic receptors. They upregulate 
costimulatory molecules important for antigen presentation- CD40, CD54, CD80 and 
CD86, which bind with CD40L, CD11a, CD28 and CTLA4 respectively on T cells, 
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providing a second signal in addition to the MHC/peptide binding to the T cell receptor 
(TCR), required for T cell activation. They also upregulate CCR7 and undergo changes in 
morphology that increase cellular motility, so they can migrate to lymph nodes in 
response to CCL19/21 and present antigen to T cells there (Banchereau et al., 2000, 
Bosnjak et al., 2005a). 
DCs also play an important role in activating NK cells, by the production of 
cytokines such as Interleukin (IL)-15, important for survival and proliferation (Chan et al., 
2011), and IL-12 and IL-18, important for activating NK cell cytokine production and 
cytotoxic functions (Egan et al., 2013). Type I IFN is also important for the induction of 
NK cell cytotoxicity (Theofilopoulos et al., 2005). The DCs primarily responsible for 
Type I IFN production (especially IFN-α) are pDCs, and may be particularly important 
for stimulating NK cell killing of target cells (Chan et al., 2011, Bosnjak et al., 2005a). 
LCs are the resident DCs in the epidermis of skin and are the first to encounter 
HSV upon infection (Cunningham et al., 2010). In murine studies, depletion of LCs from 
murine skin prior to footpad HSV2 infection led to increased HSV virulence (Sprecher 
and Becker, 1986). Subsequently, LCs were reported to accumulate in draining lymph 
nodes after subcutaneous administration of HSV1 (Sprecher and Becker, 1989). However, 
another murine study showed that it was CD8α+ DCs and not LCs that presented HSV 
antigen to T cells (Allan et al., 2003). We recently investigated the initial response to 
HSV infection in humans by comparing topically HSV1 infected foreskin explants with 
biopsies of initial (primary) genital herpes lesions. LCs were infected with HSV in the 
epidermis and underwent apoptosis whilst migrating to the dermis. In the dermis, they 
formed large cell clusters with two types of dermal DC subsets, and fragments of HSV-
expressing LCs were observed inside the dermal DC subsets. Therefore, a viral antigen 
relay took place where HSV-infected LCs were taken up by dermal DCs (Kim et al., 
2015). This likely explains why other DC subsets have been observed presenting HSV 
antigens to T cells in lymph nodes, rather than LCs. The classification of tissue-residing 
DC subpopulations is becoming increasingly complex (Haniffa et al., 2015). Over the 
next few years it will become increasingly clear what role different DC subpopulations 
play in the interactions with adaptive immune cells. 
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1.2.2  Adaptive immune response 
 A. Overview 
 The acquired or adaptive immune system is the second line of defence and is 
distinct from the innate immune response; being antigen-specific, with responses that 
improve on repeated exposure to an antigen, a characteristic referred to as 
“immunological memory” (Delves and Roitt, 2000, Dutton et al., 1998). The adaptive 
immune response is largely driven by lymphocytes: B cells and T cells. The relative 
activities of B and T cell populations determine the type of immune response generated in 
response to infection. Humoral immunity involves antibodies generated from antigen-
specific B cells, and Cell-mediated immunity involves the activation of antigen-specific T 
cells. However, adaptive immune responses can only be initiated via antigen presentation 
by innate antigen-presenting cells to CD4+ helper T cells, which then “help” B cells and 
CD8+ cytotoxic T cells develop memory responses (Pasquale et al., 2015). 
B. B cells 
 B cells are the key immune cells of the Humoral immune response, producing 
antibodies important for protection against many infectious pathogens. However, the role 
of antibody-mediated protection against HSV2 pathogenesis is unclear (Chan et al., 2011, 
Schiffer and Corey, 2013). Infection with HSV2 results in production of HSV2 specific 
antibody, immunoglobulin G (IgG), in the genital tract (Ashley et al., 1992, Chan et al., 
2011). Furthermore, the presence of HSV2-specific maternal antibodies reduces neonatal 
transmission of HSV2 (Brown et al., 1991, Schiffer and Corey, 2013). An in vitro study 
showed that neutralising antibodies could bind to virus in the gap between neuron 
endings and epithelial cells, and may limit bidirectional transfer between the two tissues 
(Mikloska et al., 1999, Schiffer and Corey, 2013).  
A number of mouse studies demonstrated the importance of the antibody-response 
to HSV. A study demonstrated that IgG isolated from HSV2 vaccinated mice neutralised 
wild-type HSV2 in vitro. Adoptive transfer of serum IgG from immunised mice into the 
vaginal lumen of naïve mice reduced viral load and pathological signs of disease, 
demonstrating the capability of protection from a lethal dose of virulent HSV2 (Chan et 
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al., 2011, Parr and Parr, 1997). Other studies showed that antibodies played a role in 
controlling viral titres and limiting replication. B cell-deficient mice immunised with 
attenuated HSV2 had greater levels of viral titres in vaginal epithelium than wild-type 
controls (Parr and Parr, 2000). While B cell-deficient mice immunised with attenuated 
HSV2 controlled viral replication in the genital mucosa, the mice were not completely 
protected from genital and neurologic disease (Morrison et al., 2001). A study comparing 
B cell and T cell depletion found that B cell deficient mice had higher viral titres and less 
robust protection, however protection was severely compromised by T cell depletion. 
This suggested that HSV-specific antibody limited infection, however, prevention of viral 
spread depended on robust T cell responses (Dudley et al., 2000). 
 Other mouse studies showed that humoral immunity alone was unable to control 
HSV infection and failed to protect against infection. Dudley et al. and Harandi et al. both 
found that T cells, rather than B cells, were critical for protection against lethal challenge 
of HSV2 (Dudley et al., 2000, Harandi et al., 2001). Also, passive transfer of immune 
serum (Morrison et al., 2001) or anti-HSV mAbs (McDermott et al., 1990) failed to 
protect against vaginal infection. It has also been suggested that the effect of mucosal 
antibodies may be limited, as spread of infection within ulcers occurs via direct cell-to-
cell spread across tight junctions, mediated by HSV gE-gI heterodimers, and that these 
tight junctions are inaccessible to antibodies (Collins and Johnson, 2003, Schiffer and 
Corey, 2013).  
In humans, a recombinant vaccine containing HSV2 glycoproteins gB and gD, 
which induced high levels of neutralising antibodies, failed to be more protective in 
minimising viral acquisition compared to a placebo group (Corey et al., 1999). It has been 
suggested that the principal role of B cells in the immune response to HSV may not be 
the production of neutralising antibodies (Egan et al., 2013). Deshpande et al. reported 
that B cells had a dual role in mediating innate and adaptive immune responses to HSV. 
They demonstrated that the production of IgM antibodies reactive with HSV had an anti-
viral effect in the early innate control of primary HSV infection. Furthermore, B cells 
functioned as an antigen-presenting cell for the stimulation of HSV-specific CD4+T cells 
(Deshpande et al., 2000).  
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 Therefore, the findings of these murine studies regarding the importance of 
humoral immunity in HSV infection remain contradictory. In humans, a greater 
correlation between anti-HSV antibody levels, rather than CD4+T cell responses, and 
protection against genital herpes by an adjuvanted (dMPL) glycoprotein D vaccine was 
shown. Humoral immunity may play an early beneficial role in primary HSV infection, 
but ultimately Cell-mediated immunity is necessary for HSV clearance and protection 
(Chan et al., 2011). 
C. CD4+T cells 
 CD4+T cells are referred to as “helper” T cells since both B cells and CD8+T cells 
require their “help” to become activated. B cells in particular require CD4+T cell help for 
generating class-switched antibodies (Murphy and Stockinger, 2010). CD4+T cells were 
originally divided into T helper 1 (Th1) and Th2 subsets (Delves and Roitt, 2000), 
however it is now known that many states of CD4+T cell differentiation exist (Murphy 
and Stockinger, 2010). These subsets are defined by the transcription factors they express 
and the cytokines they produce. Th1 cells express T-bet and produce IFN-γ and IL-2, Th2 
cells express GATA3 and produce IL-4 and IL-13, Th17 express RORγt and produce IL-
17, regulatory T cells (Treg) express Foxp3 and produce IL-10, IL-35 and TGF-β, and 
follicular helper T cells (Tfh) express Bcl-6 and produce IL-21 (O'Shea and Paul, 2010). 
Th1 cells are involved in Cell-mediated immunity and are thought to be particularly 
important in immunity against viruses such as HSV (Kaisho and Akira, 2002). 
 In human herpes lesions, CD4+T cells are the first T cells to infiltrate, as early as 
12 hours after onset (Cunningham et al., 1985, Koelle et al., 1998). In a mouse study, 
non-cytolytic IFN-γ-mediated antiviral protection was shown to be important for limiting 
HSV2 viral replication and spread throughout the vaginal mucosa. Memory CD4+T cells 
were re-stimulated to secrete IFN-γ via MHC class II antigen presentation by local DCs 
and B cells at the site of infection (Cunningham et al., 1985, Iijima et al., 2008, Schiffer 
and Corey, 2013). IFN-γ inhibits viral replication through expression of antiviral genes 
such as protein kinase RNA-activated (PKR), which inhibits translation within infected 
cells (Egan et al., 2013). IFN-γ also upregulates MHC Class II and restores the 
downregulation of MHC Class I on HSV-infected cells (Mikloska and Cunningham, 
1998). CD4+T cell depletion studies in mice have also highlighted their importance in the 
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immune response to HSV. In one study, CD4-depletion before vaginal challenge with a 
high dose of HSV was more detrimental to mice than CD8-depletion, with higher viral 
tires that persisted for longer (Kuklin et al., 1998). A study from the same year showed 
that depletion of CD4+T cells also resulted in significantly higher viral titres and delayed 
viral clearance compared to depletion of CD8+T cells (Milligan et al., 1998). Another 
murine study found that CD4+T cell deficient or depleted mice failed to recruit CD8+T 
cells to the vaginal epithelium. This study investigated the mechanism of CD4+T cell-
mediated recruitment of CD8+T cells and found that the production of IFN-γ stimulated 
the secretion of chemokines CXCL9 and CXCL10 from epithelial cells, which resulted in 
migration of CD8+T cells to the site of infection (Chan et al., 2011, Nakanishi et al., 
2009). In human studies, CD4+T cells have been observed persisting at sites of HSV2 
reactivation for at least 6 months after healing (Zhu et al., 2009) and continue to express 
IFN-γ early after exposure to HSV antigen and lesion healing (Schiffer and Corey, 2013). 
D. CD8+T cells 
 CD8+ “cytotoxic” T cells (CTLs) infiltrate into herpes lesions later than CD4+T 
cells (Cunningham et al., 1985, Koelle et al., 1998), mediated by chemokine production 
by infected or IFN-γ stimulated keratinocytes (Mikloska et al., 1998, Nakanishi et al., 
2009). The multi-step process of viral antigen transport from the site of infection to 
secondary lymphoid compartments, antigen presentation to CD8+T cells, activation and 
migration back to the site of infection occurs while the number of HSV2 infected cells 
rapidly expands (Schiffer and Corey, 2013). Stimulation of CD8+T cell expansion by 
CD4+T cells and DCs is necessary for viral clearance, and clearance is correlated with 
CD8+T cell recruitment (Koelle et al., 1998, Schiffer and Corey, 2013, Wakim et al., 
2008). CD8+T cells usually exert their effector functions through the secretion of IFN-γ, 
TNF, perforin and granzymes after engaging antigens on MHC class I molecules on 
target cells. They also mediate cell killing via CD95L, which binds to CD95 on a target 
cell initiating apoptosis via activation of caspase 8. Apoptosis of the infected cells limits 
the production of new virus and viral spread (Egan et al., 2013). 
 Following the first encounter with antigen, two distinct populations of memory T 
cells develop. Central memory T cells (TCM) are retained in Secondary Lymphoid Organs 
(SLO) and rapidly proliferate upon re-exposure to antigen. Effector memory T cells (TEM) 
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circulate the blood and various tissues, sampling the environment for their specific 
antigen. These cells are ready to clear infection upon encounter without the need to 
proliferate or differentiate (Egan et al., 2013). In mice, it has been shown that infection of 
mouse flank results in rapid influx of a highly localised, non-migratory subset of HSV-
specific CD8+ memory T cells that remain at the site for at least 100 days. They show 
lower homeostatic proliferation and greater expression of E-cadherin and extracellular 
matrix-binding proteins than circulating HSV-specific CD8+T cells (Gebhardt et al., 2009, 
Schiffer and Corey, 2013, Zhu et al., 2007). It is now thought that a distinct population of 
memory T cells are retained in the tissue of initial exposure for extended periods without 
replenishment from the circulating pool of CD8+T cells, referred to as Tissue resident 
memory T cells (TRM). TRM cells are highly localised at the site of first infection in the 
epidermis in mice and at the dermo-epidermal junction in humans, as infection at a 
separate skin locus is poorly controlled on re-exposure (Gebhardt et al., 2009, Schiffer 
and Corey, 2013). HSV-specific CD8+T cells also appear to play a critical role in 
preventing HSV reactivation and maintaining HSV in a latent state in the trigeminal 
ganglia (Egan et al., 2013, Hoshino et al., 2007, Knickelbein et al., 2008, Liu et al., 2000). 
CD8+T cells residing close to peripheral nerve endings at the dermo-epidermal junctions 
have been captured by laser dissection microscopy, and transcriptional profiling found 
expression of perforin, granzymes A and B, and antiviral cytokines during clinical 
quiescence, demonstrating active immunosurveillance after episode clearance (Peng et al., 
2012, Schiffer and Corey, 2013). 
While CD8+T cells play an important role in viral clearance in the later stages of 
the response, and in maintaining latency, IFN-γ producing CD4+T cells are also essential 
to restore MHC class I expression on target cells for CD8+T cells as discussed. Therefore, 
an effective response against HSV ultimately requires strong responses from both CD4+ 
and CD8+T cells (Chan et al., 2011) 
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Figure 1.3. Immune response to HSV. Both innate and adaptive immunity are necessary 
in fighting HSV infection. The innate system is important for early control of HSV 
infection. (A) HSV infects the epithelium and is detected by TLRs on epithelial cells, 
antigen-presenting cells, pDCs and NK cells. TLRs induce Type I IFN production in a 
positive feedback loop. Both IFN-α and IFN-β drive surrounding epithelial cells into an 
antiviral state by inhibiting translation and promoting degradation of viral mRNA. Type I 
IFNs also drive DC maturation and IL-15 production, which promotes NK cell survival 
and proliferation. (B) NK cells release IFN-γ and induce apoptosis of virally infected 
cells through perforin and granzymes. IFN-γ aids the antiviral response by activating 
iNOS. (C) The adaptive immune system is responsible for viral clearance. CD4+T cells 
are recruited to the infection site and activated by MHC class II antigen presentation on 
antigen-presenting cells such as DCs. (D) Activated CD4+T cells produce IFN-γ and 
induce secretion of chemokines CXCL9 and CXCL10 by epithelial cells. The chemokine 
gradient attracts cytotoxic CD8+T cells to the site and stimulates nitric oxide release from 
epithelia. (E) HSV-specific CD8+T cells also release IFN-γ and kill infected cells through 
perforin and Fas pathways. (F) B cells are recruited to the site of infection and are 
activated by CD4+T cells to produce antibodies. Release of viral glycoproteins allows 
HSV to by-pass the effects of antibody-mediated protection (Chan et al., 2011). 
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1.2.3  HSV immune evasion strategies 
 Although the immune system has several strategies involving several cell types to 
combat viral infections, HSV1 and 2 both have evolved sophisticated mechanisms of 
immune evasion that are the reason why infection is so common amongst various 
populations. A major mechanism of immune evasion of the cell-mediated immune 
response is inhibition of TAP by ICP47, resulting in inhibition of peptide loading and 
downregulation of MHC Class I (Fruh et al., 1995, Smith and Khanna, 2013) in human 
but not mouse cells (Mikloska and Cunningham, 1998). However, as mentioned above, 
this is partially reversed by IFN-γ secreted by CD4+T cells. HSV gB also partly disables 
MHC class II presentation by diverting MHC class II molecules to the exosome pathway 
(Temme et al., 2010). HSV can also induce the apoptosis of T cells (Han et al., 2007). T 
cells that are not killed can be inhibited from becoming activated via interference of TCR 
signal transduction, and selective production of the immunosuppressive cytokine IL-10 
(Sloan et al., 2006, Sloan and Jerome, 2007) 
Another strategy is interference with DC function. HSV can infect DCs and in 
doing so, downregulates surface expression of several key costimulatory and adhesion 
molecules including CD40, CD54, CD80 and CD86 (Bosnjak et al., 2005a). By blocking 
expression of these molecules via the protein ICP47, HSV inhibits DCs ability to 
stimulate T cells (Neumann et al., 2003). Downregulation of CD40 on infected DCs may 
also lead to decreased IL-12 production upon contact with T cells, such that IFN-γ 
secretion by T cells is inhibited and restoration of MHC expression inhibited as well. 
HSV1 and 2 infected DCs undergo rapid apoptosis unlike most other HSV infected target 
cells, as HSV produces anti-apoptotic proteins in non-immune cells. Apoptosis usually 
suppresses the spread of virus to other cells. However, in the context of low HSV 
productive infection of DCs, apoptosis could be seen as deleterious to the host as it 
removes them from the pool of cells capable of carrying viral antigens to LN for T cell 
activation (Bosnjak et al., 2005a). This can be circumvented by the uptake of apoptotic 
DCs by other uninfected bystander DCs, enabling cross-presentation to CD8+T cells 
(Bosnjak et al., 2005b). 
Since HSV has acquired multiple mechanisms to evade the immune system, and is 
a significant global health burden as discussed previously, it is critical to develop a 
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vaccine that produces an effective immune response that overcomes immune evasion, 
controls disease and ultimately prevents infection. 
1.3 HSV vaccine development 
Developing prophylactic and therapeutic vaccines are the major long-term 
strategy for preventing Genital Herpes, its complications, other HSV diseases and 
ultimately HSV infection itself (Cunningham and Mikloska, 2001). An ideal prophylactic 
vaccine would significantly decrease the probability of acquisition per coital act, although 
a therapeutic vaccine that decreased severity and shedding frequency (and therefore 
decreased likelihood of transmission) would also be very useful (Schiffer and Corey, 
2013). However, apart from overcoming immunoevasive mechanisms, difficulties 
associated with developing a vaccine include a limited understanding of the virus life 
cycle, its establishment of latency in neurons and the role of immunity in preventing 
infection, clinical symptoms and unimpeded replication of reactivated endogenous virus 
(Rajcani and Durmanova, 2006, Aurelian, 2004, Cunningham et al., 2006a). 
1.3.1  Types of vaccines 
 A. Live-attenuated/whole-inactivated virus vaccines 
 The conventional approach to vaccine development has involved administration 
of whole live-attenuated microorganisms. Attenuated viruses cause greatly reduced 
pathology while maintaining immunogenicity, eliciting immune responses similar to 
unattenuated pathogens (Ferenczy, 2007). Several live-attenuated HSV1 and HSV2 
vaccines have been tested in animal models. The HSV1 strain HF clone 10 (HF10) 
exhibits impaired neuroinvasiveness and was protective against lethal challenge with 
HSV1 and HSV2 (Mori et al., 2005). A study using the MP strain of HSV (a less virulent 
strain) inoculated in the cornea found that immunised animals were protected from 
keratitis and encephalitis when challenged with virulent strains of HSV1 compared to 
unimmunised controls (Sandstrom et al., 1986). An HSV2 glycoprotein E deletion mutant 
was assessed in mice and it caused no death or disease after vaginal, intravascular or 
intramuscular inoculation and no virus was recovered from DRG or spinal cord. However, 
it was unable to completely prevent infection with challenge virus or recurrent vaginal 
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shedding (Awasthi et al., 2012). In humans, a clinical trial was conducted using a 
recombinant HSV virus ICP10deltaPK in HSV2 infected patients. Whilst vaccinated 
patients had fewer recurrences than placebo, the vaccine completely prevented 
recurrences in only 37.5% of patients (Casanova et al., 2002). Another live attenuated 
vaccine studied in humans is strain R7020. The virus, based on strain F, is attenuated by a 
deletion extending from UL54 (encoding ICP27) through the promoter region of ICP4. In 
a dose-escalation study, local reactions and systemic side effects were observed in HSV1 
infected individuals (Chentoufi et al., 2012, Koelle and Corey, 2003). A major problem 
with live-attenuated vaccines is that since these vaccine strains can replicate, safety issues 
abound due to instability and the risk of reversion back to wild-type, pathogenic forms, 
and the ability to infect the immunocompromised (Ferenczy, 2007, Moyle and Toth, 2008, 
Zhu et al., 2014). The risk of reversion can be circumvented by the use of double 
mutations such as dl5-29, where the genes UL5 and UL29 were both deleted, the 
products of which are essential for HSV DNA synthesis (Da Costa et al., 1999). 
An alternative to live-attenuated virus is to use whole-inactivated or killed virus 
as a vaccine. No inactivated viral vaccines have been shown to be effective in controlled 
clinical trials for HSV (Burke, 1992, Ferenczy, 2007). An inactivated vaccine known as 
the “Bulgarian” vaccine has been used therapeutically in Bulgaria for decades. Whilst the 
vaccine was not harmful, there is no data showing any proven efficacy. In vaccinated 
patients there was an overall contraction rate of genital herpes of 5.4%. However, a 
formal clinical trial as a double blind, randomised study including adequate controls and 
placebos would be required to properly assess the efficacy (Coleman and Shukla, 2013, 
Ferenczy, 2007, Skinner et al., 2000). 
B. DNA vaccines 
 DNA vaccines, which originated in the 1990s, opened up a new path for vaccine 
development for HSV2. The genes for HSV2 gD and gB have been widely used in DNA 
vaccines because these are two major antigens that induce immune responses (Zhu et al., 
2014). Some recent DNA vaccines tested in animal models were shown to induce 
protective responses against HSV2. A gD2 plasmid DNA encoding UL46 and UL47 
provided complete protection against both primary and recurrent genital skin disease 
following intravaginal challenge, and significantly reduced latent HSV2 DNA in Dorsal 
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Root Ganglia (DRG) compared to controls (Veselenak et al., 2012). Another gD2 plasmid 
DNA vaccine adjuvanted with Vaxfectin showed significant IgG titres, reduced vaginal 
and DRG HSV2 viral load and an 80% survival rate (Shlapobersky et al., 2012). However, 
an earlier animal study comparing the vaccines: recombinant gD2, plasmid expressing 
gD2 (DNA), and the dl5-29 strain of replication defective HSV2 (attenuated virus) found 
that the latent dl5-29 virus was superior in inducing neutralising antibody and 
accumulation of HSV2-specific CD8+T cells in the trigeminal ganglia after challenge 
with wild-type virus than the other vaccines (Hoshino et al., 2005). Therefore the 
attenuated virus vaccine had greater efficacy than the recombinant and DNA vaccines. In 
humans, a phase I study using a DNA vaccine encoding gD2 has been completed and was 
found to be safe. However, cellular responses occurred in only a small proportion of 
subjects immunised with the highest dose of DNA, and no antibody response was elicited 
(Cattamanchi et al., 2008, Shin and Iwasaki, 2013).  
C. Subunit vaccines 
 Subunit vaccines are safer than whole virus vaccines, containing the minimal 
microbial components needed to stimulate an appropriate immune response (Moyle and 
Toth, 2008). However, some drawbacks to subunit vaccines include a reduced antigenic 
breadth of the immune response compared to live attenuated vaccines (Halford, 2014), 
shorter duration in vivo, cold storage requirements due to instability, and the requirement 
of adjuvants to activate adaptive immune responses (Ferenczy, 2007, Strugnell et al., 
2011). Nevertheless, among licensed vaccines, the majority use a subunit approach 
(Strugnell et al., 2011). Furthermore, the most promising human clinical trial vaccines 
against HSV to-date were HSV glycoprotein subunit vaccines. The first trial from Chiron 
(Biocene) contained 30 µg of both gD and gB in combination with adjuvant MF59, a 5% 
squalene oil-in-water emulsion (Corey et al., 1999).  The vaccine induced high levels of 
specific neutralising antibody (Aurelian, 2004), which was hoped would prevent 
acquisition of genital HSV2 infection based on an association between HSV2 specific 
antibodies and a reduction in maternal-foetal HSV2 transmission (Corey et al., 1999). In 
the trial development of infection was slower in vaccinated subjects in the first 5 months, 
however protection was only partial, transient and insignificant with an overall efficacy 
rate of 9% (Jones and Cunningham, 2004, Corey et al., 1999). 
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 The second trial vaccine from GlaxoSmithKline (GSK), Simplirix, provided 
partial efficacy against Genital Herpes disease (Jones and Cunningham, 2004, Stanberry 
et al., 2002). It contained gD formulated with a mixture of alum and 3-O-deacylated-
monophosphoryl lipid A (3-dMPLA) as the adjuvant (Aurelian, 2004). A study of 
couples discordant for Genital Herpes showed 73-74% efficacy in preventing genital 
herpes in HSV-seronegative women whose partners had Genital Herpes, but was not 
efficacious in HSV seropositive women or in men (Stanberry et al., 2002). It was 
suggested that since women display greater systemic Th1 responses than men, the sex 
bias observed in the trial could be due to local effects of the Th1 response in enhancing 
genital mucosal cell responses, enhancing the resistance of female genital mucosa so it 
becomes similar to male genital mucosa (Cunningham et al., 2006a). Unfortunately, the 
efficacy rate observed for seronegative women in the first trial was not observed in a 
follow-up study vaccinating the general population of HSV-seronegative women. The 
overall vaccine efficacy was only 20% against genital herpes disease, yet there was 
significant (58%) efficacy against HSV1 genital disease and 35% efficacy against HSV1 
infection (with or without disease). However, efficacy against HSV2 infection was not 
observed (Belshe et al., 2012). The vaccine elicited neutralizing antibody and CD4+T cell 
responses, but not CD8+T cell responses (Belshe et al., 2014).  
The best correlates of immunity to HSV are found in data from partially 
successful vaccines, where, in this case, the combination of neutralizing antibody and 
CD4+T cell responses conferred some protection against HSV in seronegative women. In 
a comment discussing the relative failure of this vaccine candidate, Stanberry and Belshe 
agreed that seronegative women in discordant couples have chronic exposure to herpes 
antigen over time, indicating an immunological explanation for the differing results 
compared to the general seronegative population. Corey commented that next-generation 
vaccines need to target “killer” (CD8+T) cells to clear HSV2 infected cells, as well as 
target innate immune responses (Cohen, 2010). Recent data offers further support for the 
importance of CD8+T cell responses, where the quantity of CD8+T cells in herpes lesions 
inversely correlated with quantity of virus shed (Schiffer, 2013). This needs to be 
confirmed in future vaccine studies. 
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 D. Peptide vaccines 
 It has already been established that the HSV glycoproteins gD and gB are key 
antigens for the activation of CD4+T cells (Aurelian, 2004). Glycoprotein D contains 
multiple MHC class II restricted “promiscuous” epitopes for CD4+T cells (Kim et al., 
2008). However, the possibility of using smaller peptides in vaccines has been advocated, 
rather than whole recombinant proteins. Advantages of using peptides include their 
ability to focus the immune response to specific epitopes in multiple immunogenic 
combinations whilst avoiding those that are immunosuppressive, their non-infectious 
nature, capacity to incorporate non-natural components and stability in freeze-dried form, 
such that transportation is easier (Moyle and Toth, 2008). Furthermore, a comparison of 
pooled, overlapping peptides and whole protein found that peptides trafficked to the 
cytosol and the endosome, allowing presentation to and activation of both CD8+ and 
CD4+T cell responses, whereas whole protein only trafficked to the endosome, primarily 
activating CD4+T cells (Zhang et al., 2009a). However, peptides alone tend to be poorly 
immunogenic. Epitopes lack the ability to provide appropriate signals for DC maturation 
and inflammatory cytokine release. This is now understood to be a critical property of 
potent adjuvants, thus necessitating their co-administration with peptides (Jackson et al., 
2004). 
1.3.2  Vaccine adjuvants 
 An adjuvant is a compound that enhances the immune response against an antigen 
(Marciani, 2003). An important adjuvant function is overcoming the poor 
immunogenicity of subunit and peptide vaccines by improving pathogen recognition and 
inducing a response similar to the natural innate immune response (Pasquale et al., 2015). 
Adjuvants are classified according to their chemical nature, origin, physical and chemical 
properties. There are a variety of mechanisms adjuvants use to exert their augmenting 
effects on immune responses: establishing an antigen depot in tissue, direct or indirect 
immunomodulation and antigen-targeting effects. Different adjuvants tend to bias the 
immune system towards different arms of the immune responses e.g. such as Th1 or Th2 
(Lycke, 2007). 
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 Aluminium salt adjuvants are the most common adjuvant used (Moyle and Toth, 
2008). These adjuvants establish an antigen depot within an insoluble emulsion. The 
emulsion is sequestered at the injection site and antigen released over time to stimulate 
and be endocytosed by antigen-presenting cells (Marciani, 2003). Aluminium salt 
adjuvants primarily increase antibody production via activating the inflammasome, and 
are therefore suitable for vaccines targeting pathogens killed primarily by antibodies. 
However, aluminium-adjuvanted vaccines have not been successful in preventing 
infection due to intracellular pathogens requiring a Cell-mediated response (Marrack et 
al., 2009, Pasquale et al., 2015). Furthermore, although the antigen-depot effect of alum 
is associated with relatively mild tissue inflammation at the site of injection, there is 
increasing concern about allergic reactions to aluminium-based adjuvants (Lycke, 2007). 
MF59, the adjuvant used in the Chiron HSV vaccine, is an oil-in-water emulsion of 
Squalene sourced from shark liver oil, but is also found in human tissues such as adipose 
tissues, skin, arterial walls, skeleton, muscles and lymph nodes. Its major immune effects 
are increased antigen-presenting cell activation, and promoting antigen uptake and 
migration of cells to lymph nodes (Pasquale et al., 2015).  
 It is becoming increasingly recognised that in the 21st century, more sophisticated 
approaches are required to develop successful vaccines against challenging pathogens 
such as malaria, tuberculosis, HIV and HSV. Deeper understanding of the characteristics 
of the pathogens themselves and the characteristics of the target immune cell populations 
are required, to tailor the immune response elicited by the vaccine to meet the specific 
requirements of each disease (Pasquale et al., 2015). More effective targeting of the 
immune response is achieved by using adjuvants containing PAMPs recognised by PRRs 
on antigen-presenting cells (Marciani, 2003). The role of TLRs in innate immunity and 
their ability to trigger a variety of host responses was discussed previously. In the same 
way that TLRs are important in the initiation of innate immune responses to pathogens 
and hence the ensuing adaptive response, they also play an important role in the 
functioning of many adjuvants (Moyle and Toth, 2008). Thus, the development of 
adjuvants that specifically target TLRs and innate immunity could greatly advance the 
development of vaccines. Currently, the TLR4 agonist monophosphoryl lipid A (also 
used in Simplirix) has been approved as an adjuvant component in a hepatitis B vaccine 
and an HPV vaccine (Casella and Mitchell, 2008, Didierlaurent et al., 2009, Lester and Li, 
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2014). The TLR9 agonist CpG ODN is also being used as an adjuvant in the hepatitis B 
vaccine, Hepislav, which is in phase III clinical trials (Cooper and Mackie, 2011, Lester 
and Li, 2014). In a guinea pig model, the TLR7/8 agonist imiquimod was shown to be an 
effective adjuvant in a therapeutic HSV glycoprotein vaccine, with reduction in the 
frequency of HSV2 recurrence (Bernstein et al., 1995, Harrison et al., 2001, Melchjorsen, 
2012) but failed in human trials (personal communications, Cunningham A.L.). A more 
rational selection of antigens and adjuvants will lead to the development of new vaccines 
targeting diseases against which older vaccine technologies were ineffective (Pasquale et 
al., 2015). 
1.3.3  Self-adjuvanting lipopeptide vaccines 
 The discovery that some lipid structures are powerful adjuvants has led to their 
attachment to peptide antigens in the effort to produce “self-adjuvanting” lipopeptide 
vaccines (Jackson et al., 2004, Moyle and Toth, 2008). In addition to their adjuvant 
capabilities, the observation that lipopeptides seem to be well tolerated and do not exhibit 
harmful side effects has also brought attention to their potential use in vaccines (Chua et 
al., 2007, Moyle and Toth, 2008). In particular, the selection of TLR2-targeting adjuvants 
for peptide vaccines has focussed on bacterial lipopeptides and their synthetic analogues 
(Zaman and Toth, 2013). Two HIV lipopeptide vaccines have been tested in human trials. 
Both were safe and well tolerated, and were capable of increasing CD4+ and CD8+T cell 
responses to HIV epitopes, even in HIV2 chronically infected patients (Gahery et al., 
2006, Richert et al., 2013, Salmon-Ceron et al., 2010). A meningococcal B recombinant 
lipoprotein vaccine has also been shown to be safe, well tolerated and immunogenic in a 
phase II trial (Richmond et al., 2012). 
	 Di-palmytoyl-S-glycerylcysteine or Pam2Cys is a synthetic analogue of the lipid 
moiety of Macrophage Activating Lipopeptide 2 (MALP2) derived from Mycoplasma 
(M.) fermentans and is a ligand for TLR2 coupled with TLR6 (Moyle and Toth, 2008). 
Clinical trials have shown that Pam2Cys and MALP2 are well tolerated and safe to use, 
with few or no side effects (Schmidt et al., 2007, Seth, 2000). In a comparison of 
Pam2Cys and the TLR4 agonist LPS, LPS induced a fever response in rabbits whereas 
Pam2Cys showed no discernible pyrogenic or other acute toxic effect (Wu et al., 2010). 
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Pam2Cys also lacked detectable pro-inflammatory activity, unlike TLR8 agonists, which 
were pro-inflammatory and could exert systemic toxicity (Hood et al., 2010). All of these 
properties make Pam2Cys a good candidate for use as an adjuvant in vaccine candidates 
against HSV. 	
Pam2Cys lipopeptides have been studied by numerous investigators and have 
been shown to be effective in priming immunity against a variety of pathogens and 
stimuli such as viruses (Alphs et al., 2008, Day et al., 2007), bacteria (Batzloff et al., 
2006), M.tuberculosis (Tyne et al., 2013), tumours (Jackson et al., 2004), and for the 
modulation of hormone action in immunocontraceptive vaccines (Chua et al., 2007, Zeng 
et al., 2002, Zeng et al., 2007). Pam2Cys lipopeptides induce DC maturation (Chua et al., 
2008b, Jackson et al., 2004, Jones et al., 2008, Lau et al., 2006), followed by the 
triggering of various targeted immune responses, depending on the peptide epitopes used. 
In some studies, CD4+T cells responded predominantly in a Th1 manner with production 
of IFN-γ (Gowthaman et al., 2011, Jones et al., 2008, Zhu et al., 2004). In others they 
responded in a Th2 manner with production of IL-13 and IL-4 (Redecke et al., 2004, 
Wenink et al., 2009). CD4+T cells can also respond in a Th17 manner with production of 
IL-17 (Reynolds et al., 2010, Wenink et al., 2009). A lipopeptide based on the M2 protein 
of influenza induced a robust antibody response, as the peptide contained an epitope that 
induced CD4+T cells able to promote B cell responsiveness (Pejoski et al., 2010). 
Likewise, other studies have demonstrated antibody responses to lipopeptides (Jackson et 
al., 2004, Zeng et al., 2012). Importantly, lipopeptides have also been shown to induce 
CD8+T cell responses and long-lived memory responses when CD8 epitopes have also 
been incorporated in the lipopeptides (Chua et al., 2008a, Deliyannis et al., 2006, Jackson 
et al., 2004, Lau et al., 2006, Tan et al., 2012, Zhang et al., 2009b, Zhang et al., 2012). In 
addition, our laboratory has unpublished data showing that Pam2Cys enhances cross-
presentation of peptides to CD8+T cells. 
There is no commercially available adjuvant that stimulates CD8+T cells. This is 
important in the context of HSV since both CD4+ and CD8+T cells are likely to be 
important for optimal clearance of HSV from skin and the nervous system (as discussed 
previously). Therefore, an appropriately designed vaccine should target both cell types, 
and Pam2Cys could be a good candidate adjuvant to achieve this goal. An illustration of 
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Pam2Cys lipopeptide uptake by DCs and presentation to CD4+ and CD8+T cells is 
presented in Figure 1.4. 
 
Figure 1.4.  Pam2Cys lipopeptide uptake by DCs and presentation to CD4+ and 
CD8+T cells. Pam2Cys lipopeptide is taken up by immature DCs via TLR2, resulting in 
DC maturation. This involves processing the lipopeptide to display peptide epitopes on 
MHC molecules alongside costimulatory molecules to T cells. Epitopes recognised by 
CD4+T cells are loaded onto MHC Class II molecules, allowing CD4+T cells to become 
activated and respond. Likewise, epitopes recognised by CD8+T cells are loaded onto 
MHC Class I molecules, allowing CD8+T cells to become activated and respond. CD4+T 
cells also produce cytokines that “help” CD8+T cells, resulting in their enhanced 
activation and proliferation. This results in a Cell-mediated immune response with CTLs 
primed to respond to infection (Zaman and Toth, 2013). 
	
1.3.4  Development of a lipopeptide vaccine 
 Previously in our lab, immunodominant peptide epitopes of HSV2 gD (gD2) that 
were recognised by CD4+T cells from both HSV1 and HSV2 seropositive individuals 
were identified (Kim et al., 2008). A set of 39 overlapping 20-mer peptides spanning the 
entire gD2 amino acid sequence was screened. Four of the 20-mers 2, 24, 30 and 34 
(underlined in Figure 1.5) were subject to fine mapping using a panel of 9 internal 12-
mers for each 20mer. More than one epitope was found in each 20-mer and the epitopes 
bound to multiple HLA-DR types. In particular, the 12-mers 24-4 and 30-5 (highlighted 
in boxes in Figure 1.5) were selected for use in subsequent studies. Both of these peptides 
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bound to a broad range of HLA-DR molecules and were cross-reactive, recognised by 
both HSV1 and HSV2 infected individuals due to sequence homology. To enhance their 
immunogenicity, these peptides were conjugated to Pam2Cys in collaboration with David 
Jackson’s laboratory, at the University of Melbourne. 
 
Figure 1.5. The amino acid sequence of gD2 and identified peptides. The amino acid 
sequence of gD2 with key 20-mer peptides 2, 24, 30 and 34 underlined. Nine 12-mers 
were synthesised from each of these 20-mer peptides (Kim et al., 2008). Two of the 12-
mer peptides: 24-4 (blue box) and 30-5 (red box) were used in our subsequent study (Kim 
et al., 2012). 
 
1.4 Natural killer cells 
1.4.1  Previous findings in response to an HSV lipopeptide 
 We previously demonstrated that Pam2Cys conjugation of immunodominant gD2 
peptides stimulated CD4+T cell IFN-γ responses within the mixed population of 
peripheral blood mononuclear cells (PBMC) or in coculture with monocyte-derived DCs 
(MDDCs). Interestingly, NK cells were found to contribute markedly to PBMC responses, 
as depletion of the NK cells markedly decreased the IFN-γ response. Furthermore, NK 
cells alone were able to directly respond to the Pam2Cys-conjugated gD2 peptides with 
production of IFN-γ and upregulation of the MHC Class II molecules HLA-DR and 
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HLA-DQ. In coculture experiments, the presence of NK cells with lipopeptide-stimulated 
MDDCs and CD4+T cells significantly enhanced the CD4+T cell responses above those 
induced by coculture of MDDCs and CD4+T cells only. NK cells could also significantly 
activate CD4+T cell responses in the absence of MDDCs. Immunological synapse (IS) 
formation was observed between lipopeptide-stimulated NK cells and CD4+T cells, and 
in a recurrent herpes lesion biopsy a large proportion of NK cells were seen in contact 
with CD4+T cells in the dermal infiltrate. Therefore, NK cells were shown to respond to 
the TLR2-stimulating Pam2Cys-conjugated gD2 peptides and could present antigen to 
CD4+T cells alone and enhance activation mediated by DCs (Kim et al., 2012).  Selected 
results from this publication can be viewed in Figure 1.6. Another investigator in our 
laboratory showed that the Pam2Cys-conjugated gD2 peptides were also cross-presented 
to CD8+T cells, inducing multi-functional responses with the production of cytokines 
IFN-γ, TNF and IL-2, and increased cytotoxicity shown by the degranulation marker 
CD107a/b (Bertram, 2014). 
Our findings regarding NK cells were novel, as NK cell responses to TLR 
agonists had not been widely studied. Furthermore, the mechanism of Pam2Cys 
activation of NK cells and the induction of cross-talk between NK cells with DCs and 
CD4+T cells was not understood. Therefore, a more fundamental investigation of NK 
cells and their responses to Pam2Cys lipopeptides was required. 
 
 
 
 
 
 
 
 
Figure 1.6. Selected previous findings in response to Pam2Cys lipopeptides. (A) IFN-
γ ELISPOT in response to gD2 peptide, with or without Pam2Cys when MDDCs, NK 
cells and CD4+T cells were cultured in different combinations (MDDC-CD4+T, MDDC-
CD4+T-NK, NK-CD4+T, MDDC alone, CD4+T alone and NK alone). (B) The expression 
of CD69 on CD4+T cells in response to gD2 peptide, Pam2Cys-conjugated gD2 peptide 
or DMSO as negative control, when CD4+T cells were cultured with NK cells (left panel) 
or alone (right panel). (C) Pam2Cys conjugated gD2 peptide-stimulated NK cell-gD2 
peptide-specific CD4+T cell conjugates showing an IS. (D) Direct contact of CD4+T cells 
and NK cells in the dermal infiltrate of a recurrent herpes lesion. NK cells (green) are 
adjacent to and in contact with CD4+T cells (red) at 40x magnification (left panel) and 
100x magnification (right panel) (Kim et al., 2012). 
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1.4.2  NK cell fundamentals 
 A. Functions 
NK cells account for 10-15% of peripheral blood lymphocytes (Dalbeth et al., 
2004). Their antiviral activities involve both direct lysis of infected target cells and 
release of antiviral cytokines (Degli-Esposti and Smyth, 2005). In humans, they are 
defined phenotypically by their expression of CD56 and lack of expression of CD3 
(Cooper et al., 2001). 
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B. Activating and inhibitory receptors 
 The engagement of surface activating and inhibitory receptors regulates NK cell 
activity, as well as the ligation of various adhesion and costimulatory molecules (Vivier 
et al., 2008, Cooper et al., 2001). Activating receptors detect ligands on cells in “distress”, 
such as stress-induced self-ligands ULBP (UL-16 binding protein), MIC-A (Major 
Histocompatibility Complex (MHC) class I chain-related A) and MIC-B (Vivier et al., 
2008, Luci and Tomasello, 2008). Other alert molecules include infectious non-self 
ligands such as viral peptides (Vivier et al., 2008). Activating receptors are divided into 
those that interact with immunoreceptor tyrosine-based activatory motif (ITAM)-bearing 
polypeptides including CD16, NKG2C/CD94, NKp30, NKp44 and NKp46, and those 
interacting with non-ITAM-bearing polypeptides including NKG2D, 2B4 and CD2 
(Krzewski and Strominger, 2008, Carrega et al., 2008). 
 NK inhibitory receptors prevent NK cell activation on encounters with normal 
MHC class I molecules and detect the absence of these molecules on susceptible target 
cells (Vivier et al., 2008). Inhibitory receptors have cytoplasmic immunoreceptor 
tyrosine-based inhibitory motifs (ITIMs) (Krzewski and Strominger, 2008). They include 
the Killer cell Ig-like receptors (KIRs) and the CLR family receptor NKG2A-CD94 
(Vivier et al., 2008, Krzewski and Strominger, 2008). KIRs recognise the MHC class I 
molecules HLA-A, -B and -C, and the NKG2A-CD94 receptors recognise HLA-E 
(Carrega et al., 2008, Cooper et al., 2001). Downregulation of MHC class I molecules on 
target cells commonly occurs during viral infection, releasing NK cells from inhibitory 
signals and allowing lysis of target cells (Robertson, 2002). 
C. Subsets  
 Human NK cells have been divided into two main subsets based on their relative 
expression of CD56, as well as other markers (Luci and Tomasello, 2008). These subsets 
are referred to as CD56dimCD16+ and CD56brightCD16-/dim (Figure. 1.7) (Vivier et al., 
2008). CD56dim NK cells are the major portion of NK cells in peripheral blood (≥95%), 
whereas ≤5% are CD56bright (Carrega et al., 2008). However, CD56bright NK cells 
constitute 75% of NK cells present in lymph nodes (LN) and tonsils. (Brilot et al., 2008).   
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Figure 1.7.	 	CD56bright and CD56dim NK 
cell	subsets. NK cells can be divided into 
two subsets based on relative CD56 
expression. CD56dimCD16+ cells comprise  
≥95% of total circulating NK cells, 
whereas CD56brightCD16-/dim cells 
comprise ≤5% of total NK cells in 
circulation (Cooper et al., 2001). 
 
 
 
CD56dim NK cells express higher levels of perforin, granzymes, cytolytic granules 
and CD16 than CD56bright NK cells, with potent cytolytic functions against infected or 
tumour target cells (Cooper et al., 2001, Poli et al., 2009). CD56bright NK cells do not 
exert cytolytic functions, although they can acquire cytotoxicity after prolonged 
activation with IL-2 (Hanna and Mandelboim, 2007, Strowig et al., 2008a). Instead, they 
are the primary source of NK cell-derived immunoregulatory cytokines including IFN-γ, 
TNF, lymphotoxin, IL-10, IL-13 and granulocyte macrophage-colony stimulating factor 
(GM-CSF) (Cooper, 2001), particularly in response to cytokine stimulation by IL-12 and 
IL-18 (Poli et al., 2009). 	
 CD16 or the low-affinity Fc IgG receptor FcγRIII, expressed on the CD56dim 
subset is important for antibody-dependent cell-mediated cytotoxicity (ADCC) (Vivier et 
al., 2008). Ligation of CD16 by antibody-coated target cells results in signalling via 
CD3ζ and FcεR1γ chains, resulting in increased intracellular calcium, tyrosine 
phosphorylation of phospholipase-γ1 and γ2, and generation of inositol triphosphate 
(Borrego et al., 1994, Cassatella et al., 1989, Mota et al., 2004, O'Shea et al., 1991, Vivier 
et al., 1991). These early signalling events are followed by expression of activation 
antigens, cytokine production and lysis of antibody-coated target cells by ADCC 
(Anegon et al., 1988, Borrego et al., 1994, Cecchetti et al., 2007, Mota et al., 2004, 
Romee et al., 2013).  
Both CD56bright and CD56dim NK cells express the activating receptors NKG2D, 
NKp30 and NKp46 (Strowig et al., 2008b).  However, they exhibit differential expression 
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of other receptors. CD56bright NK cells have high level expression of CD94-NKG2A 
inhibitory receptors and L-selectin, which mediates interactions with vascular 
endothelium.  However, <10% express KIR activating receptors.  In contrast, >85% of 
resting CD56dim NK cells are KIR+ but have low-level expression of CD94-NKG2A 
inhibitory receptors. Additionally, CD56dim NK cells lack L-selectin but express PEN5, 
which, in combination with P-selectin glycoprotein ligand 1 (PSGL-1), mediates binding 
to L-selectin. This implies a potential interaction between L-selectin+ CD56bright NK cells 
and PEN5-PSGL-1+ CD56dim NK cells, which has not been characterised. CD56dim NK 
cells also have high expression of the adhesion molecule leukocyte function-associated 
antigen-1 (LFA-1) compared to CD56bright NK cells (Cooper, 2001, Cooper et al., 2001, 
Poli et al., 2009). 
 All NK cells express a functional heterodimeric IL-2 receptor (IL-2Rβγ) with 
intermediate affinity for IL-2. However, CD56bright NK cells also express a high affinity 
IL-2 receptor (IL-2Rαβγ or CD25), and respond to picomolar amounts of IL-2 with 
proliferation and IFN-γ production. CD56bright NK cells also express the c-kit receptor 
tyrosine kinase whose ligand (Stem Cell Factor, SCF) enhances IL-2-induced 
proliferation. In contrast, CD56dim cells are c-kit negative and proliferate weakly in 
response to high (nanomolar) levels of IL-2 (Cooper, 2001). IL-7 receptor α (IL-7Rα) is 
also exclusively expressed on CD56bright NK cells, enabling IL-7 to promote the survival 
of this subset (Michaud et al., 2010). 
A summary of differences in receptor expression and function between CD56bright 
and CD56dim NK cells can be seen in Figure 1.8. 
 
Figure 1.8.  Receptors on CD56bright and CD56dim NK cells. (A) CD56bright NK cells 
have low-density CD16 and KIRs, but high-level expression of CD94-NKG2A inhibitory 
receptor. They uniquely express the high-affinity IL-2 receptor (IL-2Rαβγ), chemokine 
receptor CCR7 and L-selectin. Functionally, CD56bright NK cells produce high levels of 
cytokines and exhibit low cytotoxicity and ADCC. (B) CD56dim NK cells have high-
density CD16 and KIR expression. They express only the intermediate affinity IL-2 
receptor (IL-2Rβγ) and chemokine receptors CXCR1 and CX3CR1, lack L-selectin but 
express PEN5-PSGL-1, a different adhesion molecule. Functionally, CD56dim NK cells 
produce low levels of cytokines, but are potent mediators of cytotoxicity and ADCC 
(Cooper et al., 2001). 
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In 2016, an updated review of CD56bright NK cells commented that the lineage 
relationship between CD56bright and CD56dim NK cells remains unresolved. That is, 
whether CD56bright are precursors of CD56dim, or whether they are two separate NK cell 
lineages with different origins and properties (Michel et al., 2016). Several lines of 
evidence support the first hypothesis of a linear-differentiation model where CD56bright 
NK cells mature to become CD56dim NK cells. The CD56bright subset is the major NK cell 
population derived early in vitro when CD34+ haematopoietic precursor cells are cultured 
with IL-15 in NK development supportive conditions, whereas the CD56dim subset 
develops later over time (Mrozek et al., 1996). The CD56bright subset accumulates earlier 
in blood following bone marrow or stem cell transplantation than the CD56dim subset 
(Dulphy et al., 2008). CD56bright NK cells have longer telomeres than CD56dim NK cells, 
suggesting that CD56dim NK cells have undergone more rounds of proliferation than 
CD56bright NK cells (Ouyang et al., 2007, Romagnani et al., 2007). Purified CD56bright NK 
cells can develop into CD56dim NK cells both in vitro and in vivo (Chan et al., 2007, 
Huntington et al., 2009). Finally, NK cells with intermediate features between CD56bright 
and CD56dim have been described in adult human blood. CD94highCD56dim NK cells 
express CD62L (L-selectin), CD2, KIR, IFN-γ, perforin and granzyme B at levels 
between CD56bright and CD94lowCD56dim NK cells (Yu et al., 2010). Similarly, it has been 
proposed that CD56brightCD16+ NK cells are a functional intermediate, able to kill target 
cells by both ADCC and direct lysis, unlike CD56brightCD16- NK cells. These cells were 
generated in the presence of autologous T cells in in vitro experiments (Beziat et al., 
2011). 
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However, the possibility that CD56bright and CD56dim NK cells represent distinct 
terminal maturation pathways in the NK cell lineage has not been formally disproven 
(Freud et al., 2014). An argument in favour of the two subsets having different 
haematopoietic origins is the observation that patients with GATA2 mutations have a 
selective absence of CD56bright NK cells, suggesting ontogenic independency, although 
CD56dim subsets in these patients were reduced in number and functionally impaired 
(Mace et al., 2013). A more recent study confirmed that GATA2 was expressed at higher 
levels in CD56bright than CD56dim NK cells (Maciejewski-Duval et al., 2016). Whilst it is 
commonly understood that NK cells are derived from common lymphoid progenitors, it 
has also been shown that common myeloid progenitors can directly differentiate into NK 
cells with features of the CD56dim subset, with higher cytotoxicity and KIR expression 
(Grzywacz et al., 2011, Michel et al., 2016). 
Whilst a lot of evidence supports CD56bright NK cells being less mature or a 
precursor to CD56dim NK cells, there may be some plasticity in the process of NK cell 
development. That is, more than one differentiation pathway may be capable of inducing 
the development of the CD56bright and CD56dim NK cell subsets. 
1.4.3  NK cell complexities: more than an innate killer 
A. TLRs 
	 Although it is well known and understood that NK cells are activated by target 
cells via activating receptors and a lack of inhibitory signals, NK cells directly 
responding to TLR ligands have been less studied. A number of TLRs were shown to be 
expressed in NK cells at the mRNA level by Hornung et al., particularly TLR1, TLR2, 
TLR3, TLR5 and TLR6 (Hornung et al., 2002). Since then, a number of studies have 
shown that NK cells respond to a number of TLR2 agonists, including Leishmania (L.) 
major lipophosphoglycan (LPG) (Becker et al., 2003), Klebsciella (K.) pnemoniae outer 
membrane protein A (KpOmpA) (Chalifour et al., 2004), peptidoglycan (PGN) (Lauzon 
et al., 2006) M. bovis bacille Calmette–Guerin (BCG) (Marcenaro et al., 2008), diacyl 
lipopeptides (Azuma et al., 2010), Helicobacter (H.) pylori lipoprotein HpaA (Lindgren 
et al., 2011), and heat-killed Staphylococcus (S.) aureus (HKSA) (Souza-Fonseca-
Guimaraes et al., 2012). TLR2 agonists were shown to induce NK cell production of IFN-
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γ and TNF (Becker et al., 2003, Chalifour et al., 2004, Marcenaro et al., 2008, Lauzon et 
al., 2006, Azuma et al., 2010, Lindgren et al., 2011, Souza-Fonseca-Guimaraes et al., 
2012), α-defensin production (a bactericidal peptide) (Chalifour et al., 2004) and the 
killing of target cells and immature DCs (Lauzon et al., 2006, Marcenaro et al., 2008). 	
Likewise, studies have shown that NK cells respond to the TLR3 agonist 
polyinosinic-polycytidylic acid (poly[I:C]) (Lauzon et al., 2006, Neves et al., 2009, 
Schmidt et al., 2003, Sivori et al., 2004, Zhang et al., 2007a), the TLR5 agonist flagellin 
(Lauzon et al., 2006, Tsujimoto et al., 2005), TLR7/8 agonists such as R848 and 
imiquimod (Gorski et al., 2006, Hart et al., 2005, Schlaepfer and Speck, 2008) and the 
TLR9 agonist CpG (Lauzon et al., 2006, Neves et al., 2009, Sivori et al., 2004). Thus, 
another pathway for activation of NK cells appears be direct recognition of microbial 
products via TLRs. 
 B. Antigen-presenting cell 
Over a decade ago, it was reported that NK cells had the ability to directly cross-
talk with CD4+T cells and had antigen-presenting characteristics. Gene expression 
profiling of both CD56bright and CD56dim subsets revealed that the CD56bright subset in 
particular had upregulated expression of genes in the MHC class II family- HLA-DRA, 
HLA-DRB, HLA-DMA, HLA-DPA, HLA-DQA, HLA-DPB and CD74. Additionally, 
activated CD16+ NK cells expressed genes for costimulatory signals required for T cell 
activation: OX40L, CD70 and CD86 (Hanna et al., 2004a). The same investigators then 
demonstrated that NK cells were able to directly regulate T cell activation. Activated NK 
cells upregulated surface MHC class II molecules and costimulatory ligands CD80, CD86, 
CD70 and OX40L. Blocking CD80 and CD86 reduced NK cell-mediated T cell 
activation. NK cells were shown to acquire antigen-presenting properties after target-cell 
killing and in vivo expression of MHC class II and costimulatory molecules on human 
NK cells was demonstrated by isolating NK cells from inflamed tonsils (Hanna et al., 
2004b). We also showed that NK cells expressed MHC class II molecules and directly 
activated CD4+T cells in the absence of other antigen-presenting cells in response to 
stimulation with HSV lipopeptides (Kim et al., 2012). Other investigators have also 
documented the expression of MHC class II on NK cells (Zingoni et al., 2004, Burt et al., 
2008) and have further characterised costimulatory receptor-ligand interactions.   
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Zingoni et al. studied the interaction between OX40 on CD4+T cells and OX40L 
on NK cells. OX40L was present on activated NK cells, when the activating receptors 
NKp30, NKp44, NKp46, CD16 or activating KIRs were engaged. The authors suggested 
that since OX40 is a major regulator of anti-apoptotic proteins such as Bcl-xL and Bcl-2, 
the OX40-OX40L interaction might be important for T cell survival. OX40-OX40L also 
induced the production of IFN-γ and not IL-4 from activated T cells, suggesting the 
interaction induced Th1 polarisation (Zingoni et al., 2004). Assarsson et al. studied the 
interaction between 2B4 expressed on NK cells and CD48 on CD4+T cells. 2B4 (or 
CD244) is a cell surface glycoprotein from the CD2 subset of Ig family receptors. The 
interaction appeared to play a role in the proliferation of CD8+ and CD4+T cells, as 
addition of anti-2B4 or anti-CD48 antibodies inhibited T cell proliferation. The authors 
concluded that although cross-linking of 2B4 on NK cells stimulated lytic activity, IFN-γ 
secretion and granule exocytosis, the function of 2B4 engagement on T cells was not 
clear (Assarsson et al., 2004).   
These studies all provided intriguing evidence for direct NK cell cross-talk with 
CD4+T cells, and the capability of presenting antigen, driving adaptive responses. 
However, much remains to be determined regarding the mechanisms of NK cell antigen 
processing and presentation. 
C. Innate or adaptive? 
 Although NK cells have been classified as innate immune cells, recent evidence 
suggests NK cell might also have memory-like or adaptive-like responses (Campbell and 
Hasegawa, 2013). Romee et al. reported that cytokine-activated NK cells had functional 
memory-like properties. NK cells that were preactivated with cytokine combinations 
including IL-12, IL-15 and IL-18, followed by a 7 to 21-day rest, had enhanced IFN-γ 
production after restimulation with IL-12+IL-15, IL-12+IL-18 or K562 leukaemia cells. 
In CD56dim NK cells, the memory-like IFN-γ response was correlated with expression of 
CD94, NKG2A, NKG2C, and CD69, whilst lacking CD57 and KIR (Romee et al., 2012). 
In a recent phase I clinical trial, adoptively transferred cytokine-induced memory-like NK 
cells proliferated and expanded in patients with acute myeloid leukaemia and generated 
robust responses against leukaemia targets (Romee et al., 2016). Another recent study has 
shown that infection with human cytomegalovirus (HCMV, a betaherpesvirus) induces 
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“adaptive” NKG2C+ NK cells with features in common with CD8+T cells, demonstrated 
by studies of genome-wide epigenetic diversification. These adaptive subsets had altered 
cytokine responsiveness and reduced ability to recognise and eradicate autologous 
activated T cells. However, these adaptive NK cells appeared to be specialised for 
recognition of HCMV infected cells (Schlums et al., 2015). Thus, NK cells are capable of 
responding in both innate and adaptive-like ways, highlighting the complex mechanisms 
involved in NK cell activation and function, as well as a blurring of the lines between 
defining “innate” and “adaptive” immune responses. 
1.4.4  NK cell cross-talk 
 A. NK-DC interactions 
NK cells and DCs have been shown to reciprocally activate one another. A wide 
variety of microbial stimuli and signalling can induce DC maturation and the production 
of cytokines. Mature DCs can then activate resting NK cells to produce cytokines, 
proliferate and increase their cytotoxic capacity via both cell-contact dependent and 
independent signals (Brilot et al., 2008). The DC cytokines IL-12, IL-18, IL-15 and Type 
I IFN are particularly important. IL-12 induces IFN-γ secretion and proliferation in NK 
cells (Strowig et al., 2008b, Walzer et al., 2005).  IL-12 acts in synergy with IL-2 to 
enhance IFN-γ production and provides IFN-γ mRNA stability as well as enhancing 
cytotoxicity (Loza and Perussia, 2004).  IL-18 also induces IFN-γ secretion in NK cells, 
but unlike IL-12 does not affect cytotoxicity and induces a helper phenotype with 
expression of CD83 and CCR7 (Hanna and Mandelboim, 2007, Mailliard et al., 2005). 
IL-15 is important for NK cell survival and proliferation and can be found polarised at the 
IS between mature DCs and NK cells (Brilot et al., 2008, Brilot et al., 2007). The main 
Type I IFN secreting cells are pDCs, and NK cell cytotoxicity is preferentially enhanced 
via this cytokine (McKenna et al., 2005, Gerosa et al., 2005, Ferlazzo and Munz, 2009). 
Activation of NK cells is also dependent on contact with mature DCs (Piccioli et al., 
2002). Cross-talk between DCs and NK cells, mediated by direct contact and delivery of 
DC-derived cytokines (IL-12, IL-15 and IL-18) requires the formation of a DC-NK IS 
(Krzewski and Strominger, 2008). Each of these cytokines has been observed polarised at 
the DC-NK IS (Borg et al., 2004, Brilot et al., 2007, Semino et al., 2005).    
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Reciprocally, activated NK cells are able to induce DC maturation via secretion of 
IFN-γ and TNF (Brilot et al., 2008, Carrega et al., 2008). The engagement of NKp30 on 
NK cells by DCs triggers NK cell cytokine production, particularly TNF (Vitale et al., 
2005). TNF induces DC maturation by enhancing DC expression of the maturation 
marker CD83 as well as costimulatory molecules such as CD80 and CD86, important for 
their ability to present antigen to adaptive immune cells (Sato, 1999). IFN-γ induces 
increased production of MHC Class I and II molecules on DCs, which are also critical for 
their antigen-presenting capabilities (Schroder, 2004). The proinflammatory cytokine 
high mobility group B1 (HMGB1) has also been shown to be a key mediator of NK cell 
induced DC maturation (Semino et al., 2005, Semino et al., 2007). 
Immature DCs can also be killed by activated NK cells, dependent on the NK cell 
activating receptors NKp30 and NKp46 (Ferlazzo and Munz, 2009, Spaggiari et al., 
2001). Mature DCs are protected from NK cell cytotoxicity due to the upregulation of 
MHC class I molecules (Ferlazzo et al., 2002). Interestingly, it has been shown that the 
killing of immature MDDCs is confined to an NK cell subset expressing CD94/NKG2A 
but lacking KIR, which is characteristic of the CD56bright subset (Della Chiesa et al., 
2003). Furthermore, NK cell-dependent killing of immature DCs involves the 
TRAIL/DR4 signalling pathway and is not perforin dependent. CD56bright NK cells tend 
to have a much higher expression of TRAIL than CD56dim NK cells, however after 
contact with DCs both subsets express TRAIL suggesting that the killing of immature 
DCs is not restricted to the CD56bright subset (Melki et al., 2010). Nevertheless it is very 
interesting that the CD56bright subset, classically defined as non-cytolytic due to low 
perforin-mediated killing, are adept at TRAIL-mediated killing of immature DCs. NK 
cell-mediated killing of immature DCs is referred to as “DC editing” and is thought to be 
an immune regulatory mechanism important for controlling downstream adaptive 
immune responses (Della Chiesa et al., 2003).  
Apart from DCs, NK cells have also been shown to cross-talk with monocytes, 
macrophages and neutrophils via both cytokine stimulation and cell-to-cell contact 
(Bellora et al., 2010, Costantini and Cassatella, 2011, Costantini et al., 2011, Kloss et al., 
2008, Nedvetzki et al., 2007). 
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B. NK-T cell interactions 
As mentioned previously, IL-2 is important for NK cell proliferation and 
stimulates IFN-γ secretion. CD56bright NK cells are particularly responsive due to the 
expression of high-affinity IL-2Rαβγ. IL-2 is secreted by antigen-activated CD4+T cells 
in the LN (Fehniger et al., 2003). In response to IL-2 produced by activated CD4+T cells, 
NK cells are induced to secrete IFN-γ, which in turn directs CD4+T cells to a Th1 
response by inducing CD4+T cell production and secretion of IFN-γ along with IL-12 
from DCs (Hanna and Mandelboim, 2007, Zingoni et al., 2005). Our laboratory were the 
first to report the formation of an IS between isolated NK cells and CD4+T cells, with the 
polarisation of talin and CD4 molecules at the interface. Furthermore, NK cells and 
CD4+T cells were observed in contact with each other in a recurrent herpes lesion biopsy 
(Kim et al., 2012). As discussed in the section on antigen presentation, there are 
candidate receptor-ligand pairs that may be involved in providing costimulatory 
signalling to CD4+T cells by NK cells in response to antigen. 
Considering that interactions have been characterised between NK cells and DCs, 
DCs and CD4+T cells, and NK cell and CD4+T cells, in a physiological setting, one could 
envisage that interactions may in fact occur between all three cell types in fairly close 
proximity (Assarsson et al., 2004). Indeed, we showed that in vitro coculture of NK-DC-
CD4+T cells augmented the activation of CD4+T cells (Kim et al., 2012). On a cytokine 
level, NK cells depend on a cytokine microenvironment consisting of cytokines from 
both DCs and CD4+T cells, namely IL-2, IL-12, IL-15, IL-18 and IFN-γ, for their 
activation, proliferation and survival (Vivier et al., 2008). Furthermore, after NK cell 
activation by DCs, the IFN-γ they secrete stimulates CD4+T cells to develop a Th1 
response (Strowig et al., 2008b). Similarly, early NK cell-mediated cytokine production 
of IFN-γ and TNF that promotes optimal DC maturation would also result in priming of a 
Th1 adaptive response (Marcenaro et al., 2008). 
Regarding cell-to-cell contacts, it has been observed that IFN-γ secreting NK cells 
that are recruited to LN upon infection with Leishmania contact the same DCs as antigen-
specific CD4+T cells (Strowig et al., 2008b). T cells could receive their activation signals 
from DCs with additional signals from NK cells, or perhaps activated NK cells might 
fine-tune T cell activation and costimulation (Assarsson et al., 2004, Hanna et al., 2004b). 
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Certainly, much remains to be characterised about the nature of the simultaneous 
interactions between these three cell types. 
1.4.5  NK cells in skin and HSV infection 
 The immune cells present in the skin are the key effectors involved in the immune 
response to skin infiltrating pathogens such as HSV. The recruitment of immune effectors 
to the skin requires the expression of chemokine receptors that follow the chemokine 
gradient produced by keratinocytes and other cells resident to the skin (Heath and 
Carbone, 2013). The chemokine receptor repertoire of both subsets of NK cells has been 
known for some time. CD56dim NK cells express CXCR1 and CX3CR1, which migrate in 
response to the chemokines IL-8 and fractalkine respectively, which would allow them to 
migrate to inflammatory sites (Campbell et al., 2001). CD56bright NK cells express CCR7 
and L-selectin, which allow them to traffic to SLO (Campbell et al., 2001, Strowig et al., 
2008b). However, CD56bright NK cells also express CCR5, which would allow them to 
migrate to inflammatory sites in response to the chemokines Macrophage Inflammatory 
Protein (MIP)-1α, MIP-1β and RANTES (Dalbeth et al., 2004). The expression of these 
chemokine receptors indicates that both NK cell subsets have the potential to home to 
skin and the genital tract, particularly under inflammatory conditions. Tseng et al. showed 
that NK cells were present in the genital tract in mice during chlamydial infection and 
that they provided a major source of IFN-γ early in the infection and were also necessary 
for the development of the Th1 CD4+T cell response and control of infection (Tseng and 
Rank, 1998). Interestingly, MyD88 deficiency, a critical mediator of TLR signalling 
pathways, resulted in recruited NK cells failing to produce IFN-γ, as well as impaired 
recruitment of CD4+T cells to the genital tract and delayed clearance of infection 
(Nagarajan et al., 2011). A study in rhesus macaques showed that CD16- NK cells, 
phenotypically similar to human CD56bright NK cells, were enriched in rectal and vaginal 
mucosal tissues and SLO in both uninfected and SIV-infected animals, however they 
were functionally altered during chronic SIV infection (Reeves et al., 2010).  
 A number of human studies have shown that NK cells of a CD56brightCD16- 
phenotype infiltrate into inflammatory sites. A study showed that CD56bright NK cells 
were enriched in a number of inflammatory sites in a variety of clinical diseases, such as 
pleural fluid in malignant pulmonary disease, synovial fluid and tissue in patients with 
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inflammatory arthritis, and peritoneal fluid from patients with bacterial peritonitis 
(Dalbeth et al., 2004). In another study, analysis of synovial tissue-infiltrating NK cells in 
osteoarthritis and periprosthetic inflammation revealed that the majority of the NK cells 
had a noncytotoxic, immunoregulatory phenotype similar to blood CD56brightCD16- NK 
cells (Huss et al., 2010). Recently, CD56brightCD16- NK cells were also found increased 
in the tumour microenvironment in patients with papillary thyroid cancer, whereas 
CD56dimCD16+ NK cells were more highly expressed in nodular goitre, but also 
infiltrated into papillary thyroid gland in the advanced stages of cancer (Gogali et al., 
2013). Similarly, studies have shown that CD56brightCD16- NK cells infiltrated in 
inflammatory skin conditions such as psoriasis (Ottaviani et al., 2006), allergic contact 
dermatitis (Carbone et al., 2010), and in X-linked severe combined immunodeficiency 
(SCID) where a patient had red erythroderma-like skin lesions (Shibata et al., 2007). 
Although we and others have observed the presence of NK cells in recurrent 
herpes lesions, the role of NK cells in response to HSV, and the distribution of NK cell 
subsets, is not understood. There has been no demonstrable correlation between NK cell 
activity and viral clearance in mice or in humans. A mouse study showed that HSV2 
clearance from vaginal mucosa was independent of IFN-γ producing NK cells, rather 
only IFN-γ produced from T cells 3 days after the onset of infection played a role in 
clearance (Milligan et al., 1998). In humans, although Koelle et al. observed enrichment 
of NK cells in recurrent lesions there was no apparent correlation between NK cell 
activity and viral clearance (Chan et al., 2011, Koelle et al., 1998). 
However, a number of studies have shown that a specific lack of NK cells 
correlated with increased susceptibility to severe HSV infections. In mice, a study using 
knockout mice lacking NK and natural killer T (NKT) cells found they were more 
susceptible to HSV infection compared to mice lacking both T and B cells (Ashkar and 
Rosenthal, 2003). Similarly, a murine study depleted NK cells and found increased levels 
of HSV2 infection in the spinal cord, brain stem and vaginal tissues (Thapa et al., 2007). 
In humans, a case study of an adolescent female specifically lacking NK cells reported 
that she had severe herpesvirus infections- initially with life-threatening VZV infection at 
age 13. A few years later she suffered from severe HCMV infection, then primary HSV 
infection with a severe rash and fever. Analysis of the patient’s immune cell subsets 
found that her immune functions including specific T cell and antibody responses to viral 
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antigens were normal or nearly normal, except for the extreme deficiency of NK cells 
(Biron et al., 1989). Another clinical study found that two patients with myelodysplasia (a 
bone marrow disorder) and undetectable NK cells and pDCs, had severe HSV2 infection 
(Dalloul et al., 2004). These studies strongly suggest that NK cells play an important role 
in herpesvirus infections. Nonetheless, the precise role of NK cells in the response to 
HSV remains unclear. As a result, NK cells have been overlooked in the design of 
previous HSV vaccine candidates, and their responses have not been assessed in the 
previous studies examining immune responses with clinical trial vaccines. 
1.5 Project aims 
 Improved understanding of the functional roles of the NK cells subsets in 
response to vaccines and HSV infection is important. Therefore, this study aimed to: 
1. Selectively enrich the CD56bright subset in culture without enhancing cytotoxicity, 
using cytokines that promote survival and proliferation of this subset 
2. Characterise and compare the responses of CD56bright and CD56dim NK cells in 
response to the HSV lipopeptide Pam2Cys-30-5 
3. Compare the ability of CD56bright and CD56dim NK cells to mature DCs following 
Pam2Cys-30-5 stimulation 
4. Analyse the presence of the NK cell subsets in normal and primary HSV-infected skin 
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Chapter 2: Materials and Methods 
2.1 Media and solutions 
2.1.1  Cell culture medium 
 RPMI 1640 with 2 mM L-glutamine (Lonza, Walkerville, MD) supplemented 
with 10% heat-inactivated human AB serum (Life Technologies, Grand Island, NY), 
referred to as “RH10”, was the usual cell culture medium used. Alternatively, where 
specified, RPMI 1640 supplemented with 10% heat-inactivated foetal bovine serum 
(FBS) (Lonza), referred to as RF10, or serum-free RPMI 1640 alone were used as the cell 
culture medium. Media was stored at 4°C, then pre-warmed to 37°C prior to use. 
2.1.2  Freezing medium 
 Heat-inactivated FBS supplemented with 10% dimethylsulfoxide (DMSO) 
(Sigma-Aldrich, St. Louis, MO). Kept at 4°C for storage and use. 
2.1.3  Stemcell Buffer 
 Phosphate-buffered saline (PBS) (Lonza) supplemented with 2% FBS. Kept at 
4°C for storage and use. 
2.1.4  PSG Buffer 
 PBS Saponin Gelatin (PSG) buffer was made as a 10-times (10x) stock consisting 
of 0.5 g saponin (Sigma-Aldrich), 27.5 mL fish skin gelatin (Sigma-Aldrich) 45% stock, 
0.2 g sodium azide (Sigma-Aldrich) and sterile PBS to 500 mL. The 10x stock solution 
was diluted to a 1x working solution for use. Solutions were stored at 4°C. 
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2.1.5  Cytokines 
Table 2.1. Cytokines 
Target Supplier Stock concentration 
Interleukin-2 (IL-2) Roche, Basel, Switzerland 1 x 104 U/mL, 5µg/mL 
Interleukin-4 (IL-4) Biosource, Life Technologies 2.9 x 10
7 U/mL, 1mg/mL 
Interleukin-7 (IL-7) Miltenyi Biotec, Auburn, CA ≥ 2 x 10
7 U/mg, 50µg/mL 
Interleukin-15 (IL-15) Miltenyi Biotec ≥ 2 x 106 U/mg, 10µg/mL 
Granulocyte-Macrophage 
Colony Stimulating Factor 
(GM-CSF) 
Biosource, 
Life Technologies 1 x 10
7 U/mL, 1mg/mL 
Stem Cell Factor (SCF) PeproTech, Rocky Hill, NJ ≥ 5 x 105 U/mg, 20µg/mL 
 
2.2 HSV peptides 
2.2.1  Synthesis and concentration 
 The gD2 peptide 30-5 (30-5), Pam2Cys-conjugated gD2-30-5 (Pam2Cys-30-5) 
and carboxyfluorescein (FITC)-conjugated 30-5 and Pam2Cys-30-5 were synthesised by 
Weiguang Zeng and David Jackson (University of Melbourne) as previously described 
(Kim et al., 2012). Briefly, the amino acid sequence of peptide 30-5 was 
PEDPEDSALLED. Peptide 30-5 was synthesised using conventional solid phase 
methodology and Fmoc chemistry (Jackson et al., 1999). Pam2Cys-30-5 was synthesised 
by covalently coupling the Pam2Cys lipid moiety through two serine residues to the 
parental peptide (Zeng et al., 2002). For FITC conjugation to peptide 30-5 (FITC-30-5), 
the N-terminal of the Fmoc group was removed following the last acylation reaction, and 
5(6)-carboxyfluorescein (Fluka Biochmika, Buchs, Switzerland) was coupled to the 
exposed amino acid group using 4-fold molar excess in the presence of equimolar 
amounts of O-benzotriazole-N,N,N’,N’-tetramethyluronium-hexafluorophosphate (Merck, 
Darmstadt, Germany) and 1-hydroxybenzotriazole (Merck) and a 1.5-fold excess of 
diisopropylethylamine (Fluka Biochmika) for 4 hours (hrs) (Kim et al., 2012). For FITC 
conjugation to Pam2Cys-30-5, (FITC-30-5-Pam2Cys), the Pam2Cys moiety was coupled 
to the epsilon amino group of a lysine residue at the C-terminal end of the peptide 30-5, 
then the carboxyfluorescein group was coupled to the N-terminus of the peptide as 
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described above. This configuration was designed to ensure Pam2Cys had no interference 
by the FITC group for binding. All peptides were cleaved from the solid phase support 
and side chain protecting groups were simultaneously removed before being purified and 
characterised as described previously (Zeng et al., 2002). A schematic diagram of the 
structures of the peptides and conjugated peptides can be viewed in Figure 2.1. 
 All peptides and conjugated peptides were solubilised in DMSO at a 
concentration of 10 mM and stored at -80°C. 
 
Figure 2.1. Schematic structures of synthesised peptides and conjugated peptides. 
Structures of synthesised HSV2 glycoprotein D (gD2) peptide 30-5 (30-5), Pam2Cys-
conjugated gD2 peptide 30-5 (Pam2Cys-30-5) and FITC-conjugated Pam2Cys-30-5 
(FITC-30-5-Pam2Cys) that were used in experiments. 
2.2.2  Peptide pulsing of cells 
 Cells were resuspended at 1 x 106 cells/100 µL in serum-free RPMI 1640, 
followed by addition of the peptides listed above, or DMSO as a negative control, to a 
final concentration of 10 µM unless otherwise specified. The cells were incubated at 
37°C in 5% CO2 for 1 hr, or shorter times if specified. After incubation, peptides were 
washed out with RPMI 1640 by centrifugation at 300 x g, 5 min, 4°C. Supernatant was 
discarded and cells were resuspended in serum-free RPMI 1640 or RH10 as indicated in 
individual experiments. 
 
30-5: 	
FITC-Pam2Cys-SS-PEDPEDSALLED
FITC-S-S-KKKK
FITC-S-S-PEDPEDSALLED
FITC-PEDPEDSALLED-K
Pam2Cys-S-S
FITC-(PEG)11-K
Pam2Cys-S-S
FITC-S-S-KKKK-K
Pam2Cys-S-S
Peptide  mad  in Augus 2015 for Professo  
Cunningham's group in August 2015
Pam2Cys-30-5: 	FITC-Pam2Cys-SS-PEDPEDSALLED
FITC-S-S-KKKK
FITC-S-S-PEDPEDSALLED
FITC-PEDPEDSALLED-K
Pam2Cys-S-S
FITC-(PEG)11-K
Pam2Cys-S-S
FITC-S-S-KKKK-K
Pam2Cys-S-S
Peptides made in August 2015 for Professor 
Cunningham's group in August 2015
FITC-30-5-
Pam2Cys: 	
FITC-Pam2Cys-SS-PEDPEDSALLED
FITC-S-S-KKKK
FITC-S-S-PEDPEDSALLED
FITC-PEDPEDSALLED-K
Pam2Cys-S-S
FITC-(PEG)11-K
Pam2Cys-S-S
FITC-S-S-KKKK-K
Pam2Cys-S-S
Peptides mad in August 2015 fo  Professor 
Cu ningham's group in August 2015
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2.3 Cell isolation, enrichment and culture 
2.3.1  Separation of PBMC from whole blood 
 PBMC were isolated from whole blood (Sydney Red Cross Blood Bank) using 
Ficoll-density gradient centrifugation (Ficoll-Hypaque Plus, GE Healthcare, Uppsala, 
Sweden). 500 mL of blood was diluted with 200mL sterile PBS (a 1:1.4 dilution) and 
Ficoll was gently under laid using a sterile cannula. Samples were centrifuged at 450 g 
for 20 minutes (mins) at room temperature (RT), without a brake. PBMC were collected 
from the plasma-Ficoll interface and washed three times in sterile PBS at 300 g for 5 
mins at RT. Cells were counted using a haemocytometer by diluting an aliquot of cells 
1:10 in sterile PBS, then 1:1 with 0.04% Trypan blue diluted from 0.4% stock (Life 
Technologies). 
2.3.2  Cryopreservation: freezing and thawing PBMC 
 PBMC were resuspended in freezing medium (see section 2.1.2) at 1-2 x 107 
cells/mL. 1 mL aliquots were dispensed into cryotubes and placed into a Cryo 1°C 
freezing container (Nalgene, Rochester, NY) then stored at -80°C overnight, freezing at a 
rate of -1°C/minute. The next day cells were transferred to a liquid nitrogen tank for 
preservation until use. 
 To thaw frozen PBMC, cryotubes were removed from liquid nitrogen and quickly 
thawed in a 37°C water bath with gentle agitation. PBMC were then washed three times 
with pre-warmed RF10 by centrifugation at 300 g for 5 mins at RT. An aliquot of PBMC 
was counted at a 1:1 dilution with 0.04% Trypan Blue using a haemocytometer as in 
section 2.3.1. 
2.3.3  Isolation of CD14+ monocytes, generation of Monocyte-Derived 
Dendritic Cells (MDDCs) and maturation 
 CD14+ monocytes were obtained from fresh PBMC using positive selection of 
CD14+ cells using anti-CD14-coated magnetic beads (Miltenyi Biotec). PBMC were 
resuspended in sterile cold PBS at 107 cells/80 µL, then incubated with CD14 beads (20 
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µL/107 cells) for 15 mins at 4°C. Cells were washed with sterile cold PBS by 
centrifugation at 300 g for 5 mins, then resuspended at 108 cells/500 µL cold PBS and 
loaded on a MACS LS column. The column was washed three times with cold PBS, and 
then CD14+ monocytes were then purged from the column using the LS column plunger. 
An aliquot of cells was counted at a 1:1 dilution with 0.04% Trypan Blue using a 
haemocytometer as in 2.3.1. 
 Where CD14+ monocytes were cultured to generate MDDCs, cells were 
resuspended at 5x105 cells/mL in RH10. IL-4 (0.3 µg/mL) and GM-CSF (0.3 µg/mL) 
were added (see section 2.1.5). Monocytes were cultured at 37°C in 5% CO2, for 5-6 days 
to generate immature MDDCs. For experiments measuring maturation of MDDCs after 
culture with NK cells or NK cell supernatants, a maturation mix containing IL-1β (10 
ng/mL), IL-6 (1000 IU/mL), TNF (10 ng/mL) (all R&D Systems, Minneapolis, MN) and 
Prostaglandin E2 (1 µg/mL, Sigma-Aldrich) was used as a positive control. 
2.3.4  Isolation of natural killer cells  
NK cells were usually isolated from fresh PBMC, except for experiments 
coculturing with MDDCs, where they were isolated from autologous frozen PBMC after 
the 5-6 days of MDDC differentiation. NK cells were isolated by negative enrichment 
using the EasySep Negative Selection Human NK cell enrichment kit and “Big Easy” 
Silver EasySep magnet (Stemcell Technologies, Vancouver, BC), according to the 
manufacturer’s instructions: PBMC were resuspended at 5x107 cells/mL in Stemcell 
Buffer (see 2.1.3) and incubated with 50 µL/mL with Human NK cell enrichment cocktail, 
followed by 100 µL/mL of D Magnetic Particles. The cell suspension was brought to a 
total volume of 5 mL for <108 cells or up to 8 mL for a maximum of 4x108 cells per tube. 
The tube was incubated in the magnet for 2.5 mins, and then inverted and the desired 
fraction poured off. An aliquot of negatively selected cells was counted at a 1:1 dilution 
with 0.04% Trypan Blue using a haemocytometer as in section 2.3.1. Purity was checked 
and found to be >95% in all experiments, a representative example is shown in Figure 2.2. 
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2.3.5  Isolation of CD4+T cells 
 CD4+T cells were isolated from fresh PBMC. CD4+T cells were isolated by 
negative enrichment using the EasySep Human CD4 T cell enrichment kit and purple 
EasySep magnet (Stemcell Technologies). Cells were isolated similarly to NK cells 
(section 2.3.4), except the cell suspension final volume was 2.5 mL for up to 108 cells, 
and the tube was placed in the magnet for 5 mins before the desired fraction was poured 
off. An aliquot of negatively selected cells was counted at a 1:1 dilution with 0.04% 
Trypan Blue using a haemocytometer as in section 2.3.1. Purity was checked and found 
to be ≥98% in all experiments. 
2.3.6 Cell culturing 
 For details of specific culturing conditions, please refer to figure legends in the 
results chapters. Generally, cells were cultured in RH10 medium (or serum-free RPMI 
1640 where indicated), at 1 x 106 cells/mL for NK cells and 5 x 105 cells/mL for MDDCs, 
at 37°C in 5% CO2. For experiments utilising transwell plates, 24-well plates with inserts 
of 0.4µm membrane pore size (Corning, NY) were used. All other plasticware used was 
from BD (San Jose, CA) unless otherwise specified. 
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2.4 Flow Cytometry and Cell Sorting 
2.4.1  Antibodies 
Table 2.2. Flow Cytometry antibodies 
Target Clone Isotype Fluorochrome Supplier Dilution 
CD3 UCHT1 Mouse IgG1κ FITC BD Pharmingen 1:25 
CD3 SK7 Mouse IgG1κ PerCP BD Biosciences 1:25 
CD3 UCHT1 Mouse IgG1κ APC BD Pharmingen 1:25 
CD3 SK7 Mouse IgG1κ APCCy7 BD Pharmingen 1:25 
CD14 M5E2 Mouse IgG2aκ APC BD Pharmingen 1:25 
CD16 3G8 Mouse IgG1κ FITC BD Pharmingen 1:25 
CD16 3G8 Mouse IgG1κ PerCP 
BioLegend,  
(San Diego, CA) 1:25 
CD56 AF12-7H3 Mouse IgG1κ PE Miltenyi Biotec 1:10 
CD62L DREG-56 Mouse IgG1κ APCCy7 BioLegend 1:20 
CD69 L78 Mouse IgG1κ APC BD Biosciences 1:25 
CD80 L307.4 Mouse IgG1κ FITC BD Pharmingen 1:25 
CD83 HB15e Mouse IgG1κ PE BD Pharmingen 1:25 
CD117 (c-kit) 104D2 Mouse IgG1κ PECy5 BioLegend 1:20 
CD158a/h 
(KIR2DL1/S1) 
11PB6 
(EB6) Mouse IgG1κ FITC Miltenyi Biotec 1:20 
DC-SIGN DCN46 Mouse IgG2bκ PE BD Pharmingen 1:25 
HLA-DR L243 Mouse IgG2aκ PECy7 BioLegend 1:25 
IFN-γ B27 Mouse IgG1κ PECy7 BD Pharmingen 1:20 
Perforin δG9 Mouse IgG2bκ FITC BD Biosciences 1:25 
TLR2 REA109 Recombinant human IgG1 κ 
PEVio770 Miltenyi Biotec 1:25 
 
2.4.2  Cell staining and phenotyping 
A. NK cells 
 To identify NK cells and/or to check purity after negative enrichment, PBMC, 
isolated NK cells, or sorted NK cell subsets were placed into FACS tubes and washed 
with PBS by centrifugation at 300 g for 5 mins. Cells were resuspended in 50 µL PBS 
and antibodies were added for CD56, CD16 and CD3. Cells were incubated with 
antibodies for 25 mins at RT, then washed with PBS by centrifugation at 300 g for 5 mins. 
To gate on NK cells during flow cytometry (Figure 2.2), the first gate was made on the 
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lymphocyte population in a forward scatter (FSC) vs. side scatter (SSC) plot. A second 
gate was made in a plot of CD56 vs. CD3, where CD56+ CD3- cells were identified as 
NK cells. Thirdly, viewing a CD56 vs. CD16 plot defined NK cell subsets as CD56bright 
CD16-/dim and CD56dimCD16+. For results in Chapter Four, a third population CD56dim 
CD16-/dim was also gated (marked in red on Figure 2.2). 
B. MDDCs 
 To phenotype immature MDDCs on day 5-6 after culture from CD14+ monocytes 
(see section 2.3.3), samples of cells were taken from the culture, washed with PBS by 
centrifugation at 300 g for 5 mins, resuspended in 50 µL PBS and stained with Live/Dead 
Fixable Aqua Dead Cell Stain (Life Technologies) for 25 mins at RT, washed again in 
PBS and labelled for surface phenotype markers CD80, CD83, CD14 and DC-SIGN. 
Cells were incubated with antibodies for 25 mins at RT, and then washed with PBS by 
centrifugation at 300 g for 5 mins. To gate on immature MDDCs during flow cytometry 
(Figure 2.3), the first gate was made on the DC population based on forward and side 
scatter properties, followed by live cells, then each of the phenotype markers separately. 
CD80 and CD83 were measured as markers of maturation after culture in the same 
manner as the immature DCs. For experiments coculturing NK cells with MDDCsb, 
MDDC death was measured using Propidium Iodide (PI, Life Technologies). At the flow 
cytometer, samples were spiked with a 1:50 dilution of PI and mixed gently immediately 
prior to data acquisition and analysis. 
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Figure 2.2. Phenotyping NK cell subsets. The gating strategy shown was used to 
distinguish NK cell subsets by flow cytometry. Cells were gated initially by size, 
followed by CD56+ CD3- NK cells. NK cells were then distinguished by density of CD56 
and CD16 labelling into two main subsets. CD56bright CD16-/dim (“CD56bright”), and 
CD56dim CD16+ (“CD56dim”). In Chapter Four, a third population CD56dimCD16-/dim was 
also gated (shown in red). Representative FACS plots of the gating strategy applied to 
purified NK cells are shown. 
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Figure 2.3. Phenotyping MDDCs. The gating strategy shown was used to phenotype 
immature MDDCs by flow cytometry. Cells were initially gated by size, followed by Live 
and Dead cells. Live cells were then examined for the expression of CD14, CD83, CD80 
and DC-SIGN. Immature MDDCs were CD14, CD83 and CD80 low, and DC-SIGN 
high. In maturation experiments, maturing MDDCs were gated in the same manner and 
examined for CD80 and CD83 expression. Representative FACS plots are shown. 
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2.4.3  Cell Sorting 
 Freshly isolated NK cells were resuspended in PBS at 1-2 x 107 cells/500 µL. 
Cells were labelled with 5 µL/106 cells of anti-CD56 and 2 µL/106 cells of anti-CD3 for 
30 mins at RT, protected from light. Cells were washed with PBS at 300 g for 5 mins at 
RT, resuspended in 500 µL of PBS and filtered into a 5 mL FACS tube with a 35 µm cell 
strainer cap (BD Falcon) with 3 washes of 500 µL PBS. NK cells were sorted on the cell 
sorters BD FACS Vantage SE Diva and BD FACS Aria III. The gating strategy used to 
sort CD56dim and CD56bright NK cells is shown in Figure 2.4. At the end of cell sorting, a 
sample of each was checked for purity at the cell sorter as shown in Figure 2.4, and purity 
was always ≥99%.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Gating strategy for cell sorting NK cell subsets and example post-sort 
purity. The gating strategy shown was used to sort CD56dim and CD56bright NK cells by 
FACS. Cells were gated initially by size, followed by single cells. CD56bright and CD56dim 
NK cells were distinguished by their density of CD56 on a plot excluding CD3+ cells. 
Cells were sorted for high purity of 99% or greater. Representative FACS plots shown. 
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2.4.4  Intracellular staining 
 For intracellular staining of perforin in NK cells, on day 0 before culture, freshly 
isolated NK cells were labelled for surface phenotype markers CD56, CD16 and CD3 as 
in section 2.4.2A. Following washing in PBS at 300 g for 5 mins at RT, cell were fixed 
with Cytofix/Cytoperm (BD Biosciences) for 20 mins at RT then washed with 1 x BD 
PermWash solution (BD Biosciences). NK cells were then labelled with Perforin or 
isotype control in the presence of 1 x BD PermWash for 25 mins at RT, protected from 
light. Cells were washed with PBS and run on the flow cytometer on the same day. On 
day 7 of culturing, NK cells had 1 µg/mL of Golgi Plug containing Brefeldin A (BD 
Chapter 2: Materials and Methods 
	 55 
Biosciences) added to the culture and incubated for a further 5 hrs at 37°C, prior to 
washing and labelling cells as on day 0. 
For intracellular staining of IFN-γ, after cells were pulsed for 1 hr at 37°C with 10 
µM DMSO, peptide 30-5 or Pam2Cys-30-5 at 1 x 106 cells/100 µL serum-free RPMI 
1640, cells were washed in RPMI 1640 at 300 g for 5 mins at RT, and resuspended at 1 x 
106 cells/mL in RH10 and cultured overnight at 37°C in the presence of 10 µg/mL 
Brefeldin A (Sigma-Aldrich). After culture, cells were washed twice in PBS, stained with 
Live/Dead Fixable Aqua Dead Cell Stain (Life Technologies) as per manufacturer’s 
instructions for 25 mins at RT, washed again in PBS and labelled for surface phenotype 
markers CD3, CD56 and CD16 as in 2.4.2A. Following washing with PBS at 300 g for 5 
mins at RT, cell were fixed with Cytofix/Cytoperm (BD Biosciences) for 20 mins at RT 
then washed with 1 x BD PermWash (BD Biosciences). Cells were then labelled with 
IFN-γ or isotope control in the presence of 1 x BD PermWash for 25 mins at RT, 
protected from light. Cells were washed with PBS and run on the flow cytometer on the 
same day. 
2.4.5  Cell proliferation assay 
 Freshly isolated NK cells (3 x 106 cells) and PBMC (2 x 106 cells) were 
resuspended in RPMI 1640 at 1 x 106 cells/mL and incubated with 5 µM CellTrace Violet 
(Life Technologies) for 20 mins at 37°C. After staining, five times the original staining 
volume of RPMI 1640 was added and incubated for 5 mins at RT to quench the dye. 
Cells were centrifuged at 300 g for 5 mins at RT and resuspended in RF10 at 1 x 107 
cells/mL. NK cells were divided into 3 tubes, and PBMC into 2 tubes. Each tube had 
additional RF10 added to a final concentration of 1 x 106 cells/mL. NK cell tubes had 0.1 
ng/mL IL-2, 1 ng/mL IL-7 and 0.1 ng/mL IL-2 + 200 ng/mL SF added respectively. 
PBMC tubes had Phytohaemagglutinin (PHA, Sigma-Aldrich) 5 µg/mL + 10 ng/mL IL-2 
added to one tube as a positive control for proliferation and no cytokines added to the 
other tube to serve as a positive stained compensation control. An additional 1 x 107 
unstained PBMC were resuspended at 1 x 106 cells/mL in RF10 with 1 ng/mL IL-2 for 
use as compensation controls. All cells were then cultured for 7 days at 37°C, 5% CO2. 
Additional freshly isolated NK cells were labelled for phenotyping for CD56, CD16 and 
CD3 on day 0 as in section 2.4.2A. On day 7, NK cell samples were counted and all cells 
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resuspended in PBS. NK cells were labelled for CD56, CD16 and CD3. Cells were 
incubated with antibodies for 25 mins at RT then washed with PBS by centrifuging at 300 
g for 5 min at RT. PBMC stained with CellTrace Violet only were also washed with PBS 
and all samples resuspended in PBS to run on the flow cytometer. 
 NK cell samples were gated to distinguish CD56bright and CD56dim NK cells as 
described in section 2.4.2. Then CellTrace Violet proliferation for each subset was 
analysed separately. PBMC samples were analysed for CellTrace Violet proliferation as a 
whole population. Daughter gates were identified using the PBMC positive control 
stimulated with PHA + IL-2, and transferred to the NK cell samples to identify daughter 
populations. 
2.4.6 Data acquisition and analysis 
 Flow cytometry was performed on BD flow cytometers: Canto A, Canto II, LSRII 
or LSR Fortessa using FACSDiva software version 5.0 or 6.0 (BD). Analysis was 
performed using FlowJo v7.6.5 or v10.0.7r2 (Tree Star Inc. Ashland, OR). All statistical 
analyses were performed using GraphPad Prism versions 5 and 7. To obtain quantitative 
statistical data, tests such as paired or unpaired t tests, and ANOVA with multiple pair-
wise comparisons were utilised. As some analyses were conducted on data from a limited 
number of donor samples, where indicated, data were log transformed to stabilise the 
variance prior to analysis as described (Kim et al., 2012). 
2.4.7 Cytometric Bead Array (CBA) 
A. 10-plex cytokine and chemokine CBA 
 NK cells were cell sorted into subsets as described in section 2.4.3 and pulsed 
with mock (DMSO), Pam2Cys-30-5 (10 µM) or Lipopolysaccharide (LPS, Sigma-
Aldrich) (2.5 µg/mL). After pulsing, cells were washed in RPMI 1640 at 300 g for 5 mins 
and then cultured for 24 hrs in RH10 at 37°C. After culture, cells were centrifuged at 300 
g for 5 min. Supernatants were collected and stored at -80°C until use. 
The BD Cytometric Bead Array (CBA) was setup and performed according to the 
manufacturer’s instructions: 10 analytes, referred to as “Flex sets” were analysed: IFN-γ, 
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TNF, MIP-1α, MIP-1β, RANTES, IL-8, GM-CSF, IL-12p70, IL-4 and IL-10. Briefly, 
lyophilised standards of each flex set were pooled into one tube, reconstituted and serially 
diluted in 2-fold dilutions from 2500 pg/mL to 10 pg/mL, plus a 0 pg/mL negative 
control. Capture Beads for each flex set were combined at a volume of 1 µL per bead type 
per sample and diluted in the provided diluent to a total volume of 50 µL per sample. PE 
Detection Reagents for each flex set were combined and diluted as per the capture beads. 
50 µL of each standard or sample (NK cell culture supernatant) were combined with 50 
µL of the Capture Beads mixture for 1 hr at RT, followed by 50 µL of the PE Detection 
Reagent for 2 hrs at RT. Tubes were washed with the provided wash buffer by 
centrifugation at 200 g for 5 mins prior to data acquisition. 
 Sample data were acquired on the BD Canto II flow cytometer with FACSDiva 
software 6.0 (BD). Cytometer settings were adjusted according to manufacturer 
instructions and using the setup beads provided. Data was analysed using FCAP Array 
software v3.0 (BD). 
B. Custom CD16 CBA 
 BD Cytometric Bead Array provides a Functional Bead Conjugation Buffer Set 
for custom assays. Custom beads were prepared for conjugation to antibodies according 
to the manufacturer’s instructions: Beads were sonicated (Table-top ultrasonic cleaner) 
for 1 minute, then 1 M DTT (1,4-Dithiothreitol, Sigma-Aldrich) was added and vortexed 
for 5 seconds. Beads were incubated on an orbital shaker for 1 hr at RT, protected from 
light. Beads were then washed three times with the provided coupling buffer by vortexing 
for 5 seconds, followed by centrifugation at 900 g for 3 mins, and the supernatant 
aspirated and discarded. The beads were then resuspended in coupling buffer. 
 Antibodies were prepared for conjugation to the custom beads according to the 
manufacturer’s instructions: The antibodies were purified mouse-anti human CD16 
(clone 3G8, BioLegend) and its isotype control mouse-anti human IgG1 (BioLegend). 
The antibodies were required to have a stock concentration of 1 mg/mL, and have all 
proteins and amino groups such as BSA, Tris or glycine removed from the buffer. A 
buffer exchange was conducted to remove the proteins and amino groups using Bio-Spin 
P-30 Gel Columns (Bio-Rad, CA). First, each antibody had 2 mg/mL of sulfo-SMCC (4-
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(N-Maleimidomethyl)cyclohexane-1-carboxylic acid 3-sulfo-N-hydroxysuccinimide ester 
sodium salt, Sigma-Aldrich) added, vortexed for 5 seconds, then incubated on an orbital 
shaker for 1 hr at RT, protected from light. Next, the packing buffer was drained from the 
columns and replaced with coupling buffer, which was drained through the column by 
gravity three times. The column was centrifuged at 1000 g for 1 minute. Finally, each 
antibody/sulfo-SMCC solution was applied to its own column and centrifuged at 1000 g 
for 2 mins, transferring each modified antibody into a capture tube resuspended in 
coupling buffer. 
 To conjugate the antibodies to the beads, each modified antibody was transferred 
to tubes containing the prepared custom beads. Tubes were vortexed for 5 seconds, and 
then incubated on an orbital shaker for 1 hr at RT, protected from light. 2 mg/mL of NEM 
(N-Ethylmaleimide, Sigma-Aldrich) was added to each antibody-bead conjugation, 
vortexed for 5 seconds and incubated for 15 mins on an orbital shaker. Tubes were 
washed three times with the provided storage buffer by centrifugation at 900 g for 3 mins. 
Supernatants were aspirated and discarded. Beads were then resuspended in storage 
buffer and stored at 4°C overnight prior to first use. 
Freshly isolated NK cells were cultured with mock (DMSO) or Pam2Cys-30-5 
(10 µM) for 0 or 2 hours at 1 x 107 cells /mL in serum-free RPMI 1640 for 2 hrs at 37°C. 
As a positive control, some NK cells were cultured with PMA (Phorbol 12-myristate 13-
acetate, 10 ng/mL, Sigma-Aldrich) for 1 hr at 37°C. After culture, cells were centrifuged 
at 300 g for 5 mins. Supernatants were collected and stored at -80°C until use. 
The CD16 CBA assay was performed as per the manufacturer’s instructions for 
the Human CBA Enhanced Sensitivity kit (BD Biosciences): Recombinant Human Fc 
gamma RIIIA/CD16a (R&D Systems) was prepared as a set of standards in the provided 
assay diluent and serially diluted in 2-fold dilutions from 10 ng/mL to 80 pg/mL, plus a 0 
pg/mL negative control of assay diluent only. Custom conjugated CD16 functional beads 
were diluted 1:50 in the provided diluent. 50 µL of each standard or sample (NK cell 
culture supernatant) were combined with 50 µL of the diluted CD16 functional beads and 
incubated for 2 hrs at RT. An isotope control sample was prepared in the same manner 
using 50 µL of the middle standard (1.25 ng/mL) and incubating with 50 µL of 1:50 
diluted IgG1 functional beads. A biotinylated mouse anti-human CD16 (clone DJ130c, 
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AbD Serotec, Oxford, UK) was diluted 1:50 in the provided diluent and 50 µL added to 
all standards and samples including the isotope control. Tubes were incubated for a 
further 2 hrs at RT then washed with the provided wash buffer by centrifugation at 200 g 
for 5 mins. Streptavidin-conjugated to PE (BD Biosciences) was then diluted 1:400 in the 
provided diluent and 50 µL added to each standard and sample. Tubes were incubated for 
1 hr at RT, washed with the provided wash buffer as before, and then resuspended in 
wash buffer for data acquisition. 
Sample data were acquired on the BD Canto II flow cytometer with FACSDiva 
software 6.0 (BD). Cytometer settings were adjusted according to manufacturer 
instructions and using the setup beads provided. Data was analysed using FCAP Array 
software v3.0 (BD). 
2.5 Microscopy 
2.5.1  Antibodies 
A. Primary antibodies 
Table 2.3. Primary antibodies for microscopy 
Target Clone Isotype Format Supplier Dilution 
CD14 HCD14 Mouse IgG1κ Purified BioLegend 1:50 
CD16 3G8 Mouse IgG1κ 
LEAF 
Purified BioLegend 1:50 
CD16 YFC120.5 Rat IgG2b κ Purified AbD Serotec 1:50 
CD56 
(NCAM) 123C3 Mouse IgG1κ Purified 
Thermo Fisher 
Scientific 1:50 
HSV-1 gD  Polyclonal Rabbit Purified Abcam (Cambridge, UK) 1:100 
TLR2 T2.5 Mouse IgG1κ Purified 
eBiosciences  
(San Diego, CA) 1:50 
TLR2 EPR2078Y Rabbit IgG Purified Abcam 1:50 
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B. Secondary antibodies 
Table 2.4. Secondary antibodies for microscopy 
Target Host Format Supplier Dilution 
Mouse IgG Goat Alexa Fluor 647 Life Technologies 1:400 
Mouse IgG Goat Alexa Fluor 488 Life Technologies 1:400 
Rabbit IgG Goat Alexa Fluor 633 Life Technologies 1:400 
Rat IgG Goat Alexa Fluor 546 Life Technologies 1:400 
 
C. Conjugated antibodies 
Table 2.5. Conjugated antibodies for microscopy 
Target Clone Isotype Format Supplier DDilution 
CD16 3G8 Mouse IgG1κ FITC BD Pharmingen 1:1:10 
 
2.5.2  Slide preparation, cell preparation and staining of isolated cells 
 Coverslips (22x60mm, Menzel-Gläser, Braunschweig, Germany) were mounted 
with 8- or 12-well FlexiPERM cell culture chambers (ISC Bioexpress, Kaysville, UT). 
Cell-Tak tissue adhesive (Corning) was applied to coverslips by the adsorption method 
recommended by the manufacturer, where Cell-Tak was diluted 1:20 in a 0.1M Sodium 
Bicarbonate buffer, followed by addition of 1M Sodium Hydroxide equal to half the 
volume of Cell-Tak. The solution was immediately distributed to the wells of the culture 
chamber (100 µL per well for 8-well, 40 µL per well for 12-well) and allowed to set on 
the coverslip for 20 mins at RT. The solution was then aspirated, wells washed once with 
distilled H2O and air-dried. 
 For experiments examining TLR2 and FITC-30-5-Pam2Cys, and TLR2 and CD16 
colocalisation, cells were treated with 1 µM FITC-30-5-Pam2Cys or mock (DMSO) for 1 
hour at 4°C. Cells were washed with cold PBS and incubated with primary antibodies 
diluted in 10% normal goat serum (NGS) for 45 minutes at 4°C. Cells were washed with 
cold PBS then fixed with 3% paraformaldehyde (PFA) (Electron Microscopy Sciences, 
Hatfield, PA) for 20 mins at RT, then loaded into wells of the FlexiPERM chamber and 
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centrifuged at 75 g for 3 mins at 4°C. PFA was aspirated from the wells and neutralised 
by 3 x 3 min washes with 50 mM Ammonium Chloride (Sigma-Aldrich). Cells were 
permeabilised for 1 min with 0.05% Triton X-100 (Sigma-Aldrich), washed once with 
PBS, treated with 1 x PSG buffer (see section 2.1.4) for 15 mins at RT, followed by 
Image-iT FX Signal Enhancer (Life Technologies) for 20 mins at RT. Secondary 
antibodies diluted in 1 x PSG buffer were incubated for 30 mins at RT in a dark 
humidified chamber. After 4 x 3 min washes with 1 x PSG buffer and a brief rinse with 
PBS, the FlexiPERM chambers were removed. Coverslips were mounted onto slides with 
Prolong Gold or Diamond anti-fade reagent with DAPI (Life Technologies) and left to 
cure in the dark at RT overnight. 
 For experiments examining CD16 internalisation, cells were treated with 10 µM 
Pam2Cys-30-5 or mock (DMSO) for 0 and 2 hrs at 37°C, washed with cold PBS and 
fixed and permeabilised as described above. After incubation with Image-iT FX Signal 
Enhancer, cells were transferred to a dark humidified chamber for all antibody 
incubations and all antibodies were diluted in 1 x PSG buffer. Cells were incubated with 
a 1:40 dilution Phalloidin-Alexa Fluor 488 (Life Technologies) for 45 mins at RT, 
washed for 3 x 3 min with 1 x PSG buffer then incubated with primary antibodies for 45 
mins at RT. Following 3 x 3 min washes with 1 x PSG buffer, incubation with secondary 
antibodies and subsequent washing and mounting to slides were performed as described 
above. 
2.5.3  Proximity Ligation Assay 
 NK cells were treated with 10 µM Pam2Cys-30-5 or DMSO for 0 or 30 mins at 
37°C and washed with cold PBS, then they were fixed, permeabilised and loaded on 8-
well FlexiPERM chambers as in section 2.5.2, however the chambers were removed after 
the cytospin step and borders between samples were drawn using a delimiting pen (Dako, 
Glostrup, Denmark). Positive and negative control cells, CD14+ monocytes and CD4+T 
cells respectively were also isolated in the same experiment. They were unstimulated, but 
otherwise fixed and permeabilised in the same manner as the NK cells. Proximity 
Ligation Assay (PLA) (Duolink®, Sigma-Aldrich) was performed according to the 
manufacturer’s instructions: Cells were blocked with 1 x PSG buffer for 30 mins prior to 
adding the primary antibodies rabbit anti-TLR2 and mouse anti-CD16 (or mouse anti-
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CD14 for monocytes), which were diluted in 1 x PSG buffer and incubated with cells for 
45 mins at 37°C in a pre-warmed humidity chamber. All subsequent incubations at 37°C 
were in the pre-warmed humidity chamber. Following 3 x 3 min washes with 1 x PSG 
buffer, plus and minus (anti-rabbit and anti-mouse) PLA probes were diluted 1:5 in 1 x 
PSG buffer and incubated with the cells for 1 hr at 37°C. Following 4 x 2 min washes 
with the provided Wash Buffer A, a 1:5 dilution of ligation stock containing a 1:40 
dilution of the Ligase was added to the cells for 30 mins at 37°C. Following 3 x 2 min 
washes with Wash Buffer A, cells were incubated with a 1:5 dilution of amplification 
stock containing a 1:80 dilution of Polymerase for 100 mins at 37°C. Cells were washed 
4 x 2 mins with Wash Buffer B, followed by a brief wash with 0.01% Wash Buffer B, 
prior to mounting the coverslips to slides using the provided mounting media with DAPI. 
2.5.4  Tissue preparation, sectioning and immunofluorescence staining 
 An initial penile herpetic lesion biopsy and normal outer foreskin tissue had 
previously been collected and stored as described (Kim et al., 2015). Briefly, a 3 mm 
punch biopsy of the lesion was obtained 3 days after onset, snap-frozen in O.C.T 
(ProSciTech, Kirwan, QLD, Australia) and kept at -80°C for cryosectioning. Normal 
foreskin tissue samples were obtained from circumcision operations. The outer foreskin 
was cut into pieces > 6 mm diameter and immediately snap-frozen in O.C.T (ProSciTech) 
and kept at -80°C for cryosectioning. Samples were cut into 7 µm sections and kept at -
80°C until immunofluorescence staining. 
 To stain the samples, sections were thawed and fixed in ice-cold 
methanol:acetone (1:1) for 10 mins, followed by blocking with 10% NGS for 30 mins at 
RT. Samples were stained with primary antibodies diluted in 10% NGS for 45 mins at 
37°C then washed once with PBS containing 0.05% Tween-20 (PBST, Sigma-Aldrich) 
followed by four washes with PBS. Samples were stained with secondary antibodies 
diluted in 10% NGS for 30 mins at 37°C, washed once with PBST followed by five 
washes with PBS. Where conjugated antibodies were also used, samples were then 
labelled with conjugated antibody for 30 mins at 37°C, then washed as in the previous 
step. Samples were mounted in Prolong Gold or Diamond anti-fade reagent with DAPI 
for nuclear staining (Life Technologies) and left to cure in the dark at RT overnight.  
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2.5.5  Image acquisition and analysis 
 Slides were visualised through a 60x or 100x 1.35 NA oil-immersion lens with an 
inverted Olympus IX-70 microscope (DeltaVision Image Restoration Microscope, 
Applied Precision/Olympus). Images were acquired with a Photometrics CoolSnap QE 
camera and analysed using DeltaVision SoftWorx deconvolution software 5.5.1 RC3 and 
FIJI (ImageJ version 2.0.0-rc-43). In all imaging experiments, z-stack images were 
collected and deconvolved, from which maximal intensity projections and orthogonal 
views were generated, showing the slices in one plane or as a volume/3D rotated image 
respectively. 
 Colocalisation of TLR2 and FITC-conjugated Pam2Cys-30-5, or TLR2 and CD16, 
were measured using DeltaVision SoftWorx software. To generate images where white 
indicated overlapping fluorescence, the “Colocalization” tool was used, selecting an 
individual cell as a “region” to calculate through all the z-slices. To calculate Pearson’s 
Coefficient of Correlation across samples, the “Colocalization ROI” tool was used, where 
every cell in each field of view was selected as a “Region of Interest” (ROI) to calculate 
through all the z-slices. One Pearson coefficient was generated as an average for all cells 
in one field of view. The values for 10 fields of view were graphed and compared for 
colocalisation of Pam2Cys-TLR2 and CD16-TLR2. More than 70 cells in total were 
analysed. Statistical analysis was performed in GraphPad Prism v7. 
 For PLA analysis, the number of fluorescent dots per cell was counted manually 
and a tally of the number of dots per cell (0-1 dots, 2-5 dots, 6-9 dots etc.) was generated 
using the cell counter tool in FIJI. The percentage of cells in each grouping was 
calculated for each cell type and treatment, and graphed accordingly. Approximately 100 
cells per condition were evaluated in each experiment. 
Relative enrichment (RE) analysis for CD16 internalisation experiments was 
adapted from a method provided by Dr Fabienne Brilot-Turville for determining RE at 
synapses between cells (Brilot et al., 2007). In this case, the RE of intracellular vs. 
surface enrichment of CD16 was determined in individual cells. Using the ROI Manager 
tool in FIJI, two rectangular regions of constant length of the cell membrane were 
selected, encompassing surface and internal fluorescence of approximately equivalent 
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area. The two regions were spaced at least 1/3rd of the cell circumference apart. Within 
each region of interest (ROI), the surface and intracellular regions were also defined, 
enabling the measurement of the average fluorescence in each of the total, surface and 
intracellular ROIs. The measurements were repeated for the 5 middle/central z-sections 
of each cell, but not outer z-sections to avoid fluorescence at the top and bottom of the 
cell being interpreted as intracellular fluorescence. At each ROI, the surface and 
intracellular enrichment of fluorescence were both calculated as a ratio of total 
fluorescence, then RE of intracellular to surface fluorescence was determined as a ratio. 
The average of the calculations from the 5 z-sections of the two ROIs per cell were used 
as the final calculation of RE for each cell (Figure 2.5). The RE scores of individual cells 
at 0 hr, and 2 hrs after treatment with mock or Pam2Cys-30-5 were graphed and 
statistical analysis was performed using GraphPad Prism v7. 
Slides containing tissue specimens were imaged using a “panel and stitch” method 
using the DeltaVision SoftWorx software during image acquisition to combine a series of 
neighbouring images into one large image. Cells were counted in the individual panels 
and totalled for the whole image. Counts per mm2 were calculated by determining the 
area of each panel in µm2 by conversions of the total number of pixels and the number of 
pixels per µm as determined by FIJI. The area of the whole image in mm2 was 
determined by multiplying the area of one panel by the total number of panels. The 
multiplication factor required to increase the image area to 1 mm2 was determined and 
applied to the initial total cell counts to determine the counts per mm2. 
 
 
 
 
Figure 2.5. Measuring relative enrichment (RE) of intracellular fluorescence. The 
average total (2), surface (3) and intracellular (1) fluorescence of the 5 middle z-sections 
at each of two ROIs per cell were measured using phalloidin staining as the boundary 
determining the intracellular region. Surface and intracellular enrichment were each 
calculated as a ratio of total fluorescence: 1/2 = a, and 3/2 = b. Finally, RE was calculated 
by dividing intracellular enrichment by surface enrichment: a/b. 
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2.6 Pam2Cys-CD16 binding ELISA 
 ELISA was conducted by Mark Hogarth’s laboratory at the Burnet Institute, 
Melbourne. MaxiSorp plates (Nunc, VWR International, Dietikon, Switzerland) were 
coated with 200 µg/mL and doubling dilutions of Influenza peptide M2e or Pam2Cys-
conjugated M2e (P2C-M2e), or a positive control of 20 µg/mL and 2-fold dilutions of 
aggregated human IgG (Hagg) for 1 hr at 37°C. Plates were washed five times with PBS 
then blocked with 2% casein in PBS (2% casein/PBS) for 1 hr at RT. Plates were washed 
three times with 2% casein/PBS, then biotinylated CD16 dimers (V158 or F158 
polymorphic forms) were added at 0.2 µg/mL and incubated for 1 hr at RT. Plates were 
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washed five times with 2% casein/PBS. High sensitivity Streptavidin-HRP (Thermo 
Fisher Scientific, Lenexa, KS) was added at a 1:10000 dilution for 1 hr at RT, then 
washed eight times with 2% casein/PBS. A colorimetric reaction was developed using 
TMB substrate (Thermo Fisher Scientific), stopped with an equal volume of 1 M HCl, 
and absorbance at 450 nm was determined immediately. 
2.7 IFN-γ Enzyme Linked ImmunoSpot assay (ELISPOT) 
 ELISPOT plates (immunobilon-P PVDF membrane, Millipore, Nillerica, MA) 
were coated with a purified IFN-γ capture antibody (1D1K, Mabtech, Nacka Strand, 
Sweden) at a concentration of 10 µg/mL, 50 µL/well, and incubated overnight at 4°C. 
Plates were washed three times with sterile PBS then blocked with RH10 for 1 hr at RT. 
Plates were washed three times with sterile PBS, then 2 x 104 sorted CD56bright or 
CD56dim NK cells were added per well in a final volume of 100 µL. Cells were treated in 
duplicate with 10 µM mock (DMSO), peptide 30-5 or Pam2Cys-30-5, or with 1 ng/mL 
IL-2 + 5 µg/mL PHA as a positive control. Plates were then incubated for about 40 hrs at 
37°C. Plates were washed three times with sterile PBS, then three times with PBST. A 
biotinylated IFN-γ detection antibody (7-B6-1, Mabtech) was diluted to 1 µg/mL in 
PBST containing 1% BSA and added at 100 µL/well. Plates were incubated for 2 hrs at 
RT then washed six times with PBST. Streptavidin-alkaline phosphatase (Bio-Rad) was 
diluted 1:1000 in sterile PBS then added at 100 µL/well for 45 mins at RT. Plates were 
washed three times with PBST, followed by washing four times with sterile PBS. 
BCIP/NBT plus substrate (Bio-Rad) was added at 100 µL/well and incubated for 
approximately 5 mins or until spots were visible. Spot development was stopped by 
rinsing plates extensively under running water. The plate was allowed to dry before spots 
were counted using an ELISPOT reader (AID, Straussberg, Germany). 
2.8 DNA Microarray 
2.8.1  RNA isolation 
 RNA was isolated from sorted CD56bright and CD56dim NK cells using the RNeasy 
Mini kit (Qiagen, Valencia, CA). A cell lysis buffer containing a 1:100 dilution of β-
mercaptoethanol in the provided Buffer RLT was freshly prepared. After collecting and 
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counting sorted cells, they were resuspended in the lysis buffer and thoroughly mixed and 
vortexed before being stored at -80°C until ready to extract RNA. 
 Cell lysate samples were thawed and RNA extracted according to the 
manufacturer’s protocol: An equal volume of 70% ethanol was added to the cell lysate 
and mixed well. The mixture was placed in an RNeasy spin column with a collection tube. 
Columns were centrifuged for 15 seconds at 8000 g, and then flow through was discarded. 
Columns were washed with Buffer RW1 with the same centrifugation conditions. 
Columns were then washed with Buffer RPE also with the same centrifugation conditions. 
Upon a second wash with Buffer RPE, columns were centrifuged for 2 mins at 8000 g, 
and then flow through was discarded. To remove trace Buffer RPE, columns were placed 
in a new collection tube and centrifuged for 1 minute at full speed. Columns were then 
placed in a 1.5 mL eppendorf tube and RNA was collected with two washes of RNase 
free water by centrifugation at 8000 g for 1 minute. The concentration of RNA was 
measured using a Nanophotometer (Implen GmbH, Munich, Germany). A minimum 
concentration of 25 ng/µL was required for subsequent procedures. Where samples 
measured at a lower concentration they were placed in a vacuum evaporation 
concentrator (Eppendorf, Hamburg, Germany) at RT for approximately 45 mins. Samples 
were then re-measured by Nanophotometer to ensure the concentration was >25 ng/µL. 
RNA samples were then stored at -80°C until samples from all experiments were 
obtained. Once all the RNA samples were obtained, the quality was assessed using an 
Agilent Bioanalyzer. 
 First- and second-strand cDNA was synthesised and biotinylated using the 
TargetAmp Nano Labelling Kit for Illumina Expression BeadChip (Illumina, San Diego, 
CA). The T7-Oligo (dT) Primer was annealed to the sample by incubation at 65°C for 5 
mins in a thermocycler. The 1st-strand cDNA synthesis master mix was prepared using 
SuperScript III Reverse Transcriptase (Life Technologies) combined with the DTT and 
1st-strand cDNA PreMix provided. The master mix was added to the samples and mixed, 
then incubated for 30 mins at 50°C in a thermocycler. The 2nd-strand cDNA synthesis 
master mix was prepared by combining the 2nd-strand cDNA PreMix and DNA 
Polymerase provided. The 2nd-strand master mix was then added to the samples and 
mixed. Samples were incubated at 65°C for 10 mins, briefly microcentrifuged, then 
incubated at 80°C for 3 mins. An in vitro transcription reaction then produced Biotin-
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aRNA (anti-sense RNA, also called cRNA) by incorporating Biotin-UTP into the RNA 
transcripts. The reaction contained a T7 transcription buffer, UTP/Biotin-UTP, NTP 
PreMix, DTT and T7 RNA Polymerase, which was mixed with the samples and 
incubated at 42°C for 4 hrs in a thermocycler. RNase-free DNase was added to each 
reaction for 15 mins at 37°C. Biotin-aRNA was then purified using the same RNeasy 
Mini Kit (Qiagen) and protocol as described for the RNA isolations. The required yield of 
purified biotin-aRNA was 750 ng/ 5 µL, measured using a Nanophotometer. Where 
required, samples with a lower yield were placed in a vacuum evaporation concentrator 
(Eppendorf) until the required yield was obtained. 
2.8.2  Preparation for microarray hybridisation 
Quantified Biotin-aRNA was prepared for microarray hybridisation according to 
the Illumina Whole-Genome Gene Expression Direct Hybridisation protocol and the 
HumanHT-12 v3 Expression BeadChip Kit, using all equipment specified: Briefly, aRNA 
samples were heated to 65°C for 5 mins, vortexed and pulse-centrifuged at 250 g, then 
cooled to RT. The required mass of each sample was combined with RNase-free water 
and the provided Hyb Mix at the volumes specified. Samples were loaded on a BeadChip, 
placed in a Hyb Chamber and incubated at 58°C overnight (14-20 hrs). A 1 x High-Temp 
Wash Buffer was prepared and heated to 55°C overnight. The following day the 
BeadChip was rinsed with a provided Wash E1BC solution, followed by a series of 
washes: high-temperature wash (55°C) for 10 mins, Wash E1BC solution for 5 mins at 
RT, 100% ethanol for 10 mins at RT, then Wash E1BC solution for 2 mins at RT. The 
BeadChip was blocked with Block E1 buffer for 10 mins at RT, then incubated with a 
1:1000 dilution of Cy3-streptavidin in Block E1 buffer for 10 mins at RT, protected from 
light. The BeadChip was washed with Wash E1BC solution for 5 mins at RT then dried 
by centrifugation at 1400 rpm for 4 mins. Data was obtained from the BeadChip by 
scanning on a BeadArray Reader. 
2.8.3  Data analysis 
Data were initially formatted in the Illumina GenomeStudio Gene Expression 
Module. A “Gene Expression” analysis was performed, generating a list of genes 
significantly expressed above background levels in each sample. The “average” 
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normalisation parameter was used without background correction, as per the instructions 
of the Partek Report Plug-in. The plug-in was used to export the data to analyse in Partek 
Genomics Suite (PGS).   
Analysis was conducted using the Gene Expression workflow in PGS. The 
imported samples were grouped into three sample groups: CD56dim cells, CD56bright cells 
and IL7 CD56bright cells and a Principal Components Analysis of all samples was 
conducted, using these sample groupings. Differentially expressed genes were identified 
using a one-way analysis of variance (ANOVA) by setting each of the sample groups as 
contrast levels: IL-7 CD56bright vs. CD56bright, IL-7 CD56bright vs. CD56dim, and CD56bright 
vs. CD56dim. Selecting for genes that vary across all samples based on sample group 
(cell-type), with a p-value of <0.05 reduced the list of genes to analyse. Separate gene 
lists were then generated for up and downregulation in each pair-wise comparison with 
fold-change cut-offs of <-2 for downregulation and >2 for upregulation, which can be 
found in Appendix 4.  
A Venn diagram of overlapping upregulated genes was generated by selecting on 
the three upregulation gene lists: IL-7 CD56bright vs. CD56bright, IL-7 CD56bright vs. 
CD56dim, and CD56bright vs. CD56dim. Likewise, a Venn diagram of overlapping 
downregulated genes was generated with the corresponding downregulation gene lists of 
the pair-wise comparisons. To focus on the top 100 genes in each analysis, gene lists 
were filtered to exclude the genes outside the top 100, and Venn Diagrams were 
generated in the same way as described. The top 100 genes in each analysis were also 
graphed by fold change, and genes that appeared in common across the analyses were 
colour-coded. The gene names or descriptions for the top 100 genes were identified in the 
PubMed Gene database (www.ncbi.nlm.nih.gov/gene) and, unless otherwise referenced, 
the known functions of the proteins they encode were found in the UniProt 
Knowledgebase (www.uniprot.org). 
Finally, the PGS Gene Ontology (GO) Enrichment Tool was used to categorise 
the genes in each of the Top 100 analyses into the functional groups: molecular function, 
biological process and cellular component. Each Top 100 up or downregulation analysis 
had a GO Enrichment list generated in the “Gene set analysis” tool. From the GO-
Enrichment lists, new gene lists were generated where each gene had all of its associated 
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GO function terms combined. Many genes had hundreds of GO function categories 
associated with them, therefore functional groups with an enrichment score of less than 5 
were filtered out. Functional groups that were repetitive or very similar to each other 
were also removed e.g. protein metabolic process and cellular protein metabolic process, 
the latter was removed. The lists of top 100 genes with GO Function categories are in 
Appendix 3. 
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Chapter 3: Utilising differential cytokine responses to enrich 
the CD56bright subset 
3.1  Introduction 
Human peripheral blood NK cells have been divided into two subsets based on 
their expression of CD56 and CD16. CD56dimCD16+ NK cells are the major subset 
(>95%) and the remaining <5% are CD56brightCD16-/dim (Cooper et al., 2001). We 
previously observed that the CD56bright subset was able to prime CD4+T cell activation in 
response to HSV lipopeptides and that unseparated NK cells augmented HSV-specific 
CD4+T cell activation by DCs that had taken up lipopeptides (Kim et al., 2012). The 
CD56bright subset was considered most likely to perform this function. Therefore, we were 
interested to study this non-cytolytic NK cell subset further, particularly in interactions 
with cells such as CD4+T cells and DCs. To enrich and expand the CD56bright subset in 
culture; we sought to culture NK cells with cytokines that selectively induce CD56bright 
survival and proliferation without priming them for cytotoxic activity. This was 
particularly important for coculture studies as MDDCs take 5-7 days to differentiate.  
There are some differentially expressed cytokine receptors on CD56bright and 
CD56dim NK cells that could allow these cytokines to selectively enrich CD56bright NK 
cells in culture. Both CD56bright and CD56dim NK cells express the intermediate affinity 
IL-2 receptor, IL-2Rβγ, containing the 75kDa βγ subunit. However CD56bright NK cells 
uniquely express the high affinity IL-2Rαβγ receptor, containing the additional 55kDa α-
subunit, also known as CD25 (Caligiuri et al., 1990, Carson et al., 1997). As a 
consequence of their unique expression of the high affinity IL-2 receptor, CD56bright NK 
cells selectively proliferate in response to low (picomolar) concentrations of IL-2. In 
contrast, CD56dim NK cells show almost no proliferation, even in response to high 
(nanomolar) concentrations of IL-2, however cytotoxic activity is significantly enhanced 
(Caligiuri, 1993, Baume et al., 1992, Caligiuri et al., 1990). After stimulation with IL-2, 
increased cytotoxic activity in the CD56bright subset has also been observed after 
prolonged exposure, even at low doses (Caligiuri et al., 1990, Ferlazzo et al., 2004b). 
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 CD56bright NK cells uniquely express the c-kit (CD117) tyrosine kinase receptor 
(Matos et al., 1993). It was demonstrated that the combination of the c-kit ligand Stem 
Cell Factor (SCF) and IL-2 synergistically augmented the proliferative capacity of 
CD56bright NK cells (Matos et al., 1993). More recently, it was reported that SCF could 
combine with either IL-2 or IL-15 to enhance MAPK-mediated proliferation of NK cells, 
presumably the CD56bright subset (Benson et al., 2009). 
IL-15 shares many properties with IL-2, especially on NK cells (Zwirner and 
Domaica, 2010). Both cytokines have roles in the development, survival, proliferation 
and effector functions of NK cells, such as cytotoxic activity (Becknell and Caligiuri, 
2005). When the proliferative response of CD56bright NK cells in response to IL-2 and IL-
15 was compared, it was found that IL-15 was capable of inducing proliferation at 10 
ng/mL, but unlike IL-2, not at lower concentrations ranging from 0.01-1 ng/mL. In 
contrast, CD56dim NK cells exhibited minimal to no proliferation in response to IL-2 or 
IL-15 (Carson et al., 1994). NK cells have been shown to display cytotoxic activity 
against target cells after incubation with concentrations of IL-2 that saturate the 
intermediate affinity IL2Rβγ receptor (Caligiuri et al., 1990). This activity was abrogated 
in the presence of anti-IL-2Rβ antibody (Phillips et al., 1989). Similarly, IL-15 induced 
cytotoxic activity against target cells by CD56dim NK cells, which was also inhibited by 
anti-IL-2Rβ antibody, demonstrating that IL-15 also signals through the IL-2Rβγ receptor 
(Carson et al., 1994).  
Unlike IL-15Rα, the high affinity receptor for IL-7, IL-7Rα (CD127), is 
specifically expressed on CD56bright NK cells with little to no expression on CD56dim NK 
cells. Michaud et al. examined IL-7Rα expression on NK cells and compared the effects 
of IL-7 stimulation with IL-15. After culture for 72 hours, IL-7 (10 ng/mL) did not induce 
any significant cytotoxic activity of NK cells against K562 target cells, unlike IL-15 (50 
ng/mL). After 48 hours of culture, higher levels of IFN-γ were produced in response to 
IL-15 than IL-7. After 7 days of culture, IL-7 had not significantly induced expression of 
activation markers CD25 and CD69, unlike IL-15. IL-7 also did not induce CD56bright NK 
cell proliferation as measured by CFSE after 7 days culture. However, IL-7 specifically 
preserved the survival of the CD56bright population by the upregulation of Bcl2 in this 
subset. The authors concluded that IL-7 specifically promoted the survival of CD56bright 
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NK cells, but did not influence activation, cytotoxicity or proliferation of this subset in 
comparison to IL-15 (Michaud et al., 2010). 
In contrast, an earlier study by Dadmarz et al. reported differing observations. 
They found that IL-7, also at 10 ng/mL, significantly augmented CD56bright NK 
cytotoxicity against K562 target cells after 16 hours of culture, similar to that induced by 
20 U/mL of IL-2. In addition they measured the proliferative response of both NK cell 
subsets to IL-2 or IL-7 after 3 and 7 days culture by 3H-labelled thymidine incorporation. 
IL-2 induced proliferation in both CD56bright and CD56dim NK cells, although growth was 
significantly greater in the CD56bright population. In contrast, IL-7 induced proliferation 
only in CD56bright NK cells. IL-7-induced growth was maximal by day 3, but it was 10 to 
20-fold lower than the IL-2 induced proliferation of CD56bright NK cells. Thus the authors 
concluded that IL-2 had potent proliferative activity on both subsets but, unlike Michaud 
et al., IL-7 had moderate proliferative and cytotoxic activity confined to the CD56bright 
population (Dadmarz et al., 1994). 
Another study by Vukicevic et al. compared cytokine-stimulated CD56bright NK 
cells from normal subjects with CD56bright NK cells at an early stage after Haematopoietic 
Stem Cell transplant. Amongst their observations they found that CD56bright NK cells 
cultured with IL-15 had downregulated expression of CCR7, and upregulated CD94, 
HLA-DR and perforin compared to unstimulated CD56bright NK cells. They also 
compared the expression of c-kit, CD127 (IL-7Rα) and CCR7 on CD56bright NK cells 
cultured with IL-15, IL-2 or IL-7 for 6 days. IL-15 and IL-2 resulted in similar levels of 
downregulation of c-kit, CD127 and CCR7, whereas IL-7 only downregulated CD127 to 
the same extent as IL-2 and IL-15 but had markedly less effect on c-kit and CCR7 
expression (Vukicevic et al., 2010). 
Thus, a number of studies reported the selective action of IL-15, IL-2 and IL-7 on 
the NK cell subsets, which in some cases differed in relation to survival, cytotoxicity, 
proliferation and phenotypic markers. Therefore, we compared the effects of culturing 
NK cells with these cytokines to determine whether a method to selectively enhance the 
survival and proliferation of CD56bright NK cells could be established without altering 
their functional properties. The following comparisons were made: IL-7 and IL-15 effects 
on the survival and cytotoxic potential of both NK cell subsets, and IL-2 and IL-7 on 
Chapter 3: Utilising differential cytokine responses to enrich the CD56bright subset 
	 74 
selective promotion of CD56bright NK cell survival and proliferation. We further 
investigated the effects of IL-7 on CD56bright NK cells by comparing the gene expression 
profile of IL-7 CD56bright NK cells with freshly isolated CD56bright and CD56dim NK cells 
using DNA microarray. Finally, a sample of key surface receptors expressed on 
CD56bright or CD56dim NK cells were examined before and after culture with IL-7 by flow 
cytometry and compared to the gene expression results. The implications of the changes 
induced by IL-7 on CD56bright NK cell function are discussed. 
3.2  Results 
3.2.1 Optimal concentrations of IL-15 and IL-7 for NK cell viability 
As reported in the literature, both IL-15 and IL-7 have been characterised as 
cytokines important for NK cell survival, specifically CD56bright NK cells in the case of 
IL-7. However, as discussed above, the observations regarding the effects of IL-7 are 
inconsistent, and some contradictory, in relation to cytotoxicity and proliferation. 
Therefore, this study began by comparing the effects of IL-15 and IL-7 on the NK cell 
subsets survival and cytotoxic potential. Firstly, the concentration of each cytokine was 
optimised for the best maintenance of NK cell viability. 
NK cells were cultured with serial concentrations of IL-15 or IL-7 for 7 days, then 
analysed by flow cytometry for the percentage of viable cells, determined by forward and 
side-scatter properties. In the absence of either cytokine a marked decrease in viability 
was observed. For the IL-15 control-treated cells, the viability of NK cells before culture 
ranged from 72-95%, and decreased to 17-31% after 7 days in the absence of cytokine (0 
ng/mL) (Figure 3.1A). Viability was maximal at an IL-15 concentration of 10 ng/mL, at 
47-69%. Therefore, the concentration of 10 ng/mL of IL-15 was chosen as optimal. In the 
IL-7 control-treated cells, initial viability ranged from 93-94% and decreased to 8-13% 
after 7 days in the absence of cytokine (0 ng/mL) (Figure 3.1B). In the presence of 1 
ng/mL, 10 ng/mL and 20 ng/mL of IL-7, NK cell viability was 19-34%, 25-35% and 20-
38% respectively. Since the range in percentage of cell viability between 1-20 ng/mL of 
IL-7 was overlapping, the minimal concentration of 1 ng/mL was chosen as optimal. 
Subsequently, the effects of IL-15 and IL-7 on NK cell viability were compared at 
optimised concentrations. NK cells were cultured in the absence (mock) or presence of 
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IL-15 (10 ng/mL) or IL-7 (1 ng/mL) for 7 days and analysed by flow cytometry. After 7 
days culture, partial maintenance of NK cell viability was observed in NK cells cultured 
in the presence of IL-15 compared to mock and IL-7 (Figure 3.1C). In mock cultures, 
after 7 days without cytokine the percentage of viable NK cells significantly decreased 
from 87 ± 5% before culture to 19 ± 19% (**p<0.01) (Figure 3.1D). After culture with 
IL-15, the percentage of viable NK cells was significantly restored compared to mock, at 
62 ± 25% (*p<0.05). The decrease in cell viability after culture with IL-15 compared to 
before culture was not significant. However, after culture with IL-7, the percentage of 
viable NK cells significantly decreased to 44 ± 24% compared to before culture 
(*p<0.05). Therefore IL-15 maintained a greater percentage of viable NK cells than IL-7. 
 
 
 
 
 
 
 
 
 
Figure 3.1. Comparison of optimised concentrations of IL-15 and IL-7 on NK cell 
viability. NK cells were cultured in the presence of graded concentrations of IL-15 or IL-
7 for 7 days and analysed by flow cytometry for the percentage of viable cells, 
determined by forward and side scatter properties. (A) The percentage of viable cells 
measured before and after 7 days culture in the presence of 0-10 ng/mL IL-15, n=3. (B) 
The percentage of viable cells measured before and after 7 days culture in the presence of 
0-20 ng/mL IL-7, n=2. (C&D) NK cells were cultured in the absence (mock) or presence 
of IL-15 (10 ng/mL) or IL-7 (1 ng/mL) for 7 days. (C) Representative plots of the 
percentage of viable cells before and after 7 days culture with mock, IL-15 and IL-7 are 
shown. (D) The percentage of total viable NK cells before (blue bars) and after 7 days 
culture (red bars) with mock, IL-15 or IL-7 are shown as mean ± S.D., n=4, *p<0.05, 
**p<0.01 (Paired t test). 
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3.2.2 IL-7 specifically enhanced survival of CD56bright NK cells, IL-15 maintained 
survival of both NK cell subsets 
Although IL-15 maintained NK cell viability to a greater extent than IL-7, this 
was with the total NK cell population, rather than defining specific effects of these 
cytokines on CD56bright and CD56dim NK cells. Therefore the effects of IL-15 and IL-7 on 
the proportions of each subset within the viable population of NK cells were compared.  
 The percentages of CD56bright and CD56dim NK cells before and after culture in 
IL-15 and IL-7 are shown in representative FACS plots (Figure 3.2A). Changes in 
percentage of CD56bright and CD56dim NK cells were calculated as fold change (log2) 
relative to before culture. In the presence of IL-15, the fold change (log2) in percentage of 
CD56dim and CD56bright NK cells was -0.4 ± 0.3-fold and -0.1 ± 1.2-fold respectively, 
which did not significantly change from before culture (Figure 3.2B). In the presence of 
IL-7, the fold change (log2) in percentage of CD56dim NK cells decreased by -2.2 ± 1.2-
fold, and for CD56bright NK cells increased by 1.7 ± 0.9-fold, compared to before culture. 
There was a statistically significant increase in CD56bright NK cells compared to CD56dim 
NK cells after culture with IL-7 (*p<0.05). Therefore, IL-15 maintained the survival of 
both NK cell subsets, whereas IL-7 specifically enhanced the survival of CD56bright NK 
cells. 
 
 
 
 
 
 
Figure 3.2. The proportion of each subset in the surviving NK cells with IL-15 or IL-
7. NK cells were cultured in the absence (mock) or presence of IL-15 (10 ng/mL) or IL-7 
(1 ng/mL) for 7 days and analysed by flow cytometry. (A) Representative plots of the 
percentages of each NK cell subset before and after culture with mock, IL-15 or IL-7 are 
shown. (B) Fold change (log2) in the percentage of CD56bright (purple bars) and CD56dim 
(green bars) NK cells on day 7 after culture with mock, IL-15 or IL-7, relative to before 
culture. Bars display mean ± S.D., n=3, *p<0.05 (Paired t test). 
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3.2.3 IL-15 maintained or increased perforin expression in both NK cell subsets to a 
greater extent than IL-7 
Following the confirmation that IL-7 had a specific effect on enhancing survival 
of CD56bright NK cells, its effect on potential cytotoxic activity was compared to that of 
IL-15. Perforin was chosen as an indicator of potential cytotoxicity as the upregulation of 
its expression is indicative of priming for cytolytic activity against target cells. As 
discussed in Chapter One, CD56dim NK cells have been characterised as more cytotoxic 
than CD56bright NK cells, and express higher levels of perforin. We confirmed this in our 
experiments and found that in freshly isolated NK cells, the Mean Fluorescence Intensity 
(MFI) of perforin in CD56dim NK cells was 4.8 ± 1.6-fold higher than that of CD56bright 
NK cells (Figure 3.3A). 
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To examine the effect of IL-7 on perforin expression compared to IL-15, NK cells 
were cultured in the absence (mock) or presence of IL-15 (10 ng/mL) or IL-7 (1 ng/mL) 
for 7 days and analysed for the intracellular expression of perforin by flow cytometry. 
After 7 days culture without cytokine (mock), the MFI of perforin in CD56dim and 
CD56bright NK cells, shown as fold change (log2) relative to before culture, decreased by  
-4.0-fold (median, IQR -4.8 to -1.1-fold) and -3.0-fold (median, IQR -3.7 to 0.2-fold) 
respectively (Figure 3.3C). After culture with IL-15, the fold change (log2) relative to 
before culture of perforin MFI in CD56dim NK cells was 0.3-fold (median, IQR -0.8 to 
0.6-fold), whereas after culture with IL-7, the perforin MFI decreased by -1.3-fold 
(median, IQR -2.8 to -0.6-fold). For CD56bright NK cells, after culture with IL-15 the 
perforin MFI increased by 2.3-fold (median, IQR -0.2 to 2.8-fold), whereas after culture 
with IL-7 the perforin MFI was -0.3-fold (median, IQR -1.3 to 1.5-fold) (Figure 3.3C). 
Therefore, although IL-7 slightly increased perforin expression in CD56bright NK cells in 
some subjects, the increase induced by IL-15 was greater and more consistently observed. 
Overall, IL-15 maintained or increased perforin expression in both NK cell subsets to a 
greater extent than IL-7. 
 
 
 
 
Figure 3.3. Perforin expression in each NK cell subset with IL-15 or IL-7. (A) 
Freshly isolated NK cells were analysed for intracellular perforin expression in CD56bright 
and CD56dim subsets. Perforin expression (MFI) in CD56dim relative to CD56bright NK 
cells. Black bars indicate mean ± S.D., n=7, ***p<0.001 (Paired t test). (B-C) NK cells 
were cultured in the absence (mock) or presence of IL-15 (10 ng/mL) or IL-7 (1 ng/mL) 
for 7 days and analysed by flow cytometry. (B) Representative histograms of intracellular 
perforin expression in CD56bright and CD56dim NK cells before (grey filled histogram) and 
after 7 days culture in the presence of mock (dotted line), IL-7 (thin line) or IL-15 (thick 
line). (C) Fold change (log2) in perforin expression (MFI) in CD56bright and CD56dim NK 
cells on day 7 after culture with mock, IL-15 or IL-7, relative to before culture. Black 
bars indicate median and interquartile range (IQR), n=5 (mock n=3), *p<0.05 (One-way 
ANOVA with multiple pair-wise comparisons).  
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3.2.4 Optimising the IL-2 concentration for specific survival of the CD56bright subset 
In the next part of this study, we conducted experiments comparing the survival 
and proliferative capacity of the NK cell subsets in response to IL-2 and IL-7. Firstly, the 
concentration of IL-2 was titrated to determine the concentration where only CD56bright 
NK cell survival was observed. 
NK cells were cultured for 7 days without cytokine (0 ng/mL) or with graded 
concentrations of IL-2 (0.1 ng/mL (6.67 pM), 1 ng/mL  (66.7 pM), 10 ng/mL (667 pM), 
or 20 ng/mL (1.33 nM)). The percentage of viable cells was then analysed by flow 
cytometry, using forward and side-scatter properties, compared to cells prior to culture 
(Figure 3.4A). Initial viability ranged from 93-94% and decreased to 8-13% without 
cytokine (0 ng/mL). In the presence of 0.1 ng/mL of IL-2, viability increased slightly 
compared to no cytokine, to 20-30%. NK cell viability was maximal at an IL-2 
concentration of 1 ng/mL, at 61-77%. Increasing the concentration further to 10 and 20 
ng/mL did not further increase viability, with values at 49-63% and 49.6-49.8% 
respectively. 
 Additionally, the percentages of CD56dim and CD56bright NK cells within the total 
NK cell population were examined under the same conditions (Figure 3.4B). The initial 
proportion of CD56dim NK cells was 88-94%, which decreased to 44-50% after 7 days 
culture without cytokine (0 ng/mL). In the presence of 0.1 ng/mL IL-2, the proportion of 
CD56dim NK cells did not increase above those cultured without cytokine, at 30-50%. The 
proportion of CD56dim NK cells was maximal with an IL-2 concentration of 10 ng/mL, at 
66-84%, as increasing the concentration to 20 ng/mL did not further increase viability, at 
65-81%. The initial proportion of CD56bright NK cells was 1.5-2.3%, which increased 
slightly to 3.5-8% after 7 days culture without cytokine (0 ng/mL). The proportion of 
CD56bright NK cells was increased to 8-23% in the presence of 0.1 ng/mL IL-2, which 
was not further increased at the higher concentrations of 1, 10 and 20 ng/mL IL-2, at 8-
22%, 10-21.5% and 10-21% respectively. Therefore, only the CD56bright subset was 
maintained in the presence of 0.1 ng/mL IL-2, whereas the CD56dim subset was 
maintained at higher concentrations. Therefore the IL-2 concentration of 0.1 ng/mL was 
chosen for studies comparing the selective action of IL-2 with IL-7 on CD56bright NK 
cells. 
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Figure 3.4. Effect of graded concentrations of IL-2 on the viability and proportion of 
NK cell subsets. NK cells were cultured in the presence of a series of concentrations of 
IL-2 for 7 days, and analysed by flow cytometry. (A) The percentage of viable cells, 
determined by forward and side scatter, before and after 7 days culture in the presence of 
0-20ng/mL IL-2, n=2. (B) The percentage of CD56bright and CD56dim NK cell subsets 
within the viable population from the same experiments as in (A). 
3.2.5 IL-7 specifically increased the proportion of CD56bright NK cells to a similar 
extent as IL-2 
After titrating the concentration of IL-2 and observing that a concentration of 0.1 
ng/mL was sufficient to maintain CD56bright NK cell survival, experiments were 
performed to directly compare IL-7 and IL-2 at their optimised concentrations, in 
specifically enhancing CD56bright NK cell survival. NK cells were cultured for 7 days in 
the absence (mock) or presence of IL-2 (0.1 ng/mL) or IL-7 (1 ng/mL), and then analysed 
by flow cytometry for the percentage of viable cells determined by forward and side-
scatter properties, compared to cells prior to culture (Figure 3.5A). Before culture, the 
percentage of viable NK cells was 90 ± 5%, and after mock culture (no cytokines), viable 
NK cells significantly decreased to 10 ± 5% (***p<0.001). In the presence of IL-2 or IL-
7, the percentage of viable NK cells was also significantly decreased to 30 ± 11% and 30 
± 12% respectively (***p<0.001), but were still significantly increased compared to 
mock (*p<0.05). 
Within the viable NK cell population, the percentage of CD56bright and CD56dim 
NK cells before and after culture in the absence (mock) or presence of IL-2 or IL-7 was 
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also assessed by flow cytometry. After culture with IL-2 or IL-7, the percentage of the 
CD56bright subset increased, while the CD56dim subset decreased compared to before 
culture (Figure 3.5B) Changes in percentage of CD56bright and CD56dim NK cells were 
calculated as fold change (log2) relative to before culture (Figure 3.5C). After culture 
with IL-2, the fold change (log2) in percentage of CD56dim NK cells decreased by 0.9 ± 
0.5-fold whereas with CD56bright NK cells it increased by 1.5 ± 0.9-fold. The difference in 
fold change (log2) between CD56dim and CD56bright NK cells was significant (**p<0.01). 
After culture with IL-7, the fold change (log2) in percentage of CD56dim NK cells 
decreased by 0.3 ± 0.2-fold, whereas it increased by 1.9 ± 0.5-fold in CD56bright NK cells 
relative to before culture. The difference in fold change (log2) between CD56dim and 
CD56bright NK cells was highly significant (***p<0.001 IL-7, **p<0.01 IL-2). However, 
there was no significant difference between IL-7 and IL-2 in fold change (log2) in 
survival of CD56bright NK cells. Therefore both IL-2 and IL-7 selectively maintained the 
survival of CD56bright NK cells and were equivalent. 
 
 
 
 
 
 
Figure 3.5. The proportion of each NK cell subset within the surviving NK cells with 
IL-2 or IL-7. NK cells were cultured in the absence (mock) or presence of IL-2 (0.1 
ng/mL) or IL-7 (1 ng/mL) for 7 days and analysed by flow cytometry. (A) The percentage 
of total viable NK cells, determined by forward and side scatter, before (blue bar) and 
after 7 days culture (red bars) with mock, IL-2 or IL-7 are shown as mean ± S.D. n = 7 
(mock n=4), *p<0.05, ***p<0.001 (One-way ANOVA with multiple pair-wise 
comparisons). (B) Representative plots of the percentages of each NK cell subset before 
and after culture with mock, IL-2 or IL-7 are shown. (C) Fold change (log2) in the 
proportion of CD56bright (purple bars) and CD56dim (green bars) NK cells on day 7 after 
culture with mock, IL-2 or IL-7, relative to before culture, shown as mean ± S.D. n=7 
(mock n=4), **p<0.01 ***p<0.001 (Paired t test). 
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3.2.6 IL-7 increased the number of CD56bright NK cells after culture to a similar 
extent as IL-2 
Although IL-2 and IL-7 were found to be similarly effective in enhancing the 
survival of CD56bright NK cells, it was not known whether both cytokines were inducing 
an increase in the number of CD56bright NK cells due to proliferation, or whether the 
increase in proportion was only due to the significant decrease in CD56dim NK cells. To 
determine whether the number of CD56bright NK cells was increasing in IL-7 as well as 
IL-2, total NK cell counts were performed before and after 7 days culture in the absence 
(mock) or presence of IL-2 (0.1 ng/mL) or IL-7 (1 ng/mL). After analysis by flow 
cytometry, the cell count of each subset was determined by applying the percentage of 
CD56bright and CD56dim NK cells to the total cell count. Representative cell counts show 
that the number of CD56bright NK cells increased after culture with IL-2 or IL-7, whereas 
the number of CD56dim NK cells decreased (Figure 3.6A). Changes in cell counts of 
CD56bright and CD56dim NK cells were calculated as fold change (log2) relative to before 
culture. 
After culture without cytokine (mock), the fold change (log2) in cell count of 
CD56bright decreased by -4.9-fold (median, IQR -6.3 to -4.2-fold) (Figure 3.6B). After 
culture with IL-2, the fold change (log2) in cell count of CD56bright NK cells increased by 
0.7-fold (median, IQR 0.4 to 1.3-fold). For IL-7, the fold change (log2) in cell count of 
CD56bright NK cells increased by 1.2-fold (median, IQR 0.8 to 1.6-fold). Therefore, the 
number of CD56bright NK cells was significantly increased by both IL-2 and IL-7 
compared to mock (***p<0.001). After mock culture, CD56dim NK cells decreased in cell 
count by -5.2-fold (median, IQR -6.2 to -3.7-fold). After culture with IL-2, CD56dim NK 
cells decreased by -2.1-fold (median, IQR -2.3 to -1.3-fold), and IL-7 decreased CD56dim 
NK cells by -1.8-fold (median, IQR -2.0 to -1.5-fold) compared to before culture. 
Although CD56dim cell counts decreased compared to before culture with IL-2 and IL-7, 
they were still significantly greater than mock (***p<0.001). Importantly, the fold change 
(log2) in cell count of CD56bright NK cells after culture with either IL-2 or IL-7 was 
significantly increased compared to CD56dim NK cells for both cytokines (***p<0.001). 
However, there was no significant difference in fold change (log2) in cell count of the 
CD56bright NK cells between IL-7 and IL-2 cultures. Therefore, IL-2 and IL-7 increased 
the number of CD56bright NK cells to a similar extent.  
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CD56bright NK cell counts 
Day 0 Day 7 
 Mock IL-2 IL-7 
0.99x104 0.06x104 2.1x104 3.2x104 
 
CD56dim NK cell counts 
Day 0 Day 7 
 Mock IL-2 IL-7 
2.82x105 0.26x105 1.33x105 1.25x105 
 
B 
 
Figure 3.6. CD56bright and CD56dim NK cell counts with IL-2 or IL-7. NK cells were 
cultured in the absence (mock) or presence of IL-2 (0.1 ng/mL) or IL-7 (1 ng/mL) for 7 
days and analysed by flow cytometry. Cell numbers were counted before and after 
culture. The cell count of each subset was determined by applying the percentage of 
CD56bright and CD56dim NK cells obtained by flow cytometry to the total cell counts. (A) 
Cell counts of CD56bright and CD56dim NK cells before and after culture with mock, IL-2 
or IL-7 from a representative experiment. (B) Fold change (log2) in the number of 
CD56bright and CD56dim NK cells on day 7 after culture with mock, IL-2 or IL-7, relative 
to before culture. Box-whisker plots represent median (line), minimum (lower whisker) 
and maximum (upper whisker) values, first and third quartiles are represented by the 
lower and upper boundaries of the box, n=6 (mock n=4), ***p<0.001 (One-way ANOVA 
with multiple pair-wise comparisons). 
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3.2.7 Optimising the concentration of Stem Cell Factor (SCF) to augment the number 
of CD56bright NK cells in combination with IL-2 
Since it was observed that IL-7 appeared to increase the number of CD56bright NK 
cells to a similar extent as IL-2, we next wanted to compare the effect of each cytokine on 
proliferation. However, before conducting these experiments, the concentration of Stem 
Cell Factor (SCF) was also optimised in combination with IL-2, since it had been 
reported previously that the proliferation of CD56bright NK cells was synergistically 
augmented in the presence of both IL-2 and SCF (Matos et al., 1993).  
NK cells were cultured for 7 days in the absence (mock) or presence of IL-2 (0.1 
ng/mL) with or without the addition of serial concentrations of SCF, then analysed by 
flow cytometry. The highest percentage of CD56bright NK cells was 18% when cultured 
with IL-2 + 200 ng/mL SCF (Figure 3.7A upper panel). At this concentration, the highest 
cell count of CD56bright NK cells was also observed, at          3.9 x 104 (Figure 3.7A lower 
panel). Inversely, the lowest percentage of CD56dim NK cells was also observed with IL-2 
+ 200 ng/mL SCF, at 67% (the same percentage was observed with IL-2+ 10 ng/mL 
SCF) (Figure 3.7B upper panel). In the IL-2 + 200 ng/mL SCF condition, the cell count 
of CD56dim NK cells was 1.5 x 105, which was slightly decreased compared to mock, but 
increased compared to IL-2 only (Figure 3.7B lower panel). Since CD56bright NK cells 
were at the highest percentage and cell count in IL-2 + 200 ng/mL SCF, this 
concentration was chosen as optimal for SCF. 
 
 
 
 
 
Figure 3.7. Titration of Stem Cell Factor (SCF) in combination with IL-2 to increase 
CD56bright NK cells. NK cells were cultured in the absence (mock) or presence of IL-2 
(0.1 ng/mL) with or without the addition of graded concentrations of SCF (0-400 ng/mL) 
for 7 days and analysed by flow cytometry. The percentage of each subset within the total 
NK cell population, and the cell count of each subset were determined before and after 
culture by flow cytometry. The cell count of each subset was determined as in Figure 3.6. 
(A) The percentage (upper panel) and cell count (lower panel) of CD56bright NK cells. (B) 
The percentage (upper panel) and cell count (lower panel) of CD56dim NK cells. 
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3.2.8 IL-7 induced proliferation in a similar percentage of CD56bright NK cells as IL-2 
and IL-2 + SCF 
A proliferation assay was conducted to compare the percentage of proliferated 
CD56bright NK cells after culture with IL-2, IL-7 or IL-2 + SCF. NK cells were labelled 
with CellTrace Violet and then cultured for 7 days in the absence (mock) or presence of 
IL-2 (0.1 ng/mL), IL-7 (1 ng/mL) or IL-2 + SCF (0.1 ng/mL IL-2 + 200 ng/mL SCF) and 
analysed for the percentage of proliferated CD56bright and CD56dim NK cells, measured by 
flow cytometry. Proliferation was observed in CD56bright NK cells following culture with 
each cytokine examined (Figure 3.8A). After culture with IL-2, 24 ± 14% of CD56bright 
NK cells were proliferated, which was significantly greater than CD56dim NK cells (0.7 ± 
0.4%, *p<0.05) (Figure 3.8B). IL-7 induced 35 ± 4% of CD56bright NK cells to proliferate, 
which was significantly increased compared to CD56dim NK cells (0.4 ± 0.2%, 
***p<0.001). IL-2 + SCF induced 41 ± 26% of CD56bright NK cells to proliferate, which 
was also significantly greater than CD56dim NK cells (1.0 ± 0.8%, *p<0.05). All three 
cytokine conditions also induced a significantly greater percentage of CD56bright NK cells 
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to proliferate than mock culture. Due to the variability in proliferative response to each 
cytokine condition across subjects, there was no statistically significant difference 
between the percentage of proliferated CD56bright NK cells cultured in IL-2, IL-7 or IL-2 
+ SCF, although IL-7 tended to induce fewer rounds of replication than the other 
cytokines (Figure 3.8A). Therefore, IL-7 induced proliferation in the CD56bright NK cell 
subset, and in an equivalent percentage of cells as IL-2 and IL-2 + SCF. 
 
B 
 
Figure 3.8. The percentage of proliferating CD56bright NK cells when cultured with 
IL-7, IL-2 or IL-2+SCF. CellTrace Violet-labelled NK cells were cultured in the absence 
(mock) or presence of IL-2 (0.1 ng/mL), IL-7 (1 ng/mL) or IL-2+SCF (0.1 ng/mL + 200 
ng/mL) for 7 days and analysed by flow cytometry. (A) Representative plots show 
proliferation of CD56bright NK cells in the presence of mock, IL-2, IL-7 and IL-2+SCF 
after 7 days culture. (B) The percentage of proliferated CD56bright (purple bars) or 
CD56dim (green bars) after 7 days culture in the presence of mock, IL-2, IL-7 or IL-
2+SCF are shown as mean ± S.D., n=4 (mock n=3), *p<0.05, ***p< 0.001 (Unpaired t 
tests for all CD56bright comparisons to mock, paired t-tests for comparisons between 
CD56bright and CD56dim). 
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3.2.9 Gene expression profiling of IL-7 cultured CD56bright NK cells compared with 
resting CD56bright and CD56dimNK cells 
So far, this study showed that IL-7 induced proliferation of the CD56bright subset 
without significantly enhancing perforin expression as a marker of cytotoxicity. We next 
wanted to determine whether IL-7 cultured CD56bright NK cells were a suitable surrogate 
to study CD56bright NK cells in maintaining similar functional properties. Therefore, the 
next part of the study compared the gene expression profile of IL-7 cultured CD56bright 
NK cells (IL-7 CD56bright) with freshly isolated CD56bright and CD56dim subsets by DNA 
microarray. Some key phenotypic and functional markers were then assessed at the 
protein level by flow cytometry.  
To analyse gene expression by DNA microarray, NK cells were cell sorted into 
CD56bright and CD56dim subsets. Additionally, some unsorted NK cells were cultured with 
IL-7 (1 ng/mL) for 7 days, and then sorted for CD56bright NK cells. RNA was extracted 
from each of the three cell types and these samples were collected from three subjects. 
Samples were prepared for hybridisation to an Illumina BeadChip and run on the 
BeadArray Reader. Data was initially formatted in the Illumina GenomeStudio Gene 
Expression Module, and then exported to Partek Genomics Suite (PGS) for analysis. 
A Principal Components Analysis (PCA) was conducted of the gene expression of 
IL-7 CD56bright, CD56bright and CD56dim NK cells for three subjects. PCA is a 
mathematical algorithm that reduces the dimensionality of highly dimensional data while 
retaining most of the variation in the data set. It identifies directions, called principal 
components, along which the variation in the data is maximal. The first principal 
component is the direction along which the samples show the greatest variation, the 
second component is the direction uncorrelated to the first where the samples show the 
largest variation, and the third component is the direction uncorrelated to the first and 
second that shows the largest variation (Ringner, 2008). Points that are close together in 
the plot have similar intensity values across the probe sets on the whole chip (genome), 
and points that are far apart in the plot are dissimilar. In Figure 3.9, the first principle 
component (PC #1) has the greatest variance of 49.1%, then PC#2 is 16.1%, then PC#3 is 
8.74%. Combined, these components show 73.9% variance of the data. Each point 
represents one sample (one cell type from one subject), and the colours represent each 
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cell type: red is IL-7 CD56bright, blue is CD56bright and green is CD56dim. The plots 
demonstrate that the samples within each subset cluster closely together. In some ways, 
IL-7 CD56bright and CD56bright are similar as shown in the plot PC#1 vs. PC#3, however 
each NK cell type clusters distinctly from each other, indicating each has a distinct 
pattern of gene expression. Although one of the CD56dim samples appeared to cluster 
somewhat apart from the others, we chose to include this sample for further grouped 
analyses in order to conduct the statistical analyses with equal sample numbers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Principal components analysis (PCA) of gene expression in IL-7 
CD56bright compared to CD56bright and CD56dim NK cells. PCA identified the three 
directions (PC1, PC2 and PC3) along which the data had the largest variance, with their 
combined variance shown as the percentage at the top of the figure. Three plots PC1 vs. 
PC2, PC1 vs. PC3 and PC2 vs. PC3 are shown. Each dot represents one subject’s sample 
of CD56bright, CD56dim or IL-7 CD56bright, and three subjects were analysed, or a total of 
nine samples (dots). Each cell-type is coloured: CD56bright (blue), CD56dim (green) and 
IL-7 CD56bright (red), and each cluster is marked with an ellipsis based on cell-type. 
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3.2.10 Overlap of up and downregulated genes in each pair-wise comparison: IL-7 
CD56bright vs. CD56bright, IL-7 CD56bright vs. CD56dim and CD56bright vs. CD56dim 
An Analysis of variance (ANOVA) of the grouped data was generated to detect 
differentially expressed genes by comparing the three cell types in pairs: IL-7 CD56bright 
vs. CD56bright, IL-7 CD56bright vs. CD56dim, and CD56bright vs. CD56dim.  This generated 
fold-change data for each of the cell-type pairings for 34,694 genes. The list of genes to 
analyse was reduced to 6,397 by selecting for genes that vary across all samples based on 
cell type and setting a p-value cut-off of p<0.05. Then data for up and downregulation 
were analysed separately for each pair-wise analysis of IL-7 CD56bright vs. CD56bright, IL-
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7 CD56bright vs. CD56dim and CD56bright vs. CD56dim. Refer to Appendix 4 for the full lists 
of up and downregulated genes for each pair-wise comparison. 
Venn diagrams showing the intersections of these lists of genes up or 
downregulated in each of the pair-wise analyses were generated (Figure 3.10A). There 
were 115 significantly upregulated genes in CD56bright compared to CD56dim (purple 
circle). However, there were many more genes upregulated in IL-7 CD56bright compared 
to either CD56bright (pink circle) or CD56dim (green circle) at 1549 and 1471 genes 
respectively. There was some similarity between CD56bright and IL-7 CD56bright cells with 
80 genes significantly upregulated in common compared to CD56dim (overlap of purple 
and green circles). Twenty of those 80 genes were further significantly upregulated in IL-
7 CD56bright compared to CD56bright (central overlap). However, 118 genes were 
significantly upregulated in IL-7 CD56bright compared to both CD56bright and CD56dim 
cells (overlap of pink and green circles). Overall there were less significantly 
downregulated genes, however the pattern of overlap was similar, where more genes 
were significantly downregulated in the IL-7 CD56bright compared to both CD56bright and 
CD56dim cells. Taken together, these data indicate that IL-7 CD56bright cells have a distinct 
pattern of gene expression with more differentially expressed genes compared to both 
CD56bright and CD56dim cells.  
Refining the analysis to the top 100 genes in each pair-wise comparison changed 
the pattern of overlapping genes (Figure 3.10B). An increased proportion of genes were 
commonly upregulated in CD56bright and IL-7 CD56bright compared to CD56dim at 33%, 33 
genes out of 100 (overlap of purple and green circles). In the previous Venn diagram 
(Figure 3.10A) only 5.4% (80 genes out of 1471 genes upregulated in IL-7 CD56bright vs. 
CD56dim) were upregulated in common with CD56bright vs. CD56dim. There was a similar 
increase in the proportion of genes downregulated in common in CD56bright and IL-7 
CD56bright compared to CD56dim in the Top 100 downregulated genes. Taken together, 
these data show there was an enrichment of genes in common between IL-7 CD56bright 
and CD56bright compared to CD56dim in the Top 100 most up and downregulated genes. 
Refer to Appendix 3 for lists of the Top 100 up and downregulated genes for each pair-
wise comparison including Gene Ontology (GO) functional categories. 
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Figure 3.10. Overlapping and distinct gene expression in IL-7 CD56bright compared 
to CD56bright and CD56dim NK cells. (A) Venn diagrams were generated by the 
intersection of the lists of up or downregulated genes with fold-change cut offs of >2 or 
<-2 in at least one of the three pair-wise comparisons: IL-7 CD56bright vs. CD56bright (pink 
circle); IL-7 CD56bright vs. CD56dim (green circle); CD56bright vs. CD56dim (purple circle). 
(B) The top 100 genes in the lists used to generate (A) were used to generate Venn 
diagrams of the intersections of up or downregulated genes for the top 100 genes for the 
three pair-wise comparisons: IL-7 CD56bright vs. CD56bright (pink circle); IL-7 CD56bright 
vs. CD56dim (green circle); CD56bright vs. CD56dim (purple circle). 
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3.2.11 Comparing the Top 100 upregulated genes in IL-7 CD56bright vs. CD56bright, and 
IL-7 CD56bright vs. CD56dim 
The top 100 genes in each pair-wise comparison were graphed and the functions of the 
proteins encoded by particular genes of interest were obtained from the UniProt 
Knowledgebase. Figure 3.11 shows the comparison of the top 100 upregulated genes in 
IL-7 CD56bright vs. CD56dim and IL-7 CD56bright vs. CD56bright. Genes upregulated in IL-7 
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CD56bright compared to both CD56bright and CD56dim are coloured blue. Table 3.1 shows 
the Top 20 “blue” genes, i.e. genes commonly upregulated in IL-7 CD56bright compared to 
both CD56bright and CD56dim, grouped according to the most common GO function 
categories, obtained from Partek’s GO Enrichment tool. The most common GO Function 
categories were various “metabolic processes”, “response to stimulus”, “mitotic cell cycle 
process” and “immune system process”. Upregulation of genes related to “mitotic cell 
cycle process” was expected since we confirmed that IL-7 induced proliferation in 
CD56bright NK cells. Of greatest functional interest were genes under the “immune system 
process” category. Only four of the twenty genes were in this category. Two of the genes, 
LTB (lymphotoxin beta) and KIT (KIT proto-oncogene receptor tyrosine kinase) were 
also expressed in CD56bright, but were further upregulated in IL-7 CD56bright (these genes 
are shown in Figure 3.11 and 3.12 as blue and pink striped bars). The other two genes in 
this category were AMICA1 (also known as JAML- Junction adhesion molecule-like 1) 
and RAB10. AMICA1 encodes the JAML protein, a protein associated with leukocyte 
migration. RAB10 encodes the Ras-related protein Rab-10, one of the Rab GTPases that 
regulate intracellular membrane trafficking. Rab-10 is mainly involved in transport of 
proteins from the Golgi to the plasma membrane.  
 
 
 
 
 
 
 
Figure 3.11. Analysis of the top 100 upregulated genes in IL-7 CD56bright compared 
to CD56bright and CD56dim NK cells. The top 100 genes upregulated in IL-7 CD56bright 
compared to CD56dim (upper graph) and IL-7 CD56bright compared to CD56bright (lower 
graph). Columns represent the fold change in the mRNA level of each gene by IL-7 
CD56bright compared to either NK cell subset. Blue genes were upregulated by IL-7 
CD56bright compared to both CD56dim and CD56bright. Pink genes were upregulated in 
common by IL-7 CD56bright and CD56bright compared to CD56dim (discussed in Figure 
3.12). Blue and pink striped genes were commonly upregulated by IL-7 CD56bright and 
CD56bright compared to CD56dim, but were also further significantly upregulated in IL-7 
CD56bright compared to CD56bright. Magenta genes were upregulated in IL-7 CD56bright 
compared to CD56bright, but were downregulated in CD56bright compared to CD56dim 
(discussed in Figure 3.15). Grey genes featured only in the top 100 of that particular pair-
wise comparison.  
 	 97 
 
 
 
 
0 
10 
20 
30 
40 
LT
B	
KI
T	
GZ
M
K	
M
AL
	
CC
R7
	
IL
7R
	
GP
R6
8	
TO
P2
A	
LE
F1
	
N
EL
L2
	
AM
IC
A1
	
EB
I2
	
AD
CY
3	
HL
A-
DM
B	
M
M
P2
5	
CD
2	
DC
AF
7	
PC
M
T1
	
CD
C2
0	
RC
BT
B2
	
XC
L1
	
DL
L1
	
N
U
SA
P1
	
SE
LL
	
RN
F1
44
	
IL
12
RB
2	
PR
AG
M
IN
	
CD
CA
5	
TY
M
S	
S1
00
A1
1	
AA
RS
	
CX
CR
3	
E2
F2
	
M
YC
	
RA
B1
0	
AT
P8
B4
	
TM
EM
14
C	
N
O
D2
	
CA
PG
	
RN
F1
44
A	
LO
C7
30
27
8	
AS
PM
	
PR
O
SC
	
KL
RC
1	
DP
YS
L2
	
HM
M
R	
ST
S-
1	
AC
AD
M
	
PD
E7
B	
CE
P5
5	
LP
XN
	
M
RP
S6
	
SS
BP
2	
ST
6G
AL
1	
CS
DA
	
TS
T	
DN
CL
1	
ZM
IZ
1	
AS
XL
2	
DE
N
N
D5
A	
TM
BI
M
4	
TT
F2
	
KI
FC
1	
AR
PC
5	
PC
M
TD
1	
VP
S3
5	
IG
FB
P4
	
GL
S	
CD
44
	
HS
.1
37
97
1	
TM
EM
12
3	
VI
M
	
ST
AM
BP
L1
	
VP
S3
6	
ER
M
P1
	
HA
DH
	
FV
T1
	
DL
GA
P5
	
ZN
F5
12
	
CA
PN
12
	
TM
EM
14
D	
DY
N
LL
1	
TM
EM
10
6B
	
IL
32
	
KR
CC
1	
E2
F3
	
SL
C4
4A
1	
AX
IN
2	
PR
DM
8	
W
DR
40
A	
EG
R2
	
CA
BL
ES
1	
EG
R1
	
PA
IC
S	
CY
P1
B1
	
N
CA
PD
2	
N
CA
PG
	
CD
27
	
M
RP
S3
1	
SP
IN
K2
	
Fo
ld
 C
ha
ng
e 
IL-7 CD56bright vs. CD56dim upregulation 
0 
5 
10 
15 
20 
25 
RC
BT
B2
	
AM
IC
A1
	
M
AL
	
TO
P2
A	
PC
M
T1
	
DC
AF
7	
GI
M
AP
4	
CD
C2
0	
KI
T	
RN
F1
44
	
DN
CL
1	
AA
RS
	
LP
XN
	
PR
AG
M
IN
	
IL
32
	
RA
B1
0	
M
M
P2
5	
DY
N
LL
1	
S1
00
A1
1	
HM
M
R	
GP
R6
8	
N
U
SA
P1
	
AR
PC
5	
ST
6G
AL
1	
P2
RY
5	
GN
PD
A1
	
CE
P5
5	
SL
AM
F6
	
LT
B	
RN
F1
44
A	
PR
O
SC
	
AC
AD
M
	
LO
C7
30
27
8	
AS
XL
2	
DA
D1
	
TY
M
S	
GL
S	
AS
PM
	
W
DR
40
A	
CY
P1
B1
	
VP
S3
5	
KR
CC
1	
C5
O
RF
51
	
PC
M
TD
1	
ST
S-
1	
W
AS
PI
P	
FL
J1
42
13
	
CS
TB
	
M
6P
R	
PR
DX
1	
EG
R2
	
PD
E7
B	
PR
KC
A	
EG
R1
	
TM
BI
M
4	
PT
GD
R	
DL
GA
P5
	
C2
O
RF
42
	
ZN
F5
59
	
M
RP
S6
	
ZN
F5
12
	
VP
S3
6	
GI
M
AP
1	
M
RP
L5
1	
TM
EM
10
6B
	
LO
C4
39
94
9	
KI
FC
1	
CC
DC
56
	
HS
.4
52
44
5	
C1
0O
RF
6	
ZM
YM
6	
CH
U
RC
1	
M
IT
D1
	
U
GD
H	
AP
BB
1I
P	
TS
T	
VK
O
RC
1	
LG
AL
S1
	
M
TI
F3
	
HS
.1
37
97
1	
M
RP
S3
1	
M
ET
TL
13
	
HA
DH
	
N
DU
FA
F3
	
GL
O
1	
CA
PG
	
DN
AJ
A3
	
PR
DX
6	
TA
F4
	
HD
HD
2	
PA
FA
H1
B1
	
LO
C6
42
97
5	
PE
CA
M
1	
TM
EM
12
6B
	
RA
SG
RP
1	
HC
P5
	
CC
N
B2
	
FL
I1
	
U
SO
1	
GP
R1
8	F
ol
d 
C
ha
ng
e 
IL-7 CD56bright vs. CD56bright upregulation 
Chapter 3: Utilising differential cytokine responses to enrich the CD56bright subset 
	 98 
Table 3.1. Top 20 commonly upregulated genes in IL-7 CD56bright vs. CD56bright and IL-7 CD56bright vs. 
CD56dim. Grouped by GO Function categories with common categories colour-coded. 
3.2.12 Comparing the Top 100 upregulated genes in IL-7 CD56bright vs. CD56dim, and 
CD56bright vs. CD56dim 
A comparison of the top 100 upregulated genes in IL-7 CD56bright vs. CD56dim and 
CD56bright vs. CD56dim is shown in Figure 3.12. Genes upregulated in common by IL-7 
CD56bright and CD56bright are coloured pink. Table 3.2 shows the Top 20 “pink” genes, 
Gene Gene description 
IL-7 CD56bright     
vs. CD56dim 
Fold Change 
IL-7 CD56bright     
vs. CD56bright 
Fold Change GO Function categories 
TOP2A 
Topoisomerase (DNA) II 
alpha 16.47 11.35 
Mitotic cell cycle process, nuclear chromosome segregation, 
response to stimulus, macromolecule metabolic process, DNA 
metabolic process, protein metabolic process, nitrogen compound 
metabolic process, protein binding, enzyme binding, nucleotide 
binding 
CDC20 Cell division cycle 20 10.31 9.37 
Mitotic cell cycle process, mitotic nuclear division, cell cycle phase 
transition, macromolecule metabolic process, protein metabolic 
process, electron transport chain, protein binding, enzyme binding 
NUSAP1 
Nucleolar and spindle 
associated protein 1 8.99 6.89 
Mitotic cell cycle process, mitotic nuclear division, cytokinesis, 
nuclear chromosome segregation, protein binding 
TYMS Thymidylate synthetase 7.91 6.38 
Mitotic cell cycle process, cell cycle phase transition, response to 
stimulus, macromolecule metabolic process, DNA metabolic process, 
phosphate-containing compound metabolic process, nitrogen 
compound metabolic process, methylation, protein binding, 
nucleotide binding 
LTB Lymphotoxin beta 30.86 6.71 
Immune system process, response to stimulus, macromolecule 
metabolic process, protein binding 
KIT 
KIT proto-oncogene 
receptor tyrosine kinase 24.92 9.20 
Immune system process, leukocyte activation, leukocyte 
chemotaxis, response to stimulus, programmed cell death, 
macromolecule metabolic process, protein metabolic process, 
phosphate-containing compound metabolic process, nitrogen 
compound metabolic process, protein binding, enzyme binding, 
nucleotide binding 
AMICA1 
Junction adhesion 
molecule like (JAML) 12.70 14.57 
Immune system process, leukocyte activation, leukocyte 
chemotaxis, protein binding 
RAB10 
RAB10, member RAS 
oncogene family 7.09 7.65 
Immune system process, response to stimulus, protein binding, 
nucleotide binding 
MAL 
Mal, T-cell 
differentiation protein 22.99 12.97 Programmed cell death, protein binding 
GPR68 
G protein-coupled 
receptor 68 16.94 7.14 Response to stimulus 
MMP25 
Matrix metallopeptidase 
25 10.72 7.27 
Response to stimulus, macromolecule metabolic process, protein 
metabolic process 
AARS Alanyl-tRNA synthetase 7.75 8.17 
Response to stimulus, macromolecule metabolic process, nitrogen 
compound metabolic process, nucleotide binding 
DCAF7 
DDB1 and CUL4 
associated factor 7 10.42 9.65 
Macromolecule metabolic process, protein metabolic process, 
protein binding 
PCMT1 
Protein-L-isoaspartate 
(D-aspartate) O-
methyltransferase 10.41 9.73 
Macromolecule metabolic process, protein metabolic process, 
methylation, protein binding 
RNF144 Ring finger protein 144A 8.34 8.63 
Macromolecule metabolic process, protein metabolic process, protein 
binding, enzyme binding 
PRAGMIN 
Homolog of rat pragma 
of Rnd2 8.28 7.99 
Macromolecule metabolic process, protein metabolic process, 
phosphate-containing compound metabolic process, nucleotide 
binding 
RNF144A Ring finger protein 144A 6.88 6.69 
Macromolecule metabolic process, protein metabolic process, protein 
binding, enzyme binding 
RCBTB2 
RCC1 and BTB domain 
containing protein 2 9.85 14.89 Protein binding 
S100A11 
S100 calcium binding 
protein A11 7.86 7.19 Protein binding 
CAPG 
Capping actin protein, 
gelsolin like 6.89 4.50 Protein binding 
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grouped by GO function categories. The most common categories were “immune system 
process”, “response to stimulus”, “programmed cell death” and various “metabolic 
processes”. The majority of genes included “immune system process” in their GO 
function categories. Several are well-established identifiers of CD56bright NK cells that 
have been previously discussed, including KIT, CCR7, IL-7R, HLA-DMB, SELL 
(Selectin-L) and CXCR3. There were also a number of other immune system process 
genes upregulated in common by IL-7 CD56bright and CD56bright compared to CD56dim. 
LEF1 (Lymphoid enhancer binding factor-1) is associated with leukocyte activation and 
proliferation GO Function categories. EBI2 (G-protein coupled receptor 183, GPR183) is 
also associated with leukocyte activation. ADCY3 (Adenlyate cyclase 3), which catalyses 
the formation of the signalling molecule cAMP in response to G-protein signalling. CD2 
(CD2 molecule) interacts with LFA-3 and CD48/BCM1 to mediate adhesion with other 
cell types, and associated with leukocyte activation and migration. XCL1 (X-C 
chemokine ligand 1) encodes the protein Lymphotactin and, associated with leukocyte 
chemotaxis and migration. DLL1 (Delta-like 1) protein is a ligand for the receptors 
NOTCH1, 2 and 3 and is associated with leukocyte activation. Notch signalling is also 
involved in immune cell subset development and differentiation, and is more abundantly 
expressed in CD56bright than CD56dim NK cells. Finally, Granzyme K, although not falling 
under “immune system process” GO function category, is known as the only granzyme 
expressed by CD56bright NK cells. In summary, many of the genes in the top 20 
commonly upregulated genes in IL-7 CD56bright and CD56bright compared to CD56dim are 
genes that indicate common immune functions and are genes known to be characteristic 
of CD56bright NK cells. 
Figure 3.12. Analysis of the top 100 upregulated genes in IL-7 CD56bright and 
CD56bright compared to CD56dim NK cells. The top 100 genes upregulated in IL-7 
CD56bright compared to CD56dim (upper graph) and CD56bright compared to CD56dim 
(lower graph). Columns represent fold change in the mRNA level of each gene in IL-7 
CD56bright or CD56bright relative to CD56dim. Pink genes were upregulated in common by 
IL-7 CD56bright and CD56bright compared to CD56dim. Blue genes were upregulated by IL-
7 CD56bright compared to both CD56dim and CD56bright (discussed in Figure 3.11). Blue 
and pink striped genes were commonly upregulated by IL-7 CD56bright and CD56bright 
compared to CD56dim, but were also further significantly upregulated in IL-7 CD56bright 
compared to CD56bright. Yellow genes were upregulated in CD56bright compared to 
CD56dim, but were downregulated in IL-7 CD56bright compared to CD56bright (discussed in 
Figure 3.15). Grey genes featured only in the top 100 of that particular pair-wise 
comparison.
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Gene Gene description 
IL-7 CD56bright 
vs. CD56dim 
Fold Change 
CD56bright      
vs. CD56dim    
Fold Change GO Function categories 
LTB Lymphotoxin beta 30.86 4.60 
Immune system process, response to stimulus, 
macromolecule metabolic process, protein binding 
KIT 
KIT proto-oncogene receptor 
tyrosine kinase 24.92 2.71 
Immune system process, leukocyte activation, leukocyte 
chemotaxis, leukocyte proliferation, leukocyte migration, 
response to stimulus, programmed cell death, 
macromolecule metabolic process, protein metabolic 
process, protein binding, enzyme binding, nucleotide 
binding 
CCR7 C-C motif chemokine receptor 7 19.10 4.44 
Immune system process, leukocyte chemotaxis, 
lymphocyte activation, response to stimulus, protein binding 
IL7R Interleukin 7 receptor 17.79 9.61 
Immune system process, leukocyte activation, leukocyte 
proliferation, response to stimulus, protein binding 
LEF1 
Lymphoid enhancer binding factor 
1 14.19 3.74 
Immune system process, leukocyte activation, leukocyte 
proliferation, response to stimulus, programmed cell death, 
macromolecule metabolic process, DNA metabolic process, 
protein metabolic process, protein binding, enzyme binding 
EBI2 
G protein-coupled receptor 183 
(GPR183) 12.46 22.87 
Immune system process, leukocyte activation, response to 
stimulus 
ADCY3 Adenylate cyclase 3 11.21 4.04 
Immune system process, response to stimulus, phosphate-
containing compound metabolic process, protein binding, 
nucleotide binding 
HLA-DMB 
Major Histocompatibility 
complex, Class II, DM beta 11.16 5.48 
Immune system process, antigen processing and 
presentation of peptide or polysaccharide antigen via MHC 
class II, response to stimulus, protein binding 
CD2 CD2 molecule 10.57 2.96 
Immune system process, leukocyte activation, leukocyte 
migration, programmed cell death, membrane raft 
organisation, protein binding 
XCL1 X-C chemokine ligand 1 9.62 2.46 
Immune system process, leukocyte chemotaxis, leukocyte 
migration, response to stimulus, protein binding 
DLL1 Delta-like 1 (Drosphila) 9.38 3.44976 
Immune system process, leukocyte activation, 
macromolecule metabolic process, protein metabolic 
process, protein binding 
SELL Selectin L 8.79839 3.95785 
Immune system process, leukocyte migration, response to 
stimulus, protein binding, enzyme binding 
CXCR3 
C-X-C motif chemokine receptor 
3 7.67 4.03 
Immune system process, leukocyte chemotaxis, leukocyte 
migration, response to stimulus, programmed cell death, 
protein binding 
GPR68 G protein-coupled receptor 68 16.94 2.37 Response to stimulus 
IL12RB2 
Interleukin 12 receptor subunit 
beta 2 8.30 2.18 
Response to stimulus, macromolecule metabolic process, 
protein metabolic process, phosphate-containing compound 
metabolic process, protein binding, enzyme binding 
MYC 
v-myc avian myelocytomatosis 
viral oncogene homolog 7.17 3.89 
Response to stimulus, programmed cell death, 
macromolecule metabolic process, protein metabolic 
process, phosphate-containing compound metabolic process, 
protein binding 
GZMK Granzyme K 23.83 16.29 
Macromolecule metabolic process, protein metabolic 
process 
TMEM14C Transmembrane protein 14C 6.95 2.12 Nitrogen compound metabolic process, protein binding 
NELL2 Neural EGFL like 2 13.70 4.14 Protein binding 
ATP8B4 
ATPase phospholipid transporting 
8B4 (putative) 7.08 2.38 Nucleotide binding 
Table 3.2. Top 20 commonly upregulated genes in IL-7 CD56bright vs. CD56dim and CD56bright vs. CD56dim. 
Grouped by GO Function categories with common categories colour-coded. 
3.2.13 Comparing the Top 100 downregulated genes in IL-7 CD56bright vs. CD56bright, 
and IL-7 CD56bright vs. CD56dim 
A comparison of the top 100 downregulated genes in IL-7 CD56bright vs. 
CD56dim and IL-7 CD56bright vs. CD56bright is shown in Figure 3.13. Genes downregulated 
by IL-7 CD56bright compared to both CD56bright and CD56dim are coloured green. Table 
3.3 shows the Top 20 “green” genes, grouped by GO function categories. The most 
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common GO Function categories were regulatory including regulation of biological, 
cellular and metabolic processes. Many genes also had “response to stimulus” and/or 
various “metabolic processes” associated with them, including “RNA metabolic 
processes” which had not been observed in the top upregulated gene comparisons. Four 
of the twenty genes were associated with “Immune system process”. YES1 (YES proto-
oncogene 1, Src family kinase) is involved in regulation of cell growth and survival, 
apoptosis, cell-cell adhesion, cytoskeleton remodelling and differentiation. TNFAIP3 
(TNFalpha-induced protein 3) is involved in immune and inflammatory responses 
signalled by cytokines such as TNF, IL-1β, or pathogens signalling via TLRs through 
NFκB activity. SKP1 (S-phase kinase-associated protein 1) is part of the SKP1-CUL1-F-
box protein ubiquitin ligase complex, which mediates the ubiquitination of proteins 
involved in cell cycle progression, signal transduction and transcription including NFκB 
and NOTCH. CXCR4 is the receptor for CXCL12/SDF-1 that transduces a signal by 
increasing intracellular calcium ion levels and enhancing MAPK activation. It acts as a 
coreceptor (CD4 being the primary receptor) for HIV1 and as a primary receptor for 
some HIV2 isolates. It also binds to bacterial LPS and mediates the LPS-induced 
inflammatory response. In Table 3.1, upregulation in IL-7 CD56bright compared to 
CD56bright and CD56dim, the most common GO Function categories were various 
“metabolic processes”. In Table 3.3, downregulation in IL-7 CD56bright compared to 
CD56bright and CD56dim, the inverse was most common with the “regulation” of biological, 
metabolic and cellular processes.  Therefore, the genes most up and downregulated by IL-
7 culture of CD56bright NK cells appear to be complementary.   
Figure 3.13. Analysis of the top 100 downregulated genes in IL-7 CD56bright 
compared to CD56bright and CD56dim NK cells. The top 100 genes downregulated in IL-
7 CD56bright compared to CD56dim (upper graph) and IL-7 CD56bright compared to 
CD56bright (lower graph). Columns represent fold change in the mRNA level of each gene 
in IL-7 CD56bright compared to either NK cell subset. Green genes were downregulated 
by IL-7 CD56bright compared to both CD56dim and CD56bright. Purple genes were 
downregulated in common by IL-7 CD56bright and CD56bright compared to CD56dim 
(discussed in Figure 3.14). Green and purple striped genes were commonly 
downregulated by IL-7 CD56bright and CD56bright compared to CD56dim, but were also 
further significantly downregulated by IL-7 CD56bright compared to CD56bright. Yellow 
genes were downregulated in IL-7 CD56bright compared to CD56bright, but were 
upregulated in CD56bright compared to CD56dim (discussed in Figure 3.15). Grey genes 
featured only in the top 100 of that particular pair-wise comparison. 
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Gene Gene description 
IL-7 CD56bright     
vs. CD56dim 
Fold Change 
IL-7 CD56bright     
vs. CD56bright 
Fold Change GO Function categories 
YES1 
YES proto-oncogene 1, Src 
family tyrosine kinase -10.94 -4.80 
Immune system process, response to stimulus, regulation of 
biological process, regulation of metabolic process, regulation of 
cellular process, macromolecule metabolic process, protein 
metabolic process, protein binding, enzyme binding 
TNFAIP3 TNF alpha induced protein 3 -6.27 -11.95 
Immune system process, response to stimulus, regulation of 
biological process, regulation of metabolic process, regulation of 
cellular process, macromolecule metabolic process, protein 
metabolic process, nucleic acid binding, protein binding, enzyme 
binding 
SKP1 
S-phase kinase-associated 
protein 1 -5.56 -3.86 
Immune system process, response to stimulus, regulation of 
biological process, regulation of metabolic process, regulation of 
cellular process, macromolecule metabolic process, protein 
metabolic process, protein binding 
CXCR4 
C-X-C motif chemokine 
receptor 4 -5.43 -5.09 
Immune system process, response to stimulus, regulation of 
biological process, regulation of metabolic process, regulation of 
cellular process, protein binding, enzyme binding 
NR4A2 
Nuclear receptor subfamily 4, 
group A, member 2 -22.83 -15.38 
Response to stimulus, regulation of biological process, 
regulation of metabolic process, regulation of cellular process, 
macromolecule metabolic process, RNA metabolic process, 
nucleic acid binding, protein binding 
RBM38 RNA binding motif protein 38 -9.46 -7.34 
Response to stimulus, regulation of biological process, 
regulation of metabolic process, regulation of cellular process, 
macromolecule metabolic process, RNA metabolic process, 
nucleic acid binding 
LITAF 
Lipopolysaccharide induced 
TNF factor -6.25 -4.19 
Response to stimulus, regulation of biological process, 
regulation of metabolic process, regulation of cellular process, 
macromolecule metabolic process, RNA metabolic process, 
protein binding 
RGS2 
Regulator of G-protein 
signalling 2 -20.63 -11.39 
Regulation of biological process, regulation of metabolic 
process, regulation of cellular process, protein binding 
TSC22D3 
TSC22 domain family member 
3 -10.59 -16.01 
Regulation of biological process, regulation of metabolic 
process, regulation of cellular process, protein binding 
GARNL4 
RAP1 GTPase activating 
protein 2 (RAP1GAP2) -7.56 -4.29 
Regulation of biological process, regulation of metabolic 
process, regulation of cellular process, protein binding 
CBX4 Chromobox 4 -7.37 -5.58 
Regulation of biological process, regulation of metabolic 
process, regulation of cellular process, macromolecule metabolic 
process, RNA metabolic process, protein metabolic process, 
nucleic acid binding, protein binding, transcription factor 
binding, enzyme binding 
TP53INP2 
Tumor protein p53 inducible 
nuclear protein 2 -7.29 -3.69 
Regulation of biological process, regulation of metabolic 
process, regulation of cellular process, macromolecule metabolic 
process, RNA metabolic process, protein metabolic process, 
protein binding 
CASZ1 Castor zinc finger 1 -7.11 -3.83 
Regulation of biological process, regulation of metabolic 
process, regulation of cellular process, macromolecule metabolic 
process, RNA metabolic process, nucleic acid binding 
USP36 Ubiquitin specific peptidase 36 -6.82 -4.28 
Regulation of biological process, regulation of metabolic 
process, regulation of cellular process, macromolecule metabolic 
process, protein metabolic process, nucleic acid binding 
AXUD1 
Cystein and serine rich nuclear 
protein 1 (CSRNP1) -5.88 -9.30 
Regulation of biological process, regulation of metabolic 
process, regulation of cellular process, macromolecule metabolic 
process, RNA metabolic process, nucleic acid binding, protein 
binding 
SIK1 Salt inducible kinase 1 -5.83 -10.35 
Regulation of biological process, regulation of metabolic 
process, regulation of cellular process, macromolecule metabolic 
process, protein metabolic process, protein binding, enzyme 
binding 
VPS37B VPS37B, ESCRT-I subunit -5.65 -3.08 
Regulation of biological process, regulation of cellular process, 
macromolecule metabolic process, protein metabolic process, 
protein binding 
PAPD5 
PAP associated domain 
containing 5 -5.86 -4.05 
Macromolecule metabolic process, RNA metabolic process, 
nucleic acid binding 
ATG2A Autophagy related 2A -7.39 -6.78 Protein binding 
LOC645381 
Transducin like enhancer of 
split 1 pseudogene 1 (TLE1P1) -7.42 -2.98   
Table 3.3. Top 20 commonly downregulated genes in IL-7 CD56bright vs. CD56bright and IL-7 CD56bright vs. 
CD56dim. Grouped by GO Function categories with common categories colour-coded. Where GO Function 
categories are blank, genes had no GO terms associated or their enrichment score was <5. 
Chapter 3: Utilising differential cytokine responses to enrich the CD56bright subset 
	 105 
3.2.14 Comparing the Top 100 downregulated genes in IL-7 CD56bright vs. CD56dim, 
and CD56bright vs. CD56dim 
A comparison of the top 100 downregulated genes in IL-7 CD56bright vs. CD56dim 
and CD56bright vs. CD56dim is shown in Figure 3.14. Genes downregulated in common by 
IL-7 CD56bright and CD56bright are coloured purple. Table 3.4 shows the Top 20 “purple” 
genes, grouped by GO function categories. The most common GO Function categories 
were regulatory, including regulation of biological, cellular and metabolic processes. 
Many genes also had various metabolic processes associated with them. There were also 
four genes associated with “immune system process”. YES1 also featured in genes 
downregulated by IL-7 CD56bright compared to CD56bright (Table 3.3). It is striped green 
and purple as it was commonly downregulated in IL-7 CD56bright and CD56bright 
compared to CD56dim, yet even further significantly downregulated in IL-7 CD56bright 
compared to CD56bright. SPON2 (Spondin 2) is a cell adhesion protein that binds directly 
to bacterial components such as LPS, and is essential in the initiation of the innate 
immune response. It was identified as upregulated in CD56dim compared to CD56bright NK 
cells in the gene expression profiling conducted by Hanna et al. (Hanna et al., 2004a). 
KIR2DL1 is a receptor expressed predominantly on CD56dim NK cells, which recognises 
HLA-C alleles and is important in inhibiting cell lysis by NK cells. CD6 is a scavenger 
receptor known as a T-cell differentiation antigen, however it has also been shown 
expressed on CD56dim NK cells, and is associated with secretion of cytokines and 
chemokines IFN-γ, TNF, CXCL10 (IP10) and CXCL1 (Braun et al., 2011). In Table 3.2 
majority of the top 20 upregulated genes in IL-7 CD56bright and CD56bright compared to 
CD56dim were associated with immune system processes and indicated common immune 
functions between IL-7 CD56bright and CD56bright cells. In comparison there are fewer 
genes associated with immune system processes in the top 20 downregulated genes in IL-
7 CD56bright and CD56bright compared to CD56dim (Table 3.4), however the genes that are 
associated with immune system processes indicate IL-7 CD56bright NK cells are retaining 
differences seen in CD56bright compared to CD56dim NK cells. 
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Figure 3.14. Analysis of the top 100 downregulated genes in IL-7 CD56bright and 
CD56bright compared to CD56dim NK cells. The top 100 genes downregulated in IL-7 
CD56bright compared to CD56dim (upper graph) and CD56bright compared to CD56dim 
(lower graph). Columns represent fold change in the mRNA level of each gene in IL-7 
CD56bright or CD56bright compared to CD56dim. Purple genes were downregulated in 
common by IL-7 CD56bright and CD56bright compared to CD56dim. Green genes were 
downregulated by IL-7 CD56bright compared to both CD56dim and CD56bright (discussed in 
Figure 3.13). Green and purple striped genes were commonly downregulated by IL-7 
CD56bright and CD56bright compared to CD56dim, but were also further significantly 
downregulated by IL-7 CD56bright compared to CD56bright. Magenta genes were 
downregulated in CD56bright compared to CD56dim, but were upregulated in IL-7 
CD56bright compared to CD56bright (discussed in Figure 3.15). Grey genes featured only in 
the top 100 of that particular pair-wise comparison. 
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Gene Gene description 
IL-7 CD56bright 
vs. CD56dim 
Fold Change 
CD56bright      
vs. CD56dim    
Fold Change GO Function categories 
YES1 
YES proto-oncogene 1, Src family 
tyrosine kinase -10.94 -2.28 
Immune system process, response to stimulus, 
regulation of biological process, regulation of 
metabolic process, regulation of cellular process, 
macromolecule metabolic process, protein metabolic 
process, protein binding, enzyme binding 
SPON2 Spondin 2 -8.16 -4.33 
Immune system process, response to stimulus, 
regulation of biological process, regulation of 
response to stimution, protein binding 
KIR2DL1 
Killer cell immunoglobulin like 
receptor, two Ig domains and long 
cytoplasmic tail 1 -5.76 -4.46 
Immune system process, response to stimulus, 
regulation of biological process, regulation of cellular 
process, protein binding 
CD6 CD6 molecule -5.72 -5.65 
Immune system process, response to stimulus, 
regulation of biological process, regulation of cellular 
process, regulation of response to stimulus, protein 
binding 
PTGDS Prostaglandin D2 synthase -11.16 -6.69 
Response to stimulus, response to endogenous 
stimulus, regulation of biological process, regulation 
of cellular process, regulation of cell proliferation, 
protein binding 
TSPYL2 TSPY-like 2 -6.05 -2.73 
Response to stimulus, regulation of biological 
process, regulation of metabolic process, regulation 
of cellular process, macromolecule metabolic process, 
RNA metabolic process, protein metabolic process, 
nucleic acid binding 
ZEB2 
Zinc finger E-box binding 
homeobox 2 -7.04 -2.57 
Regulation of biological process, regulation of 
metabolic process, regulation of cellular process, 
macromolecule metabolic process, RNA metabolic 
process, nucleic acid binding, protein binding 
S1PR5 Sphingosine-1-phosphate receptor 5 -14.10 -5.10 
Regulation of biological process, regulation of 
cellular process 
ENC1 Ectodermal-neural cortex 1 -9.10 -3.38 
Regulation of biological process, regulation of 
metabolic process, regulation of cellular process, 
macromolecule metabolic process, protein metabolic 
process, protein binding, 
CENTG2 
ArfGAP with GTPase domain, 
ankyrin repeat and PH domain 1 
(AGAP1) -8.91 -5.35 
Regulation of biological process, regulation of 
metabolic process, regulation of cellular process 
IFNGR1 Interferon gamma receptor 1 -6.96 -2.75 
Regulation of biological process, regulation of 
cellular process, regulation of immune response, 
protein binding 
FKBP11 FK506 binding protein 11 -9.25 -4.29 
Macromolecule metabolic process, protein metabolic 
process 
PRSS23 Protease, serine 23 -8.26 -4.34 
Macromolecule metabolic process, protein metabolic 
process 
MGAT4A 
Mannosyl (alpha-1,3-)-glycoprotein 
beta-1,4-N-
acetylglucosaminyltransferase, 
isozyme A -7.18 -3.13 
Macromolecule metabolic process, protein metabolic 
process 
KRT73 Keratin 73 -6.44 -3.89 Protein binding 
FGFBP2 
Fibroblast growth factor binding 
protein 2 -6.39 -7.35 Protein binding 
TKTL1 Transketolase-like 1 -7.38 -6.04 
 
LOC645381 
Transducin like enhancer of split 1 
pseudogene 1 (TLE1P1) -7.43 -2.49   
FAM53B 
Family with sequence similarity 53 
member B -6.87 -5.18   
TTC38 Tetratricopeptide repeat domain 38 -6.08 -2.72   
Table 3.4. Top 20 commonly downregulated genes in IL-7 CD56bright vs. CD56dim and CD56bright vs. 
CD56dim. Grouped by GO Function categories with common categories colour-coded. Where GO Function 
categories are blank, genes had no GO terms associated or their enrichment score was <5. 
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3.2.15 Contrasts in the Top 100 up and downregulated genes in IL-7 CD56bright and 
CD56bright 
Although many similarities were identified in the gene expression profiles of IL-7 
CD56bright and CD56bright compared to CD56dim NK cells, there were a few genes where 
expression was downregulated in IL-7 CD56bright vs. CD56bright that were upregulated in 
CD56bright vs. CD56dim (coloured yellow in Figure 3.12 and 3.13), as well as the converse 
where genes upregulated in IL-7 CD56bright vs. CD56bright were downregulated in 
CD56bright vs. CD56dim (coloured magenta in Figure 3.11 and 3.14). These genes were 
investigated to determine whether any of these changes could potentially alter IL-7 
CD56bright function compared to CD56bright, particularly immune-related functions. Figure 
3.15A combines the “yellow” genes from Figure 3.12 and 3.13 in a separate graph. Table 
3.5 lists these genes and their GO Function categories. Regulatory and metabolic process 
functions were the most common. However, four of the genes also had “immune system 
process” attributed to their functions. HOXA5 (Homeobox 5) is a sequence-specific 
transcription factor that is part of a developmental regulatory system that includes 
regulation of immune cell differentiation. FOXC1 (Forkhead box C1) is an important 
regulator of cell viability and resistance to oxidative stress and also has a regulatory role 
in haematopoietic progenitor cell differentiation. IRAK3 (Interleukin 1 receptor 
associated kinase 3) inhibits the dissociation of IRAK1 and IRAK4 from the TLR 
signalling complex and plays a regulatory role in cytokine-mediated signalling pathways. 
CD83 is known as a marker of maturation on dendritic cells and may play a significant 
role in antigen presentation or the cellular interactions that follow lymphocyte activation. 
CD83 expression in NK cells, particularly CD56bright NK cells, was not mentioned in the 
previous gene expression studies by Hanna et al. and Wendt et al. (Hanna et al., 2004a, 
Wendt et al., 2006). However, a study by Mailliard et al. found that culture with IL-18 
induced the surface expression of CD83 on “helper”-like NK cells that expressed CCR7 
and CD25 (IL-2Rα) (Mailliard et al., 2005). 
Figure 3.15B combines the “magenta” genes from Figure 3.11 and 3.14 in a 
separate graph. Table 3.6 lists these genes and their GO Function categories. There were 
only three genes in this analysis and two of them have “immune system process” 
attributed to them as GO Function categories. LGALS1 (Lectin, galactoside binding 
soluble 1) encodes Galectin 1, a receptor of beta-galactoside and an array of other 
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complex carbohydrates. It is associated with leukocyte activation and plays a role in 
regulating apoptosis, cell proliferation and cell differentiation. RASGRP1 (RAS guanyl 
releasing protein 1) has many functions attributed to it including activation or the 
Erk/Map kinase cascade and the regulation of a number of immune processes such as T- 
and B- lymphocyte development, NK cell cytotoxicity and ITAM-dependent cytokine 
production. Although these “immune system process”- related genes have contrasting 
expression on IL-7 CD56bright and CD56bright NK cells, they are a mixture of regulatory 
and “activatory” genes in their involvement in immune processes. Therefore the potential 
impact of these differences on IL-7 CD56bright NK cell immune function is uncertain. 
In summary, the analyses of gene expression comparing IL-7 CD56bright NK cells 
with freshly isolated CD56bright and CD56dim NK cells identified that IL-7 CD56bright NK 
cells were distinct in their pattern of gene expression compared CD56bright and CD56dim 
cells, with a large number of up and downregulated genes compared to both subsets. 
However, when the focus was confined to the top 100 up and downregulated genes in 
each pair-wise comparison, it was found that several “immune system process” genes 
known to be characteristic of CD56bright NK cells remained upregulated on IL-7 
CD56bright compared to CD56dim NK cells. The main functional categories of the genes up 
and downregulated by IL-7 CD56bright compared to both CD56bright and CD56dim tended to 
be “metabolic processes” and “regulation of biological, cellular and metabolic processes” 
respectively, rather than predominantly related to immune function. There were a small 
selection of genes where IL-7 CD56bright NK cells up or downregulated genes related to 
“immune system process” in contrast to the expression of CD56bright NK cells. However, 
these were a combination of genes involved in regulation and activation of immune 
processes, making interpretation of their potential impact on IL-7 CD56bright immune 
function uncertain. Furthermore, although genomic data provides insights into biological 
behaviour, supporting data at the protein level and from functional assays is required to 
determine functional differences in cell types. 
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Figure 3.15. Contrasts in the top 100 up and downregulated genes in IL-7 CD56bright 
compared to CD56bright. (A) Genes that featured in the top 100 upregulated genes in 
CD56bright compared to CD56dim (in Figure 3.12) and the top 100 downregulated genes in 
IL-7 CD56bright compared to CD56bright (in Figure 3.13), coloured yellow, were combined. 
(B) Genes that featured in the top 100 upregulated genes in IL-7 CD56bright compared to 
CD56bright (Figure 3.11) and in the top 100 downregulated genes in CD56bright compared 
to CD56dim (Figure 3.14), coloured magenta, were combined. 
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Table 3.5. Genes upregulated in CD56bright vs. CD56dim that are downregulated in IL-7 CD56bright vs. 
CD56bright. Grouped by GO Function categories. Where GO Function categories are blank, genes had no GO 
terms associated or their enrichment score was <5. 
Gene Gene description 
IL-7 CD56bright     
vs. CD56bright 
Fold Change 
CD56bright      
vs. CD56dim    
Fold Change GO Function categories 
 LGALS1 
Lectin, galactoside 
binding soluble 1 4.68 -3.04 
Immune system process, leukocyte activation, response to stimulus, 
programmed cell death, protein binding, nucleic acid binding 
 RASGRP1 
RAS guanyl releasing 
protein 1 4.39 -2.75 
Immune system process, leukocyte activation, leukocyte 
degranulation, cytokine production, response to stimulus, 
macromolecule metabolic process, protein metabolic process, protein 
binding 
 GIMAP4 
GTPase, IMAP family 
member 4 9.44 -2.29 Nucleotide binding 
Table 3.6. Genes upregulated in IL-7 CD56bright vs. CD56bright that are downregulated in CD56bright vs. 
CD56dim. Grouped by GO Function categories. 
3.2.16 IL-7 increased c-kit and HLA-DR expression on CD56bright NK cells, however 
CD158a/h and CD62L expression were unchanged 
To conclude this study, a selection of receptors known to be expressed by 
CD56bright (c-kit, HLA-DR and CD62L/L-selectin) as well as KIR2DL1/DS1 (CD158a/h) 
known to be expressed on CD56dim NK cells were measured at the protein-level by flow 
Gene Gene description 
CD56bright      
vs. CD56dim    
Fold Change 
IL-7 CD56bright     
vs. CD56bright 
Fold Change GO Function categories 
HOXA5 Homeobox A5 8.07 -5.21 
Immune system process, regulation of biological process, regulation 
of cellular process, regulation of metabolic process, macromolecule 
metabolic process, RNA metabolic process, nucleic acid binding, 
protein binding, nucleus 
FOXC1 Forkhead box C1 7.30 -4.61 
Immune system process, regulation of biological process, regulation 
of cellular process, regulation of metabolic process, macromolecule 
metabolic process, RNA metabolic process, nucleic acid binding, 
transcription factor binding, protein binding 
IRAK3 
Interleukin 1 receptor 
associated kinase 3 4.86 -3.29 
Immune system process, regulation of biological process, regulation 
of cellular process, regulation of metabolic process, macromolecule 
metabolic process, RNA metabolic process, protein metabolic 
process, protein binding 
CD83 CD83 molecule 2.32 -3.34 
Immune system process, leukocyte activation, lymphocyte 
differentiation, response to stimulus, regulation of biological process, 
regulation of cellular process 
NFKBIZ NFKB inhibitor zeta 3.29 -5.22 
Response to stimulus, regulation of biological process, regulation of 
cellular process, regulation of metabolic process, macromolecule 
metabolic process, RNA metabolic process, protein binding, 
transcription factor binding 
KLF4 Kruppel-like factor 4 2.58 -3.08 
Response to stimulus, regulation of biological process, regulation of 
cellular process, regulation of metabolic process, macromolecule 
metabolic process, RNA metabolic process, protein metabolic 
process, nucleic acid binding, transcription factor binding, protein 
binding, enzyme binding 
FURIN 
Furin, paired basic amino 
acid cleaving enzyme 2.39 -3.75 
Regulation of biological process, regulation of cellular process, 
regulation of metabolic process, macromolecule metabolic process, 
protein metabolic process, protein binding, enzyme binding 
MAFF 
MAF bZIP transcription 
factor F 2.17 -4.24 
Regulation of biological process, regulation of cellular process, 
regulation of metabolic process, macromolecule metabolic process, 
RNA metabolic process, nucleic acid binding 
WHAMM 
WAS protein homolog 
associated with actin, Golgi 
membranes and 
microtubules 2.12 -4.49 
Regulation of biological process, regulation of cellular process, 
protein binding, enzyme binding 
HAPLN3 
Hyaluronan and 
proteoglycan link protein 3 6.43 -4.53   
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cytometry on IL-7 CD56bright compared to CD56bright and CD56dim NK cells. For each 
experiment, the expression of the receptor on NK cells was analysed by flow cytometry 
before and after 7 days culture with IL-7 (1 ng/mL). NK cells were analysed for their 
expression of c-kit (CD117) (Figure 3.16). Before culture, 24 ± 8% of CD56bright NK cells 
expressed c-kit on the surface whereas CD56dim NK cells did not express c-kit (0.2 ± 
0.1%). The difference in c-kit expression on resting CD56bright and CD56dim NK cells was 
significant (*p<0.05). After culture with IL-7, the expression of c-kit on CD56bright NK 
cells significantly increased to 89 ± 6% (***p<0.001). On CD56dim NK cells, in one of 
three subjects, c-kit expression was induced by IL-7, increasing from 0.1% to 20%, 
however in the other two subjects, expression was only slightly induced, from 0.2% to 
2.7%, and 0.2% to 1.7% respectively. Overall, the increases in c-kit expression on 
CD56dim NK cells were not significant or consistent. After culture with IL-7, CD56bright c-
kit expression was more highly expressed than at baseline (***p<0.001) and was more 
significantly increased compared to the CD56dim subset (**p<0.01). Therefore, IL-7 
significantly increased the expression of c-kit on CD56bright NK cells, and it remained 
significantly increased compared to CD56dim NK cells. 
Analysis of HLA-DR expression (Figure 3.17) showed that before culture, the 
percentage of CD56bright NK cells expressing HLA-DR was greater than CD56dim NK 
cells (*p<0.05). After culture with IL-7, the expression of HLA-DR on CD56bright NK 
cells markedly increased compared to before culture (*p<0.05). There was a slight 
increase in HLA-DR expression on CD56dim NK cells after culture with IL-7, which was 
not significant. Therefore, HLA-DR expression was significantly upregulated on 
CD56bright NK cells after culture with IL-7 compared to before culture, and remained 
significantly increased compared to the CD56dim subset (*p<0.05). 
Expression of CD158a/h (KIR2DL1/DS1) and CD62L were also examined 
(Figure 3.18). Before culture, CD158a/h expression on CD56bright and CD56dim NK cells 
were 3 ± 1% and 16 ± 8% respectively. After culture with IL-7, the percentage of 
CD56bright NK cells expressing CD158a/h increased slightly to 6 ± 2%. However, for 
CD56dim NK cells after culture with IL-7, there was no significant change in CD158a/h 
expression, at 16 ± 13%. In two subjects CD158a/h expression slightly decreased after 
culture and in one subject expression slightly increased. Before culture, CD62L 
expression on CD56bright and CD56dim NK cells were 95 ± 4% and 20 ± 11% respectively. 
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After culture with IL-7, in all three subjects the percentage of CD62L+ CD56bright NK 
cells slightly decreased to 84 ± 9%. However, on CD56dim NK cells, the change in 
expression after culture with IL-7 was variable at 29 ± 20%. In two subjects the 
expression increased and in the other subject the expression slightly decreased. 
Therefore, IL-7 significantly increased expression of c-kit and HLA-DR on 
CD56bright NK cells, however expression of CD158a/h and CD62L on CD56bright and 
CD56dim NK cells were not significantly changed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16. C-kit expression on the NK cell subsets before and after culture with 
IL-7. NK cells were cultured with IL-7 (1 ng/mL) for 7 days and analysed by flow 
cytometry. Representative histograms compare the expression of c-kit on CD56bright (A) 
and CD56dim (B) NK cells before (Day 0) and after (Day 7) 7 days culture in the presence 
of IL-7, with grey filled histograms as isotype controls. (C) The percentage of c-kit+ 
CD56bright (purple bars) and CD56dim (green bars) NK cells before (Day 0) and after (Day 
7) culture with IL-7 are shown as mean ± S.D., n = 3. *p<0.05, **p<0.01, *** p ≤ 0.001 
(Paired t test). 
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  C 
               
Figure 3.17. HLA-DR expression on the NK cell subsets before and after culture 
with IL-7. NK cells were cultured with IL-7 (1 ng/mL) for 7 days and analysed by flow 
cytometry. Representative histograms compare the expression of HLA-DR on CD56bright 
(A) and CD56dim (B) NK cells, before (Day 0) and after (Day 7) 7 days culture in the 
presence of IL-7, with grey filled histograms as isotype controls. (C) The percentage of 
HLA-DR+ CD56bright (purple bars) and CD56dim (green bars) NK cells (log transformed) 
before (Day 0) and after (Day 7) culture with IL-7 are shown as mean ± S.D., n = 3, 
*p<0.05 (Paired t test). 
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Figure 3.18. CD158a/h (KIR2DL1/DS1) and CD62L (L-selectin) expression before 
and after culture with IL-7. NK cells were cultured with IL-7 (1 ng/mL) for 7 days and 
analysed by flow cytometry. Representative histograms compare the expression of 
CD158a/h and CD62L on CD56bright (A) and CD56dim (B) NK cells before (Day 0) and 
after (Day 7) 7 days culture in the presence of IL-7. (C&D) The percentage of 
CD158a/h+ (C) and CD62L+ (D) CD56bright (purple) and CD56dim (green) NK cells before 
(Day 0) and after (Day 7) culture with IL-7 are shown as mean ± S.D., n=3. 
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3.3  Discussion 
 This study began with the aim of selectively enriching the CD56bright NK cell 
subset in culture, with the use of a cytokine that selectively enhances CD56bright survival 
and proliferation without increasing cytotoxicity. IL-15 and IL-7 were compared for their 
effects on survival and perforin expression. IL-7 selectively enhanced the survival of 
CD56bright NK cells, whereas IL-15 maintained both NK cell subsets, but also maintained 
or increased their perforin expression to a greater extent than IL-7. 
There was a conflict in the literature regarding whether IL-7 was capable of 
inducing cytotoxicity in CD56bright NK cells. In one study, after 72 hours of culture with 
IL-7 (10 ng/mL) significant cytotoxic activity against K562 target cells was not detected 
(Michaud et al., 2010). In another study, CD56bright cytotoxicity against K562 target cells 
after 16 hours culture with IL-7 (10 ng/mL) was significantly augmented (Dadmarz et al., 
1994). The time-points of 16 and 72 hours used in these studies appear to have resulted in 
different outcomes and conclusions. 
Da
y 0
Da
y 7
Da
y 0
Da
y 7
0
10
20
30
40
%
 C
D
15
8a
/h
 +
 c
el
ls
Da
y 0
Da
y 7
Da
y 0
Da
y 7
0
20
40
60
80
100
%
 C
D
62
L+
 c
el
ls
CD56bright
CD56dim
Chapter 3: Utilising differential cytokine responses to enrich the CD56bright subset 
	 118 
In our study, NK cells were cultured for a much longer time of 7 days to allow 
sufficient time to enrich the CD56bright subset while the CD56dim subset died away, as 
well as to ensure that the CD56bright subset could survive long enough to be co-cultured 
with other cells such as MDDCs in future studies. If we had also looked at early time-
points after culture with IL-7, we may have seen increased perforin expression 
complementary to the findings by Dadmarz et al. (2010). However, we also cultured NK 
cells with 1 ng/mL of IL-7 rather than 10 ng/mL and the specific activity of our cytokine 
was lower than Dadmarz et al. (at ≥ 2 x 107 U/mg compared to 4 x 107 U/mg). The lower 
concentration of cytokine used by us may be sufficient to increase CD56bright NK cells 
survival and proliferation, but not induce increased cytotoxicity. Taken together, results 
in the literature and ours indicate that culturing CD56bright NK cells with IL-7 may result 
in a transient, early increase in perforin (16 hours) that disappears by 3 days of culture 
and remains decreased by 7 days. Future kinetic studies using IL-7 would more 
accurately confirm how perforin expression changes in the presence of IL-7 over time. 
Furthermore, future studies of IL-7 cultured CD56bright NK cells should directly assess 
cytotoxicity against K562 target cells over time, to ensure correlation with perforin 
expression. 
Despite CD56bright NK cells initially being characterised as the less cytotoxic, 
more regulatory subset, it is intriguing that various cytokine stimuli can induce their 
increased cytotoxicity against target cells. Studies have shown that after prolonged 
exposure to IL-2, CD56bright NK cells had increased cytotoxicity (Caligiuri et al., 1990, 
Ferlazzo et al., 2004b). We also showed increased perforin expression in CD56bright NK 
cells after culture with IL-15, correlating with the increased cytotoxicity reported in a 
previous study (Carson et al., 1994). Finally, as mentioned above, IL-7 was shown to 
increase CD56bright cytotoxic activity at early time points (Dadmarz et al., 1994). It 
appears that, at least in regard to cytotoxicity, CD56bright NK cells may not be that 
different to CD56dim NK cells and that there may be functional plasticity within the NK 
cell subsets. 
IL-2 and IL-7 were compared for their selective promotion of CD56bright NK cell 
survival and proliferation. We found that IL-7 increased the number of CD56bright NK 
cells, based on cell counts, and detected their proliferation in response to IL-7 to a similar 
extent as IL-2. However, there was also conflict in the literature regarding whether IL-7 
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induced proliferation of CD56bright NK cells or only enhanced their survival. According to 
Michaud et al., IL-7 did not induce CD56bright proliferation as measured by CFSE after 7 
days of culture (Michaud et al., 2010). However, Dadmarz et al. reported that a 
proliferative response to IL-7 was measurable in CD56bright NK cells by H3-labelled 
thymidine incorporation, which was maximal on day 3 but still detectable on day 7 
(Dadmarz et al., 1994).  
These studies used different methods to detect proliferation, which suggests 
perhaps there is a difference in sensitivity in being able to detect low-level proliferation. 
Our study used CellTrace Violet, which labels cells in a similar way to CFSE, but may be 
more sensitive than CFSE at detecting low rounds of replication. In our hands IL-7 
tended to induce one to two rounds of replication in CD56bright NK cells. A direct 
comparison of CFSE and CellTrace Violet would confirm whether CellTrace Violet is 
more sensitive. It should also be noted that although the percentage of total proliferating 
cells was similar with IL-7 and IL-2, the cells cultured in IL-2 tended to proliferate 
beyond two rounds of replication, which would explain why other studies measuring 
proliferation found IL-2 had far higher proliferative readouts than IL-7. 
The selective effects of IL-7 on CD56bright NK cells inducing survival and 
proliferation without increased cytotoxicity were intriguing. IL-7 is a multifunctional 
cytokine produced by bone marrow stroma, keratinocytes, neurons, antigen-presenting 
cells and endothelial cells (Sportes et al., 2009). IL-7 plays an important role in T-cell 
development. This was confirmed by the analysis of SCID patients with mutations 
involving the IL-7 receptor or its signalling pathway. In X-linked SCID, mutation of the 
γ-chain of IL-7 receptor resulted in patients that are T and NK cell deficient (Noguchi et 
al., 1993). However, patients with a defective α-chain were T cell deficient, but had 
normal CD16+ NK cells (they did not assess levels of CD56bright NK cells) (Puel et al., 
1998). IL-7 also plays an important role for the survival and homeostasis of mature T 
cells (ElKassar and Gress, 2010). 
IL-7 is being investigated as a potential immunotherapy in a number of clinical 
settings. Treatment of cancer patients with IL-7 has been shown to produce a compelling 
profile of T cell reconstitution, with the restoration of a broadened diversity of T cell 
repertoire and the migration of these cells to lymph nodes and tissues (Morre and Beq, 
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2012). IL-7 treatment also induced a sustained increase of naïve and central memory CD4 
and CD8 T cells in HIV-infected patients (Levy et al., 2009). However, the studies and 
clinical trials of IL-7 have not examined CD56bright NK cells to determine how IL-7 
treatment may alter this cell-type rather than T cells. 
In this study, IL-7 effects on CD56bright NK cells were further investigated by 
analysing changes in gene expression by DNA microarray. Global gene expression 
patterns suggested IL-7 CD56bright NK cells were distinct from CD56bright and CD56dim 
NK cells as shown by PCA and Venn diagrams of overlapping gene expression. However, 
analysis of the top 100 genes in each pair-wise comparison identified that a number of 
key immune system process genes characteristic of CD56bright NK remained upregulated 
in IL-7 CD56bright and in some cases were further upregulated, including KIT, CCR7, IL-
7R, HLA-DMB, SELL (Selectin-L), CXCR3, LEF1,	EBI2,	ADCY3,	CD2,	XCL1,	DLL1 
and GZMK (Granzyme K). The main functional categories of genes that were up and 
downregulated by IL-7 were metabolic processes and regulatory processes respectively. 
Changes in metabolic activity due to IL-7 inducing survival and proliferation are to be 
expected, however it is not possible to determine by gene expression alone whether these 
metabolic processes are altering other functional processes as well. Therefore, further 
investigation via functional studies is required to determine how these changes induced 
by IL-7 affect CD56bright NK cell function. 
A sample of surface receptors characteristic to CD56bright and CD56dim cells were 
also examined by flow cytometry. C-kit and HLA-DR expression were significantly 
upregulated after culture with IL-7, which complemented the microarray results where 
increases in c-kit and HLA-DMB were observed (HLA-DMA was also observed in both 
CD56bright and IL-7 CD56bright but was ranked outside of the top 100 genes in the case of 
the latter). Surface expression of CD158a/h (KIR2DL1/SL1) and CD62L (L-selectin) 
were neither significantly up nor downregulated. In the microarray, KIR2DL1 was 
strongly downregulated in both CD56bright and IL-7 CD56bright compared to CD56dim, 
however IL-7 appeared to have slightly increased surface expression compared to day 0 
CD56bright by flow cytometry. Similarly, L-selectin was not further upregulated by IL-7 
CD56bright at the surface although the fold change in gene expression was increased. 
These results indicate that whilst some changes in gene expression correlate at the protein 
level, not all changes in gene expression translate to changes in surface protein 
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expression. This highlights that caution in interpreting genomic data is required and that 
follow-up with protein and functional studies is necessary to determine global changes in 
cell function.  
Upregulation of surface HLA-DR by IL-7 is particularly interesting, as it suggests 
priming for antigen presentation. Therefore, IL-7 in the microenvironment could enhance 
CD56bright accessory antigen presentation capabilities. IL-7 appears to be priming 
CD56bright NK cells for both an enhanced proliferative response as well as for antigen 
presentation. However, this needs to be investigated by examining more markers of 
antigen presentation at the protein and functional level e.g. costimulatory markers CD80 
and CD86, and comparing autologous CD4+T cell activation stimulated by NK cells with 
and without IL-7 priming. 
Another characteristic of CD56bright NK cells, the production of cytokines such as 
IFN-γ and TNF, was not upregulated by IL-7 according to gene expression analysis. 
Three genes related to cytokine signalling or production were downregulated in IL-7 
CD56bright NK cells. TNFAIP3 was downregulated in IL-7 CD56bright compared to both 
CD56bright and CD56dim, which is involved in responses signalled by cytokines such as 
TNF. CD6 was downregulated in IL-7 CD56bright and CD56bright compared to CD56dim 
and is also associated with cytokine and chemokine secretion (Braun et al. 2011). Finally, 
IRAK3 was downregulated in IL-7 CD56bright compared to CD56bright, but was 
upregulated on CD56bright compared to CD56dim and is involved in cytokine-mediated 
signalling pathways. Taken together, these genes, combined with no upregulated genes 
associated with cytokine production in IL-7 CD56bright NK cells, suggest that IL-7 is not 
stimulating CD56bright NK cells for the production of cytokines, consistent with the basal 
state of resting CD56bright NK cells. The cytokine responses of IL-7 CD56bright NK cells 
should be compared to CD56bright NK cells after stimulation e.g. with TLR2 agonists. 
The selective properties of cytokines and the cell types that respond have 
important implications for both the laboratory and the clinic. In the laboratory, cytokines 
can be used as a tool when culturing cells to selectively induce the survival and 
proliferation of specific populations of interest, and also induce desired phenotypic or 
functional characteristics for a desired outcome. In our study, we have examined the 
selective effects of cytokines such as IL-7 in maintaining the survival and inducing 
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proliferation of CD56bright NK cells. In the clinic, cytokines have been considered useful 
as immunotherapies, for the desired effects they induce in a specific disease state. In 
particular, IL-7 is being used for reconstitution of T cell populations in 
immunocompromised patients (Sportes et al., 2009). However, cytokines such as IL-7 
can also stimulate cell-types such as NK cells, which are not being specifically targeted in 
the immunotherapy, and they can have multiple effects on cell function. Therefore, it is 
important to assess the breadth and depth of the effect cytokines could have on different 
cell types and whether these effects are desirable for use in immunotherapy.  
In conclusion, this study examined the selective properties of cytokines IL-15, IL-
2 and IL-7 on the human NK cells subsets CD56bright and CD56dim. IL-2 and IL-7 were 
both selective in enhancing CD56bright NK cell survival and proliferation, and IL-7 did not 
significantly increase perforin expression in this subset. Further investigation of the 
effects of IL-7 on CD56bright NK cells was conducted by analysis of gene expression 
profiles using DNA microarray. IL-7 CD56bright NK cells retained enhanced expression of 
similar immune function genes to CD56bright NK cells, with HLA-DM/DR and c-kit in 
particular correlated at the protein level. Expression of genes relating to cytokine 
production was not enhanced by IL-7 and some genes that were related to cytokine 
production were downregulated. That is, the IL-7 CD56bright NK cells appear to retain the 
basal state of resting CD56bright NK cells with respect to cytokine production. Future 
studies using IL-7 CD56bright NK cells as a surrogate for freshly isolated CD56bright NK 
cells may be appropriate for studies of antigen presentation. The range of cytokines 
produced after stimulation in multiple ways still needs to be compared. As a caveat, a 
large number of metabolic and regulatory process genes were up and downregulated 
respectively by IL-7 compared to resting CD56bright NK cells. These findings suggest a 
range of functional changes in this subset could occur after IL-7 stimulation that require 
further investigation by protein and functional studies and studies of their interactions 
with other immune cells in comparison to freshly isolated CD56bright NK cells. 
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Chapter 4: NK cell subset responses to an HSV lipopeptide  
4.1 Introduction 
HSV1 and 2 are prevalent human pathogens with worldwide distribution (Bosnjak 
et al., 2005a). Due to the significant global health burden associated with HSV infection, 
from treatment costs for recurrent infections through to serious consequences resulting 
from transmission to newborns and increased acquisition of HIV, the need for an 
effective vaccine is an important and medically relevant goal (Halford, 2014). 
 HSV vaccine candidates tested to-date have failed to provide protection against 
HSV2 (Zhu et al., 2014). However, lipopeptide vaccines provide a promising avenue of 
investigation since they target multiple arms of the immune response compared to 
previous clinical trial vaccines that elicited neutralizing antibody and CD4+T cell 
responses, but failed to induce CD8+T cell responses (Belshe et al., 2014). Conjugated 
lipopeptides as self-adjuvanted vaccines have demonstrated induction of antibody-
mediated, Th1, Th2 and Th17 cell-mediated immunity, and polyfunctional CD8+T cell 
responses (Pejoski et al., 2010, Zeng et al., 2012, Redecke et al., 2004, Gowthaman et al., 
2011, Wenink et al., 2009, Reynolds et al., 2010, Tan et al., 2012). In particular, it has 
been demonstrated that peptides conjugated with the TLR2/6 agonist Pam2Cys were 
effective in priming immunity against viral, bacterial and M. tuberculosis infections, as 
well as tumor growth (Alphs et al., 2008, Day et al., 2007, Batzloff et al., 2006, Tyne et 
al., 2013, Jackson et al., 2004). An HSV2 vaccine consisting of HSV peptide epitopes 
conjugated to a TLR2 agonist has been investigated in mice, which generated HSV2-
specific memory CD8+T cell responses (Zhang et al., 2009b, Zhang et al., 2012). 
However, none of these vaccines examined NK cell responses and their contribution to 
the overall protection observed. 
We have also studied an HSV lipopeptide as a potential vaccine candidate. 
Immunodominant epitopes of HSV2 gD (gD2) recognised by CD4+T cells from HSV1 
and 2 seropositive individuals were identified, called “24-4” and “30-5” (Kim et al., 
2008) and conjugated to Pam2Cys. These HSV lipopeptides induced CD4+T cell IFN-γ 
responses within PBMC and when in coculture with MDDCs. Furthermore, NK cells 
were directly activated, and induced CD4+T cell responses, even in the absence of other 
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antigen-presenting cells (Kim et al., 2012). HSV lipopeptide-stimulated NK cells also 
formed IS with CD4+T cells. Thus, HSV lipopeptide-stimulated NK cells could present 
the antigen to CD4+T cells alone and also augmented activation mediated by DCs. These 
observations were also reproduced in the same study using UV-inactivated HSV2 strain 
186, which also stimulates cells via TLR2 (Sato et al., 2006). 
Prior to our published study, and the commencement of this project, only a 
handful of studies identified NK cell responses via TLR2 in the previous decade. Becker 
et al. first described TLR2 membrane expression on NK cells and observed that LPG 
from L. major (a TLR2 ligand) was recognised by NK cells via TLR2, leading to 
activation (Becker et al., 2003). Other TLR2 ligands that have been shown to activate NK 
cells include the outer membrane protein A from K. pneumoniae (KpOmpA), M. bovis 
BCG, H. pylori membrane lipoprotein HpaA and Pam2Cys lipopeptides derived from 
lipoproteins of S. aureus (Azuma et al., 2010, Chalifour et al., 2004, Lindgren et al., 2011, 
Marcenaro et al., 2008, Martinez et al., 2010). These TLR2 ligands were shown to induce 
NK cell IFN-γ and α-defensin production, or were shown to signal via TLR2 through the 
use of TLR2 knockout mice. 
Of these studies, only Becker et al. demonstrated TLR2 membrane expression by 
microscopy, and Marcenaro et al. detected low-level TLR2 expression by flow cytometry. 
More recently, another study examined surface and intracellular TLR2 expression by 
flow cytometry on both CD56bright and CD56dim subsets. They also reported low surface 
TLR2 expression, and instead found that TLR2 was mainly expressed intracellularly 
(Souza-Fonseca-Guimaraes et al., 2012). They used HKSA as a TLR2 agonist and, in 
combination with the presence of IL-15 and IL-18, demonstrated both subsets responding 
with activation and IFN-γ secretion. Of these studies examining NK cell responses via 
TLR2, only one was examining NK cell responses to a Pam2Cys lipopeptide. 
Furthermore, these studies lacked in-depth analysis of the mechanism of TLR2 activation 
of NK cells.  
By contrast, in monocytes for example, a number of studies have identified the 
mechanism of TLR2 ligands binding to TLR2, cellular trafficking, and have identified 
coreceptors necessary for ligand recognition and response. CD14 and CD36, expressed 
on monocytes and macrophages, are involved in the responses to TLR2 ligands. CD14 
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and CD36 have been shown to directly bind to the TLR2 ligands Pam3Cys, LTA and 
FSL-1 (Pam2Cys-GDPKHPKSF (Schauber et al., 2007)) and were necessary for the 
binding and uptake of these TLR2 ligands in monocytes and macrophages (Manukyan et 
al., 2005, Nilsen et al., 2008, Shamsul et al., 2010). As such, CD14 and CD36 are 
considered important coreceptors required in the TLR2 response in monocytes and 
macrophages.  
However, TLR2 coreceptors equivalent to CD14 and CD36 have not been 
identified in NK cells to-date. This could be particularly critical for understanding the 
mechanism of NK cells responses via TLR2, especially if surface TLR2 expression is low. 
However, this is only one facet of a poorly understood response in NK cells. TLR2 ligand 
trafficking inside the NK cell, pathways leading to the activation and antigen presentation, 
and differences in the NK cell subset responses all pose similar complex questions to 
unravel. We were particularly interested in comparing the NK cell subset TLR2 responses 
since CD56bright and CD56dim NK cells had been previously described as functionally 
distinct, for example regarding cytokine production and cytotoxic potential (Cooper et al., 
2001). Identifying differences in the subset responses to TLR2 stimulation would provide 
an important first step in understanding the contribution of each subset to interactions 
with other immune cells, as we previously showed that NK cells augmented CD4+T cell 
responses to HSV lipopeptide when in coculture with DCs, and could even present the 
antigen directly to CD4+T cells (Kim et al., 2012). 
Therefore, the aim of this study was to investigate and compare the responses of 
CD56bright and CD56dim NK cells to stimulation by an HSV lipopeptide- Pam2Cys 
conjugated to the gD2 peptide “30-5”, referred to as Pam2Cys-30-5. This included 
analysis of the activation marker CD69 and HLA-DR, examination of TLR2 expression 
and an investigation of the effects of Pam2Cys-30-5 stimulation on CD16 expression in 
CD56dim NK cells. We also investigated whether CD16 played a role in NK cell TLR2 
responses, which has not been previously explored. The implications of these findings on 
our understanding of NK cell subset responses and possible mechanisms involved are 
discussed. 
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4.2 Results 
4.2.1 CD69 expression on NK cells after Pam2Cys-30-5 stimulation 
This study commenced by reproducing a previous finding in our laboratory, that 
NK cells were directly activated by Pam2Cys-30-5 in the absence of antigen-presenting 
cells (Kim et al., 2012). 
Isolated NK cells were pulsed with mock (DMSO), peptide 30-5 or P2C-30-5 for 
1 hr, cultured overnight and analysed for the expression of CD69. Representative flow 
cytometry plots showed a marked increase in CD69 expression induced by P2C-30-5 
stimulation (Figure 4.1A). Combined data from nine experiments (Figure 4.1B) showed 
the percentage of CD69+ cells after culture with P2C-30-5 was significantly increased (77 
± 18%) compared to mock (32 ± 17%) and peptide 30-5 (30 ± 16%) (***p<0.001). 
Therefore, a highly significant increase in CD69 expression was observed on NK cells 
after stimulation with P2C-30-5. 
 
 
 
 
 
 
 
 
 
Figure 4.1 CD69 expression on NK cells following Pam2Cys-30-5 stimulation. 
Isolated NK cells were pulsed for 1 hr with mock (DMSO), gD2 peptide 30-5 (30-5), or 
Pam2Cys conjugated to peptide 30-5 (P2C-30-5) (10 µM), cultured overnight and 
analysed by flow cytometry. (A) Representative plots of the percentage of CD69+ NK 
cells after culture. (B) Percentage of CD69+ NK cells shown as mean ± S.D., n=9, 
***p<0.001 (Paired t test). 
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4.2.2 CD69 expression on CD56bright and CD56dim NK cells after Pam2Cys-30-5 
stimulation 
After confirming that the total NK cell population was activated by P2C-30-5, the 
activation of the two NK cell subsets was then examined separately. CD56dim and 
CD56bright NK cells were analysed within the total NK population or after cell sorting, 
pulsed with mock, peptide 30-5, or P2C-30-5, and then cultured overnight and analysed 
for CD69 expression. Representative flow cytometry plots showed that both CD56bright 
and CD56dim NK cells had increased percentage of CD69+ cells after P2C-30-5 
stimulation compared to mock (Figure 4.2A). 
Chapter 4: NK cell subset responses to an HSV lipopeptide 
	 129 
Within the total NK population, after culture with P2C-30-5, the percentage of 
CD69+ CD56bright NK cells was significantly increased (30 ± 10%) compared to both 
mock (10 ± 6%) and peptide 30-5 (10 ± 8%) (***p<0.001) (Figure 4.2B, upper panel). 
Similarly, after culture with P2C-30-5, the percentage of CD69+ CD56dim NK cells was 
significantly increased (66 ± 25%) compared to both mock (28 ± 20%) and peptide 30-5 
(27 ± 16%) (***p<0.001) (Figure 4.2C, upper panel). It was also observed that CD69 
expression was higher on CD56dim than CD56bright NK cells, whether resting or activated.  
In cultures of cell sorted CD56bright NK cells, after culture with P2C-30-5 the 
percentage of CD69+ CD56bright NK cells significantly increased (23 ± 8%) compared to 
mock (5 ± 3%) and peptide 30-5 (4 ± 0.3%) (**p<0.01) (Figure 4.2B, lower panel). 
Likewise, in cultures of cell sorted CD56dim NK cells, P2C-30-5 significantly increased 
the percentage of CD69+ CD56dim NK cells (75 ± 21%) compared to both mock (31 ± 
17%, **p<0.001) and peptide 30-5 (39 ± 17%, *p<0.05) (Figure 4.2C, lower panel). As 
with the experiments using the total NK population, these data from sorted subsets also 
demonstrated increased CD69 expression in both subsets after stimulation with P2C-30-5. 
They also demonstrate higher CD69 expression on CD56dim than CD56bright NK cells. 
However, the fold increase of CD69 expression on sorted CD56bright NK cells cultured 
with P2C-30-5 relative to mock was higher than CD56dim NK cells in most subjects (6.4 
± 3.7 compared to 3.1 ± 1.7 respectively). 
Therefore, both NK cell subsets were independently responsive to P2C-30-5 
stimulation. The overall level of CD69 expression was higher on CD56dim than CD56bright 
NK cells, but the fold increase in CD69 expression induced by P2C-30-5 was mostly 
greater in CD56bright NK cells, which had lower basal CD69 expression.  
Figure 4.2 CD69 expression on CD56bright and CD56dim NK cells following Pam2Cys-
30-5 stimulation. CD56bright and CD56dim NK cells were analysed within total NK cells 
or were cell sorted, pulsed for 1 hr with mock (DMSO), 30-5 or P2C-30-5 (10 µM), then 
cultured overnight and analysed by flow cytometry. (A) Representative plots of the 
percentage of CD69 in sorted CD56bright and CD56dim NK cells after culture with mock or 
P2C-30-5. (B) Percentage of CD69+ CD56bright NK cells within total NK cells (upper 
panel) or after cell sorting (lower panel). (C) Percentage of CD69+ CD56dim NK cells 
within total NK cells (upper panel) or after sorting (lower panel). Percentage of CD69+ 
cells and fold change in CD69 are shown as mean ± S.D. Top panels: n=9, ***p<0.001 
(Paired t-test). Bottom panels: n=6 (30-5 n=3), **p<0.01, *p<0.05 (Unpaired t test). 
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4.2.3 HLA-DR expression on CD56bright NK cells after Pam2Cys-30-5 stimulation 
In addition to examining CD69, HLA-DR expression was also compared between 
the two NK cell subsets in response to Pam2Cys-30-5 stimulation, under the same 
conditions as the sorted subsets in the previous experiment. Representative flow 
cytometry plots showed that CD56bright NK cells had a higher surface expression of HLA-
DR than CD56dim NK cells, and there was an observable increase in HLA-DR on 
CD56bright NK cells in response to P2C-30-5 stimulation (Figure 4.3A). Combined data 
from five experiments (Figure 4.3B) showed that only the CD56bright subset had a 
significant increase in HLA-DR expression by P2C-30-5 compared to mock (fold change 
(log2) of 1.7 ± 0.8-fold, **p<0.01). Whereas CD56dim HLA-DR expression did not 
significantly change after P2C-30-5 compared to mock (fold change (log2) of 0.07 ± 1-
fold). Therefore, the P2C-30-5-induced increase in HLA-DR expression was exclusive to 
CD56bright NK cells. 
4.2.4 TLR2 expression on CD16+ and CD16- NK cells 
 Since both NK cell subsets were activated by P2C-30-5, and Pam2Cys is a TLR2 
ligand, TLR2 expression was examined by microscopy. CD16 was used to distinguish 
CD56dim NK cells (CD16+) from CD56bright NK cells (CD16-). Freshly isolated NK cells 
were incubated with primary anti-TLR2 and anti-CD16 antibodies, prior to fixation and 
immunofluorescence staining, to detect surface fluorescence only. Representative images 
show examples of TLR2+ CD16+ or CD16- NK cells (Figure 4.4A). The percentage of 
TLR2+ total, CD16+ or CD16- NK cells were counted, calculated and combined from four 
replicate experiments (Figure 4.4B). A significant proportion of both CD16+ and CD16- 
NK cells expressed TLR2, although the average percentage of TLR2+ cells was higher in 
CD16+ compared to CD16- NK cells (80 ± 15% and 51 ± 19% respectively). Therefore, 
TLR2 expression was detectable on both CD16+ and CD16- NK cells, and there was a 
trend of a higher percentage of TLR2+CD16+ NK cells compared to TLR2+CD16-NK 
cells. 
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Figure 4.3 HLA-DR expression on CD56bright and CD56dim NK cells following 
Pam2Cys-30-5 stimulation. CD56bright and CD56dim NK cells were prepared as in Figure 
4.2. (A) Representative histograms of HLA-DR expression on CD56bright (upper panel) or 
CD56dim (lower panel) NK cells after culture with mock (DMSO) (blue lines) or P2C-30-
5 (red lines). (B) Fold change (log2) in the proportion of CD56bright and CD56dim NK cells 
expressing HLA-DR after culture with P2C-30-5 (red bars) relative to mock, shown as 
mean ± S.D., n=5 **p<0.01 (Paired t test). 
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Figure 4.4 TLR2 expression on NK cells. Freshly isolated NK cells were washed with 
cold PBS and incubated with primary antibodies at 4°C prior to fixation and staining for 
immunofluorescence microscopy. (A) Representative images of CD16+ and CD16- NK 
cells were stained for CD16 (red) and TLR2 (green). Scale bars = 5 µm. (B) The number 
of TLR2+ and TLR2- total, CD16+ or CD16- NK cells were counted in at least 10 fields of 
view per experiment. The percentage of TLR2+ total, CD16+ and CD16- NK cells were 
calculated, shown as mean ± S.D., n=4. 
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4.2.5 Colocalisation of Pam2Cys and TLR2, or CD16 and TLR2 on NK cells 
Since surface TLR2 expression was detected by microscopy, and since we had 
data indicating that Pam2Cys-30-5 bound to and was taken up by NK cells (see Appendix 
1), an imaging experiment examining the colocalisation between Pam2Cys and TLR2 
was conducted to demonstrate binding of Pam2Cys to TLR2.  
NK cells were incubated with FITC-conjugated P2C-30-5 (FITC-30-5-P2C) at 
4°C for 1 hr to allow specific binding to TLR2, prior to incubation with primary 
antibodies (anti-CD16 and anti-TLR2) and immunofluorescent staining. Initially, 
colocalisation between Pam2Cys and TLR2 was measured and analysed as described in 
Section 2.5.5 of Chapter Two. On observing images of FITC-30-5-P2C and TLR2 
staining in the same cells, it appeared that most of the FITC staining was not colocalised 
with TLR2 (Figure 4.5A). In the representative image, the Pearson Coefficient of 
correlation was low between Pam2Cys and TLR2 (0.4, Figure 4.5C). However, CD16 
often appeared colocalised with TLR2 (Figure 4.5B) and the Pearson Coefficient of 
correlation was higher between CD16 and TLR2 in the representative image (0.9, Figure 
4.5D). A comparison of the Pearson Coefficients of Pam2Cys-TLR2 and CD16-TLR2 
from > 70 cells in 10 fields of view were calculated (Figure 4.5E). There was a highly 
significant increase in correlation between CD16-TLR2 compared to Pam2Cys-TLR2 
(***p<0.001, median coefficient values for Pam2Cys-TLR2 and CD16-TLR2 were 0.4 
and 0.7 respectively).  
Therefore, we identified a novel incidental finding, that although Pam2Cys 
colocalisation with TLR2 was not frequently observed, CD16 and TLR2 were frequently 
colocalised.  
Figure 4.5 Colocalisation of CD16 and TLR2 compared with Pam2Cys and TLR2. 
NK cells were incubated with FITC-30-5-P2C (1 µM) for 1 hr at 4°C, washed with cold 
PBS, and incubated with primary antibodies at 4°C prior to fixation and staining for 
immunofluorescence microscopy. (A&B) Representative images of FITC-30-5-P2C 
(FITC, green) and TLR2 (red), or CD16 (yellow) and TLR2 respectively, including 
merged images and 3D (rotated) images. White colour indicates areas of colocalisation. 
Scale bars = 5 µm. (C) Pearson Coefficient of Correlation plot of (A). (D) Pearson 
Coefficient of Correlation plot of (B). (E) Pearson Coefficient of Correlation of Pam2Cys 
and TLR2 (FITC-TLR2) vs. CD16 and TLR2 (CD16-TLR2). Dots represent the averages 
of 10 fields of view within which a total of >70 cells were analysed for colocalisation. 
Bars indicate median and interquartile range. *** p<0.001 (Mann-Whitney test). 
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4.2.6 CD16 expression on CD56dim NK cells after Pam2Cys-30-5 stimulation 
Since CD16 and TLR2 appeared to be colocalised by microscopy, we examined 
whether P2C-30-5 stimulation via TLR2 affected CD16 expression on NK cells, 
particularly the CD56dim subset. 
NK cells were pulsed with mock, peptide 30-5 or P2C-30-5 for 1 hr, cultured 
overnight and analysed for CD16 expression. Representative FACS plots show an 
observable decrease in CD16 expression on CD56dim NK cells after culture with P2C-30-
5 (Figure 4.6A). Data were quantified from nine replicate experiments (Figure 4.6B) 
comparing the CD56dim CD16 expression (MFI) before culture, with those cultured 
overnight with mock, peptide 30-5 or P2C-30-5. Initially, CD16 MFI was 10723 ± 4473. 
After mock culture, CD16 MFI decreased (6948 ± 2349, *p<0.05) and a similar decrease 
was induced by peptide 30-5 (7579 ± 2599). However, after culture with P2C-30-5 there 
was a highly significant further decrease in CD16 MFI (3016 ± 1604) compared to before 
culture (***p<0.001) and all other treatments (*p<0.05).  
Additionally, CD16 expression was examined in cell sorted CD56dim NK cells 
(Figure 4.6C). After culture with P2C-30-5, CD16 MFI was significantly decreased 
compared to mock (3889 ± 1335 compared to 6262 ± 1139, **p<0.01). Therefore a 
strong and consistent downregulation of CD16 on CD56dim NK cells was observed in 
response to P2C-30-5 stimulation. 
 
 
 
Figure 4.6 CD16 expression on CD56dim NK cells following Pam2Cys-30-5 
stimulation. NK cells were analysed within the total NK population (A,B) or cell sorted 
(C), pulsed for 1 hr with mock (DMSO), 30-5 or P2C-30-5 (10 µM) (A,B) or with mock 
or P2C-30-5 only (C) then cultured overnight and analysed by flow cytometry. Some NK 
cells were also analysed before culture. (A) Representative plots from (B) which shows 
CD16 MFI as mean ± S.D. n=9 *p<0.05, ***p<0.001 (One-way ANOVA with multiple 
pair-wise comparisons). (C) CD16 MFI of sorted CD56dim NK cells as mean ± S.D., n=5 
**p<0.01 (Paired t test). 
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4.2.7 CD16 expression in response to serial concentrations of Pam2Cys-30-5 
After observing that CD16 expression was consistently downregulated when NK 
cells were stimulated by 10 µM of P2C-30-5, the concentration of P2C-30-5 was titrated 
to determine whether CD16 downregulation was dose-dependent. NK cells were pulsed 
with 0, 10, 100, 1000, 10000 and 20000 nM of P2C-30-5 and cultured overnight. CD16 
expression on the CD56dim population was compared at the range of concentrations tested 
(Figure 4.7). With increasing concentrations of P2C-30-5, the CD16 MFI on the CD56dim 
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population decreased (0 nM: 7761 ± 1832, 10 nM: 7620 ± 1808, 100 nM: 6284 ± 1399, 
1000 nM: 4659 ± 1368, 10000 nM: 3427 ± 1876, 20000 nM: 3297 ± 1683). 
Concentrations of P2C-30-5 of 1000 nM and above induced significant downregulation 
of CD16 compared to 0 and 10 nM, and concentrations of 10000 nM and above also had 
significant downregulation of CD16 compared to 100 nM (see Figure 4.7 legend for p-
values). These results indicate that the extent of CD16 downregulation is dose-dependent, 
with a minimum concentration of 1000 nM required to induce significant downregulation. 
 
Figure 4.7 CD16 expression in response to serial concentrations of Pam2Cys-30-5. 
NK cells were pulsed for 1 hr with 0-20000 nM P2C-30-5, cultured overnight and 
analysed for CD16 expression by flow cytometry. CD16 MFI is shown as mean ± S.D., 
n=5, **p<0.01, ***p<0.001 (Repeated measures ANOVA with multiple pair-wise 
comparisons). For clarity in the figure, only pair-wise comparisons for 0 nM are marked. 
Other statistically significant comparisons were 10 nM vs. 1000 nM (**p<0.01), 10 nM 
vs. 10000 nM (***p<0.001), 10 nM vs. 20000 nM (***p<0.001), 100 nM vs. 10000 nM 
(**p<0.01), and 100 nM vs. 20000 nM (**p<0.01). 
4.2.8 CD16 downregulation over time following Pam2Cys-30-5 stimulation 
After demonstrating a consistent downregulation of CD16 after overnight 
stimulation by P2C-30-5 and determining the dose-dependent response, the kinetics of 
CD16 downregulation over time was observed to determine how rapidly it was occurring. 
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NK cells were cultured in the presence of 10 µM P2C-30-5 or mock over a time-
series: 0, 10 (0.166 hr), 30 (0.5 hr) and 60 (1hr) mins, then 2, 4, 6 and 18 hrs. 
Representative histograms show CD16 expression in mock and P2C-30-5 stimulated NK 
cells (Figure 4.8A), with a decrease in CD16 MFI evident in P2C-30-5 stimulated cells 
over time, with the greatest decrease at 6 hrs (an MFI of 1846 compared to 9376 at 0h). 
Five experiments were combined and graphed as the percentage of maximal (0h) CD16 
MFI for each time point (Figure 4.8B). Comparisons between P2C-30-5 at time 0 with all 
time points beyond 0.5 hrs were significantly decreased. Furthermore, as early as 0.5 hrs 
after stimulation, there was a statistically significant decrease in % maximal CD16 
expression in NK cells treated with P2C-30-5 compared to mock (70 ± 14% compared to 
90 ± 10%). This continued to decrease over time to 6 hrs and was statistically significant 
at all the time points investigated (1 hr: 57 ± 13% P2C-30-5 compared to 89 ± 11% 
mock; 2 hr: 51 ± 15% P2C-30-5 compared to 86 ± 14% mock; 4hr: 41 ± 14% P2C-30-5 
compared to 87 ± 12% mock; 6hr: 33 ± 17% P2C-30-5 compared to 77 ± 9% mock). By 
18 hrs, there was still a statistically significant decrease in the % maximal CD16 
expression in NK cells treated with P2C-30-5 compared to mock (40 ± 21% P2C-30-5 
compared to 82 ± 16% mock), although expression was starting to restore compared to 6 
hours (see Figure 4.8 legend for p-values). 
Therefore, there was a significant decrease in CD16 expression from 30 mins after 
stimulation with Pam2Cys compared to mock. CD16 expression continued to decrease in 
P2C-30-5 treated cells until 6 hrs after treatment. By 18 hrs, CD16 was still significantly 
decreased in P2C-30-5 treated cells, but expression was starting to restore.		
4.2.9 CD69 and IFN-γ expression in Pam2Cys-30-5 stimulated CD56dimCD16-/dim 
cells 
It was next investigated whether CD16 downregulation correlated functionally 
with increased activation. Therefore, the expression of IFN-γ and CD69 were compared 
in CD56bright, CD56dimCD16+, and the emerging CD56dimCD16-/dim NK cells following 
P2C-30-5 stimulation. 
IFN-γ expression was measured by intracellular cytokine staining, gating on each 
of the subsets separately. Representative FACS plots show a marked increased in IFN-γ 
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expression in CD56dimCD16-/dim cells after P2C-30-5 treatment compared to the other 
subsets (Figure 4.9A). IFN-γ expression was then quantified and graphed for three 
replicate experiments, and was significantly increased in CD56dim CD16-/dim cells (21 ± 
10%) compared to the other subsets (2 ± 1% CD56bright and 4 ± 3% CD56dimCD16+, 
*p<0.05) following P2C-30-5 treatment (Figure 4.9B). Similarly, CD69 expression was 
compared on the three subsets. CD56bright NK cells had the lowest CD69 expression 
(Median 31% CD69+). Although CD56dimCD16+ NK cells had high CD69 expression 
(Median 77% CD69+), CD56dimCD16-/dim cells had significantly higher expression 
following P2C-30-5 treatment than both CD56bright and CD56dimCD16+ NK cells (Median 
91% CD69+, ***p<0.001 and **p<0.01 respectively) (Figure 4.9C). 
 Taken together, these results show that the CD56dim NK cells that are 
downregulating CD16 are also becoming the most activated as measured by IFN-γ and 
CD69 expression, which indicates CD16 downregulation is functionally relevant and 
correlated with increased activation. 
 
 
 
 
 
Figure 4.8 Time course of CD16 downregulation following Pam2Cys-30-5 
stimulation. NK cells were pulsed for 1 hr with mock (DMSO) or P2C-30-5 (10 µM), 
cultured in serum-free RPMI 1640 over a time series of 0, 10 (0.166 hr), 30 (0.5hr), 60 (1 
hr) mins and 2, 4, 6 and 18 hrs, then analysed by flow cytometry. (A) Representative 
histograms of CD16 expression in mock and P2C-30-5 treated cells over time. (B) The 
percentage of maximal CD16 MFI (maximal is time 0), shown as mean ± S.D. n=5. P-
values comparing P2C-30-5 and mock at each time point were determined by paired t-test 
**p<0.01, ***p<0.001. P-values comparing P2C-30-5 at time 0 with all other time points 
were determined by One-way ANOVA with multiple pair-wise comparisons. For clarity 
in the figure, only time 0 vs. 18 hrs significance is marked. Other statistically significant 
time points were: 0 hr vs. 0.5 hr *p<0.05, 0 hr vs. 1 hr **p<0.01, 0 hr vs. 2 hr, 0 hr vs. 4 
hr. 0 hr vs. 6 hr, 0 hr vs. 18 hr all ***p<0.001, 0.166 hr vs. 2 hr *p<0.05, 0.166 hr vs. 4 hr 
**p<0.01, 0.166 hr vs. 6 hr ***p<0.001, 0.166 hr vs. 18 hr **p<0.01, 0.5 hr vs. 6 hr 
*p<0.05. 
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Figure 4.9 CD69 and IFN-γ expression in Pam2Cys-30-5 stimulated CD56dimCD16-
/dim NK cells. (A&B) Cells were pulsed for 1 hr with mock (DMSO), 30-5 or P2C-30-5 
(10 µM), cultured overnight in Brefeldin A (10 µg/mL), and analysed by flow cytometry. 
(A) Representative plots of IFN-γ expression in CD56bright, CD56dimCD16+ and 
CD56dimCD16-/dim after treatment with mock, 30-5 or P2C-30-5. (B) The percentage of 
IFN-γ+ CD56bright, CD56dimCD16+ and CD56dimCD16-/dim shown as mean ± S.D. n=3 
*p<0.05 (One-way ANOVA with multiple pair-wise comparisons). (C) The percentage of 
CD69+ cells after treatment with P2C-30-5 in CD56bright, CD56dimCD16+ and 
CD56dimCD16-/dim. Bars represent median values, n=9 **p<0.01, ***p<0.001 (Repeated 
measures ANOVA with multiple pair-wise comparisons). 
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4.2.10 CD16 and TLR2 proximity on NK cells 
CD16 downregulation was correlated with increased activation in response to 
P2C-30-5, therefore, it was important to determine the mechanism or relationship 
between Pam2Cys stimulation and CD16 expression. Since by microscopy, CD16 and 
TLR2 appeared largely colocalised on NK cells, we wanted to explore the possibility of 
CD16-TLR2 interactions, and examined the literature regarding interactions between 
FcRs and TLRs. 
Recently, there has been discussion in the literature about collaboration and cross-
talk between TLRs and Fc receptors (FcRs) in innate immunity. It was reported that 
antibody-opsonised bacteria induce cross-talk between FcRs and TLRs, resulting in 
synergistic release of inflammatory cytokines including TNF, IL-23 and IL-1β. This 
synergistic cytokine release was dependent on activation via MyD88 and ITAM 
signalling pathways through TLRs and FcRs respectively (Bakema et al., 2015). However, 
other reports of TLR and FcR interaction observed regulation of one pathway by the 
other rather than synergy. In macrophages, co-ligation of FcγRs along with TLR ligands 
such as LPS or LTA, activated an anti-inflammatory response characterised by IL-10 
induction, rather than the proinflammatory IL-12 production induced by TLR stimulation 
alone (Mukhopadhyay et al., 2004). Conversely, in the setting of T cell-independent, 
FcγR-mediated arthritis, TLR2 was found to have a protective role in immune complex-
driven disease. TLR2 deficiency accelerated the onset and severity of disease due to 
TLR2 specifically upregulating the inhibitory receptor FcγRIIB (CD32b) that reduces the 
proinflammatory response. In this setting TLR2 was shown to control acute immune-
complex driven arthritis by controlling the FcγR response (Abdollahi-Roodsaz et al., 
2013).  
Although these studies were mainly demonstrating one pathway modulating the 
signalling pathway of the other, other studies have demonstrated direct physical 
interactions between FcγRs and TLRs. In the setting of systemic lupus erythematosus, 
DNA-containing immune complexes within lupus serum stimulated pDCs to produce 
cytokines and chemokines via cooperative interaction between TLR9 and CD32 
(FcγRIIA). Furthermore, the DNA-containing immune complexes transiently colocalised 
with CD32 and TLR9 in a subcellular compartment, demonstrating that CD32 delivered 
Chapter 4: NK cell subset responses to an HSV lipopeptide 
	 144 
the DNA-containing immune complexes to TLR9 in intracellular lysosomes (Means et al., 
2005). Another study identified cross-talk between CD16 and TLR4 in macrophages and 
neutrophils. Cells incubated with IgG immune complexes or LPS and then 
immunoprecipitated with anti-TLR4 were found associated with CD16 by western 
blotting. This study demonstrated heterodimerisation of TLR4 and CD16 in the presence 
of their respective ligands (Rittirsch et al., 2009). 
In NK cells, CD16 interactions with TLRs or TLR ligands have not been 
previously explored, however CD16 has been shown to colocalise with IL-12R, by 
microscopy and cellular fractionation experiments, in lipid raft domains at the cell surface 
when costimulated with immobilised IgG and IL-12. The dual recruitment of these 
receptors enhanced activation of downstream signalling events leading to increased 
production of IFN-γ compared with stimulation with either agent alone (Kondadasula et 
al., 2008). In this setting CD16 was synergistic with IL-12R in enhancing IFN-γ 
production rather than regulating the response, unlike the anti-inflammatory FcR 
responses that tended to be observed in macrophages (Mukhopadhyay et al., 2004). Since 
the interactions between FcRs and TLRs have been varied depending on stimulus and 
cell-type, it was important to examine the possibility of CD16 cross-talk with TLR2 on 
NK cells. Therefore, we examined more precisely whether CD16 and TLR2 on NK cells 
were in close enough proximity to one another to interact. 
Duolink’s Proximity Ligation Assay (PLA) enables detection, visualisation and 
quantification of protein-protein interactions in cell samples prepared for microscopy. A 
pair of oligonucleotide labelled secondary antibodies (PLA probes) label anti-CD16 and 
anti-TLR2 primary antibodies. A ligation solution is added consisting of two 
oligonucleotides and Ligase, which hybridise to the two PLA probes and join to a closed 
circle if they are in close proximity (<40 nm). Finally an amplification solution is added 
consisting of fluorescently labelled oligonucleotides and Polymerase. The oligonucleotide 
arm of one of the PLA probes acts as a primer for a rolling-circle amplification (RCA) 
reaction. The fluorescently labelled oligonucleotides hybridise to the RCA product and 
the signal becomes visible as a distinct fluorescent dot for each detected pair of PLA 
probes. In our experiments, we used CD4+T cells as a negative control for TLR2-CD16 
proximity since they lack expression of CD16, and CD14+ monocytes were used as a 
positive control for the system, measuring TLR2-CD14 proximity, as these receptors are 
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known to interact. Finally, NK cells at 0 and 30 mins after treatment with mock (DMSO) 
and P2C-30-5 were analysed for TLR2-CD16 proximity. 
Representative images show no dots in CD4+T cells and many dots in CD14+ 
monocytes, as expected (Figure 4.10A). For NK cells, a few dots were observed at both 0 
and 30 mins, whether stimulated with P2C-30-5 or not. When the data of the percentage 
of cells with a particular number of dots was analysed from three subjects, there was a 
trend of more CD16-TLR2 proximity before stimulus (Figure 4.10B). However, the 
number of dots observed was rarely more than 2-5 dots, although some cells had 6-9 dots, 
and in one subject a few cells had between 10-19 dots before stimulus. Therefore, close 
proximity between CD16 and TLR2 was detectable, however, it was infrequent and with 
some variability between subjects. 
 
 
 
 
 
 
 
 
 
Figure 4.10 CD16 and TLR2 proximity on NK cells. NK cells were treated with mock 
(DMSO) or P2C-30-5 (10 µM) for 0 and 30 mins at 37°C, washed with cold PBS and 
prepared for immunofluorescence staining and Proximity Ligation Assay. Unstimulated 
CD4+T cells and CD14+ monocytes were prepared in the same manner as negative and 
positive controls respectively. (A) Representative images of the number of dots seen per 
cell in CD4+T cells, NK cells at 0 mins mock and 30 mins P2C-30-5, and CD14+ 
monocytes. Scale bars = 5 µm. (B) Three replicate experiments showing the percentage 
of cells with a certain number of dots, in each cell-type and treatment. Approximately 
100 cells per condition were evaluated in each experiment. 
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4.2.11 CD16 blocking and the binding of Pam2Cys-30-5 to NK cells 
Although close proximity between CD16 and TLR2 was only infrequently 
detected, since it was detectable to some extent, we wanted to investigate whether this 
close proximity was sufficient to inhibit or reduce P2C-30-5 binding to NK cells when 
CD16 is blocked. Two blocking agents were used: an anti-CD16 antibody, and human 
AB serum, in which IgG molecules bind to CD16 (an FcR). 
NK cell CD16 was blocked with serial concentrations of anti-CD16 antibody or 
human AB serum prior to incubation with FITC-conjugated P2C-30-5, then binding of 
Pam2Cys on NK cells was measured by FITC expression by flow cytometry. 
Representative histograms show an observable reduction in FITC MFI on NK cells 
blocked with 1:5 dilution of anti-CD16 (from no blocking MFI of 170 to 145), and more 
notably with 2% or 10% human AB serum (decreased to 115 and 87 respectively) (Figure 
4.11A). Data from five experiments were quantified, determining the percentage of 
maximum FITC MFI compared to cells with no blocking, which were set at 100% 
(Figure 4.11B). These data confirm that statistically significant reductions in FITC MFI 
were observed on NK cells blocked with a 1:5 dilution of anti-CD16 (72 ± 8%, **p<0.01). 
Further significant reductions were observed by 2% and 10% human AB serum (27 ± 
25% and 5 ± 6%, **p<0.01 and ***p<0.001 respectively). Therefore, blocking CD16 on 
NK cells reduced, and in the case of human AB serum severely inhibited, the binding of 
Pam2Cys to NK cells. 
 
 
 
Figure 4.11 CD16 blocking and Pam2Cys-30-5 binding to NK cells. NK cell CD16 
was blocked with purified anti-CD16 antibody (clone 3G8) or human AB serum for 30 
mins, followed by 10 mins incubation with FITC-conjugated P2C-30-5 (100 nM) at 37°C. 
Cells were washed and fixed immediately. (A) Representative histograms of FITC 
expression (MFI) on NK cells in the presence or absence of anti-CD16 antibody or 
human AB serum. (B) Percentage of maximum FITC MFI (cells with no blocking) shown 
as mean ± S.D. n=5 **p<0.01, ***p<0.001 (One-way ANOVA with multiple pair-wise 
comparisons). 
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4.2.12 CD16 and Pam2Cys binding by ELISA 
Since blocking CD16 reduced binding of Pam2Cys to NK cells, we investigated 
whether Pam2Cys and CD16 could bind directly. This experiment was performed in 
collaboration with Mark Hogarth’s laboratory at the Burnet Institute in Melbourne. They 
have expertise in CD16 ELISA, utilising biotinylated dimers of CD16, both V158 and 
F158 polymorphisms. The dimers increase the strength of binding of CD16 to its ligands. 
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In this ELISA, the plate was coated with Pam2Cys-conjugated Influenza peptide 
M2e, M2e alone or aggregated IgG as a positive control, incubated with the biotinylated 
CD16 dimers, then a colorimetric reaction was developed using Streptavidin HRP and 
TMB substrate. The results show that even at the highest concentration of P2C-M2e used 
(200 µg/mL), no binding was detected above the background control of Streptavidin HRP 
only (Figure 4.12). Therefore, binding of CD16 to Pam2Cys was not detected. 
 
Figure 4.12 CD16 and Pam2Cys binding ELISA. Pam2Cys binding to CD16 was 
measured by ELISA. Plates were coated with Influenza peptide M2e, Pam2Cys-
conjugated M2e (P2C-M2e) or aggregated human IgG (hagg), blocked with 2% 
casein/PBS and incubated with biotinylated CD16 dimers (V158 (A) or F158 (B)). An 
ELISA with no addition of biotinylated CD16 dimer was used as a control (C). 
Colorimetric reaction was developed using Streptavidin-HRP and TMB substrate, and 
absorbance measured at 450 nm. 
 
Chapter 4: NK cell subset responses to an HSV lipopeptide 
	 150 
4.2.13 Soluble CD16 in NK cell supernatants following Pam2Cys-30-5 stimulation 
Since CD16 and Pam2Cys binding was not detectable, yet CD16 downregulation 
appeared to be correlated to the most activated CD56dim NK cells responding to P2C-30-5, 
we wanted to investigate the mechanism of CD16 downregulation to begin understanding 
the significance. 
Both CD16 shedding and internalisation have been reported in the literature, 
although more studies have reported shedding as the mechanism observed. Numerous 
stimuli have been shown to induce CD16 shedding, including CD16 cross-linking with 
anti-CD16 antibodies, ligation with IgG or antibody-coated target cells, phorbol ester 
(PMA) and exposure to stimulatory cytokines such as IL-2 or IL-15 (Borrego et al., 1994, 
Romee et al., 2013, Trinchieri et al., 1984, Harrison et al., 1991, Peruzzi et al., 2013). 
Harrison et al. were the first to identify that metalloprotease activity was involved in 
PMA-induced CD16 shedding from NK cells, using an inhibitor of zinc-dependent 
metalloproteases (Harrison et al., 1991). Borrego et al. demonstrated that the same 
metalloprotease activity was involved in CD16 shedding induced by CD16 cross-linking. 
However, they also demonstrated that staurosporine, a PKC inhibitor, blocks PMA-
induced but not CD16 cross-linking-induced downregulation, suggesting that CD16 
downregulation can be achieved by more than one mechanism, at least one that is PKC 
dependent and one that is not (Borrego et al., 1994).  
More recently the precise metalloprotease involved was identified, a disintegrin 
and metalloprotease 17 (ADAM17), the selective inhibition of which resulted in 
abrogated CD16 shedding and enhanced IFN-γ production (Romee et al., 2013). In the 
same year, another group reported that the membrane-type 6 (MT6) matrix 
metalloprotease 25, or MMP25, was the proteinase responsible for CD16 downregulation 
in NK cells. Activation with IL-2 induced increased MMP25 transcript levels and cell 
surface expression by translocation of intracellular MMP25 to the cell surface. This 
upregulation correlated with CD16 downmodulation, and siRNA (small interfering 
RNA)-mediated disruption of MMP25 expression enhanced ADCC capacity and restored 
activation-induced loss of CD16. The authors suggested that MMP25 might trigger a 
proteolytic cascade activating other metalloproteases, perhaps ADAM17 (Peruzzi et al., 
2013). 
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Since CD16 shedding was quite well documented in the literature, we investigated 
whether CD16 downregulation induced by P2C-30-5 stimulation was also due to CD16 
shedding into the supernatant. To measure CD16 shedding, soluble CD16 needed to be 
detected in NK cell supernatants after culture. A well-established, commercially available 
human soluble CD16 ELISA was not available, however, Wang et al. published the use 
of custom CBA for the detection of soluble CD16 cleaved from human neutrophils 
(Wang et al., 2013). In personal communications with us, the authors recommended use 
of this method rather than the colorimetric ELISA they also published (Romee et al., 
2013). Therefore, we also utilised custom CBA for the detection of soluble CD16 in our 
experiments. 
NK cells were cultured in serum-free RPMI, and supernatants were collected at 
baseline (before culture), after 1 hr of PMA stimulation as a positive control, or after 2 
hrs of stimulation with mock or P2C-30-5. We did not stimulate for longer time-points to 
avoid degradation of any shed CD16. Also, based on our flow cytometry results (Figure 
4.2.8), by 2 hrs there was already a significant decrease in surface CD16 expression that 
should be sufficient for determining if CD16 was being shed into the supernatant. The 
results from three experiments were graphed for the concentration of CD16 detected in 
the supernatants (Figure 4.13A). In all three experiments, the highest concentration of 
CD16 was detected after 2 hrs of P2C-30-5 stimulation (6475, 5734 and 3673 pg/mL). 
There was a 28 ± 1.4% increase in CD16 concentration at 2 hrs P2C-30-5 compared to 
mock, which was statistically significant (***p<0.001). Therefore, shed CD16 was 
detected in the supernatants and was increased after P2C-30-5 stimulation compared to 
mock.  
 
Figure 4.13 Measuring soluble CD16 in NK cell supernatants following Pam2Cys-
30-5 stimulation. Supernatants were collected from NK cells immediately after isolation 
(baseline), after culture with PMA (10 ng/mL, positive control) for 1 hr, or with mock 
(DMSO) or P2C-30-5 (10 µM) for 2 hrs at 37°C, cultured at 1x107 cells/mL in serum-free 
RPMI 1640. Samples were analysed for the presence of soluble CD16 by custom CBA. 
(A) Three replicate experiments measuring CD16 (pg/mL) in each of the four conditions 
described. (B) The percentage increase in CD16 supernatant concentration at 2 hrs P2C-
30-5 compared to 2 hrs mock (normalised to 100%), shown as mean ± S.D. n=3 
***p<0.001 (Paired t test). 
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4.2.14 Internalised CD16 in NK cells following Pam2Cys-30-5 stimulation 
Although a modest increase in shed CD16 concentration was detected in P2C-30-
5 stimulated NK cell supernatants compared to mock, the magnitude of increase did not 
appear to correspond with the difference in surface downregulation of CD16 by P2C-30-5 
compared to mock observed by flow cytometry at 2 hours (Figure 4.2.8). Therefore, 
CD16 internalisation was also investigated as an additional mechanism of surface CD16 
downregulation. 
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A study demonstrated CD16 internalisation in NK cells following cross-linking of 
CD16 by specific monoclonal antibodies. Strong and rapid decrease in surface CD16 
expression occurred within 30 mins and redistributed in the cytoplasmic region within 10 
mins of culture. They suggested the internalised CD16 was likely degraded and that this 
degradation could be important for inactivating stimulated receptors. New CD16 
molecules were also quickly re-expressed on the outer membrane, determined using 
cyclohexamide (CHX), a protein synthesis inhibitor that blocked the renewal of CD16 at 
the surface. Endocytosis of CD16 was independent of ATP but required a functional actin 
cytoskeleton, as determined by actin interference by Jasplakinolide and Latrunculin A. 
CD16 surface expression was correlated with expression of phosphatidylcholine-specific 
phospholipase C (PC-PLC). Inhibition of PC-PLC caused dramatic decreases in both 
CD16 and PC-PLC surface expression and reduced CD16-mediated cytotoxicity. The 
authors concluded that PC-PLC could play an important role in regulating CD16 
membrane expression, CD16-mediated cytotoxicity and CD16 signal transduction 
(Cecchetti et al., 2007). 
In our study, we initially attempted to measure CD16 internalisation by 
comparing surface and intracellular CD16 expression by flow cytometry, however, 
following fixation and permeabilisation, required for intracellular staining, CD16 was no 
longer recognised by our anti-CD16 flow cytometry antibodies. A method of measuring 
internalisation that has been used for decades termed “acid-stripping” was also attempted 
(Hopkins and Trowbridge, 1983, Salazar and Gonzalez, 2002, Sandgren et al., 2013). In 
this approach, NK cells were labelled with fluorescently conjugated anti-CD16 antibodies 
first, stimulated with P2C-30-5 or mock (DMSO), then washed at acidic pH at 4°C to 
remove surface anti-CD16 antibody. Any internalised CD16, with its accompanying 
fluorescently tagged anti-CD16 antibody would be preserved and detectable by flow 
cytometry. However in controls, anti-CD16, as reported in the literature, caused CD16 
downregulation without P2C-30-5 stimulation. Therefore, this method was invalid for the 
measurement of CD16 internalisation in response to P2C-30-5. 
Instead, similarly to Cecchetti et al. (Cecchetti et al., 2007), we examined CD16 
internalisation by microscopy, comparing NK cells before treatment (0 hr) and after 2 hr 
treatments with mock or P2C-30-5. Rather than simply observing whether CD16 
internalised, we quantified the relative enrichment (RE) of intracellular to surface 
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fluorescence. This method of image acquisition and analysis was described in section 
2.5.5 of Chapter Two. Phalloidin (F-actin) staining was used to distinguish intracellular 
from surface CD16 fluorescence, since the actin cortex lies directly beneath the plasma 
membrane (Salbreux et al., 2012), thus any fluorescence inside this boundary could be 
considered intracellular. Representative images after 2 hrs of P2C-30-5 stimulation show 
that some CD16 fluorescence was observable within the phalloidin boundary, indicative 
of fluorescence inside the cell (Figure 4.14A). The RE of intracellular CD16 was 
calculated for all the cells observed in 10 fields of view per time-point and treatment, 
then graphed to compare intracellular RE of CD16 in NK cells at 0 and 2 hrs after mock 
or P2C-30-5 stimulation (Figure 4.14B). Statistically significant increases in CD16 
intracellular RE were determined after 2 hrs of P2C-30-5 stimulation (Median 0.6, IQR 
0.4 to 0.9) compared to 0 hr (Median 0.2, IQR 0.1 to 0.3, ***p<0.001) and 2 hrs mock 
(Median 0.3, IQR 0.1 to 0.4, **p<0.01). Therefore, a significant enrichment in 
intracellular CD16 was detectable after 2 hours of P2C-30-5 stimulation. Furthermore, 
together with the previous result, these data suggest that both CD16 shedding and 
internalisation occur in response to P2C-30-5 stimulation. 
 
 
 
 
Figure 4.14 Measuring internalised CD16 in NK cells following Pam2Cys-30-5 
stimulation. NK cells were cultured with mock (DMSO) or P2C-30-5 (10 µM) for 0 and 
2 hrs, fixed and stained for immunofluorescence microscopy. (A) Representative images 
of an NK cell at 0 hr, and 2 hrs after mock and P2C-30-5 treatment. CD16 (purple), 
phalloidin (green) and merged images with DAPI (blue) are shown. Rectangles highlight 
ROIs selected to measure relative enrichment (RE). Scale bar = 5 µm. (B) To measure 
intracellular RE, two rectangular regions per cell were selected, spaced at least 1/3rd of 
the cell circumference apart, encompassing surface and intracellular regions that were 
also defined within the ROI. The average CD16 fluorescence of the total, surface and 
intracellular regions at each ROI were measured and averaged from the two regions per 
cell. Intracellular RE of CD16 fluorescence for individual cells in each condition was 
calculated according to the formula in Figure 2.5. Graph shows the CD16 RE for ten 
individual cells per condition, lines and bars indicate median with IQR, **p<0.01, 
***p<0.001 (Mann-Whitney test). 
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4.3 Discussion 
In this study we investigated and compared the responses of CD56bright and 
CD56dim NK cells to stimulation by the HSV lipopeptide Pam2Cys-30-5. Both CD56bright 
and CD56dim NK cells expressed the activation marker CD69 in response to Pam2Cys-
30-5 stimulation. This is consistent with the study that also demonstrated increased CD69 
expression in both subsets responding to the TLR2 agonist HKSA (Souza-Fonseca-
Guimaraes et al., 2012). However, our study also examined the NK cell subset responses 
after cell sorting, demonstrating both subsets could respond independently of the other, or 
indeed independently of other immune cells within PBMC. This likely explains why the 
percentage of CD69+ CD56bright NK cells was generally lower and more specific in our 
hands, as we were observing their response alone, without the presence of other cells 
responding to the TLR2 agonist (such as monocytes) increasing basal levels of activation 
of the NK cells. 
In response to Pam2Cys-30-5, only the CD56bright subset significantly upregulated 
HLA-DR. In our published study, we also observed that CD56bright NK cells expressed 
higher levels of HLA-DR and DQ than CD56dim NK cells, both constitutively and when 
increased in response to Pam2Cys-30-5 stimulation (Kim et al., 2012). It was first 
postulated some time ago that the CD56bright NK cell subset could act as an accessory 
antigen-presenting cell with upregulated HLA-DR and secretion of IFN-γ, enhancing 
CD4+T cell responses (Hanna et al., 2004b, Hanna and Mandelboim, 2007). We also 
previously demonstrated that NK cells alone could activate CD4+T cells to respond to 
Pam2Cys-30-5 and form IS (Kim et al., 2012). The capacity and mechanism of CD56bright 
NK cell antigen presentation to CD4+T cells, as well as HLA-DR upregulation, requires 
further investigation and will be the subject of future studies. 
In most of the previous studies of NK cell responses to TLR2 ligands, surface 
TLR2 expression was not described. One study demonstrated TLR2 expression by 
microscopy (Becker et al., 2003) and two others examined TLR2 expression by flow 
cytometry, reporting low to undetectable surface expression (Marcenaro et al., 2008, 
Souza-Fonseca-Guimaraes et al., 2012). In our published study, we also examined TLR2 
expression by flow cytometry, demonstrating that between approximately 2-8% of cells 
expressed TLR2 in both CD56bright and CD56dim NK cells (Kim et al., 2012). In the 
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current study, we demonstrated TLR2 expression on NK cells by immunofluorescence 
microscopy, similar to the study by Becker et al. (Becker et al., 2003). We utilised a 
method aimed at specifically labelling surface TLR2, rather than total intracellular TLR2 
by labelling the primary antibody at 4°C prior to fixation, permeabilisation and secondary 
antibody staining. In so doing, we demonstrated that TLR2 expression was detectable at 
the surface, and on a much higher percentage of NK cells than reports analysing by flow 
cytometry. There is a perplexing disparity across the studies examining TLR2 expression 
on NK cells by flow cytometry and fluorescence microscopy. All three studies analysing 
TLR2 expression on NK cells by flow cytometry, including our own published study, 
reported a fairly low (to undetectable) percentage of cells expressing surface TLR2. 
However the study by Becker et al. and this study both clearly demonstrated surface 
TLR2 staining on most cells by immunofluorescence microscopy.  
We considered the possibility that different antibody clones or sources of antibody 
across the studies may explain the different levels of detection observed. Whilst it could 
be a contributing factor, even within our own observations in this study and our published 
study, the antibodies used were of the same clone (TL2.1) and supplier, the only 
difference being the antibody was the purified form in microscopy and fluorochrome 
conjugated in flow cytometry, yet the difference in percentage of cells observed 
expressing TLR2 utilising the two technologies was quite different. Some amplification 
of signal may be contributing through the use of primary and secondary antibody 
combinations compared to a conjugated antibody. However, another possible explanation 
could be related to the staining pattern of TLR2 observed. By microscopy, TLR2 staining 
was often quite scattered on the surface, and the fluorescence somewhat dim. The 
DeltaVision Image Restoration Microscope that we used has the ability to amplify weak 
signals, particularly with the use of restorative deconvolution (McNally et al., 1999), and 
so perhaps is better equipped to detect scattered focal signals than as averaged by the 
flow cytometer. Nevertheless, unless the causes of these differences can be fully 
identified, different studies may continue to report different finding regarding TLR2 
expression on NK cells. Multiple methods of detection should be used in future 
investigations. 
Despite it being known for many years that TLR2 ligands such as Pam2Cys bind 
to TLR2, the analysis of their molecular interactions have only been demonstrated in 
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more recent years. A study determining the crystal structure of the TLR2-TLR6-
Pam2Cys lipopeptide showed differences in the lipid channel of TLR6 and TLR1 (Kang 
et al., 2009). The lipid channel of TLR6 was blocked by two phenylalanines, resulting in 
the TLR2-TLR6 complex having reduced affinity for triacylated lipopeptides (Pam3Cys) 
compared to diacylated lipopeptides (Pam2Cys). However both lipopeptides bound 
similarly to TLR1-TLR2 complexes. Furthermore, the precise binding of Pam2Cys to the 
TLR2-TLR6 heterodimer was demonstrated. 
We therefore sought to demonstrate Pam2Cys binding to TLR2 on NK cells by 
incubating the cells at 4°C to facilitate specific binding but not uptake into the cell. 
However colocalisation between FITC-conjugated Pam2Cys-30-5 and TLR2 was not 
often observed and the Pearson coefficient of correlation was low. It could be that 
incubating at 4°C was not the right condition for observing the TLR2-Pam2Cys 
interaction, however when we incubated at 37°C instead, the interaction and uptake of 
Pam2Cys was rapid: Pam2Cys was already internalised 15 minutes after addition 
(Appendix 1). We were also interested in the incidental observation that TLR2 and CD16 
were often colocalised on NK cells and therefore investigated whether TLR2 stimulation 
affected CD16 expression and whether CD16 could play any role in NK cell TLR2 
responses. 
We observed a strong, dose-dependent downregulation of CD16 over 18 hours 
following Pam2Cys-30-5 stimulation, with the greatest decrease observed at 6 hours. To 
our knowledge, this is the first studying reporting the loss of CD16 expression in 
response to a TLR2 ligand. There are many studies reporting downregulation of CD16 in 
response to a variety of stimuli, including PMA, CD16 cross-linking with anti-CD16 
antibodies, ligation with IgG or antibody-coated target cells and exposure to stimulatory 
cytokines such as IL-2 or IL-15 (Borrego et al., 1994, Romee et al., 2013, Trinchieri et al., 
1984, Harrison et al., 1991, Peruzzi et al., 2013, Cecchetti et al., 2007, Mota et al., 2004). 
However, the kinetics of CD16 downregulation differed depending on the stimulus. PMA 
induced rapid loss of CD16 expression, with significant downregulation after 1 hour and 
more than 90% of membrane CD16 lost within 2 hours (Harrison et al., 1991, Romee et 
al., 2013). Targeting of CD16 with anti-CD16 antibody induced a gradual decline in 
CD16 expression with the lowest expression observed at 240 minutes (4 hours) and 
remaining at the same low level by 360 minutes (6 hours) (Cecchetti et al., 2007). 
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Downregulation of CD16 by cytokine treatment such as IL-2, induced slower 
downregulation, detected at the earliest time of 6 hours post IL-2 treatment. However, at 
6 hours, only 10% downregulation of CD16 was observed, whereas by 12 and 24 hours, 
the levels of CD16 decreased by 25% and 50% respectively (Peruzzi et al., 2013). In 
comparison to these stimuli, the kinetics of CD16 downregulation in our experiments 
using a TLR2 ligand were most similar to the kinetics induced by anti-CD16 antibody, 
although our peak decline was at 6 hours rather than 4 hours. 
The CD16 downregulation we observed on CD56dim NK cells was not merely an 
unrelated observation: the CD56dim NK cells that were losing CD16 (which we termed 
CD56dimCD16-/dim NK cells) had the highest expression of CD69 and IFN-γ, so CD16 
downregulation had functional significance. It was unexpected that CD56dim NK cells 
would have a significantly higher proportion of cells expressing IFN-γ than CD56bright 
NK cells since the latter were originally thought of as the main cytokine producing subset 
(Cooper et al., 2001). Furthermore, our observation differed from that of Souza-Fonseca-
Guimaraes et al., who observed higher IFN-γ expression in CD56bright NK cells 
responding to their TLR2 ligand HKSA compared to CD56dim NK cells, although 
CD56dim NK cells still expressed significant levels of IFN-γ (Souza-Fonseca-Guimaraes 
et al., 2012).  A key difference between their study and ours was the use of cytokines IL-
15 and IL-18 in their culture conditions. We did not use any cytokines to maintain our 
cultures in this study, unlike in Chapter Three, as we were examining the initial, early 
response and not culturing for long time periods (i.e. hours rather than days). Furthermore, 
in Chapter Three we observed that such “survival” cytokines do not merely enhance 
survival of NK cells, but impact on their cytotoxicity, proliferation, and the expression of 
chemokine homing receptors and HLA-DR. Therefore, we excluded the influence of 
cytokines when examining the NK cell responses to TLR2 stimulation. 
Upon re-examining more recent literature regarding NK cell subset function, it 
became apparent that the original paradigm of CD56dim NK cells being the cytolytic 
subset and CD56bright NK cells being cytokine producers has shifted. A study comparing 
CD56bright and CD56dim subsets for the production of IFN-γ after triggering via NKp46 
and NKp30 receptors found that CD56dim NK cells were rapid producers of IFN-γ, as 
early as 2 to 4 hours after stimulus, whereas CD56bright NK cells produced IFN-γ after 16 
hours (De Maria et al., 2011). Another study reported that CD16 cross-linking on NK 
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cells induced IFN-γ production, however the accompanying increase in CD56 expression 
meant these cells had the appearance of CD56bright NK cells (Marquez et al., 2010). 
However, since CD56dim NK cells express CD16 rather than CD56bright NK cells, it is 
likely that at least some of cells producing IFN-γ were CD56dim NK cells that also 
upregulated CD56 on the surface, or were CD56bright NK cells maturing into CD56dim NK 
cells. More recently, when NK cells were stimulated via activating receptors such as 
NKG2D, NKp30, NKp46, 2B4, DNAM and CD16, the IFN-γ producing NK cells 
responding were CD56dim (Lajoie et al., 2014). The authors suggested that it may be more 
appropriate to define CD56dim and CD56bright NK cells as target cell responsive and 
cytokine responsive, respectively. Our observations agree with this suggestion, but we 
would propose modifying it to say that CD56dim NK cells appear to produce IFN-γ in 
response to receptor-ligand interactions, whereas CD56bright NK cells produce IFN-γ in 
response to cytokines. Therefore, they could be referred to as receptor-ligand responsive 
and cytokine responsive respectively. 
Since we observed a functional correlation of CD16 downregulation and IFN-γ 
production, as well as colocalisation between CD16 and TLR2, and also in light of 
reports about cross-talk between TLRs and Fc receptors, we examined the proximity 
between CD16 and TLR2 proximity (or likely protein-protein interactions) using PLA. 
However, even though the colocalisation experiments indicated a lot of colocalisation 
between CD16 and TLR2, proximity interactions were detected infrequently. Where 
proximity interactions were detected, each as a fluorescent dot, the cells usually had 
between 2 and 5 dots, and rarely >6. Therefore, it appears that not many molecules of 
TLR2 and CD16 were in close enough proximity with each other to interact, despite 
appearing colocalised in the previous experiments. Furthermore, PLA only identifies that 
proteins are in close enough proximity to interact rather than directly demonstrating this. 
Future experiments utilising co-immunoprecipitation or FRET may confirm whether 
direct binding occurs or not. 
Although relatively few proximity interactions were observed between TLR2 and 
CD16, blocking CD16 significantly reduced Pam2Cys binding to NK cells nonetheless. 
Possible reasons for this could be that Pam2Cys is capable of binding to CD16 directly, 
and thus blocking CD16 prevents Pam2Cys from binding, or, since CD16 resides closely 
to TLR2, blocking CD16 interferes with Pam2Cys binding to TLR2 due to steric 
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hindrance. To address whether CD16 is capable of binding to Pam2Cys, an ELISA was 
constructed where plates were coated with Pam2Cys, then biotinylated CD16 dimers 
were added, and bound CD16 was detected using streptavidin HRP. The ELISA did not 
show any binding between Pam2Cys and CD16. Possible reasons for this could be that 
Pam2Cys and CD16 do not interact at all, that the region of Pam2Cys bound to the plate 
is the CD16 binding region, that the association between Pam2Cys and CD16 was 
transient or weak in affinity, or that three-way binding between Pam2Cys, TLR2 and 
CD16 is triggered only on the cell surface. In a study examining Pam3Cys binding to 
CD14 by surface plasmon resonance, the affinity between Pam3Cys and CD14 was 
described as weak and explained by non-specific binding due to hydrophobicity of the 
lipopeptide (Nakata et al., 2006). Despite having a weak affinity, CD14 was 
demonstrated as required for binding the lipopeptide and inducing formation of the 
lipopeptide-TLR2-TLR1 complex. Therefore, weak associations not detectable in assays 
reliant on strong binding affinity may still carry physiological relevance.  
Nonetheless, we were unable to demonstrate direct binding and instead focussed 
on determining the mechanism of CD16 downregulation. The observed downregulation 
of CD16 from the surface of CD56dim NK cells could be due to three possibilities: 
receptor cleavage or shedding from the surface, receptor internalisation, or receptor 
conformational change such that the epitope recognised by the anti-CD16 antibody is lost 
(Bazil and Strominger, 1991). As described earlier, both CD16 shedding and 
internalisation have been observed in NK cells, although more studies have reported 
CD16 shedding. We detected CD16 shedding by CBA, and there was a small but 
significant increase in the concentration of soluble CD16 in samples stimulated by 
Pam2Cys-30-5 compared to mock after 2 hours of stimulation. However, to detect these 
levels of CD16 in the supernatant, it required culturing the cells at a higher density than 
other experiments (1x107 cells/mL compared to 1x106 cells/mL) and the increased CD16 
in the supernatant induced by Pam2Cys did not appear to reflect the difference in CD16 
expression observed by flow cytometry. Therefore, we also examined CD16 
internalisation to determine whether both mechanisms could be occurring. 
As discussed earlier, we were unable to use more conventional methods of 
measuring internalisation such as intracellular flow cytometry and acid-stripping of 
surface staining. Therefore, we examined CD16 internalisation by microscopy, and in 
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order to quantitate any change in CD16 fluorescence from surface to intracellular, we 
utilised a method known as relative enrichment (RE), originally used for measuring the 
enrichment of fluorescence at immunological synapses (IS). This method calculated 
enrichment by measuring the average intensity of both surface and intracellular 
fluorescence by dividing the average fluorescence of each region by the average 
fluorescence of the total area selected, spanning both the surface and intracellular regions. 
Then RE of intracellular fluorescence was determined as a ratio of intracellular 
enrichment divided by surface enrichment. A statistically significant increase in RE of 
CD16 intracellular fluorescence was determined in response to Pam2Cys-30-5 
stimulation. However, this result should be validated using an alternative method of 
internalisation. If a different clone of anti-CD16 antibody is identified that recognises its 
epitope after fixation with paraformaldehyde, such as the rat clone we used in microscopy 
experiments, intracellular flow cytometry could be revisited as an alternative method of 
detection. Additionally, if CD16 is degraded after internalisation (as suggested by 
Cecchetti et al. (Cecchetti et al., 2007)), the use of cathepsin inhibitors should prevent 
degradation, allowing internalised CD16 to accumulate inside the cell and be more 
clearly visualised at later time-points. Another possibility for quantifying internalised vs. 
shed CD16 could be the use of cell-surface biotinylation followed by capture of 
internalised or shed CD16 using Avidin, and identification with anti-CD16 antibody post 
stimulation. 
We have therefore demonstrated both CD16 shedding and internalisation in 
response to Pam2Cys-30-5 stimulation. Ultimately, inhibitors of both CD16 shedding and 
internalisation will be necessary to confirm the importance of each mechanism and to 
determine whether CD16 downregulation occurs to enhance or regulate the response. 
ADAM17 inhibitors such as TAPI-2, and inhibitors of endocytosis such as the tyrosine 
kinase inhibitor genistein, are examples of such inhibitors. 
The significance of the striking CD16 downregulation induced by Pam2Cys-30-5 
and its effects on ADCC need further exploration. Downregulation of functionally 
relevant molecules from the surface has been shown to be a powerful regulatory process 
(Borrego et al., 1994) and likewise, CD16 shedding is considered a regulatory process. 
Proteolytic processing regulates cell surface density of various cell surface molecules on 
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leukocytes and inhibition of ADAM17 enhances the production of cytokines (Romee et 
al., 2013). It has been suggested that downregulation of CD16 could play a physiological 
role in the NK cell activation process by releasing immune complexes or target cells 
bound via CD16 and halting signal transduction (Harrison et al., 1991, Borrego et al., 
1994). Nonetheless, studies have also suggested that activation induced shedding of 
CD16 does decrease NK cell ADCC (Trinchieri et al., 1984, Romee et al., 2013). To 
determine the effects of CD16 downregulation on ADCC, Pam2Cys-30-5 stimulated NK 
cells could be cultured with antibody-coated target cells such as Raji or Daudi lymphoma 
cell lines to determine if and for how long they have reduced capacity to perform ADCC. 
It is also not clear what repercussions this would have on protection against infection and 
thus it should also be determined whether CD16 downregulation compromises NK cells 
ability to respond to infections including HSV. 
Soluble CD16 has physiological roles and is the major species of soluble FcγR 
found in blood (de la Salle et al., 1997). Soluble CD16 has been shown to interact with 
complement receptors CR3 and CR4 and induce proinflammatory cytokines IL-6 and IL-
8 by monocytes (Galon et al., 1996). It has been shown to bind to peripheral blood 
mononuclear cells and inhibit pokeweed-mitogen induced responses (Teillaud et al., 
1993). Interestingly, soluble CD16 has also been shown to induce DC maturation, with 
upregulation of markers CD40, CD80, CD86 and HLA- class I and class II, as well as 
production of cytokines IL-1β, IL-6, IL-8, GM-CSF and IL12p70, via binding to the 
complement receptors CR3 and CR4 (de la Salle et al., 1997).  
Although shed/soluble CD16 may have multiple physiological roles, the interface 
between NK cell activation and CD16 downregulation still needs further exploration. In 
particular, in response to stimulation via TLR2. If TLR2 and CD16 do not directly 
interact in response to Pam2Cys-30-5 stimulation, do the signalling pathways of TLR2 
stimulation and CD16 downregulation intersect downstream? Or is CD16 downregulation 
merely an epi-phenomenon due to activation of the NK cells, triggered by TLR2 
stimulation, but not directly linked to TLR2? The use of inhibitors at different points in 
the TLR2 signalling pathway may be informative, if their use blocks CD16 
downregulation. This is also important for further assessment of the use of TLR2 agonists 
as vaccine adjuvants and the functional significance of the responses they induce. 
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In conclusion, we have shown that both CD56bright and CD56dim NK cells were 
responsive to stimulation by the TLR2 ligand and HSV lipopeptide Pam2Cys-30-5. Both 
CD16+ and CD16- NK cells expressed TLR2 by microscopy, and TLR2 was colocalised 
with CD16. Stimulation with Pam2Cys-30-5 induced significant downregulation of CD16 
and the resulting CD56dimCD16-/dim NK cells became the most activated shown as 
expression of IFN-γ. CD16 and TLR2 were infrequently found in close enough proximity 
for molecular interactions, but blocking CD16 significantly reduced Pam2Cys-30-5 
binding to NK cells. No direct binding between Pam2Cys and CD16 was detected, 
however both CD16 shedding and internalisation were detected after Pam2Cys-30-5 
stimulation. The NK cell subsets functional capabilities seem to change depending on the 
type of stimulus they receive, rather than only being capable of cytotoxicity or cytokine 
production, as CD56dim NK cells expressed more IFN-γ than CD56bright NK cells in the 
context of TLR2 stimulation. Understanding the functional significance of CD16 
downregulation in response to a TLR2 agonist will be important for further assessment of 
the use of TLR2 agonists as adjuvants in vaccine candidates. 
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Chapter 5: NK cell subset effects on DC maturation and 
presence in HSV-infected skin 
5.1 Introduction 
Several studies have demonstrated that lipopeptides induce DC maturation and 
subsequently, CD4+T cell responses (Zhu et al., 2004, Bettahi et al., 2006, Jones et al., 
2008, Warshakoon et al., 2009). Previously, we developed HSV lipopeptides consisting 
of the TLR2 agonist Pam2Cys conjugated to HSV2 gD (gD2) peptides, and demonstrated 
that coculture of CD4+T cells with DCs stimulated with Pam2Cys-conjugated gD2 
peptides resulted in enhanced CD4+T cell IFN-γ responses. Furthermore, the presence of 
NK cells augmented DC-CD4+T cell responses to the Pam2Cys-conjugated gD2 peptides 
(Kim et al., 2008, Kim et al., 2012). Cross-talk between NK cells and either DCs or 
CD4+T cells have been described, but in particular, numerous studies have demonstrated 
the importance of NK-DC interactions in the immune response. 
NK cells have been shown to facilitate both the maturation and killing of 
immature DCs (Chijioke and Munz, 2011). In vitro studies have demonstrated that a low 
ratio of NK cells to immature DCs (1:5) promotes DC maturation, whereas a higher NK 
cell to immature DC ratio (5:1) results in NK cell-mediated killing of immature DCs 
(Piccioli et al., 2002). Given our previous findings demonstrating the presence of NK 
cells enhancing DC-CD4+T cell responses to the TLR2 stimulating HSV lipopeptide, we 
were particularly interested in investigating NK cells ability to mature DCs in this context. 
Many studies investigating DC-NK interactions in the context of TLR stimulation have 
not focussed on the NK cells being directly activated via TLRs, but rather on DC-
mediated activation of NK cells. Several studies have shown the importance of DC 
cytokines IL-12 and IL-18 in activating NK cells to produce IFN-γ in response to TLR 
agonists such as LPS (TLR4) and poly(I:C) (TLR3) (Gerosa et al., 2002, Borg et al., 2004, 
Gerosa et al., 2005, Walzer et al., 2005, Yu et al., 2001). IL-18 has also been 
demonstrated to induce a helper-type NK cell characterised by expression of CD56, 
CD16, CD83, CCR7 and CD25, and did not enhance cytotoxicity (Mailliard et al., 2005). 
Type I IFNs have been shown to have a critical role in the induction of NK cell 
cytotoxicity. In particular, pDCs produce high levels of IFNα/β in response to ssRNA 
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(TLR7,8) or unmethylated CpG (TLR9) (Gerosa et al., 2005, Walzer et al., 2005, 
Colonna et al., 2004).  
Apart from DC cytokines, cell-to-cell contact has also been shown to be important 
for optimal NK cell activation (Barreira da Silva and Munz, 2011). A study by Borg et al. 
found that whilst IL-12 had a critical role in NK cell IFN-γ production induced by LPS-
stimulated DCs, cell-to-cell contact was also required. They demonstrated the formation 
of an IS characterised by polarisation of IL-12 at the interface. Furthermore, disruption of 
the DC cytoskeleton, and therefore inhibition of synapse formation, abolished DC-
mediated NK cell activation (Borg et al., 2004). A study investigating pDC responses to 
the TLR9 ligand CpG-ODN, found that pDCs activated by CpG-ODN promoted NK cell 
cytotoxicity and IFN-γ production through type I IFN and glucocorticoid-induced tumour 
necrosis factor receptor ligand (GITRL) interaction with GITR (Hanabuchi et al., 2006). 
More recently, a mouse study investigating coculture of poly(I:C) pre-treated myeloid 
DCs and NK cells found that NK cell activation was contact-dependent and identified the 
IRF-3-dependent NK-activating molecule (INAM), which was expressed on both DCs 
and NK cells and was required to facilitate efficient NK activation mediated by DCs 
(Ebihara et al., 2010). Finally, an in vitro human study of DCs matured with bacterial 
fragments of K. pneumoniae (which trigger via TLR2 and 4), recruited NK cells in a 
CCR5-dependent manner. NK cell recruitment was characterised by induction of CCR7 
on CD56dimCD16+ NK cells after physical contact with K. pneumoniae-matured DCs. 
This study indicated that NK cell contact with DCs is not only important for NK cell 
activation but also migration, facilitating NK-DC interactions both in the periphery and in 
lymphoid tissue (Van Elssen et al., 2010). 
Other studies of NK-DC interactions and TLR stimulation have also examined 
NK cell responses to TLR stimulation directly. A study in mice showed that the TLR5 
ligand flagellin directly induced proliferation of NK cells, however the proliferative 
response, as well as CD69 expression, were enhanced by the presence of DCs (Tsujimoto 
et al., 2005). Another mouse study examined a panel of Pam2Cys-conjugated peptides 
derived from S. aureus and assessed their functional properties using bone marrow-
derived DCs and NK cells. They found that cell-to-cell contact rather than soluble 
mediators were required to induce NK cell activation via Pam2Cys peptide-stimulated 
DCs. Whilst most of the lipopeptides induced NK cell activation via the DC 
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TLR2/MyD88 pathway, some also induced direct activation of NK cells. They also 
identified that the peptide sequence near the N-terminus determined whether NK cells 
were activated. Hydrophobic or proline-containing sequences at the second amino acid 
interfered with lipopeptide induction of DC-mediated NK activation (Azuma et al., 2010). 
A study examining responses to dsRNA and CpG found that NK cells also responded 
directly to stimulation. In particular, they showed that the NK cells lysed immature DCs 
upon stimulation with dsRNA or CpG (Sivori et al., 2004).  
During inflammation, activated myeloid DCs and pDCs can secrete chemokines 
such as MIP-1β (CCL4), RANTES (CCL5), fractalkine (CX3CL1), IL-8 (CXCL8) and 
IP-10 (CXCL10) (Ferlazzo and Munz, 2009). Each NK cell subset is able to migrate 
according to the chemokine receptors they express. CD56dimCD16+ NK cells express 
CXCR1 and CX3CR1, the receptors for IL-8 and fractalkine respectively. CD56bright NK 
cells express CCR5, CXCR3 and CXCR4, which allow migration in response to 
RANTES, MIP-1β, ITAC (CXCL11) and IP-10 (Campbell et al., 2001). Thus DCs could 
attract both types of NK cells and interact at sites of inflammation. Some in vivo 
observations in humans support this. NK cells and DCs were observed in close contact in 
atopic dermatitis and the interaction was influenced by the allergen Malassezia yeast 
(Buentke et al., 2002). An investigation of a patient with X-linked SCID characterised by 
red erythroderma-like skin lesions, found an infiltration of CD56brightCD16- NK cells 
mixed with CD1a+ DCs in the dermal infiltrate. It was proposed that NK cell contact with 
the DCs in the inflamed skin resulted in NK cell activation and proliferation, as NK cells 
were virtually absent in normal skin (Shibata et al., 2007).  
In the context of HSV infection, NK cells have been found present in lymphocyte 
populations extracted from human genital lesion biopsies (Zhu et al., 2007). Furthermore, 
we previously demonstrated that NK cells were present in recurrent herpes lesion 
biopsies and found in close proximity with pDCs (Donaghy et al., 2009) and CD4+T cells 
(Kim et al., 2012). A review by Ferlazzo and Morandi discussed potential interactions of 
NK cells with various DC subsets in the skin. It is now known that at least four DC 
subpopulations reside in skin: epidermal Langerhans cells (LCs), dermal CD1a+ DCs, 
dermal CD14+ DCs and dermal CLEC9A+/BDCA3+/CD141+ DCs. It has been 
demonstrated that LCs can support NK cell survival via IL-15 production (Munz et al., 
2005). Ferlazzo and Morandi proposed that CD141+ DCs, which can produce high 
Chapter 5: NK cell subset effects on DC maturation and presence in HSV- 
infected skin 
	 168 
amounts of IFN-α (Meixlsperger et al., 2013), could play a key role in promoting NK cell 
cytotoxicity in peripheral tissues (Ferlazzo and Morandi, 2014). This interaction, as well 
as potential NK interactions with the other skin DC subsets, is yet to be fully investigated.  
Since our previous findings indicated that NK cells enhanced DC-CD4+T cell 
responses to HSV lipopeptide, it strongly suggested that NK cell-mediated DC 
maturation could contribute to this enhancement. Most previous studies examining NK-
DC interactions with TLR agonists focussed largely on DC-mediated activation of NK 
cells, or observed NK cell-mediated DC killing, rather than NK cell-mediated DC 
maturation. Furthermore, in humans, NK cell subsets in the skin and their response to 
HSV infection are not well understood, nor are their interactions with various skin DC 
subpopulations. 
The aims of this study were to compare the NK cell subsets in their ability to 
induce DC maturation in response to Pam2Cys-30-5 stimulation, and to begin 
investigating the presence of the NK cell subsets in normal and primary HSV-infected 
skin. This included: analysis of DC maturation markers CD80 and CD83 in response to 
NK cells stimulated with Pam2Cys-30-5, the effects of CD56bright and CD56dim NK cell 
soluble factors on DC maturation, analysis of cytokines and chemokines produced by 
both subsets. The presence of CD16+ and CD16- NK cells in normal and primary HSV-
infected tissue, their proximity to other antigen-presenting cells and expression of a skin 
homing marker were also analysed. The implications of these findings on our 
understanding of NK cell subset interactions with DCs are discussed, as well as the 
broader implications of the presence of NK cells in skin: as a participant in the immune 
response to HSV and as a potential vaccine target. 
5.2 Results 
5.2.1 Optimising the cell culture ratio of NK cells with MDDCs 
To study NK cell effects on DC maturation in the context of HSV lipopeptide, we 
used monocyte-derived DCs (MDDCs) obtained by culturing CD14+ monocytes with IL-
4 and GM-CSF for 5-6 days. Optimising the ratio of NK cells and MDDCs was necessary 
since data had been published on the ability of NK cells to both mature and kill immature 
DCs, and that the NK:DC ratio influenced the outcome of interactions (Piccioli et al., 
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2002). We wanted to investigate whether a ratio that was favourable to MDDC 
maturation without significantly outnumbering one cell type by the other was feasible. 
Therefore, we included ratios of 1:2 and 2:1, which were not reported in the previously 
published findings. MDDCs were cultured overnight alone or in ratios with NK cells of 
5:1, 2:1, 1:1, 1:2 and 1:5. MDDCs were labelled with Propidium Iodide (PI), an indicator 
of cell death, immediately prior to analysis on the flow cytometer. 
At an NK:DC ratio of 5:1, MDDC cell death was highest and statistically 
significant compared to unstimulated DCs before culture (*p<0.05) (Figure 5.1A,B). As 
the NK:DC ratio decreased there was a trend of decreasing percentage of PI+ MDDCs, 
however 2:1, 1:1 and 1:5 all had statistically greater percentages of PI+ MDDCs 
compared to DCs before culture (*p<0.05, **p<0.01, *p<0.01 respectively). The NK:DC 
ratio of 1:2 was the only ratio where the percentage of PI+ cells was not statistically 
greater than unstimulated DCs before culture. At the 1:5 ratio, two of the four subjects 
had a further decrease in MDDC cell death compared to the 1:2 ratio, and in the other two 
subjects, the least MDDC cell death was at the 1:2 ratio. In the same experiments, the 
fold change (log2) in percentage of PI+ MDDCs was also compared across the NK:DC 
ratios, relative to the 5:1 ratio (Figure 5.1C). The only statistically significant decrease in 
fold change (log2) compared to the NK:DC 5:1 ratio was at the 1:2 ratio (*p<0.05). 
Since the NK:DC ratio 1:2 appeared to be more consistent than the 1:5 ratio, and 
there was a statistically significant reduction in MDDC death at this ratio relative to the 
5:1 ratio, it was chosen for subsequent coculturing experiments investigating NK cell 
effects on MDDC maturation. 
 
Figure 5.1 Optimal ratio to culture NK cells with MDDCs to minimise MDDC death. 
Immature MDDCs were cultured overnight alone, with maturation mix, or with varying 
ratios of NK cells. MDDCs were analysed for the uptake of Propidium Iodide (PI) as an 
indicator of cell death by flow cytometry. (A) Representative histograms of (B), the 
percentage of PI+ MDDCs (log transformed) before and after culture in the absence or 
presence of maturation mix or varying ratios of NK cells are expressed as mean ± S.D. 
n=4, *p<0.05, **p<0.01, ***p<0.001 (One-way ANOVA with multiple pair-wise 
comparisons). (C) Fold change (log2) in percentage of PI+ MDDCs of the NK:DC ratios, 
relative to the 5:1 ratio. Data are shown as mean ± S.D. n=4, *p<0.05 (Paired t test). 
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5.2.2 MDDC CD83 expression in coculture with Pam2Cys-30-5-stimulated NK cells  
Immature MDDCs were cultured overnight alone, or pairs of NK cells and 
MDDCs pulsed with DMSO- mock (M) or P2C-30-5 (P) were cultured together at a 
NK:DC ratio of 1:2. The expression of maturation marker CD83 was analysed by flow 
cytometry. Representative FACS plots (Figure 5.2A) showed an increase in the 
percentage of CD83+ MDDCs when either MDDCs or NK cells or both were pulsed with 
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P2C-30-5 (P) prior to coculture. Combined data from three experiments (Figure 5.2B) 
also show a trend of increased CD83 expression on MDDCs when cocultured with NK 
cells after either or both cell types had been pulsed with P2C-30-5. The fold change (log2) 
in percentage of CD83+ MDDCs was calculated relative to MDDCs cultured alone (DC 
after, normalised to 0). There was little change in CD83 expression when MDDCs and 
NK cells were cocultured together after no P2C-30-5 stimulation (NKM+DCM, -0.1 ± 
1.0-fold). When MDDCs pulsed with P2C-30-5 were cocultured with unstimulated NK 
cells (DCP+NKM), there was an increase in CD83 expression (1.4 ± 0.6-fold, p=0.06). 
When unstimulated MDDCs were cocultured with NK cells pulsed with P2C-30-5 
(DCM+NKP), a statistically significant increase in CD83 expression was observed (1.5 ± 
0.4-fold, *p<0.05). The greatest increase in CD83 expression on MDDCs was observed 
when NK cells and MDDCs had both been pulsed with P2C-30-5 prior to coculture (3.0 ± 
0.9-fold, *p<0.05). 
Therefore, after stimulation with P2C-30-5, the presence of NK cells increased 
CD83 expression on MDDCs when either cell type had been stimulated. This effect was 
augmented when both cell types were stimulated prior to coculture. 
 
 
 
 
 
 
 
 
Figure 5.2 MDDC CD83 expression in coculture with Pam2Cys-30-5 stimulated NK 
cells. Immature MDDCs were cultured overnight alone or with NK cells. NK cells and 
MDDCs were pulsed with DMSO- mock (M) or P2C-30-5 (P) and cultured together at an 
NK:DC ratio of 1:2. MDDCs were analysed by flow cytometry. NKM = NK+Mock, 
DCM = DC+Mock, NKP = NK+P2C-30-5, DCP = MDDC+P2C-30-5. (A) 
Representative FACS plots show the percentage of CD83+ MDDCs before and after 
culture in the absence or presence of NK cells. (B) Fold change (log2) in percentage of 
CD83+ MDDCs in the presence of NK cells, relative to MDDCs cultured alone (DC after) 
shown as mean ± S.D. n=3 *p<0.05 
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5.2.3 MDDC CD80 and CD83 expression in transwell plates separated from 
Pam2Cys-30-5-stimulated NK cells 
The next part of the study determined whether NK cell contact with MDDCs was 
necessary to induce MDDC maturation when stimulated by P2C-30-5. MDDCs and NK 
cells were cocultured at a NK:DC ratio of 1:2 in transwell chambers with 0.4 µm pore 
size, to prevent cell migration. NK cells were pulsed with DMSO- mock (M), peptide 30-
5 (pep) or P2C-30-5 (P) then cultured overnight separated from or in contact with 
MDDCs (Figure 5.3A). MDDCs were also cultured alone with maturation mix as a 
positive control. MDDCs were analysed for CD80 and CD83 expression by flow 
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cytometry. CD86 was not used in these experiments due to higher basal expression than 
CD80 and CD83 on immature MDDCs. 
Compared to unstimulated MDDCs after culture (DC after, 20 ± 28%), the 
percentage of CD80+ cells increased significantly when MDDCs were cultured with NK 
cells pulsed with P2C-30-5 in a separated transwell (DC/NKP) (55 ± 28%, *p<0.05) 
(Figure 5.3B). Likewise when MDDCs were cultured with NK cells pulsed with P2C-30-
5 in coculture wells (DC+NKP), the percentage of CD80+ cells also significantly 
increased (61 ± 32%, *p<0.05). There was no significant difference or trend towards an 
increase in the percentage of CD80+ MDDCs in DC+NKP compared to DC/NKP. 
Similarly, compared to unstimulated MDDCs after culture (DC after, 17 ± 5%), the 
percentage of CD83+ cells was increased in DC/NKP (37 ± 20%, p=0.06) (Figure 5.3C). 
In DC+NKP percentage of CD83+ MDDCs was significantly increased (31 ± 13%, 
*p<0.05). There was no significant difference or trend towards an increase in the 
percentage of CD83+ DCs in DC+NKP compared to DC/NKP. These results indicated 
that NK cell soluble factors induced by P2C-30-5 stimulation were sufficient to induce 
MDDC maturation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 MDDC CD80 and CD83 expression with or without NK cell contact. 
Immature MDDCs were cultured overnight alone, or cocultured separately from (/) or 
together with (+) mock (NKM), 30-5 (NKpep) or P2C-30-5 (NKP) stimulated NK cells, 
or with maturation mix (Mat Mix), then analysed by flow cytometry. Cultures had 
transwell inserts of 0.4 µm pore size. (A) Schematic diagrams of transwell set up with 
NK cells and MDDC cocultured separately (/) or together (+). The percentage of CD80+ 
(B) and CD83+ (C) MDDCs before and after culture in the absence or presence of 
maturation mix or various separated and combined cocultures with NK cells, shown as 
mean ± S.D. n=4 *p<0.05, **p<0.01 (Paired t test). 
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5.2.4 NK cell activation induced by Pam2Cys-30-5 in transwell plates separated from 
MDDCs 
In the same experiments as in section 5.2.3, the NK cell subsets were also 
analysed for the expression of activation marker CD69 to compare their activation when 
in contact with MDDCs or separated by transwell inserts. We also included analysis of 
HLA-DR expression in some experiments.  
The percentage of CD69+ CD56bright NK cells was significantly increased when 
P2C-30-5-stimulated NK cells were cultured overnight in contact with MDDCs 
(NKP+DC, 75 ± 20%) compared to NK cells alone before (7.5 ± 5.8%, ***p<0.001) and 
after culture (9 ± 6.5%, ***p<0.001) (Figure 5.4A). NKP+DC also had significantly 
increased CD69+ CD56bright NK cells compared to all cultures where NK cells were 
separated from MDDCs by transwell inserts, whether mock (NKM/DC, 11 ± 6%, 
***p<0.001), peptide 30-5 (NKpep/DC, 12 ± 7.9%, ***p<0.001), or P2C-30-5 (NKP/DC, 
31 ± 6%, *p<0.05). In CD56dim NK cells, the percentage of CD69+ cells was significantly 
increased in all cultures where NK cells were in contact with MDDCs- NKM+DC (78 ± 
B C 
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19%), NKpep+DC (77 ± 21%) and NKP+DC (88 ± 15%), compared to NK after (25 ± 
22%, *p<0.05, (**p<0.01 for NKP+DC)), and also in comparison to NKM/DC (30 ± 
18%, *p<0.05 (**p<0.01 for NKP+DC)) (Figure 5.4B). There was also a clear trend of 
increased CD69+ cells in NKP+DC compared to NKP/DC, but it was not statistically 
significant. 
The percentage of HLA-DR+ CD56bright NK cells was significantly increased in 
NKP+DC compared to NK after (*p<0.05), NKpep/DC (*p<0.05) and NKP/DC 
(*p<0.05), and in 2 of 3 subjects, HLA-DR expression in NKP+DC was markedly 
increased compared to NKM+DC (Figure 5.4C). In CD56dim NK cells, HLA-DR 
expression was significantly increased in NKM+DC and NKpep+DC compared to NK 
after (*p<0.05), as well as significantly increased in all cultures where NK cells were in 
contact with MDDCs: NKM+DC, NKpep+DC and NKP+DC, compared to NKM/DC 
(*p<0.05, (**p<0.01 for NKpep+DC)) (Figure 5.4D). In 2 of 3 subjects, HLA-DR 
expression was also markedly enhanced in NKP+DC compared to NKM+DC. The 
presence of DC separated by transwell inserts appeared to have no effect on HLA-DR 
expression in either subset. Therefore, in contrast to MDDCs, which increased maturation 
markers via NK cell soluble factors and without cell-to-cell contact, NK cells required 
contact with MDDCs for enhanced CD69 and HLA-DR expression in response to P2C-
30-5. 
 
Figure 5.4 NK cell activation with or without MDDC contact. NK cells were analysed 
before culture (NK before), cultured alone (NK after) or pulsed with DMSO-mock 
(NKM), 30-5 (NKpep) or P2C-30-5 (NKP) and cocultured overnight separately from (/) 
or together with (+) immature MDDCs in transwells with inserts 0.4 µm pore size, then 
analysed by flow cytometry. (A&B) Replicate experiments of the percentage of CD69+ 
CD56bright (A) or CD56dim (B) NK cells, shown as mean ± S.D. n=4 *p<0.05, **p<0.01, 
***p<0.001 (One-way ANOVA with multiple pair-wise comparisons). For clarity, not all 
statistically significant pair-wise comparisons are marked in the figure. In (B) other 
significant comparisons were NK before: vs. NKM+DC, vs. NKpep+DC = *p<0.01, vs. 
NKP+DC =***p<0.001, NKpep/DC: vs. NKM+DC = *p<0.05, vs. NKP+DC = **p<0.01. 
(C&D) Replicate experiments of the percentage of HLA-DR+ CD56bright (C) and CD56dim 
(D) NK cells (log transformed), shown as mean ± S.D. n=3 *p<0.05, **p<0.01 (Repeated 
measures ANOVA with multiple pair-wise comparisons). For clarity, not all statistically 
significant comparisons are marked in the figure. In (C) other significant comparisons 
were NK before: vs. NKM/DC = *p<0.05. In (D) other significant comparisons were NK 
before: vs. NKM+DC = *p<0.05, NKpep/DC: vs. NKpep+DC = *p<0.05. 
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5.2.5 CD80 and CD83 expression on MDDCs by Pam2Cys-30-5-stimulated NK cell 
supernatants 
Since the transwell experiment indicated an importance of NK cell soluble factors 
in MDDC maturation, this was confirmed by applying supernatants from P2C-30-5-
stimulated NK cells to MDDCs, culturing overnight and analysing CD80 and CD83 
expression.  
The fold change in percentage of CD80+ MDDCs was calculated relative to 
unstimulated MDDCs before culture (DC before, normalised to 1) (Figure 5.5A). There 
was little increase in fold change in the percentage of CD80+ MDDCs in unstimulated 
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MDDCs after culture (DC after, 1.4 ± 0.9) and MDDCs cultured with NK supernatant 
treated with mock (NKM, 1.6 ± 0.5). MDDCs cultured with NK supernatant stimulated 
by P2C-30-5 (NKP) had significantly increased fold change in CD80+ MDDCs (6.0 ± 3.1, 
*p<0.05) compared to DC before and DC after culture. Similarly, fold change in 
percentage of CD83+ MDDCs was calculated relative to MDDCs before culture (DC 
before, normalised to 1) (Figure 5.5B). There was little increase in fold change in 
percentage of CD83+ MDDCs in DC after (1.6 ± 0.9) and MDDCs cultured with NKM 
supernatant (1.4 ± 0.5). MDDCs cultured with NKP supernatant had significantly 
increased fold change in CD83+ MDDCs (3.1 ± 1.3, *p<0.05), compared to DC before 
culture. Expression of both CD80 and CD83 were increased to similar levels by NKP 
supernatants as with Maturation Mix. 
Therefore, these results demonstrated that supernatants from P2C-30-5-stimulated 
NK cells increased the expression of maturation markers CD80 and CD83 on MDDCs, 
confirming the importance of NK cell soluble factors. 
 
Figure 5.5 CD80 and CD83 expression on MDDCs following culture with 
supernatants from Pam2Cys-30-5 stimulated NK cells. Immature MDDCs were 
cultured overnight alone, with Maturation Mix, or with a 1:4 dilution of supernatant from 
mock (NKM sup) or P2C-30-5 (NKP sup) stimulated NK cells, then analysed by flow 
cytometry. Fold change in the expression of CD80+ (A) and CD83+ (B) MDDCs after 
culture in the absence or presence of Maturation Mix or NK cell supernatants, relative to 
MDDCs before culture (DC before), are shown as mean ± S.D. n=4 (Mat Mix n=2), 
*p<0.05 (Paired t test). 
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5.2.6 MDDC CD80 and CD83 expression by Pam2Cys-30-5-stimulated CD56bright and 
CD56dim supernatants 
Since the previous experiments of MDDCs cultured with supernatants from the 
total NK cell population indicated an importance of soluble factors in inducing DC 
maturation, the contribution of each NK cell subset to the soluble factors inducing DC 
maturation was studied next. Immature MDDCs were cultured overnight with or without 
mock or P2C-30-5-stimulated supernatants from sorted CD56bright and CD56dim NK cells. 
MDDCs were analysed for CD80 and CD83 expression. 
When MDDCs were cultured with supernatants from P2C-30-5 stimulated 
CD56dim NK cells (CD56dim P), the percentage of CD80+ MDDCs (Figure 5.6A) 
significantly increased (54 ± 12%) compared to DC before (17 ± 9%, *p<0.05), DC after 
(13 ± 9%, *p<0.05) and CD56dim Mock (CD56dim M) cultures (17 ± 4%, **p<0.01). 
Likewise, when MDDCs were cultured with supernatants from P2C-30-5 stimulated 
CD56bright NK cells, the percentage of CD80+ MDDCs (Figure 5.6A) also significantly 
increased compared to DC before, DC after and CD56bright Mock (M) cultures (50 ± 7% 
compared to 17 ± 9%, 13 ± 9% and 16 ± 3% respectively, p-values *p<0.05, **p<0.01 
and **p<0.01 respectively). 
Similarly, culturing MDDCs with CD56dim P2C-30-5 (P) supernatants increased 
CD83 expression (67 ± 11%) compared to DC before (10 ± 6%, **p<0.01), DC after (24 
± 20%, *p<0.05) and CD56dim mock supernatants (46 ± 8%, not significant) (Figure 
5.6B). Likewise, culturing MDDCs with CD56bright P2C-30-5 (P) supernatants increased 
CD83 expression (64 ± 11%) compared to DC before (10 ± 6%, **p<0.01), DC after (24 
± 20%, *p<0.05) and CD56bright mock supernatants (39 ± 0.6%, not significant) (Figure 
5.6B). There was also no statistical difference or trend towards a difference in maturation 
marker expression induced by CD56dim P and CD56bright P compared to each other. 
Therefore supernatants from both CD56dim and CD56bright NK cells stimulated by 
P2C-30-5 increased MDDC expression of CD80 and CD83, and to a similar extent. 
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Figure 5.6 CD80 and CD83 expression on MDDCs cultured with supernatants from 
Pam2Cys-30-5 stimulated CD56bright and CD56dim NK cells. Immature MDDCs were 
cultured overnight alone, with maturation mix, or with a 1:4 dilution of supernatant from 
sorted mock (M) or P2C-30-5 (P) pulsed and cultured CD56bright or CD56dim NK cells, 
then analysed by flow cytometry. The percentage of CD80+ (A) and CD83+ (B) MDDCs 
before and after culture in the absence or presence of maturation mix or NK cell subset 
supernatants are shown as mean ± S.D. n=4 *p<0.05, **p<0.01, ***p<0.001 (One-way 
ANOVA with multiple pair-wise comparisons). For clarity, not all statistically significant 
pair-wise comparisons are marked in the figure. In (A) other significant comparisons 
were CD56dimM: vs. CD56brightP =***p<0.001, CD56bright M: vs. CD56dim P =***p<0.001. 
5.2.7 Cytokine production by CD56bright and CD56dim NK cells following Pam2Cys-
30-5 stimulation 
Since cell culture supernatants from both NK cell subsets stimulated by P2C-30-5 
increased maturation markers on DC, it indicated that both subsets were producing 
soluble factors in response to P2C-30-5. Given that it is known that NK cell cytokines 
such as IFN-γ and TNF contribute to DC maturation (Gerosa et al., 2002), the first 
soluble factors to be investigated were a known panel of cytokines and chemokines. In 
order to examine multiple cytokines and chemokines within the same experiment, we 
investigated multiplex technologies. BD Cytometric Bead Array (CBA) was chosen as it 
allows the quantification of multiple cytokines and chemokines simultaneously in one 
sample. It is a sensitive assay with the lowest protein standards in most kits at 10 pg/mL. 
Unlike other multiplexing technologies such as Luminex, CBA is run on flow cytometers 
rather than a specialised Luminex instrument. 
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NK cells were cell sorted into CD56bright and CD56dim subsets, pulsed with mock 
(DMSO), P2C-30-5 or LPS, to compare stimulation of a different TLR, TLR4. Cells were 
cultured for 24 hrs, and then supernatants were collected. The panel of cytokines and 
chemokines examined were: IFN-γ, TNF, MIP-1α, MIP-1β, RANTES, IL-8, GM-CSF, 
IL-10 and IL-12p70. NK cells have been reported producing each of these factors under 
particular conditions (Robertson, 2002, Perussia, 1996, Fehniger et al., 1999, Fauriat et 
al., 2010, Bluman et al., 1996, Peritt et al., 1998, Smyth et al., 1991, Marquez et al., 
2010). 
Results for IFN-γ, MIP-1α, TNF, MIP-1β and RANTES (Figure 5.7A) showed 
that both subsets had increased production of these factors after P2C-30-5 treatment 
compared to mock. However, interestingly CD56dim NK cells produced higher 
concentrations of these factors than CD56bright NK cells in all three treatments (mock, 
P2C-30-5 and LPS). In CD56bright supernatants, the median concentrations of IFN-γ, 
MIP-1α, TNF, MIP-1β and RANTES in P2C-30-5 cultures increased compared to mock 
(mock values in brackets), to 9 pg/mL (3 pg/mL), 6 pg/mL (3 pg/mL), 1.4 pg/mL (1.2 
pg/mL), 40 pg/mL (11 pg/mL) and 73 pg/mL (60 pg/mL) respectively. Compared to P2C-
30-5, LPS only induced a similar increase in concentration of RANTES and a slight 
increase in MIP-1β above mock. LPS treatment did not increase the other factors above 
mock. In CD56dim supernatants, the median concentrations of IFN-γ, MIP-1α, TNF, MIP-
1β and RANTES in P2C-30-5 cultures also increased compared to mock (mock values in 
brackets), 24 pg/mL (6 pg/mL), 527 pg/mL (181 pg/mL), 13 pg/mL (4 pg/mL), 3860 
pg/mL (1589 pg/mL), and 996 pg/mL (474 pg/mL) respectively. In CD56dim supernatants, 
LPS induced an increase in the concentration of all of these factors compared to mock, 
but the increase was smaller than that induced by P2C-30-5. 
The fold increases in IFN-γ, MIP-1α, TNF, MIP-1β and RANTES concentration 
by P2C-30-5 and LPS relative to mock were also compared between subsets (Figure 
5.7B). The median fold increases in IFN-γ, MIP-1α, TNF, MIP-1β and RANTES in 
CD56bright induced by P2C-30-5 relative to mock were 3.3, 2.4, 1.2, 3.8, and 1.4 
respectively, and in CD56dim were 4.0, 3.3, 2.7, 3.2 and 1.8 respectively. These results 
highlight that in terms of the magnitude of response to P2C-30-5, CD56bright NK cells 
were similar to CD56dim NK cells and in some subjects their fold increase relative to 
mock was higher than CD56dim NK cells, due to lower basal levels than CD56dim NK 
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cells. The fold increases induced by LPS cultures were either reduced compared to P2C-
30-5 or were not increased above mock. One analyte within the panel examined had 
concentrations higher in CD56bright rather than CD56dim supernatants, IL-8 (Figure 5.6A). 
However, there was no trend of increased IL-8 in response to P2C-30-5 treatment. The 
other factors tested, GM-CSF, IL-10 and IL-12p70, were found to be negligible or at 
undetectable concentrations in all treatments in both subsets (data not shown). 
In summary, both NK subsets produced the factors IFN-γ, MIP-1α, TNF, MIP-1β 
and RANTES. The concentrations were higher in CD56dim supernatants than CD56bright 
supernatants, even in mock stimulated cells. P2C-30-5 induced increases in the 
concentrations of these factors in both subsets. The fold increases in concentration 
induced by P2C-30-5 relative to mock were similar for both subsets, and in some subjects 
CD56bright supernatants had higher fold increases than CD56dim supernatants. 
 
 
 
 
 
 
 
 
Figure 5.7 Pam2Cys-30-5 stimulated cytokine production of CD56bright and CD56dim 
NK cells. NK cells were cell sorted, pulsed for 1 hr with DMSO (mock), P2C-30-5 (10 
µM) or LPS (2.5 µg/mL), and cultured for 24 hrs. Supernatants were collected, then 
prepared and analysed for BD™ Cytometric Bead Array. (A) Results for IFN-γ, TNF, 
MIP-1α, RANTES, MIP-1β and IL-8 from three replicate experiments in pg/mL. (B) 
Conversion of the data in (A) to fold change relative to mock. GM-CSF, IL-10 and IL-
12p70 were also tested and found to be negligible (<5pg/mL) in all conditions tested. 
Dotted lines indicate lowest and highest points on the standard curve at 10 and 2500 
pg/mL respectively. 
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5.2.8 IFN-γ production by CD56dim and CD56bright NK cells responding to Pam2Cys-
30-5 stimulation 
After determining that CD56dim NK cells secreted higher concentrations of the 
factors tested in the CBA than CD56bright NK cells in response to P2C-30-5, it was 
important to reproduce this finding by utilising an alternative method of detection. Also, 
while IFN-γ is a key cytokine produced by NK cells and contributes to DC IL-12 
production, the concentration detected was quite low by CBA and it was not detected at 
all in a Luminex assay (data not shown). ELISPOT is a highly sensitive assay that 
quantitates the number of cytokine producing cells corresponding to spots in a well. 
Although the concentrations of secreted cytokines were higher from CD56dim NK cells, 
ELISPOT would determine whether this was due to a distinct subset of responding cells 
producing a lot of cytokine, or a large number of responding cells contributing to the total 
amount of cytokine produced. 
NK cells were cell sorted, and then equal numbers of each subset were placed in 
the wells of an ELISPOT plate and cultured for 40 hrs in the presence of mock (DMSO), 
30-5, P2C-30-5 or PHA+IL-2 as a positive control. Representative images from one 
ELISPOT experiment show increases in the spot forming units (SFU) per well for both 
subsets in P2C-30-5 and PHA+IL-2 wells (Figure 5.8A), and that the SFU were increased 
in the CD56dim wells compared to CD56bright wells. Graphs of two replicate experiments 
quantifying the IFN-γ SFU in duplicate wells (Figure 5.8B) show that there were 
increased IFN-γ SFU in CD56dim compared to CD56bright wells. In both experiments, the 
number of IFN-γ SFU for CD56dim NK cells was increased in response to P2C-30-5 (204 
± 32) compared to mock (80 ± 7) and 30-5 (74 ± 16) (upper graph) (lower graph: 323 ± 
11 compared to 159 ± 24 and 130 ± 11 respectively). In these graphs, the increased 
number of IFN-γ SFU/well for CD56dim NK cells in response to P2C-30-5 corresponded 
to fold increases of 2.5 (upper graph) and 2.1 (lower graph) relative to mock. Likewise, 
the number of IFN-γ SFU/well for CD56bright NK cells was increased in response to P2C-
30-5 (19 ± 4) compared to mock (0.5 ± 0.7) and 30-5 (3 ± 1) (upper graph) (lower graph: 
107 ± 30 compared to 54 ± 0 and 54 ± 7 respectively). The increased number of IFN-γ 
SFU/well for CD56bright NK cells in response to P2C-30-5 corresponded to fold increases 
of 19.5 (upper graph) and 2.4 (lower graph) relative to mock. 
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Therefore, more CD56dim NK cells produced IFN-γ than CD56bright NK cells, even 
when mock stimulated. Both subsets increased the number of IFN-γ secreting cells in 
response to P2C-30-5. Finally, these data provide additional evidence supporting the 
observation that CD56dim NK cells are potent cytokine producers in response to P2C-30-5. 
 
Figure 5.8 CD56bright and CD56dim NK cells IFN-γ production in response to 
Pam2Cys-30-5. NK cells were cell sorted, and then 2x104cells/well were cultured for 40 
hours in the presence of mock (DMSO), 30-5, P2C-30-5 or PHA+IL-2 in an IFN-γ 
ELISPOT. After development, spots were counted using an AID ELISPOT reader. (A) 
Representative images from one ELISPOT experiment. (B) Graphs are showing mean ± 
S.D. of counts from duplicate wells of two experiments. 
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5.2.9 The proportions of CD16+ and CD16- NK cells in normal and HSV-infected 
tissue 
Our data thus far demonstrated that NK cells are direct responders to P2C-30-5 
and have the potential to modulate DC responses by promoting their maturation in 
response to P2C-30-5 as well. Such findings suggest that NK cells could be a key 
modulator of other immune cells and link innate and adaptive responses by enhancing DC 
stimulation of T cells. However, in developing a lipopeptide vaccine candidate that 
appropriately targets key immune cells involved in the immune response to HSV in the 
skin, it is important to establish in vivo relevance of studying the NK cell response by 
analysing their presence in normal and HSV-infected skin, to better define their roles in 
this setting. 
Our lab obtained very rare primary penile herpes lesion biopsies and compared 
the immune cells in these tissues compared to normal foreskin. Recently, our first 
observations in these lesions were published, of a viral relay between cells; where HSV-
infected, dying LCs migrated from the epidermis to the dermis and were taken up by 
dermal DCs (Kim et al., 2015). Prior to these findings, our lab also previously published 
the presence of NK cells in recurrent herpes lesions, and observed them in close 
proximity to pDCs (Donaghy et al., 2009) and CD4+T cells (Kim et al., 2012). Here, we 
present our initial findings investigating NK cells in one primary (not recurrent) penile 
herpes lesion compared to normal outer foreskin from a healthy donor. 
Firstly, to identify the presence of CD56dim and/or CD56bright NK cells in normal 
and infected tissue, sections were stained for CD56 and CD16, with CD16+ and CD16- 
CD56+ cells considered representative of cytolytic (CD56dim) and non-cytolytic 
(CD56bright) NK cells respectively. These sections were also stained for HSV gD to 
identify the infected region in the herpetic lesion biopsy. Representative panelled and 
stitched images highlight the differences in normal and infected tissue (Figure 5.9A). In 
normal outer foreskin there was a distinct epidermal and dermal layer with green CD56+ 
cells in the dermis and some lined up at the dermo-epidermal junction. In contrast, in the 
herpetic lesion, red gD staining highlights the infected epidermal region, which was 
enlarged and had many infiltrating cells. Dual expressing green CD56+, orange CD16+ 
cells were seen, indicated by yellow-coloured cells, observed throughout the infected 
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region. There were markedly less of these cells in the normal tissue. Representative 
images of individual cells in normal outer foreskin and the herpetic lesion showed a 
CD56+CD16- NK cell in the normal tissue, and a CD56+CD16+ NK cell that also 
appeared to be stained with gD in the herpetic lesion (Figure 5.9B). CD56+CD16+ and 
CD56+CD16- NK cells were counted in each tissue, then normalised to counts per mm2 as 
detailed in section 2.5.5 in Chapter Two (Figure 5.9C). In normal outer foreskin, CD56+ 
cells were mostly CD16- with 102 cells per mm2 compared to 20 cells per mm2 of CD16+ 
cells. In contrast, in the herpetic lesion there were more CD56+ cells than in normal outer 
foreskin, and the majority were CD16+ with 211 cells per mm2 compared to 34 cells per 
mm2 of CD16- cells. 
Therefore, these findings demonstrate that the population of CD56+ NK cells was 
shifted from normal tissue where most cells were CD16-, to the herpetic lesion where 
there was an increase in NK cells per mm2 and most were CD16+. 
 
 
 
 
 
 
 
 
Figure 5.9. CD16+ and CD16- NK cells in normal outer foreskin and a primary 
herpes lesion. Sections of an initial penile herpes lesion biopsy (3 days after onset) and 
normal outer foreskin were fixed and stained for CD56, CD16 and HSV gD for analysis 
by immunofluorescence microscopy. (A) Representative panelled images of the herpetic 
lesion (left) or normal outer foreskin (right) showing DAPI (blue), CD56 (green), CD16 
(orange) and gD (red). Scale bar = 50 µm. (B) Images of individual CD16+ and – NK cells 
in each tissue. Scale bar = 15 µm. (C) CD16+ and – NK cells were counted in each tissue, 
then counts were normalised to per mm2. 
Chapter 5: NK cell subset effects on DC maturation and presence in HSV- 
infected skin 
	 187  
Chapter 5: NK cell subset effects on DC maturation and presence in HSV- 
infected skin 
	 188 
 
  C 
CD16+ and CD16- NK cells per mm2 
Normal Outer 
Foreskin 
Initial Herpes 
lesion 
CD16- CD16+ CD16- CD16+ 
102 20 35 211 
 
5.2.10. Cutaneous lymphocyte antigen expression on NK cells in normal and HSV-
infected tissue 
Since NK cells were identified in both normal and primary HSV-infected tissue, 
and there was a contrast of CD16 expression in these tissues, we wanted to investigate the 
expression of skin homing markers on these NK cells, to elucidate the relationship 
between CD16- and CD16+ NK cells and their population shift from normal to infected 
tissue. Lymphocyte-endothelial cell adhesion molecule pairs participate in tissue-
selective lymphocyte homing (Abernathy-Carver et al., 1995). Cutaneous lymphocyte 
antigen (CLA) is the lymphocyte homing receptor for E-selectin, which is preferentially 
expressed by venules in cutaneous sites of chronic inflammation (Berg et al., 1991, 
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Santamaria Babi et al., 1995). CLA was first identified on T cells, as most T cells 
infiltrating cutaneous sites of inflammation express CLA, particularly CD45RO+ memory 
T cells (Berg et al., 1991, Santamaria Babi et al., 1995). CLA expression has also been 
identified NK cells. CLA expression was analysed on CD4+ and CD8+ T cells as well as 
CD56+ NK cells. In peripheral blood, CLA was expressed on <20% of each of these cell 
populations, whereas >60% of CD4+, CD8+ and CD56+ cells from normal skin-derived 
lymph expressed CLA (Hunger et al., 1999). Therefore, we investigated CLA expression 
on CD16+ and CD16- NK cells. 
Normal and infected tissues were stained for CD56, CD16 and CLA. 
Representative images from normal outer foreskin showed a red CD56+CD16- NK cell 
that was CLA+, whereas a green CD16+CD56+ NK cell was CLA- (Figure 5.10A). 
Likewise, in the herpetic lesion a green CD16+ CD56+ NK cell was CLA- whereas the 
CD16- CD56+ NK cell was CLA+. The percentage of CLA expressing CD16+ and CD16- 
NK cells in each tissue was calculated from cell counts of CLA+ and CLA- cells of each 
cell type (Figure 5.10B). In normal outer foreskin, 91% of CD16- CD56+ NK cells were 
CLA+, whereas no CD16+ NK cells expressed CLA. Interestingly, in the herpetic lesion 
the trend remained the same, with 60% of CD16- CD56+ NK cells being CLA+. By 
comparison a much smaller percentage, 15%, of CD16+ CD56+ NK cells were CLA+. 
Therefore, CLA was expressed predominantly on CD16- NK cells in normal and 
infected tissue, indicating that these cells are constantly turning over in the skin. However, 
taken together with the finding that most NK cells in the lesion are CD16+, this indicates 
that there is a shift in the population, perhaps at least in part from the proliferation and 
differentiation of CD16- NK cells already in the normal tissue.  
 
 
Figure 5.10 CLA expression on CD16- NK cells in normal and HSV-infected tissue. 
Sections of an initial penile herpes lesion biopsy (3 days after onset) and normal outer 
foreskin were fixed and stained for CD56, CD16 and CLA for analysis by 
immunofluorescence microscopy. (A) Representative images of individual CLA+CD16+ 
(a+c) and CD16- NK cells (b+d) in each tissue. Scale bar = 15 µm.  (B) The numbers of 
CLA+CD16+ or CD16- NK cells were counted, expressed as a percentage of the total 
number of CD16+ and CD16- NK cells in each tissue. 
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B 
Percentage of CLA+ CD16+ or CD16- NK cells 
Normal Outer Foreskin Initial Herpes lesion 
CD16- CD16+ CD16- CD16+ 
91% 0% 60% 15% 
 
5.2.11. NK cell contact with HLA-DR+ antigen-presenting cells in normal and HSV-
infected tissue 
Since the earlier experiments in this study were focussed on NK cell-induced 
maturation of MDDCs, we next determined if either or both of the NK cell subsets in 
normal and HSV infected tissue were in contact with other antigen-presenting cells. 
Definition of the DC network in skin is becoming increasingly complex, with 
heterogeneous expression of many markers including overlap with skin macrophages 
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(Haniffa et al., 2015). Combined with the constraint of being limited to 4 colours in 
immunofluorescence microscopy, it is challenging to incorporate sufficient markers to 
define DC subsets in combination with CD16+/- NK cells in an experiment. As an initial 
investigation of potential interactions between NK cells and any other antigen-presenting 
cell in the skin, the marker HLA-DR was used, an MHC class II molecule expressed on 
professional antigen-presenting cells. CD56-HLA-DR+ cells were considered 
representative of antigen-presenting cells excluding NK cells. 
Normal and infected tissues were stained for CD56, CD16 and HLA-DR. Many 
infiltrating yellow CD56+CD16+ and red HLA-DR+ cells were observed in representative 
panelled and stitched images of the Herpetic lesion, whereas few were seen in normal 
outer foreskin (Figure 5.11A). In Figure 5.11B, a representative image from normal outer 
foreskin showed a green CD56+CD16- NK cell nearby a red HLA-DR+ cell, but they were 
not in contact. In the herpetic lesion, a CD56+CD16+ NK cell was in contact with a red 
HLA-DR+ cell that also expressed CD16. The number of CD56+CD16+ and CD56+CD16- 
NK cells in contact with CD56- HLA-DR+ cells were counted in each tissue, then 
normalised to counts per mm2 (Figure 5.11C). In normal outer foreskin, no CD56+ NK 
cells appeared to be in contact with CD56- HLA-DR+ cells. However, in the herpetic 
lesion 9 CD56+CD16- NK cells per mm2 were in contact with CD56- HLA-DR+ cells, and 
32 CD56+CD16+ NK cells per mm2 were in contact with other HLA-DR+ cells. 
 Therefore, only in the infected tissue did NK cells appear to interact with HLA-
DR+ antigen-presenting cells, and more CD16+ than CD16- NK cells were in contact with 
these cells. 
 
Figure 5.11 Increased CD16+ NK cells in close proximity to HLA-DR+ antigen-
presenting cells in HSV-infected tissue. Sections of an initial penile herpes lesion 
biopsy (3 days after onset) and normal outer foreskin were fixed and stained for CD56, 
CD16 and HLA-DR for analysis by immunofluorescence microscopy. (A) Representative 
panelled images of the herpetic lesion (left) or normal outer foreskin (right) showing 
DAPI (blue), CD56 (green), CD16 (orange) and HLA-DR (red). Scale bar = 50 µm (B) 
Images of individual CD16+ and CD16- NK cells and HLA-DR+ cells in each tissue. 
White arrows indicate CD56+ NK cells and yellow arrows indicate HLA-DR+ cells. Scale 
bar = 15 µm. (C) The number of occurrences of CD16+ or – NK cells in close proximity 
to a neighbouring HLA-DR+ non-NK cell were counted in each tissue, then counts were 
normalised to per mm2. 
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B 
 
    C 
Number of cells in close proximity per mm2 
Normal Outer Foreskin Initial Herpes lesion 
CD56+CD16- 
+ HLA-DR+ 
CD56+CD16+ 
+ HLA-DR+ 
CD56+CD16- 
+ HLA-DR+ 
CD56+CD16+ 
+ HLA-DR+ 
0 0 9 33 
 
5.3 Discussion 
In this study, we investigated both NK cell subsets abilities to induce DC 
maturation in response to Pam2Cys-30-5 stimulation, and investigated the presence of the 
NK cell subsets in normal and HSV-infected skin, to begin understanding their role in 
HSV infection.  
We investigated the optimal NK:DC ratio for inducing DC maturation, following 
the findings of Piccioli et al., showing that high NK:DC ratios of 5:1 resulted in NK cell-
mediated DC killing, and low ratios of 1:5, resulting in NK cell-mediated DC maturation 
(Piccioli et al., 2002). In our hands, there was less donor/subject variability in NK cell-
mediated DC killing at an NK:DC ratio of 1:2, than at 1:5, and the reduction in cell death 
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was more significant at this ratio. This could be due to the increased contact between 
individual NK cells and DCs at a ratio of 1:2 compared to 1:5, as it has been reported that 
contact is involved in DC maturation via NKp30 (Vitale et al., 2005) and through synapse 
formation and delivery of maturation factors such as HMGB1 (Semino et al., 2005), and 
presumably for DC maturation cytokines such as TNF. However, since NKp30 has also 
been implicated in NK cell-mediated DC killing (Ferlazzo et al., 2002), perhaps the 
density of receptor-ligand pairs and the alteration with differing ratios of NK cells and 
DCs, affects downstream signalling resulting in NK cell-mediated killing when NK cells 
outnumber DCs, and NK cell-mediated DC maturation/survival when DCs outnumber 
NK cells, but are still in sufficient numbers for contact-dependent interactions. 
We also demonstrated that CD83 expression was induced on MDDCs when NK 
cells were stimulated by Pam2Cys-30-5, and that cell-to-cell contact was not essential for 
the upregulation of CD83 and CD80 on MDDCs. Interestingly, the degree of maturation 
induced by supernatants (soluble factors) from both CD56dim and CD56bright subsets 
stimulated with Pam2Cys-30-5 were approximately equivalent. Although it had been 
originally thought that CD56bright NK cells were the main cytokine producing subset 
(Cooper, 2001), we compared the cytokine and chemokine profiles of CD56bright and 
CD56dim NK cells to determine whether they were both secreting the cytokines inducing 
MDDC maturation, and to examine their cytokine responses to Pam2Cys-30-5 more 
generally. Surprisingly, the CD56dim subset produced higher concentrations of a number 
of cytokines and chemokines in response to Pam2Cys-30-5 than CD56bright NK cells- 
IFN-γ, TNF, MIP-1α, MIP-1β and RANTES. This was reminiscent of our observation in 
Chapter Four, where CD56dim NK cells downregulating CD16 expressed the highest 
levels of IFN-γ (see Figure 4.9). Additionally, we confirmed the increased IFN-γ 
secretion of CD56dim NK cells by ELISPOT. However, despite CD56dim NK cells 
producing higher concentrations of these cytokines, no significant difference in level of 
DC maturation was induced between CD56dim and CD56bright NK cells. This could mean 
that DC maturation requires a very low threshold amount of these cytokines to induce 
maturation, such that the concentrations produced by CD56bright NK cells are adequate, or 
it could indicate that other soluble factors are involved, possibly from both subsets, such 
that the induction of DC maturation ends up approximately equivalent. Examples of 
soluble factors that have been shown to induce DC maturation include HMGB1 (Semino 
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et al., 2005) and soluble CD16 (de la Salle et al., 1997), and there could also be other 
unidentified factors. Follow-up studies should incorporate the use of neutralising 
antibodies targeting the cytokines detected to establish their relative importance in the 
DC maturation induced by each NK cell subset. Furthermore, the possibility of other 
soluble factors produced by the CD56bright or CD56dim subsets should be explored. 
In contrast to NK cell-mediated DC maturation, NK cell activation was 
significantly enhanced by contact with MDDCs. This was more significant for CD56bright 
NK cells, where CD69 expression was much lower than on CD56dim NK cells at baseline. 
Furthermore, we showed for the first time that contact with MDDCs increased HLA-DR 
expression of Pam2Cys-30-5 stimulated NK cells, on both subsets. This was particularly 
interesting for the CD56dim subset, which otherwise expressed essentially no HLA-DR 
without contact with MDDCs. However, marked upregulation of HLA-DR in response to 
Pam2Cys-30-5 compared to mock NK cells in contact with MDDCs was only observed in 
2 of 3 subjects, so further confirmatory experiments are required. We previously 
demonstrated that NK cells could directly activate CD4+T cells to respond to Pam2Cys-
30-5, in the absence of DCs (Kim et al., 2012). Other labs too have reported that NK cells 
have accessory antigen-presenting cell capabilities (Hanna et al., 2004b, Hanna and 
Mandelboim, 2007). Increased HLA-DR expression on NK cells cocultured with MDDCs 
could indicate that DCs may also enhance NK cell antigen-presenting capabilities to 
CD4+T cells, and thus be a contributing factor to the enhanced CD4+T cell responses 
observed in the triple-cell coculture of NK+DC+CD4+T cells. These findings need to be 
followed up with a more thorough investigation of the mechanism of NK cell antigen-
presenting capacity, and whether that is indeed enhanced by the presence of DCs. Taken 
together, these results indicate that NK cells require contact with DCs for enhanced 
activation and increased HLA-DR expression. Contact-mediated mechanisms need to be 
further characterised. 
It was important to establish the in vivo relevance of examining NK cell responses 
to an HSV lipopeptide and their potential interactions with other important players in the 
immune response, such as DCs and CD4+T cells, by examining their presence in the skin, 
to determine their role in HSV infection and their importance as potential targets for a 
topical or intra-dermal vaccine against HSV infection. We determined that the 
proportions of CD16+ and CD16- NK cells in normal and infected tissue were altered. 
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CD16- NK cells predominated in normal foreskin, whereas CD16+ NK cells 
predominated in the initial herpes lesion, and there was an overall increase in the number 
of NK cells. Furthermore, the CD16- NK cells expressed the skin homing marker CLA. 
These results strongly suggest that CD16- NK cells are constantly migrating to the skin 
and that there is a regular turnover of these cells in normal skin. However, there is an 
alteration to this population during herpes infection, such that most NK cells are CD16+ 
and lose CLA.  
There is evidence that NK cells regularly home to skin, not only under 
inflammatory conditions, but also in steady-state. It was found that in peripheral blood, 
CLA was expressed on <20% of each of the cell populations of CD4+, CD8+ and CD56+ 
cells, whereas >60% of each of these populations expressed CLA in both normal and 
allergic contact dermatitis skin-derived lymph. The detection of NK cells in skin-draining 
lymph fluid from both healthy subjects and patients with contact dermatitis suggested 
they are recruited from blood to skin during both steady-state and inflammatory 
conditions, then return to blood via draining lymphatics (Hunger et al., 1999, Paust and 
von Andrian, 2011). A number of studies support the finding that CD16- NK cells 
migrate to skin, particularly under inflammatory conditions: A study of psoriatic skin 
found that CD56brightCD16- NK cells accumulated in the skin in response to CXCL10 and 
CCL5, however they were CLA- (Ottaviani et al., 2006). A study of allergic contact 
dermatitis also found an accumulation of CD56brightCD16- NK cells, and that they 
contribute to allergic responses by releasing cytokines IFN-γ and TNF and inducing 
keratinocyte apoptosis. More than 90% of the NK cells were CD16- and were NKG2A+, 
Perforin+, NKG2D+, NKp44+ and NKp46+ but lacked NKp30 and KIR (Carbone et al., 
2010). Finally, a study of SIV-infected macaques found that in vaginal and rectal mucosa, 
more than 70% of NK cells were CD56+CD16-. This subset, normally cytokine secreting, 
upregulated perforin, granzyme B and CD107a in SIV infection and cytokine secretions 
were decreased (Reeves et al., 2010).  
Unlike the studies demonstrating an infiltration of CD16- NK cells, we found that 
most NK cells in the inflammatory infiltrate in herpes infection were CD16+ and CLA-, 
this may be due to recruitment through the expression of chemokine receptors CX3CR1 
and CXCR1 (Campbell et al., 2001) that home to Fractalkine and IL-8 respectively in 
skin during inflammation. It may also be due to proliferation and altered differentiation of 
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CD16- NK cells that routinely home to the skin to become CD16+ in the HSV-infected 
skin. Therefore, the NK cells observed in the three inflammatory conditions of psoriasis, 
contact dermatitis and HSV infection were different. In psoriasis, NK cells were CD16- 
but they were also CLA- (Ottaviani et al., 2006), in contact dermatitis, NK cells were 
CD16- and CLA+ (Carbone et al., 2010, Hunger et al., 1999), and in our experiments of 
HSV infection, NK cells were CD16+ and CLA-. These observations strongly suggest that 
the inflammatory environment of each disease is different, and particularly in HSV 
infection where it appears that conditions may induce the expansion and differentiation of 
CD56brightCD16- to CD56dimCD16+ cells. Further definition of the differences between the 
HSV inflammatory environment and that of other inflammatory skin diseases should help 
elucidate the mechanisms driving these changes in the NK cell population. 
Upon investigating NK cell subset interactions with other antigen-presenting cells 
in skin, we observed no NK cells in close proximity/contact with other HLA-DR 
expressing cells in normal skin. Some contact between NK cells and HLA-DR+ cells was 
observed in the initial herpes lesion, and more CD16+ NK cells were in close proximity to 
HLA-DR+ cells than CD16- NK cells. It is difficult to determine whether this is merely 
due to CD16+ NK cells outnumbering CD16- NK cells leading to a higher chance of 
encounter, or whether there is a functional explanation for increased contact of CD16+ 
NK cells. Furthermore, since we used HLA-DR as a marker, which spans all antigen-
presenting cells as well as activated T cells (Effros et al., 1983), we cannot determine 
from this experiment which subsets of antigen-presenting cells (or activated T cells) are 
interacting. This observation needs to be followed up with experiments using more 
specific markers in immunofluorescence microscopy- initially with CD11c, which is 
expressed on most subsets of DCs, as well as CD141, as this subset does not express 
CD11c. Analysis of CD1a+, CD141+ and CD14+ DC subsets should also be conducted in 
serial sections to determine whether NK cells are more prone to interacting with specific 
subsets, or if their interactions with different subsets lead to different outcomes (e.g. 
killing of infected LCs, maturation of dermal DC subsets). 
We previously demonstrated that a Herpes Simplex viral relay takes place among 
skin DCs, where infected LCs migrate to the dermis and undergo apoptosis, and are then 
taken up by subsets of dermal DCs (Kim et al., 2015). We have not yet defined what role 
NK cells might play in this HSV antigen relay in skin. We and others have demonstrated 
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that NK cells are in the skin, both in steady-state and particularly in inflammatory 
infiltrate. It was suggested by Ferlazzo and Morandi, that an interaction of CD141+ DC 
with NK cells could enhance their cytotoxicity via IFN-α (Ferlazzo and Morandi, 2014, 
Meixlsperger et al., 2013). NK cells may then attempt to kill infected LCs, and they may 
also provide enhancement of DC maturation for dermal DC subsets. However, there is no 
data in human tissue defining these interactions yet. We also have not determined 
whether NK cells themselves are infected with HSV in the skin. We observed that HSV 
gD was present in and around NK cells in the herpetic lesion, but whether they were 
actually infected, taking up gD, or interacting with other infected cells requires further 
investigation, as does the proportion of infected NK cells to determine direct and indirect 
effects of HSV infection of NK cell phenotype and function. It has been demonstrated in 
vitro that HSV infection of target cells downregulated NKG2D ligands required for the 
activation of NK cell-mediated killing via NKG2D, thus impairing NK cells ability to kill 
(Campbell et al., 2015). These investigators also recently presented in vitro data at the 
International Congress of Immunology 2016, suggesting that NK cells are also directly 
infected with HSV1, although their major focus was infection with VZV (Abstract 
#1335). However, there is still much to be uncovered about the role of NK cells in the 
initial encounter of HSV in skin, and the interaction of NK cells with HSV itself as well 
as with other immune cells. 
In conclusion, we have shown that both CD56bright and CD56dim NK cells induced 
upregulation of maturation markers on MDDCs in response to the HSV lipopeptide 
Pam2Cys-30-5. This DC maturation was achieved via soluble factors rather than cell 
contact. The concentrations of cytokines and chemokines tested, notably IFN-γ and TNF, 
were higher in CD56dim compared to CD56bright supernatants, however the Pam2Cys30-5-
stimulated supernatants from both NK cell subsets matured MDDC to an approximately 
equivalent extent. Both NK cell subsets were dependent on contact with DCs for the 
upregulation of CD69 and notably HLA-DR, which indicates a possible enhancement of 
their antigen-presenting capabilities. Therefore, these findings demonstrate that both NK 
cell subsets induced DC maturation via soluble factors, and were both activated by 
contact with DCs. Despite traditionally being characterised as functionally distinct 
subsets, CD56bright and CD56dim NK cells appear to interact with DCs in a remarkably 
similar manner, resulting in similar outcomes of NK cell activation and DC maturation. 
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However, given the difference in concentrations of cytokines produced by each subset, it 
would be worthwhile determining whether they achieve DC maturation via the same 
soluble factors, or produce additional, differing soluble factors that result in the same 
outcome. 
Examination of normal and HSV-infected skin found that CD16- NK cells expressing 
CLA predominated in normal tissue, and that in HSV-infected skin, a substantial increase 
in NK cells were present, and they were predominantly CD16+. Furthermore the CD16+ 
NK cells were more frequently observed in close proximity with other HLA-DR 
expressing antigen-presenting cells. This clearly demonstrates that NK cells are in the 
skin and that they are responsive to HSV infection with an alteration to the population of 
NK cells. Further studies need to explore the nuances of HSV infection and inflammatory 
conditions that drive the shift in the NK cell population to CD16+ compared to other 
inflammatory skin diseases. Further studies also need to investigate how NK cells 
respond directly to HSV infection, and interact with the various subsets of DCs in the 
skin. Understanding the role of NK cells in HSV infection will establish the relative 
importance of targeting NK cells, in conjunction with other key immune cells, in an HSV 
vaccine candidate. 
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Chapter 6: Conclusions and Future Directions 
6.1 Rationale and project aims 
NK cells play an important role in the interface between innate and adaptive 
immunity, and in the antiviral response. Nonetheless, the role of NK cells in response to 
HSV infection is not fully understood, and they have been largely overlooked in the 
design of vaccine candidates. In humans, NK cells have been divided into two main 
subsets, CD56dimCD16+ and CD56brightCD16-/dim, thought to be functionally distinct and 
characterised as highly cytolytic or as potent cytokine producers respectively. We 
previously demonstrated that NK cells were responsive to an HSV lipopeptide vaccine 
candidate and augmented CD4+T cell activity. We also showed that NK cells were 
present in herpes lesions interacting with CD4+T cells. Therefore, we wanted to 
investigate and compare the responses of each NK cell subset to HSV lipopeptide, their 
relative abilities to mature DCs and their presence in normal and HSV-infected skin. 
The aims of this study were to: 
1. Selectively enrich the CD56bright subset in culture without enhancing cytotoxicity, 
using cytokines that promote survival and proliferation of this subset 
2. Characterise and compare the responses of CD56bright and CD56dim NK cells in 
response to the HSV lipopeptide Pam2Cys-30-5 
3. Compare the ability of CD56bright and CD56dim NK cells to mature DCs following 
Pam2Cys-30-5 stimulation 
4. Analyse the presence of the NK cell subsets in normal and primary HSV-infected skin 
6.2 CD56bright NK cell-selective cytokines 
To selectively enrich CD56bright NK cells in culture, the action of IL-15, IL-2 and 
IL-7 on the NK cell subsets were compared in relation to survival, cytotoxicity and 
proliferation. IL-7 and IL-15 were compared for survival and cytotoxic potential 
measured by perforin expression. After 7 days, IL-7 selectively enhanced survival of the 
CD56bright subset, whereas IL-15 maintained both NK cell subsets, but also increased 
Chapter 6: Conclusions and Future Directions 
	 201 
their perforin expression unlike IL-7. In combination, our results and others in the 
literature indicate that CD56bright NK cells cultured with IL-7 may have a transient, early 
increase in perforin that disappears by 3 days of culture and remains low after 7 days of 
culture. Future kinetic studies using IL-7 would further define changes in perforin 
expression in the presence of IL-7 over time and the mechanism. IL-7 and IL-2 were 
compared for survival and proliferation of the CD56bright subset. IL-7 increased the 
number of CD56bright NK cells and induced an equivalent percentage of cells to 
proliferate as IL-2, although cells tended to undergo fewer rounds of proliferation with 
IL-7. 
Since IL-7 enhanced CD56bright survival and proliferation without enhancing 
cytotoxicity, the IL-7 effects on CD56bright gene expression were analysed by DNA 
microarray. Global patterns of gene expression suggested that IL-7 CD56bright NK cells 
were distinct from CD56bright and CD56dim NK cells by PCA and Venn diagrams of 
overlapping genes. However, analysis of the top 100 up and downregulated genes in each 
pair-wise comparison identified a number of key immune system process genes 
upregulated in common between CD56bright and IL-7 CD56bright compared to CD56dim NK 
cells. C-kit and HLA-DR expression were validated at the protein level on IL-7 CD56bright 
NK cells, as the c-kit and HLA-DM genes were upregulated, genes characteristic of 
CD56bright NK cells. However, the expression of other receptors such as KIR2DL1 and L-
selectin were not altered at the protein level, despite changes in expression at the gene 
level, highlighting the importance of confirming genomic data at the protein level. 
Upregulation of HLA-DR by IL-7 suggests that IL-7 could enhance CD56bright antigen-
presenting capacity. IL-7 CD56bright NK cells may be an appropriate surrogate for 
CD56bright NK cells for some functional capabilities of this subset, such as antigen 
presentation. Since cytokines are used in the laboratory and the clinic, understanding their 
functional effects on multiple immune cell targets is important. Our findings with IL-7 
need to be followed up with further protein and functional studies. 
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6.3 CD56bright and CD56dim responses to Pam2Cys-30-5 and 
maturation of DCs 
To compare the responses of CD56bright and CD56dim NK cells to Pam2Cys-30-5, 
the early activation marker CD69 was examined, which both subsets upregulated. The 
CD56dim subset had higher levels of CD69 expression both at the basal level and after 
stimulation, however CD56bright expression of CD69 was upregulated to a greater extent 
by Pam2Cys-30-5 due to lower basal levels of CD69 compared to the CD56dim subset. 
When MDDCs were cocultured with Pam2Cys-30-5-stimulated NK cells, the CD69 
expression was significantly enhanced on both NK cell subsets when in contact with 
MDDCs, compared to when a transwell insert separated them. These results demonstrate 
that both subsets are capable of directly responding to Pam2Cys-30-5, and that contact 
with DCs rather than soluble factors was required for further enhancement of NK cell 
activation in response to Pam2Cys-30-5. 
HLA-DR expression was also examined on both NK cell subsets in direct 
response to Pam2Cys-30-5, and it was found that only the CD56bright subset significantly 
upregulated HLA-DR in response to Pam2Cys-30-5 when stimulated alone. However, 
when NK cells were cocultured in contact with DCs, both subsets strongly upregulated 
HLA-DR in response to Pam2Cys-30-5. This was particularly noticeable on the CD56dim 
subset which otherwise had low to undetectable HLA-DR expression. The increased 
HLA-DR expression in response to Pam2Cys-30-5 corresponded with previous 
observations by us (Kim et al., 2012) and others (Hanna et al., 2004b), addressing NK 
cell antigen-presenting capabilities towards autologous CD4+T cells. The augmentation 
of HLA-DR expression by DCs suggests that the presence of DCs could enhance NK cell 
antigen-presenting capacity, reciprocating NK cell-mediated enhancement of DC 
maturation and antigen presentation to T cells. This triple cell cross-talk reflects 
responses to viral infection (HSV, CMV, HIV). 
Future studies should further investigate the mechanism of antigen uptake, 
processing and presentation of NK cells to CD4+T cells. The use of inhibitors of the 
MHC class II antigen processing and presentation pathway would determine whether this 
pathway is involved in NK cell-mediated activation of CD4+T cells. For example, 
Bafilomycin A, which blocks endosomal acidification (Yoshimori et al., 1991) and the 
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cleavage of the MHC CLass II associated Invariant chain Peptide (CLIP), should prevent 
peptide loading onto MHC class II (Denzin and Cresswell, 1995, Sloan et al., 1995). 
Furthermore, to determine whether contact with DCs enhances NK cell antigen 
presentation to CD4+T cells, NK cells stimulated with Pam2Cys-30-5 could be pre-
treated by coculture with DCs, followed by separation and subsequent coculture with 
CD4+T cells, compared to being immediately cocultured with CD4+T cells without pre-
treatment with DCs. Since IL-7 culture also appeared to upregulate genes associated with 
antigen presentation, as well as surface HLA-DR on CD56bright NK cells, IL-7 CD56bright 
NK cells may also serve as a useful model for studying NK cell antigen presentation 
mechanisms. Understanding antigen processing and presentation processes in NK cells 
will help to characterise their antigen presenting capacity more thoroughly and would 
identify markers of the antigen processing pathway that could be examined in NK cells in 
vivo, to determine if and under what circumstances NK cells act as antigen presenting 
cells in a physiological setting. 
Upon examining NK cell-mediated DC maturation in response to Pam2Cys-30-5, 
it was found that cell contact was not essential for the upregulation of the maturation 
markers CD80 and CD83, and that Pam2Cys-30-5-stimulated supernatants alone from 
both NK cell subsets increased the expression of these markers on MDDCs. The CD56dim 
NK cells produced higher concentrations of cytokines than CD56bright NK cells, yet both 
subset supernatants upregulated MDDC maturation markers to an approximately 
equivalent level. Therefore, NK cell soluble factors were important for upregulating DC 
maturation markers. Follow-up studies should use neutralising antibodies targeting the 
cytokines already detected to establish their relative importance in the DC maturation 
induced by each NK cell subset. Furthermore, the possibility of other soluble factors 
being involved in inducing DC maturation should be explored, perhaps by mass 
spectrometry analysis of supernatants. 
Since Pam2Cys is a TLR2 ligand, TLR2 expression was examined on NK cells, 
and by microscopy TLR2 was detected on both CD16+ and CD16- NK cells, 
corresponding to the CD56dim and CD56bright subsets respectively. To confirm our 
findings by microscopy, studies using cell sorted, purified CD56bright and CD56dim NK 
cells, rather than the mixed NK cell population would more accurately assess the 
percentage of TLR2 expressing cells in each subset. A comprehensive assessment of 
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different clones of TLR2 antibody or combinations of primary and secondary 
fluorochrome-conjugated antibodies may also be helpful in determining if there are 
marked differences in ability to detect TLR2 on NK cells and why expression levels 
appear to be strikingly different by flow cytometry and microscopy. Furthermore, TLR2 
expression should be verified by additional, alternative methods of protein detection such 
as western blot.  
6.4 Pam2Cys-30-5-induced downregulation of CD16 on CD56dim NK 
cells 
To begin investigating the mechanisms of NK cell uptake of and activation in 
response to Pam2Cys-30-5, we sought to demonstrate Pam2Cys binding to TLR2 as the 
first step. However, colocalisation between Pam2Cys-30-5 and TLR2 was not often 
observed and the Pearson coefficient of correlation was low. Instead, we found that TLR2 
and CD16 on NK cells were significantly more colocalised than Pam2Cys and TLR2. 
Upon examining CD16 expression on NK cells (particularly the CD56dim subset), we 
observed a strong, dose-dependent downregulation of CD16 over 18 hours following 
Pam2Cys-30-5 stimulation, with the greatest decrease observed at 6 hours. The CD56dim 
NK cells losing CD16, which we termed CD56dimCD16-/dim NK cells, had the highest 
expression of CD69 and IFN-γ. This correlation suggests functional significance of CD16 
downregulation. 
Since we observed the functional correlation of CD16 downregulation and IFN-γ 
production and activation, as well as colocalisation between CD16 and TLR2, we 
examined whether CD16 and TLR2 were in close enough proximity to interact using 
PLA. Proximity interactions were infrequently detected in NK cells, indicating that not 
many individual TLR2 and CD16 proteins were in close enough proximity to interact. 
However, blocking CD16 using either anti-CD16 antibody or inactivated human serum 
containing IgG, which binds to CD16 as a ligand, significantly reduced Pam2Cys binding 
to NK cells. One possible explanation could be that Pam2Cys is capable of binding to 
CD16 directly. To address the possibility, a binding ELISA between Pam2Cys and CD16 
was conducted. However, no direct binding between Pam2Cys and CD16 was detected, 
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either due to there being no interaction, or due to a weak association that was not 
detectable in the ELISA, an assay requiring strong binding affinity. 
Most in vivo protein-protein binding is transient, yet these transient interactions 
are important biological regulators (Nooren and Thornton, 2003). Capturing weak or 
momentary interactions can be achieved with the use of chemical crosslinkers, stabilising 
the complex to enable characterisation via techniques such as electrophoresis, western 
blot, co-immunoprecipitation or mass spectrometry. Such methods would confirm 
whether a transient interaction occurs between any of the pairs: TLR2 and Pam2Cys, 
TLR2 and CD16, or CD16 and Pam2Cys. Confirming whether each of these interactions 
takes place would be important for demonstrating Pam2Cys binding to TLR2 on NK cells, 
as well as determining whether TLR2-CD16 or Pam2Cys-CD16 interactions take place, 
and whether these interactions play a role in initiating NK cell activation or CD16 
downregulation in response to Pam2Cys stimulation. 
We sought to determine the mechanism of CD16 downregulation, as both 
shedding and internalisation had been reported in the literature. Both mechanisms were 
detected in our study. However, our method of intracellular measurement using relative 
enrichment calculations should be validated by an alternative method of measuring 
internalised CD16, remembering that any method relying on labelling CD16 with anti-
CD16 antibody first and tracking its movement into the cell would be inappropriate since 
the antibody itself triggers activation of CD16. Intracellular flow cytometry could be 
revisited with a different clone of anti-CD16 antibody that is not affected by fixation with 
paraformaldehyde. Also, if CD16 is degraded once internalised, as suggested by 
Cecchetti et al. (Cecchetti et al., 2007), the use of cathepsin inhibitors should inhibit this 
process and allow for the accumulation of internalised CD16, making it more clearly 
visualised at later time-points by microscopy.  
The purpose of CD16 downregulation in response to Pam2Cys-30-5 stimulation 
and its effects of functions such as ADCC require further exploration. Use of ADAM17 
inhibitors such as TAPI-2 and inhibitors of endocytosis such as tyrosine kinase inhibitor 
genistein, should determine the relative contribution of either shedding or internalisation 
as a mechanism of CD16 downregulation and, ultimately, determine whether inhibition of 
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CD16 downregulation results in regulation or enhancement of NK cell activation in 
response to Pam2Cys-30-5.  
It is unclear where the pathways of TLR2 stimulation and CD16 downregulation 
intersect. If TLR2 and CD16 are not directly interacting upon Pam2Cys-binding, then the 
use of inhibitors at various points along of the TLR2 signalling pathway may help 
determine where the pathways overlap. This will also be important for developing a 
deeper understanding of the functional responses induced by TLR2 agonists since they 
are being used as vaccine adjuvants. These TLR2 agonists have already been tested for 
immunogenicity and safety in humans in Phase I/II trials. However, determining their 
effectiveness and the mechanisms that induce effective immune responses across 
different immune cell types will be important for developing these compounds as 
effective adjuvants in vaccine candidates. 
6.5 NK cells in HSV infected skin 
The skin is the initial site of HSV infection and as such would be the ideal 
location for topical or intra-dermal vaccination against HSV, priming the immune cells to 
respond upon initial encounter with HSV. Therefore, it is important to examine NK cells 
in skin to establish their role in response to HSV infection and as potential targets of a 
vaccine. In our study, CD16- NK cells predominated in normal foreskin, whereas CD16+ 
NK cells predominated in an initial penile herpes lesion, and there was an overall increase 
in the number of NK cells. Furthermore, CD16- NK cells expressed the skin homing 
marker CLA. These results strongly suggest that CD16- NK cells are constantly migrating 
to the skin and that there is a regular turnover of these cells in normal skin. However, 
there is an alteration to the NK cell population during HSV infection, such that there are 
greater numbers of NK cells, and most are CD16+ and lose CLA.  
It was noted that differences in the NK cell population found in skin have been 
observed under different inflammatory conditions. It will be important to determine what 
drives the changes from normal skin to HSV infected skin resulting in the altered NK cell 
phenotype, and further exploration of differences between inflammatory environments of 
HSV and other skin diseases may help elucidate the mechanisms. The chemokine 
environments and cell types present in different inflammatory settings in skin may be 
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contributing to the differences in NK cell phenotype and function, for example, when 
CD16- NK cells express markers of cytotoxicity. HSV infection of neighbouring cells or 
of NK cells themselves may also contribute to some of the changes in NK cells and 
should also be further investigated. 
MDDCs, which we used to study NK cell-mediated DC maturation in vitro are a 
model DC, although they have been shown to cluster closely with CD14+ dermal DCs in 
a study on lineage relationships of various human blood and skin DC subsets compared to 
model cells (Harman et al., 2013). However, it will be important to study the different 
dermal DC subpopulation interacting with NK cells in skin.  
Our study investigated NK cell interactions with other HLA-DR expressing 
antigen-presenting cells in normal and HSV infected skin. Whereas no contact was 
observed in normal skin, some contact between NK cells and HLA-DR+ cells was 
observed in the initial herpes lesion, and more CD16+ NK cells were in close proximity to 
HLA-DR+ cells than CD16- NK cells. It needs to be determined whether there is a 
functional explanation for increased contact with CD16+ NK cells, or whether it is simply 
due to CD16+ NK cells outnumbering CD16- NK cells in HSV infected tissue. The use of 
equal numbers of isolated cells of each subtype from skin would confirm or rule-out 
whether CD16+ interactions with HLA-DR+ cells are due to having increased numbers in 
the tissue. To determine which subsets of antigen-presenting cells are interacting with NK 
cells, subsequent work should include more specific markers of different DC subsets in 
serial sections of the tissue- CD11c, CD141 and CD1a. To determine whether 
interactions with different skin DC subsets leads to different functional outcomes, 
culturing cells isolated from skin in vitro would allow direct assessment of markers of 
cytotoxicity or cytokine receptors at the interface between NK cells and specific skin DC 
subpopulations. 
There is still much to be discovered about the role of NK cells in the initial 
encounter of HSV in skin, and the interaction of NK cells with HSV itself as well as with 
other immune cells. 
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6.6 Concluding remarks 
The human NK cell subsets were originally characterised as functionally distinct, 
with the CD56dim subset being highly cytolytic and the CD56bright subset being potent 
cytokine producers. In this study, we investigated the selective action of cytokines on the 
CD56bright subset, the responses of both NK cell subsets in response to the HSV 
lipopeptide Pam2Cys-30-5, compared the ability of both subsets to mature DCs in 
response to Pam2Cys-30-5, and began analysing normal and HSV infected skin for the 
presence of the NK cell subsets. Our findings demonstrate that rather than being 
functionally distinct, the NK cell subsets are functionally plastic with diverse responses 
depending on the stimulus.  
In response to cytokines such as IL-15, CD56bright NK cells upregulated perforin. 
Others have also reported this observation after prolonged exposure to IL-2 (Caligiuri et 
al., 1990, Ferlazzo et al., 2004a). IL-7 may also upregulate cytotoxic markers transiently, 
soon after addition to CD56bright NK cells (Dadmarz et al., 1994). In response to 
Pam2Cys-30-5, we demonstrated that the CD56dim subset were more potent producers of 
cytokines such as IFN-γ than the CD56bright subset. The CD56bright subset exclusively 
expressed HLA-DR in response to Pam2Cys-30-5, and culture with IL-7 enhanced 
CD56bright HLA-DR expression. In coculture with DCs both NK cell subsets strongly 
upregulated HLA-DR in response to Pam2Cys-30-5, indicating that DCs may augment 
NK cell antigen-presenting function and also that DC cross-talk with the CD56dim subset 
induced HLA-DR, which they do not normally express. In skin, we identified the NK cell 
subsets based on being CD16+ (CD56dim) and CD16- (CD56bright). Functional plasticity 
has also been demonstrated in skin, where under inflammatory conditions, or during 
chronic infection, infiltrating CD16- NK cells expressed perforin and granzymes as 
markers of cytotoxicity (Carbone et al., 2010, Reeves et al., 2010). 
These findings demonstrate that CD56dim and CD56bright NK cells are functionally 
plastic, and highlights that more sophisticated characterisation of the repertoire of NK 
cells is required. With technologies such as mass cytometry for the analysis of 20-30 
parameters, and approaches such as single cell RNA sequencing for the analysis of 
individual cells within a subset, multiple subpopulations within the currently defined 
subsets may be identified. These would unlikely be ontogenetically distinct, but rather 
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diverge depending on the local tissue environment as has recently been discovered for 
skin DCs. 
Overall, NK cells appear to be an important link between innate and adaptive 
immunity with the ability to rapidly respond to stimulus, influence the response of DCs 
and subsequent adaptive responses and also prime T cells directly. NK cells may play a 
key role in the control of genital HSV infection and should be considered as a target in 
vaccine development. Characterisation of the mechanism of TLR2 agonists activation of 
NK cells as well as other immune cells will provide insight into their potential use as 
vaccine adjuvants, in particular for new vaccines against HSV. 
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Appendix 1: Pam2Cys-30-5 uptake by NK cells 
 
Appendix 1. (A+B) Isolated NK cells were pulsed for 1 hour at 37°C with mock 
(DMSO), FITC-conjugated peptide 30-5 or FITC conjugated Pam2Cys-30-5 (10 µM), 
then analysed by immunofluorescence microscopy. (A) Representative images of NK 
cells after with the nuclear stain DAPI shown in blue and the FITC-conjugated peptides 
shown in green. Only Pam2Cys-conjugated 30-5 is visible in the NK cells. Scale = 15 µm. 
(B) Combined analysis of the average FITC fluorescence intensity of mock (DMSO), 
FITC-30-5 or FITC-P2C-30-5 treatment. FITC-P2C-30-5 had significantly greater FITC 
fluorescence than mock or FITC-30-5 (p<0.001 unpaired t test, n≥24 cells). (C) Isolated 
NK cells were pulsed for 0, 15 or 30 mins at 37°C with FITC-P2C-30-5 (10 µM), then 
analysed by immunofluorescence microscopy. At 15 and 30 minutes, punctate green 
fluorescence is visible in the cytoplasm of the NK cells. Scale = 5 µm. 
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Appendix 3: DNA Microarray Top 100 
analyses 
 
A. Top 100 IL-7 CD56bright vs. CD56dim upregulated genes with GO Function 
categories 
B. Top 100 IL-7 CD56bright vs. CD56bright upregulated genes with GO Function 
categories 
C. Top 100 CD56bright vs. CD56dim upregulated genes with GO Function categories 
D. Top 100 IL-7 CD56bright vs. CD56dim downregulated genes with GO Function 
categories 
E. Top 100 IL-7 CD56bright vs. CD56bright downregulated genes with GO Function 
categories 
F. Top 100 CD56bright vs. CD56dim downregulated genes with GO Function 
categories 
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1:	LTB	 Lymphotoxin	beta	 30.8612	 7.36E-10	
Molecular	function:	protein	binding,	Biological	process:	immune	system	process,	macromolecule	metabolic	
process,	response	to	stimulus	
2:	KIT	
KIT	proto-oncogene	
receptor	tyrosine	
kinase	 24.9229	 7.26E-07	
Molecular	function:	protein	binding,	protein	homodimerisation	activity,	enzyme	binding,	nucleotide	binding,	
Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	phosphate-containing	compound	
metabolic	process,	programmed	cell	death,	leukocyte	activation,	cell	activation	involved	in	immune	response,	
single	organismal	cell-cell	adhesion,	lymphocyte	activation,	leukocyte	chemotaxis,	immune	system	process,	
response	to	stress,	response	to	stimulus,	carbohydrate	derivative	metabolic	process,	nitrogen	compound	metabolic	
process,	leukocyte	proliferation,	leukocyte	migration,	Cellular	component:	cytoplasmic	part	
3:	GZMK	 Granzyme	K	 23.8332	 1.26E-06	 Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process	
4:	MAL	
Mal,	T-cell	
differentiation	protein	 22.9917	 8.91E-08	
Molecular	function:	protein	binding,	enzyme	regulator	activity,	Biological	process:	programmed	cell	death,	
membrane	raft	organisation,	Cellular	component:	cytoplasmic	part	
5:	CCR7	
C-C	motif	chemokine	
receptor	7		 19.1033	 7.93E-06	
Molecular	function:	protein	binding,	Biological	process:		leukocyte	chemotaxis,	immune	system	process,	response	
to	stress,	response	to	stimulus,	lymphocyte	activation,	Cellular	component:	cytosol,	cytoplasmic	part	
6:	IL7R	 Interleukin	7	receptor	 17.7999	 0.000411722	
Molecule	function:	protein	binding,	Biological	process:	leukocyte	activation,	leukocyte	proliferation,	single	
organismal	cell-cell	adhesion,	lymphocyte	activation,	immune	system	process,	response	to	stimulus	
7:	GPR68	
G	protein-coupled	
receptor	68	 16.9376	 1.04E-08	 Biological	process:	response	to	stress,	response	to	stimulus	
8:	TOP2A	
Topoisomerase	(DNA)	
II	alpha	 16.4729	 2.66E-05	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	protein	homodimerisation	activity,	enzyme	
binding,	nucleotide	binding,	Biological	process:	macromolecule	metabolic	process,	DNA	metabolic	process,	protein	
metabolic	process,	nucleobase-containing	compound	metabolic	process,	mitotic	cell	cycle	process,	nuclear	
chromosome	segregation,	response	to	stress,	response	to	stimulus,	nitrogen	compound	metabolic	process,	Cellular	
component:	nucleoplasm,	nucleolus,	cytoskeletal	part,	nucleus,	nuclear	part,	cytoplasmic	part	
9:	LEF1	
Lymphoid	enhancer-
binding	factor	1	 14.1873	 8.01E-07	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	enzyme	binding,	enzyme	regulator	activity,	
cysteine-type	endopeptidase	inhibitor	activity	involved	in	apoptotic	process,	Biological	process:	macromolecule	
metabolic	process,	DNA	metabolic	process,	protein	metabolic	process,	nucleobase-containing	compound	metabolic	
process,	programmed	cell	death,	leukocyte	activation,	cell	activation	involved	in	immune	response,	single	
organismal	cell-cell	adhesion,	lymphocyte	activation,	immune	system	process,	response	to	stimulus,	nitrogen	
compound	metabolic	process,	leukocyte	proliferation,	Cellular	component:	nucleoplasm,	nucleus,	nuclear	part,	
cytoplasm	
10:	NELL2	 Neural	EGFL	like	2	 13.7042	 2.62E-06	
Molecule	function:	protein	binding,	enzyme	binding,	Biological	process:	protein	complex	assembly,	
macromolecular	complex	assembly,	Cellular	component:		cytoplasm	
11:	AMICA1	
Junction	adhesion	
molecule	like	(JAML)	 12.7029	 1.89E-06	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	protein	homodimerisation	activity,	
Biological	process:	leukocyte	activation,	single	organismal	cell-cell	adhesion,	lymphocyte	activation,	leukocyte	
chemotaxis,	immune	system	process,	leukocyte	migration	
12:	EBI2	
G	protein-coupled	
receptor	183	
(GPR183)	 12.4595	 5.36E-07	
Biological	process:	leukocyte	activation,	cell	activation	involved	in	immune	response,	lymphocyte	activation,	
immune	system	process,	response	to	stimulus	
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13:	ADCY3	 Adenylate	cyclase	3	 11.2104	 2.02E-06	
Molecule	function:	lyase	activity,	protein	binding,	nucleotide	binding,	Biological	process:	nucleobase-containing	
compound	metabolic	process,	phosphate-containing	compound	metabolic	process,	nitrogen	compound	metabolic	
process,	carbohydrate	derivative	metabolic	process,	immune	system	process,	response	to	stress,	response	to	
stimulus,	Cellular	component:	nucleus,	Golgi	apparatus,	cytoplasm,	cytoplasmic	part	
14:		
HLA-DMB	
Major	
histocompatibility	
complex,	class	II,	DM	
beta	 11.1573	 2.58E-06	
Molecule	function:	macromolecular	complex	binding,	protein	binding,	Biological	process:	protein	complex	
assembly,	macromolecular	complex	assembly,	antigen	processing	and	presentation	of	peptide	or	polysaccharide	
antigen	via	MHC	class	II,	immune	system	process,	response	to	stimulus,	Cellular	component:	cytoplasmic	part	
15:	MMP25	
Matrix	
metallopeptidase	25	 10.7246	 9.58E-08	
Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	response	to	stress,	response	to	
stimulus	
16:	CD2	 CD2	molecule	 10.5695	 5.71E-05	
Molecule	function:	protein	binding,	protein	homodimerisation	activity,	Biological	process:	membrane	raft	
organisation,	programmed	cell	death,	leukocyte	activation,	single	organismal	cell-cell	adhesion,	lymphocyte	
activation,	leukocyte	migration,	immune	system	process	
17:	DCAF7	
DDB1	and	CUL4	
associated	factor	7	 10.4226	 6.94E-09	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	
process,	Cellular	component:	nucleoplasm,	transferase	complex,	nuclear	part,	cytoplasm		
18:	PCMT1	
Protein-L-isoaspartate	
(D-aspartate)	O-
methyltransferase	 10.405	 1.38E-05	
Molecular	function:	methyltransferase	activity,	protein	binding,	Biological	process:	macromolecule	metabolic	
process,	protein	metabolic	process,	Cellular	component:	cytosol,	extracellular	exosome,	cytoplasm,	cytoplasmic	
part	
19:	CDC20	 Cell	division	cycle	20	 10.3115	 3.99E-05	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	macromolecule	metabolic	process,	
protein	metabolic	process,	electron	transport	chain,	mitotic	cell	cycle	process,	mitotic	nuclear	division,	cell	cycle	
phase	transition,	Cellular	component:	nucleoplasm,	cytoskeletal	part,	microtubule	organising	centre,	transferase	
complex,	cytosol,	nucleus,	nuclear	part,	cytoplasm,	cytoplasmic	part	
20:	RCBTB2	
RCC1	and	BTB	domain	
containing	protein	2	 9.85083	 2.13E-06	 Molecular	function:	protein	binding,	Cellular	component:	cytoplasmic	part	
21:	XCL1	
X-C	motif	chemokine	
ligand	1	 9.61851	 4.55E-07	
Molecular	function:	protein	binding,	protein	homodimerisation	activity,	Biological	process:	leukocyte	chemotaxis,	
immune	system	process,	response	to	stress,	response	to	stimulus,	leukocyte	migration	
22:	DLL1	
Delta-like	1	
(Drosophila)	 9.37724	 3.97E-06	
Molecule	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	
process,	leukocyte	activation,	cell	activation	involved	in	immune	response,	lymphocyte	activation,	immune	system	
process,	Cellular	component:	cytoplasmic	part	
23:	NUSAP1	
Nucleolar	and	spindle	
assocoated	protein	1	 8.99577	 0.000470754	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	Biological	process:	mitotic	cell	cycle	
process,	mitotic	nuclear	division,	cytokinesis,	nuclear	chromosome	segregation,	spindle	localisation,	microtubule	
cytoskeleton	organisation,	Cellular	component:	nucleolus,	cytoskeletal	part,	microtubule,	nucleus,	nuclear	part,	
cytoplasm	
24:	SELL	 Selectin	L	 8.79839	 0.000112214	
Molecule	function:	protein	binding,	enzyme	binding,	Biological	process:	leukocyte	migration,	immune	system	
process,	response	to	stimulus	
25:	RNF144	
Ring	finger	protein	
144A	 8.34327	 4.98E-08	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	macromolecule	metabolic	process,	
protein	metabolic	process,	Cellular	component:	transferase	complex,	Golgi	apparatus,	cytoplasmic	part	
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26:	IL12RB2	
Interleukin	12	
receptor	subunit	beta	
2	 8.30121	 1.08E-05	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	macromolecule	metabolic	process,	
protein	metabolic	process,	phosphate-containing	compound	metabolic	process,	response	to	stimulus	
27:	
PRAGMIN	
Homolog	of	rat	
pragma	of	Rnd2	 8.28118	 9.10E-07	
Molecular	function:	nucleotide	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	
process,	phosphate-containing	compound	metabolic	process	
28:	CDCA5	
Cell	division	cycle	
associated	5	 8.03807	 0.000746789	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	Biological	process:	macromolecule	
metabolic	process,	DNA	metabolic	process,	nucleobase-containing	compound	metabolic	process,	mitotic	cell	cycle	
process,	mitotic	nuclear	division,	cell	cycle	phase	transition,	DNA	repair,	response	to	stress,	response	to	stimulus,	
nitrogen	compound	metabolic	process,	Cellular	component:	nucleoplasm,	nuclear	chromosome	part,	chromatin,	
cytosol,	nucleus,	nuclear	part,	cytoplasm,	cytoplasmic	part	
29:	TYMS	
Thymidylate	
synthetase	 7.91401	 0.000687165	
Molecular	function:	methyltransferase	activity,	protein	binding,	protein	homodimerisation	activity,	nucleotide	
binding,	Biological	process:	macromolecule	metabolic	process,	DNA	metabolic	process,	coenzyme	metabolic	
process,	nucleobase-containing	compound	metabolic	process,	phosphate-containing	compound	metabolic	process,	
mitotic	cell	cycle	process,	cell	cycle	phase	transition,	nucleobase	metabolic	process,	glycosyl	compound	
biosynthetic	process,	response	to	stimulus,	carbohydrate	derivative	metabolic	process,	nitrogen	compound	
metabolic	process,	Cellular	component:	nucleoplasm,	nucleolus,	mitochondrial	membrane,	mitochondrial	matrix,	
cytosol,	mitochondrion,	nucleus,	nuclear	part,	cytoplasm,	cytoplasmic	part	
30:	
S100A11	
S100	calcium	binding	
protein	A11	 7.85901	 3.25E-07	
Molecular	function:	protein	binding,	protein	homodimerisation	activity,	Cellular	component:	extracellular	
exosome,	nucleus,	cytoplasm	
31:	AARS	
Alanyl-tRNA	
synthetase	 7.74795	 3.26E-07	
Molecular	function:	nucleotide	binding,	Biological	process:	macromolecule	metabolic	process,	nucleobase-
containing	compound	metabolic	process,	response	to	stress,	response	to	stimulus,	nitrogen	compound	metabolic	
process,	Cellular	component:	cytosol,	extracellular	exosome,	mitochondrion,	cytoplasm,	cytoplasmic	part	
32:	CXCR3	
C-X-C	motif	
chemokine	receptor	3	 7.66854	 9.87E-07	
Molecule	function:	protein	binding,	Biological	process:	programmed	cell	death,	leukocyte	chemotaxis,	leukocyte	
migration,	immune	system	process,	response	to	stress,	response	to	stimulus,	Cellular	component:	cytosol,	
cytoplasm,	cytoplasmic	part	
33:	E2F2	
E2F	transcription	
factor	2	 7.38971	 0.000924251	
Molecule	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	
compound	metabolic	process,	nitrogen	compound	metabolic	process,	programmed	cell	death,	Cellular	
component:	nucleoplasm,	nuclear	part	
34:	MYC	
v-myc	avian	
myelocytomatosis	
viral	oncogene	
homolog	 7.1689	 1.40E-05	
Molecule	function:	macromolecular	complex	binding,	protein	binding,	Biological	process:	macromolecule	
metabolic	process,	protein	metabolic	process,	nucleobase-containing	compound	metabolic	process,	phosphate-
containing	compound	metabolic	process,	nitrogen	compound	metabolic	process,	programmed	cell	death,	response	
to	stress,	response	to	stimulus,	Cellular	component:	nucleoplasm,	nucleolus,	nucleus,	cytosol,	nuclear	part,	
cytoplasmic	part	
35:	RAB10	
RAB10,	member	RAS	
oncogene	family	 7.0993	 2.01E-07	
Molecular	function:	protein	binding,	nucleotide	binding,	Biological	process:	immune	system	process,	response	to	
stimulus,	Cellular	component:	extracellular	exosome,	Golgi	membrane,	Golgi	apparatus,	cytoplasmic	part	
36:	ATP8B4	
ATPase	phospholipid	
transporting	8B4	
(putative)	 7.08394	 6.76E-06	 Molecule	function:	nucleotide	binding,	Cellular	component:	Golgi	apparatus,	cytoplasmic	part	
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37:	
TMEM14C	
Transmembrane	
protein	14C	 6.94723	 9.99E-07	
Molecule	function:	protein	binding,	Biological	process:	cofactor	biosynthetic	process,	nitrogen	compound	
metabolic	process,	Cellular	component:	mitochondrial	membrane,	cytoplasmic	part	
38:	NOD2	
Nucleotide	binding	
oligomerisation	
domain	containing	2	 6.91574	 0.000580689	
Molecule	function:	protein	binding,	enzyme	binding,	nucleotide	binding,	Biological	process:	macromolecule	
metabolic	process,	protein	metabolic	process,	phosphate-containing	compound	metabolic	process,	protein	
complex	assembly,	macromolecular	complex	assembly,	immune	system	process,	response	to	stress,	response	to	
stimulus,	Cellular	component:	cytosol,	nuclear	part,	cytoplasm,	cytoplasmic	part	
39:	CAPG	
Capping	actin	protein,	
gelsolin	like	 6.89123	 1.04E-05	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	Biological	process:	protein	complex	
assembly,		macromolecular	complex	assembly,	Cellular	component:	nucleoplasm,	nucleolus,	cytoskeletal	part,	
extracellular	exosome,	nucleus,	nuclear	part,	cytoplasm,	cytoplasmic	part	
40:	
RNF144A	
Ring	finger	protein	
144A	 6.8849	 7.96E-08	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	macromolecule	metabolic	process,	
protein	metabolic	process,	Cellular	component:	transferase	complex,	Golgi	apparatus,	cytoplasmic	part	
41:	
LOC730278	
Similar	to	putative	
S100	calcium-binding	
protein	A11	
pseudogene	 6.77642	 1.27E-07	 		
42:	ASPM	
Abnormal	spindle	
microtubule	assembly	 6.64004	 0.000151672	
Molecular	function:	protein	binding,	Biological	process:	mitotic	cell	cycle	process,	mitotic	nuclear	division,	spindle	
localisation,	microtubule	cytoskeleton	organisation,	protein	complex	assembly,	macromolecular	complex	assembly,	
organelle	assembly,	Cellular	component:	cytoskeletal	part,	nucleus,	cytoplasm	
43:	PROSC	
Proline	synthetase	co-
transcribed	homolog	
(bacterial)	 6.5186	 6.11E-08	 Cellular	component:	extracellular	exosome,	mitochondrion,	cytoplasm,	cytoplasmic	part	
44:	KLRC1	
Killer	cell	lectin	like	
receptor	C1	(NKG2A)	 6.51372	 0.000252823	 Molecule	function:	macromolecular	complex	binding,	protein	binding	
45:	DPYSL2	
Dihydropyrimidin-ase	
like	2	 6.469	 2.18E-06	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	enzyme	binding,	Biological	process:	
nucleobase-containing	compound	metabolic	process,	response	to	stimulus,	nitrogen	compound	metabolic	process,	
Cellular	component:	cytoskeletal	part,	microtubule,	cytosol,	extracellular	exosome,	mitochondrion,	cytoplasmic	
part	
46:	HMMR	
Hyaluronan	mediated	
motility	receptor	 6.43724	 5.28E-05	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	carbohydrate	
derivative	metabolic	process,	nitrogen	compound	metabolic	process,	cytoplasm	
47:	STS-1	
Ubiquitin	associated	
and	SH3	domain	
containing	B	
(UBASH3B)	 6.37477	 9.04E-07	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	
process,	phosphate-containing	compound	metabolic	process,	Cellular	component:	nucleus,	cytoplasm	
48:	ACADM	
Acyl-CoA	
dehydrogenase,	C-4	to	
C-12	straight	chain	 6.28529	 2.40E-09	
Molecular	function:	protein	binding,	nucleotide	binding,	Biological	process:	macromolecule	metabolic	process,	
organic	acid	biosynthetic	process,	protein	complex	assembly,	macromolecular	complex	assembly,	small	molecule	
biosynthetic	process,	response	to	stress,	response	to	stimulus,	nitrogen	compound	metabolic	process,	Cellular	
component:	mitochondrial	matrix,	extracellular	exosome,	mitochondrion,	nucleus,	cytoplasmic	part	
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49:	PDE7B	 Phosphodiesterase	7B	 6.26473	 0.00146278	
Biological	process:	nucleobase-containing	compound	metabolic	process,	phosphate-containing	compound	
metabolic	process,	carbohydrate	derivative	metabolic	process,	nitrogen	compound	metabolic	process,	Cellular	
component:	cytosol,	cytoplasmic	part	
50:	CEP55	
Centrosomal	protein	
55	 6.23152	 0.000398868	
Molecular	function:	protein	binding,	Biological	process:	mitotic	cell	cycle	process,	cytokinesis,	cell	separation	after	
cytokinesis,	Cellular	component:	cytoskeletal	part,	microtubule	organising	centre,	cytoplasmic	part	
51:	LPXN	 Leupaxin	 6.2253	 4.59E-05	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	
compound	metabolic	process,	protein	complex	assembly,	macromolecular	complex	assembly,	nitrogen	compound	
metabolic	process,	Cellular	component:	cytoskeletal	part,	nucleus,	cytoplasm,	cytoplasmic	part	
52:	MRPS6	
Mitochondrial	
ribosomal	protein	S6	 6.20938	 8.18E-06	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	
process,	nitrogen	compound	metabolic	process,	Cellular	component:	mitochondrial	membrane,	cytoplasmic	part	
53:	SSBP2	
Single	stranded	DNA	
binding	protein	2	 6.19852	 1.57E-07	 Cellular	component:	nucleus,	cytoplasm	
54:	
ST6GAL1	
ST6	beta-galactoside	
alpha-2,6-
sialyltransferase	1	 6.12022	 1.50E-05	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	
process,	immune	system	process,	response	to	stimulus,	carbohydrate	derivative	metabolic	process,	protein	
glycosylation,	Cellular	component:	extracellular	exosome,	Golgi	membrane,	Golgi	apparatus,	cytoplasmic	part	
55:	CSDA	
Y-box	binding	protein	
3	(YBX3)	 6.11282	 3.18E-05	
Molecule	function:	protein	binding,	enzyme	binding,	Biological	process:	macromolecule	metabolic	process,	
nucleobase-containing	compound	metabolic	process,	nitrogen	compound	metabolic	process,	response	to	stress,	
response	to	stimulus,	Cellular	component:	nucleus,	cytoplasm,	cytoplasmic	part	
56:	TST	
Thiosulfate	
sulfurtransferase	 6.08438	 4.03E-05	
Biological	process:	nitrogen	compound	metabolic	process,	Cellular	component:	mitochondrial	membrane,	
mitochondrial	matrix,	extracellular	exosome,	mitochondrion,	cytoplasmic	part	
57:	DNCL1	
Dynein	light	chain	
LC8-type	1	 6.06214	 9.57E-06	
Molecular	function:	protein	binding,	protein	homodimerisation	activity,	enzyme	binding,	enzyme	regulator	
activity,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	nucleobase-containing	
compound	metabolic	process,	mitotic	cell	cycle	process,	cell	cycle	phase	transition,	programmed	cell	death,	
antigen	processing	and	presentation	of	peptide	or	polysaccharide	antigen	via	MHC	class	II,	nitrogen	compound	
metabolic	process,	immune	system	process,	protein	glycosylation,	mitochondrial	membrane	organisation,	Cellular	
component:	kinetochore,	cytoskeletal	part,	microtubule,	microtubule	organising	centre,	cytosol,	extracellular	
exosome,	immune	system	process,	mitochondrion,	nucleus,	nuclear	part,	cytoplasm,	cytoplasmic	part	
58:	ZMIZ1	
Zinc	finger	MIZ-type	
containing	1	 6.06168	 1.04E-06	
Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	compound	metabolic	process,	
nitrogen	compound	metabolic	process,	Cellular	component:	nucleoplasm,	nuclear	part,	cytoplasm	
59:	ASXL2	
Additional	sex	combs	
like	2,	transcriptional	
regulator	 6.05625	 1.70E-06	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	
compound	metabolic	process,	nitrogen	compound	metabolic	process,	Cellular	component:	nucleoplasm,	nuclear	
chromosome	part,	chromatin,	nuclear	part	
60:	
DENND5A	
DENN	domain	
containing	5A	 5.98555	 1.60E-06	
Molecule	function:	protein	binding,	enzyme	binding,	Biological	process:	response	to	stimulus,	Cellular	component:	
cytoplasmic	part	
61:	
TMBIM4	
Transmembrane	BAX	
inhibitor	motif	
containing	4	 5.95376	 6.77E-06	
Molecular	function:	protein	binding,	Biological	process:	programmed	cell	death,	Cellular	component:	Golgi	
membrane,	cytoplasmic	part	
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62:	TTF2	
Transcription	
termination	factor,	
RNA	polymerase	II	 5.88884	 1.16E-06	
Molecular	function:	protein	binding,	nucleotide	binding,	Biological	process:	macromolecule	metabolic	process,	
nucleobase-containing	compound	metabolic	process,	nitrogen	compound	metabolic	process,	Cellular	component:	
nuclear	part,	cytoplasm	
63:	KIFC1	
Kinesin	family	
member	C1	 5.80607	 0.000430073	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	nucleotide	binding,	Biological	process:	
mitotic	cell	cycle	process,	nuclear	chromosome	segregation,	microtubule	cytoskeleton	organisation,	protein	
complex	assembly,		macromolecular	complex	assembly,	organelle	assembly,	Cellular	component:	cytoskeletal	part,	
microtubule,	microtubule	organising	centre,	nucleus,	cytoplasmic	part	
64:	ARPC5	
Actin	related	protein	
2/3	complex	subunit	5	 5.6791	 1.68E-05	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	Biological	process:	immune	system	
process,	response	to	stress,	response	to	stimulus,	Cellular	component:	cytoskeletal	part,	cytosol,	extracellular	
exosome,	cytoplasm,	cytoplasmic	part	
65:	
PCMTD1	
Protein-L-isoaspartate	
(D-aspartate)	O-
methyltransferase	
domain	containing	1	 5.56717	 2.21E-06	
Molecular	function:	methyltransferase	activity,	Biological	process:	macromolecule	metabolic	process,	protein	
metabolic	process,	cytoplasm	
66:	VPS35	
VPS35	retromer	
complex	component	 5.56603	 1.10E-07	 Molecular	function:	protein	binding,	Cellular	component:	cytosol,	extracellular	exosome,	cytoplasmic	part	
67:	IGFBP4	
Insulin	like	growth	
factor	binding	protein	
4	 5.56553	 4.90E-05	
Molecule	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	DNA	metabolic	process,	
protein	metabolic	process,	nucleobase-containing	compound	metabolic	process,	nitrogen	compound	metabolic	
process,	response	to	stress,	response	to	stimulus,	Cellular	component:	mitochondrion	
68:	GLS	 Glutaminase	 5.56171	 1.18E-06	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	
compound	metabolic	process,	organic	acid	biosynthetic	process,	protein	complex	assembly,	macromolecular	
complex	assembly,	small	molecule	biosynthetic	process,	nitrogen	compound	metabolic	process,	Cellular	
component:		mitochondrial	matrix,	cytosol,	mitochondrion,	cytoplasmic	part	
69:	CD44	 CD44	molecule	 5.5397	 2.74E-07	
Molecule	function:	macromolecular	complex	binding,	protein	binding,	Biological	process:	macromolecule	
metabolic	process,	nitrogen	compound	metabolic	process,	carbohydrate	derivative	metabolic	process,	single	
organismal	cell-cell	adhesion,	leukocyte	migration,	immune	system	process,	response	to	stress,	response	to	
stimulus,	Cellular	component:	extracellular	exosome,	Golgi	apparatus,	cytoplasm,	cytoplasmic	part	
70:	
HS.137971	
AV737943	CB		cDNA	
clone	CBDAEG06	5	 5.484	 4.01E-05	 		
71:	
TMEM123	
Transmembrane	
protein	123	 5.4777	 4.67E-05	 Molecule	function:	protein	binding	
72:	VIM	 Vimentin	 5.45161	 0.000367062	
Molecule	function:	macromolecular	complex	binding,	protein	binding,	Biological	process:	programmed	cell	death,	
Cellular	component:	cytoskeletal	part,	extracellular	exosome,	cytosol,	cytoplasm,	cytoplasmic	part	
73:	
STAMBPL1	
STAM	binding	protein	
like	1	 5.44399	 2.58E-06	
Molecule	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	
process	
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74:	VPS36	
Vacuolar	protein	
sorting	36	homolog	 5.40895	 2.58E-06	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	
compound	metabolic	process,	organelle	assembly,	nitrogen	compound	metabolic	process,	Cellular	component:	
cytosol,	extracellular	exosome,	nucleus,	nuclear	part,	cytoplasmic	part	
75:	ERMP1	
Endoplasmic	
reticulum	
metallopeptidase	1	 5.39849	 2.32E-05	
Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	Cellular	component:	cytoplasmic	
part	
76:	HADH	
Hydroxyacyl-CoA	
dehydrogenase	 5.39035	 1.77E-06	
Molecular	function:	nucleotide	binding,	Biological	process:	response	to	stimulus,	Cellular	component:	
nucleoplasm,	mitochondrial	membrane,	mitochondrial	matrix,	mitochondrion,	nuclear	part,	cytoplasm,	
cytoplasmic	part	
77:	FVT1	
3-ketodihydrosphing-
osine	reductase	
(KDSR)	 5.38077	 1.07E-05	 Biological	process:	nitrogen	compound	metabolic	process,	Cellular	component:	cytoplasmic	part	
78:	DLGAP5	
Discs	large	homolog	
associated	protein	5	 5.35266	 0.000629465	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	
process,	phosphate-containing	compound	metabolic	process,	mitotic	cell	cycle	process,	mitotic	nuclear	division,	
cell	cycle	phase	transition,	Cellular	component:	cytoskeletal	part,	microtubule	organising	centre,	nucleus,	
cytoplasm	
79:	ZNF512	
Zinc	finger	protein	
512	 5.33919	 8.48E-08	
Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	compound	metabolic	process,	
nitrogen	compound	metabolic	process,	Cellular	component:	nucleus	
80:	CAPN12	 Calpain	12	 5.32312	 9.13E-07	 Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process	
81:	
TMEM14D	
Transmembrane	
protein	14D	 5.29218	 1.70E-05	 		
82:	DYNLL1	
Dynein	light	chain	
LC8-type	1	 5.28435	 4.48E-06	
Molecule	function:	protein	binding,	protein	homodimerisation	activity,	enzyme	binding,	enzyme	regulator	activity,	
Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	compound	metabolic	process,	
nitrogen	compound	metabolic	process,	mitotic	cell	cycle	process,	programmed	cell	death,	immune	system	process,	
protein	glycosylation,	mitochondrial	membrane	organisation,	Cellular	component:	kinetochore,	cytoskeletal	part,	
microtubule,	microtubule	organising	centre,	mitochondrion,	nucleus,	extracellular	exosome,	cytosol,	nuclear	part,	
cytoplasm,	cytoplasmic	part	
83:	
TMEM106B	
Transmembrane	
protein	106B	 5.27221	 7.65E-06	 Molecule	function:	protein	binding,	Cellular	component:	extracellular	exosome,	cytoplasmic	part	
84:	IL32	 Interleukin	32	 5.26873	 0.00557325	
Molecular	function:	protein	binding,	Biological	process:	immune	system	process,	response	to	stress,	response	to	
stimulus	
85:	KRCC1	
Lysine-rich	coiled-coil	
1	 5.25385	 2.10E-07	 		
86:	E2F3	
E2F	transcription	
factor	3	 5.20549	 4.59E-05	
Molecule	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	
compound	metabolic	process,	nitrogen	compound	metabolic	process,	Cellular	component:	nucleoplasm,	nucleus,	
nuclear	part,	cytoplasm	
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87:	
SLC44A1	
Solute	carrier	family	
44	member	1	 5.1638	 3.97E-08	
Biological	process:	phosphate-containing	compound	metabolic	process,	nitrogen	compound	metabolic	process,	
small	molecule	biosynthetic	process,	Cellular	component:	nucleoplasm,	mitochondrial	membrane,	mitochondrion,	
extracellular	exosome,	nuclear	part,	cytoplasmic	part	
88:	AXIN2	 Axin	2	 5.15447	 6.47E-05	
Molecule	function:	protein	binding,	enzyme	binding,	enzyme	regulator	activity,	GTPase	regulator	activity,	
Biological	process:	macromolecule	metabolic	process,	DNA	metabolic	process,	nucleobase-containing	compound	
metabolic	process,	nitrogen	compound	metabolic	process,	response	to	stimulus,	Cellular	component:	
nucleoplasm,	cytoskeletal	part,	microtubule,	microtubule	organising	centre,	nucleus,	cytosol,	nuclear	part,	Golgi	
apparatus,	cytoplasm,	cytoplasmic	part	
89:	PRDM8	 PR	domain	8	 5.13204	 0.000188923	
Molecule	function:	methyltransferase	activity,	macromolecular	complex	binding,	protein	binding,	Biological	
process:	macromolecule	metabolic	process,	protein	metabolic	process,	nucleobase-containing	compound	
metabolic	process,	nitrogen	compound	metabolic	process,	Cellular	component:	nucleus	
90:	
WDR40A	
DDB1	and	CUL4	
associated	factor	12	
(DCAF12)	 5.11179	 5.29E-06	
Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	Cellular	component:	cytoskeletal	
part,	microtubule	organising	centre,	transferase	complex,	cytoplasm	
91:	EGR2	
Early	growth	response	
2	 5.11131	 6.81E-05	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	enzyme	binding,	Biological	process:	
macromolecule	metabolic	process,	protein	metabolic	process,	nucleobase-containing	compound	metabolic	
process,	response	to	stimulus,	nitrogen	compound	metabolic	process,	leukocyte	activation,	Cellular	component:	
nucleus,	cytoplasm	
92:	
CABLES1	
Cdk5	and	Abl	enzyme	
subtrate	1	 5.09437	 6.58E-05	 Molecule	function:	protein	binding,	Cellular	component:	nucleus,	cytosol,	cytoplasmic	part	
93:	EGR1	
Early	growth	response	
1	 5.09399	 0.00284043	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	macromolecule	metabolic	process,	
nucleobase-containing	compound	metabolic	process,	leukocyte	activation,	single	organismal	cell-cell	adhesion,	
lymphocyte	activation,	response	to	stress,	immune	system	process,	response	to	stimulus,	nitrogen	compound	
metabolic	process,	Cellular	component:	nucleoplasm,	nucleus,	nuclear	part,	cytoplasm	
94:	PAICS	
Phosphoribosylaminoi
midazole	carboxylase;	
phosphoribosylaminoi
midazolesuccinocarbo
xamide	synthase	 5.06235	 6.64E-07	
Molecular	function:	protein	binding,	nucleotide	binding,	lyase	activity,	Biological	process:	nucleobase-containing	
compound	metabolic	process,	phosphate-containing	compound	metabolic	process,	nucleobase	metabolic	process,	
carbohydrate	derivative	metabolic	process,	nitrogen	compound	metabolic	process,	Cellular	component:	cytosol,	
extracellular	exosome,	cytoplasmic	part	
95:	CYP1B1	
Cytochrome	P450	
family	1	subfamily	B	
member	1	 5.06169	 0.000108869	
Biological	process:	single	organismal	cell-cell	adhesion,	response	to	stress,	response	to	stimulus,	nitrogen	
compound	metabolic	process,	Cellular	component:	mitochondrion,	cytoplasmic	part	
96:	NCAPD2	
Non-SMC	condensin	I	
complex	subunit	D2	 5.03131	 0.000376468	
Molecule	function:	macromolecular	complex	binding,	protein	binding,	Biological	process:	mitotic	cell	cycle	
process,	Cellular	component:	nucleoplasm,	nuclear	chromosome	part,	condensin	complex,	nucleus,	cytosol,	
nuclear	part,	cytoplasm,	cytoplasmic	part	
97:	NCAPG	
Non-SMC	condensin	I	
complex	subunit	G	 5.02363	 0.00196847	
Molecular	function:	protein	binding,	Biological	process:	mitotic	cell	cycle	process,	Cellular	component:	condensin	
complex,	cytoskeletal	part,	microtubule	organising	centre,	cytosol,	nucleus,	cytoplasm,	cytoplasmic	part	
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98:	CD27	 CD27	molecule	 4.98659	 0.00297746	
Molecular	function:	protein	binding,	enzyme	regulator	activity,	cysteine-type	endopeptidase	inhibitor	activity	
involved	in	apoptotic	process,	Biological	process:	immune	system	process,	response	to	stress,	response	to	
stimulus,	Cellular	component:	extracellular	exosome,	nucleus	
99:	MRPS31	
Mitochondrial	
ribosomal	protein	S31	 4.9406	 4.61E-07	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	
process,	nitrogen	compound	metabolic	process,	Cellular	component:	nucleolus,	mitochondrial	membrane,	
mitochondrion,	nuclear	part,	cytoplasmic	part	
100:	SPINK2	
Serine	peptidase	
inhibitor,	Kazal	type	2	 4.92774	 1.11E-05	 Molecule	function:	protein	binding,	enzyme	regulator	activity,	Cellular	component:	cytoplasmic	part	
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1:	RCBTB2	
RCC1	and	BTB	
domain	containing	
protein	2	 14.8963	 7.98E-07	 Molecular	function:	protein	binding,	Cellular	component:	cytoplasmic	part	
2:	AMICA1	
Junction	adhesion	
molecule	like	(JAML)	 14.5685	 1.38E-06	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	protein	homodimerisation	activity,	Biological	
process:	leukocyte	activation,	single	organismal	cell-cell	adhesion,	lymphocyte	activation,	leukocyte	chemotaxis,	immune	
system	process	
3:	MAL	
Mal,	T-cell	
differentiation	
protein	 12.9739	 2.96E-07	 Molecular	function:	protein	binding,	Biological	process:	programmed	cell	death,	Cellular	component:	cytoplasmic	part	
4:	TOP2A	
Topoisomerase	
(DNA)	II	alpha	 11.3489	 6.03E-05	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	protein	homodimerisation	activity,	enzyme	
binding,	nucleotide	binding,	nucleic	acid	binding,	Biological	process:	macromolecule	metabolic	process,	DNA	metabolic	
process,	protein	metabolic	process,	nucleobase-containing	compound	metabolic	process,	mitotic	cell	cycle	process,	
nuclear	chromosome	segregation,	response	to	stress,	response	to	stimulus,	nitrogen	compound	metabolic	process,	
Cellular	component:	nucleoplasm,	nucleolus,	cytoskeletal	part,	nucleus,	nuclear	part,	cytoplasmic	part	
5:	PCMT1	
Protein-L-
isoaspartate	(D-
aspartate)	O-
methyltransferase	 9.72577	 1.64E-05	
Molecular	function:	methyltransferase	activity,	protein	binding,	Biological	process:	macromolecule	metabolic	process,	
protein	metabolic	process,	methylation,	Cellular	component:	cytosol,	extracellular	exosome,	cytoplasm,	cytoplasmic	
part	
6:	DCAF7	
DDB1	and	CUL4	
associated	factor	7	 9.64605	 8.49E-09	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	
Cellular	component:	nucleoplasm,	transferase	complex,	nuclear	part,	cytoplasm	
7:	GIMAP4	
GTPase,	IMAP	family	
member	4	 9.44458	 2.17E-05	 Molecular	function:	nucleotide	binding,	Cellular	component:	cytosol,	cytoplasmic	part	
8:	CDC20	 Cell	division	cycle	20	 9.36682	 5.08E-05	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	macromolecule	metabolic	process,	protein	
metabolic	process,	electron	transport	chain,	mitotic	cell	cycle	process,	mitotic	nuclear	division,	cell	cycle	phase	
transition,	Cellular	component:	nucleoplasm,	cytoskeletal	part,	microtubule	organising	centre,	transferase	complex,	
cytosol,	nucleus,	nuclear	part,	cytoplasm,	cytoplasmic	part	
9:	KIT	
KIT	proto-oncogene	
receptor	tyrosine	
kinase	 9.20117	 6.47E-06	
Molecular	function:	protein	binding,	protein	homodimerisation	activity,	enzyme	binding,	nucleotide	binding,	Biological	
process:	macromolecule	metabolic	process,	protein	metabolic	process,	phosphate-containing	compound	metabolic	
process,	programmed	cell	death,	leukocyte	activation,	cell	activation	involved	in	immune	response,	single	organismal	
cell-cell	adhesion,	lymphocyte	activation,	leukocyte	chemotaxis,	immune	system	process,	response	to	stress,	response	to	
stimulus,	carbohydrate	derivative	metabolic	process,	nitrogen	compound	metabolic	process,	Cellular	component:	
cytoplasmic	part	
10:	RNF144	
Ring	finger	protein	
144A	 8.63229	 4.53E-08	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	macromolecule	metabolic	process,	protein	
metabolic	process,	Cellular	component:	transferase	complex,	cytoplasmic	part	
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11:	DNCL1	
Dynein	light	chain	
LC8-type	1	 8.30258	 3.73E-06	
Molecular	function:	protein	binding,	protein	homodimerisation	activity,	enzyme	binding,	Biological	process:	
macromolecule	metabolic	process,	protein	metabolic	process,	nucleobase-containing	compound	metabolic	process,	
mitotic	cell	cycle	process,	cell	cycle	phase	transition,	programmed	cell	death,	antigen	processing	and	presentation	of	
peptide	or	polysaccharide	antigen	via	MHC	class	II,	nitrogen	compound	metabolic	process,	Cellular	component:	
kinetochore,	cytoskeletal	part,	microtubule,	microtubule	organising	centre,	cytosol,	extracellular	exosome,	immune	
system	process,	mitochondrion,	nucleus,	nuclear	part,	cytoplasm,	cytoplasmic	part	
12:	AARS	
Alanyl-tRNA	
synthetase	 8.1686	 2.80E-07	
Molecular	function:	nucleotide	binding,	nucleic	acid	binding,	Biological	process:	macromolecule	metabolic	process,	
nucleobase-containing	compound	metabolic	process,	response	to	stress,	response	to	stimulus,	nitrogen	compound	
metabolic	process,	Cellular	component:	cytosol,	extracellular	exosome,	mitochondrion,	cytoplasm,	cytoplasmic	part	
13:	LPXN	 Leupaxin	 8.06795	 2.14E-05	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	
compound	metabolic	process,	protein	complex	assembly,	macromolecular	complex	assembly,	nitrogen	compound	
metabolic	process,	Cellular	component:	cytoskeletal	part,	nucleus,	cytoplasm,	cytoplasmic	part	
14:	
PRAGMIN	
Homolog	of	rat	
pragma	of	Rnd2	 7.99185	 1.01E-06	
Molecular	function:	nucleotide	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	
process,	phosphate-containing	compound	metabolic	process	
15:	IL32	 Interleukin	32	 7.71129	 0.00204466	
Molecular	function:	protein	binding,	Biological	process:	immune	system	process,	response	to	stress,	response	to	
stimulus	
16:	RAB10	
RAB10,	member	RAS	
oncogene	family	 7.64879	 1.61E-07	
Molecular	function:	protein	binding,	nucleotide	binding,	Biological	process:	immune	system	process,	response	to	
stimulus,	Cellular	component:	extracellular	exosome,	immune	system	process,	cytoplasmic	part	
17:	MMP25	
Matrix	
metallopeptidase	25	 7.27246	 2.78E-07	
Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	response	to	stress,	response	to	
stimulus	
18:	DYNLL1	
Dynein	light	chain	
LC8-type	1	 7.2536	 1.61E-06	
Molecular	function:	protein	binding,	protein	homodimerisation	activity,	enzyme	binding,	Biological	process:	
macromolecule	metabolic	process,	protein	metabolic	process,	nucleobase-containing	compound	metabolic	process,	
mitotic	cell	cycle	process,	cell	cycle	phase	transition,	programmed	cell	death,	antigen	processing	and	presentation	of	
peptide	or	polysaccharide	antigen	via	MHC	class	II,	immune	system	process,	response	to	stimulus,	nitrogen	compound	
metabolic	process,	Cellular	component:	kinetochore,	cytoskeletal	part,	microtubule,	microtubule	organising	centre,	
cytosol,	extracellular	exosome,	mitochondrion,	nucleus,	nuclear	part,	cytoplasm,	cytoplasmic	part	
19:	
S100A11	
S100	calcium	binding	
protein	A11	 7.19444	 4.22E-07	
Molecular	function:	protein	binding,	protein	homodimerisation	activity,	Cellular	component:	extracellular	exosome,	
nucleus,	cytoplasm	
20:	HMMR	
Hyaluronan	
mediated	motility	
receptor	 7.14568	 3.86E-05	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	carbohydrate	derivative	
metabolic	process,	nitrogen	compound	metabolic	process,	Cellular	component:	cytoplasm	
21:	GPR68	
G	protein-coupled	
receptor	68	 7.13869	 9.20E-08	 Biological	process:	response	to	stress,	response	to	stimulus	
22:	NUSAP1	
Nucleolar	and	
spindle	assocoated	
protein	1	 6.89922	 0.000935215	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	nucleic	acid	binding,	Biological	process:	mitotic	
cell	cycle	process,	mitotic	nuclear	division,	cytokinesis,	nuclear	chromosome	segregation,	spindle	localisation,	
microtubule	cytoskeleton	organisation,	Cellular	component:	nucleolus,	cytoskeletal	part,	microtubule,	nucleus,	nuclear	
part,	cytoplasm	
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23:	ARPC5	
Actin	related	protein	
2/3	complex	subunit	
5	 6.88455	 9.13E-06	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	Biological	process:	immune	system	process,	
response	to	stress,	response	to	stimulus,	Cellular	component:	cytoskeletal	part,	cytosol,	extracellular	exosome,	
cytoplasm,	cytoplasmic	part	
24:	
ST6GAL1	
ST6	beta-galactoside	
alpha-2,6-
sialyltransferase	1	 6.83557	 1.06E-05	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	
immune	system	process,	response	to	stimulus,	carbohydrate	derivative	metabolic	process,	Cellular	component:	
extracellular	exosome,	cytoplasmic	part	
25:	P2RY5	
Lysophosphatidic	
acid	receptor	6	
(LPAR6)	 6.78506	 2.13E-07	 		
26:	
GNPDA1	
Glucosamine-6-
phosphate	
deaminase	1	 6.76847	 3.39E-06	
Molecular	function:	protein	binding,	Biological	process:	carbohydrate	derivative	metabolic	process,	Cellular	
component:	extracellular	exosome,	cytoplasm	
27:	CEP55	
Centrosomal	protein	
55	 6.75555	 0.000315109	
Molecular	function:	protein	binding,	Biological	process:	mitotic	cell	cycle	process,	cytokinesis,	cell	separation	after	
cytokinesis,	Cellular	component:	cytoskeletal	part,	microtubule	organising	centre,	cytoplasmic	part	
28:	SLAMF6	
SLAM	family	member	
6	 6.72318	 6.46E-05	
Molecular	function:	protein	binding,	Biological	process:	immune	system	process,	response	to	stress,	response	to	
stimulus,	Cellular	component:	extracellular	exosome	
29:	LTB	 Lymphotoxin	beta	 6.70733	 2.50E-08	
Molecular	function:	protein	binding,	Biological	process:	immune	system	process,	macromolecule	metabolic	process,	
response	to	stimulus	
30:	
RNF144A	
Ring	finger	protein	
144A	 6.68922	 8.70E-08	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	macromolecule	metabolic	process,	protein	
metabolic	process,	Cellular	component:	transferase	complex,	cytoplasmic	part	
31:	PROSC	
Proline	synthetase	
co-transcribed	
homolog	(bacterial)	 6.67134	 5.67E-08	 Cellular	component:	extracellular	exosome,	mitochondrion,	cytoplasm,	cytoplasmic	part	
32:	ACADM	
Acyl-CoA	
dehydrogenase,	C-4	
to	C-12	straight	chain	 6.56629	 2.09E-09	
Molecular	function:	protein	binding,	nucleotide	binding,	Biological	process:	macromolecule	metabolic	process,	organic	
acid	biosynthetic	process,	protein	complex	assembly,	macromolecular	complex	assembly,	small	molecule	biosynthetic	
process,	response	to	stress,	response	to	stimulus,	nitrogen	compound	metabolic	process,	Cellular	component:	
mitochondrial	matrix,	extracellular	exosome,	mitochondrion,	nucleus,	cytoplasmic	part	
33:	
LOC730278	
Similar	to	putative	
S100	calcium-binding	
protein	A11	
pseudogene	 6.566	 1.40E-07	 		
34:	ASXL2	
Additional	sex	combs	
like	2,	transcriptional	
regulator	 6.41224	 1.41E-06	
Molecular	function:	protein	binding,	nucleic	acid	binding,	Biological	process:	macromolecule	metabolic	process,	
nucleobase-containing	compound	metabolic	process,	nitrogen	compound	metabolic	process,	Cellular	component:	
nucleoplasm,	nuclear	chromosome	part,	chromatin,	nuclear	part	
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35:	DAD1	
Defender	against	cell	
death	1	 6.39765	 4.23E-05	
Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	programmed	cell	death,	response	to	
stimulus,	Cellular	component:		transferase	complex,	extracellular	exosome,	cytoplasmic	part	
36:	TYMS	
Thymidylate	
synthetase	 6.38282	 0.00122374	
Molecular	function:	methyltransferase	activity,	protein	binding,	protein	homodimerisation	activity,	nucleotide	binding,	
nucleic	acid	binding,	Biological	process:	macromolecule	metabolic	process,	DNA	metabolic	process,	coenzyme	metabolic	
process,	nucleobase-containing	compound	metabolic	process,	phosphate-containing	compound	metabolic	process,	
mitotic	cell	cycle	process,	cell	cycle	phase	transition,	nucleobase	metabolic	process,	glycosyl	compound	biosynthetic	
process,	methylation,	response	to	stimulus,	carbohydrate	derivative	metabolic	process,	nitrogen	compound	metabolic	
process,	Cellular	component:	nucleoplasm,	nucleolus,	mitochondrial	membrane,	mitochondrial	matrix,	cytosol,	
mitochondrion,	nucleus,	nuclear	part,	cytoplasm,	cytoplasmic	part	
37:	GLS	 Glutaminase	 5.96231	 9.32E-07	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	
compound	metabolic	process,	organic	acid	biosynthetic	process,	protein	complex	assembly,	macromolecular	complex	
assembly,	small	molecule	biosynthetic	process,	nitrogen	compound	metabolic	process,	Cellular	component:	
mitochondrial	matrix,	cytosol,	mitochondrion,	cytoplasmic	part	
38:	ASPM	
Abnormal	spindle	
microtubule	
assembly	 5.94248	 0.000212314	
Molecular	function:	protein	binding,	Biological	process:	mitotic	cell	cycle	process,	mitotic	nuclear	division,	spindle	
localisation,	microtubule	cytoskeleton	organisation,	protein	complex	assembly,	macromolecular	complex	assembly,	
organelle	assembly,	Cellular	component:	cytoskeletal	part,	nucleus,	cytoplasm	
39:	
WDR40A	
DDB1	and	CUL4	
associated	factor	12	
(DCAF12)	 5.91365	 3.20E-06	
Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	Cellular	component:	cytoskeletal	part,	
microtubule	organising	centre,	transferase	complex,	cytoplasm	
40:	CYP1B1	
Cytochrome	P450	
family	1	subfamily	B	
member	1	 5.83416	 6.77E-05	
Biological	process:	single	organismal	cell-cell	adhesion,	response	to	stress,	response	to	stimulus,	nitrogen	compound	
metabolic	process,	Cellular	component:	mitochondrion,	cytoplasmic	part	
41:	VPS35	
VPS35	retromer	
complex	component	 5.78817	 9.62E-08	 Molecular	function:	protein	binding,	Cellular	component:	cytosol,	extracellular	exosome,	cytoplasmic	part	
42:	KRCC1	
Lysine-rich	coiled-coil	
1	 5.73001	 1.55E-07	 Biological	process:	cellular	component	disassembly	
43:	C5orf51	
Chromosome	5	open	
reading	frame	51	 5.66271	 6.28E-08	 		
44:	
PCMTD1	
Protein-L-
isoaspartate	(D-
aspartate)	O-
methyltransferase	
domain	containing	1	 5.65954	 2.09E-06	
Molecular	function:	methyltransferase	activity,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	
process,	methylation,	Cellular	component:	cytoplasm	
45:	STS-1	
Ubiquitin	associated	
and	SH3	domain	
containing	B	
(UBASH3B)	 5.64494	 1.35E-06	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	
phosphate-containing	compound	metabolic	process,	Cellular	component:	nucleus,	cytoplasm	
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46:	WASPIP	
WAS/WASL	
interacting	protein	
family	member	1	
(WIPF1)	 5.58938	 3.33E-05	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	Biological	process:	protein	complex	assembly,	
macromolecular	complex	assembly,	immune	system	process,	response	to	stress,	response	to	stimulus,	Cellular	
component:	cytoskeletal	part,	cytosol,	cytoplasmic	part	
47:	
FLJ14213	
hypothetical	protein	
FLJ1423	
(LOC2204812)	 5.54835	 3.94E-05	 		
48:	CSTB	 Cystatin	B	 5.53457	 3.27E-05	
Molecular	function:	protein	binding,	enzyme	binding,	nucleic	acid	binding,	Cellular	component:	nucleolus,	extracellular	
exosome,	nuclear	part,	cytoplasm	
49:	M6PR	
Mannose-6-
phosphate	receptor,	
cation	dependent	 5.52317	 1.58E-06	 Cellular	component:	cytoplasmic	part	
50:	PRDX1	 Peroxiredoxin	1	 5.51757	 6.48E-07	
Molecular	function:	peroxidase	activity,	protein	binding,	nucleic	acid	binding,	Biological	process:	macromolecule	
metabolic	process,	nucleobase-containing	compound	metabolic	process,	natural	killer	cell	mediated	cytotoxicity,	
immune	system	process,	response	to	stress,	response	to	stimulus,	nitrogen	compound	metabolic	process,	Cellular	
component:	cytosol,	extracellular	exosome,	mitochondrion,	nucleus,	cytoplasm,	cytoplasmic	part	
51:	EGR2	
Early	growth	
response	2	 5.48042	 5.36E-05	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	enzyme	binding,	nucleic	acid	binding,	Biological	
process:	macromolecule	metabolic	process,	protein	metabolic	process,	nucleobase-containing	compound	metabolic	
process,	response	to	stimulus,	nitrogen	compound	metabolic	process,	Cellular	component:	nucleus,	cytoplasm	
52:	PDE7B	
Phosphodiesterase	
7B	 5.47671	 0.00215294	
Biological	process:	nucleobase-containing	compound	metabolic	process,	phosphate-containing	compound	metabolic	
process,	carbohydrate	derivative	metabolic	process,	nitrogen	compound	metabolic	process,	Cellular	component:	
cytosol,	cytoplasmic	part	
53:	PRKCA	
Protein	kinase	C	
alpha	 5.46355	 1.79E-07	
Molecular	function:	protein	binding,	enzyme	binding,	nucleotide	binding,	Biological	process:	macromolecule	metabolic	
process,	protein	metabolic	process,	phosphate-containing	compound	metabolic	process,	mitotic	cell	cycle	process,	
membrane	disassembly,	nuclear	envelope	organisation,	leukocyte	chemotaxis,	immune	system	process,	response	to	
stress,	response	to	stimulus,	cellular	component	disassembly,	Cellular	component:	nucleoplasm,	mitochondrial	
membrane,	cytosol,	extracellular	exosome,	mitochondrion,	nuclear	part,	cytoplasm,	cytoplasmic	part	
54:	EGR1	
Early	growth	
response	1	 5.41798	 0.00236218	
Molecular	function:	protein	binding,	enzyme	binding,	nucleic	acid	binding,	Biological	process:	macromolecule	metabolic	
process,	nucleobase-containing	compound	metabolic	process,	leukocyte	activation,	single	organismal	cell-cell	adhesion,	
lymphocyte	activation,	response	to	stress,	immune	system	process,	response	to	stimulus,	nitrogen	compound	metabolic	
process,	Cellular	component:	nucleoplasm,	nucleus,	nuclear	part,	cytoplasm	
55:	
TMBIM4	
Transmembrane	BAX	
inhibitor	motif	
containing	4	 5.38122	 9.52E-06	 Molecular	function:	protein	binding,	Biological	process:	programmed	cell	death,	Cellular	component:	cytoplasmic	part	
56:	PTGDR	
Prostaglandin	D2	
receptor	(DP)	 5.30929	 8.29E-05	
Molecular	function:	protein	binding,	Biological	process:	nucleobase-containing	compound	metabolic	process,	response	
to	stress,	response	to	stimulus,	carbohydrate	derivative	metabolic	process,	nitrogen	compound	metabolic	process	
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57:	DLGAP5	
Discs	large	homolog	
associated	protein	5	 5.25157	 0.000669077	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	
phosphate-containing	compound	metabolic	process,	mitotic	cell	cycle	process,	mitotic	nuclear	division,	cell	cycle	phase	
transition,	Cellular	component:	cytoskeletal	part,		microtubule	organising	centre,	nucleus,	cytoplasm	
58:	C2orf42	
Chromosome	2	open	
reading	frame	42	 5.24541	 9.55E-08	 Molecular	function:	protein	binding,	Cellular	component:	nucleus,	nuclear	part	
59:	ZNF559	
Zinc	finger	protein	
559	 5.1961	 8.88E-07	
Molecular	function:	protein	binding,	nucleic	acid	binding,	Biological	process:	macromolecule	metabolic	process,	
nucleobase-containing	compound	metabolic	process,	nitrogen	compound	metabolic	process,	Cellular	component:	
nucleus	
60:	MRPS6	
Mitochondrial	
ribosomal	protein	S6	 5.16411	 1.52E-05	
Molecular	function:	protein	binding,	nucleic	acid	binding,	Biological	process:	macromolecule	metabolic	process,	protein	
metabolic	process,	macromolecular	complex	disassembly,	cellular	component	disassembly,	nitrogen	compound	
metabolic	process,	Cellular	component:	mitochondrial	membrane,	cytoplasmic	part	
61:	ZNF512	
Zinc	finger	protein	
512	 5.15244	 9.64E-08	
Molecular	function:	nucleic	acid	binding,	Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	
compound	metabolic	process,	nitrogen	compound	metabolic	process,	Cellular	component:	nucleus	
62:	VPS36	
Vacuolar	protein	
sorting	36	homolog	 5.12299	 3.13E-06	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	
compound	metabolic	process,	organelle	assembly,	nitrogen	compound	metabolic	process,	Cellular	component:	cytosol,	
extracellular	exosome,	nucleus,	cytoplasmic	part	
63:	GIMAP1	
GTPase,	IMAP	family	
member	1	 5.10032	 2.46E-05	
Molecular	function:	nucleotide	binding,	Biological	process:	leukocyte	activation,	single	organismal	cell-cell	adhesion,	
lymphocyte	activation,	immune	system	process,	Cellular	component:	cytoplasmic	part	
64:	MRPL51	
Mitochondrial	
ribosomal	protein	
L51	 5.03118	 1.48E-06	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	
macromolecular	complex	disassembly,	cellular	component	disassembly,	nitrogen	compound	metabolic	process,	Cellular	
component:	mitochondrial	membrane,	cytoplasmic	part	
65:	
TMEM106B	
Transmembrane	
protein	106B	 4.97322	 9.43E-06	 Molecular	function:	protein	binding,	Cellular	component:	extracellular	exosome,	cytoplasmic	part	
66:	
LOC439949	
PRKCQ	antisense	
RNA1	 4.96688	 8.83E-06	 		
67:	KIFC1	
Kinesin	family	
member	C1	 4.95188	 0.000715744	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	nucleotide	binding,	Biological	process:	mitotic	
cell	cycle	process,	nuclear	chromosome	segregation,	microtubule	cytoskeleton	organisation,	protein	complex	assembly,		
macromolecular	complex	assembly,	organelle	assembly,	Cellular	component:	cytoskeletal	part,	microtubule,	
microtubule	organising	centre,	nucleus,	cytoplasmic	part	
68:	CCDC56	
Cytochrome	c	
oxidase	assembly	
factor	3	(COA3)	 4.93836	 8.14E-08	
Molecular	function:	protein	binding,	Biological	process:	protein	complex	assembly,		macromolecular	complex	assembly,	
Cellular	component:	mitochondrion,	cytoplasmic	part	
69:	
HS.452445	
	mRNA;	cDNA	
DKFZp762F0616	
(from	clone	
DKFZp762F0616)	 4.89203	 4.19E-05	 		
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70:	C10orf6	
SMC5-SMC6	complex	
localization	factor	2	
(SLF2)	 4.89158	 7.41E-05	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	enzyme	binding,	Biological	process:	
macromolecule	metabolic	process,	DNA	metabolic	process,	nucleobase-containing	compound	metabolic	process,	mitotic	
nuclear	division,	DNA	repair,	response	to	stress,	response	to	stimulus,	nitrogen	compound	metabolic	process,	Cellular	
component:	chromatin,	nucleus	
71:	ZMYM6	
Zinc	finger	MYM-type	
containing	6	 4.89062	 1.10E-07	 Molecular	function:	nucleic	acid	binding,	Cellular	component:	nucleus	
72:	CHURC1	
Churchill	domain	
containing	1	 4.85609	 2.57E-06	
Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	compound	metabolic	process,	nitrogen	
compound	metabolic	process	
73:	MITD1	
Microtubule	
interacting	and	
trafficking	domain	
containing	1	 4.81158	 9.16E-07	
Molecular	function:	protein	binding,	protein	homodimerisation	activity,	Biological	process:	mitotic	cell	cycle	process,	
cytokinesis,	cell	separation	after	cytokinesis,	Cellular	component:	extracellular	exosome,	cytoplasmic	part	
74:	UGDH	
UDP-glucose	6	
dehydrogenase	 4.80403	 1.67E-07	
Molecular	function:	nucleotide	binding,	Biological	process:	macromolecule	metabolic	process,	nucleobase-containing	
compound	metabolic	process,	organic	acid	biosynthetic	process,	small	molecule	biosynthetic	process,	carbohydrate	
derivative	metabolic	process,	nitrogen	compound	metabolic	process,	Cellular	component:	nucleoplasm,	cytosol,	
extracellular	exosome,	nucleus,	nuclear	part,	cytoplasmic	part	
75:	
APBB1IP	
Amyloid	beta	
precursor	protein	
binding	family	B	
member	1	
interacting	protein	 4.74041	 1.12E-05	
Molecular	function:	protein	binding,	Biological	process:	leukocyte	activation,	cell	activation	involved	in	immune	
response,	single	organismal	cell-cell	adhesion,	lymphocyte	activation,	immune	system	process,	Cellular	component:	
cytosol,	cytoplasmic	part	
76:	TST	
Thiosulfate	
sulfurtransferase	 4.72317	 9.52E-05	
Molecular	function:	nucleic	acid	binding,	Biological	process:	nitrogen	compound	metabolic	process,	Cellular	
component:	mitochondrial	membrane,	mitochondrial	matrix,	extracellular	exosome,	mitochondrion,	cytoplasmic	part	
77:	VKORC1	
Vitamin	K	epoxide	
reductase	complex	
subunit	1	 4.71656	 4.31E-07	
Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	quinone	metabolic	process,	Cellular	
component:	cytoplasmic	part	
78:	LGALS1	
Lectin,	galactoside	
binding	soluble	1	 4.68099	 5.82E-05	
Molecular	function:	protein	binding,	protein	homodimerisation	activity,	nucleic	acid	binding,	Biological	process:	
programmed	cell	death,	leukocyte	activation,	cell	activation	involved	in	immune	response,	lymphocyte	activation,	
immune	system	process,	response	to	stress,	response	to	stimulus,	Cellular	component:	extracellular	exosome,	nucleus,	
cytoplasm	
79:	MTIF3	
Mitochondrial	
translational	
initiation	factor	3	 4.62439	 6.31E-07	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	nucleic	acid	binding,	Biological	process:	
macromolecule	metabolic	process,	protein	metabolic	process,	macromolecular	complex	disassembly,	cellular	
component	disassembly,	nitrogen	compound	metabolic	process,	Cellular	component:	mitochondrion,	cytoplasmic	part	
80:	
HS.137971	
AV737943	CB		cDNA	
clone	CBDAEG06	5	 4.60642	 7.44E-05	 		
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81:	MRPS31	
Mitochondrial	
ribosomal	protein	
S31	 4.60547	 6.03E-07	
Molecular	function:	protein	binding,	nucleic	acid	binding,	Biological	process:	macromolecule	metabolic	process,	protein	
metabolic	process,	macromolecular	complex	disassembly,	cellular	component	disassembly,	nitrogen	compound	
metabolic	process,	Cellular	component:	nucleolus,	mitochondrial	membrane,	mitochondrion,	nuclear	part,	cytoplasmic	
part	
82:	
METTL13	
Methyltransferase	
like	13	 4.57484	 2.50E-08	 Molecular	function:	methyltransferase	activity,	protein	binding,	Biological	process:	methylation	
83:	HADH	
Hydroxyacyl-CoA	
dehydrogenase	 4.572	 3.24E-06	
Molecular	function:	nucleotide	binding,	Biological	process:	response	to	stimulus,	Cellular	component:	nucleoplasm,	
mitochondrial	membrane,	mitochondrial	matrix,	mitochondrion,	nuclear	part,	cytoplasm,	cytoplasmic	part	
84:	
NDUFAF3	
NADH:ubiquinone	
oxioreductase	
complex	assembly	
factor	3	 4.57131	 1.39E-05	
Molecular	function:	protein	binding,	Biological	process:	electron	transport	chain,	protein	complex	assembly,	
macromolecular	complex	assembly,	Cellular	component:	mitochondrial	membrane,	nucleus,	cytoplasmic	part	
85:	GLO1	 Glyoxalase	I	 4.56098	 2.54E-05	
Molecular	function:	lyase	activity,	Biological	process:	nitrogen	compound	metabolic	process,	Cellular	component:	
cytosol,	extracellular	exosome,	cytoplasm,	cytoplasmic	part	
86:	CAPG	
Capping	actin	
protein,	gelsolin	like	 4.50297	 4.39E-05	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	Biological	process:	protein	complex	assembly,		
macromolecular	complex	assembly,	cellular	component	disassembly,	Cellular	component:	nucleoplasm,	nucleolus,	
cytoskeletal	part,	extracellular	exosome,	nucleus,	nuclear	part,	cytoplasm,	cytoplasmic	part	
87:	DNAJA3	
DnaJ	heat	shock	
protein	family	
(Hsp40)	member	A3	 4.4989	 0.00027884	
Molecular	function:	protein	binding,	enzyme	binding,	nucleotide	binding,	Biological	process:	macromolecule	metabolic	
process,	DNA	metabolic	process,	protein	metabolic	process,	nucleobase-containing	compound	metabolic	process,	
programmed	cell	death,	leukocyte	activation,	single	organismal	cell-cell	adhesion,	lymphocyte	activation,	immune	
system	process,	response	to	stress,	response	to	stimulus,	nitrogen	compound	metabolic	process,	Cellular	component:	
mitochondrial	matrix,	cytoskeletal	part,	transferase	complex,	cytosol,	mitochondrion,	nucleus,	cytoplasm,	cytoplasmic	
part	
88:	PRDX6	 Peroxiredoxin	6	 4.4959	 5.27E-07	
Molecular	function:	peroxidase	activity,	protein	binding,	enzyme	binding,	Biological	process:	phosphate-containing	
compound	metabolic	process,	response	to	stress,	response	to	stimulus,	Cellular	component:	cytosol,	extracellular	
exosome,	cytoplasm,	cytoplasmic	part	
89:	TAF4	
TATA-box	binding	
protein	assciated	
factor	4	 4.49378	 1.27E-06	
Molecular	function:	protein	binding,	nucleic	acid	binding,	Biological	process:	macromolecule	metabolic	process,	
nucleobase-containing	compound	metabolic	process,	nitrogen	compound	metabolic	process,	Cellular	component:	
nucleoplasm,	transferase	complex,	nuclear	part,	cytoplasm	
90:	HDHD2	
Haloacid	
dehalogenase	like	
hydrolase	domain	
containing	2	 4.47176	 5.94E-07	 Molecular	function:	protein	binding,	enzyme	binding,	Cellular	component:	extracellular	exosome	
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91:	
PAFAH1B1	
Platelet	activating	
factor	
acetylhydrolase	1b	
regulatory	subunit	1	 4.45897	 8.90E-05	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	protein	homodimerisation	activity,	enzyme	
binding,	phosphoprotein	binding,	Biological	process:	phosphate-containing	compound	metabolic	process,	mitotic	cell	
cycle	process,	mitotic	nuclear	division,	cell	cycle	phase	transition,	spindle	localisation,	membrane	disassembly,	nuclear	
envelope	organisation,	microtubule	cytoskeleton	organisation,	organelle	assembly,	cellular	component	disassembly,	
nitrogen	compound	metabolic	process,	Cellular	component:	nuclear	envelope,	kinetochore,	cytoskeletal	part,	
microtubule,	microtubule	organising	centre,	cytosol,	extracellular	exosome,	nuclear	part,	cytoplasm,	cytoplasmic	part	
92:	
LOC642975	
Transmembrane	
protein	230	
psuedogene	 4.42148	 0.00241942	 		
93:	
PECAM1	
Platelet/endothelial	
cell	adhesion	
molecule	1	 4.41349	 2.90E-07	
Molecular	function:	protein	binding,	Biological	process:	immune	system	process,	response	to	stress,	response	to	
stimulus,	Cellular	component:	extracellular	exosome,	cytoplasmic	part	
94:	
TMEM126B	
Transmembrane	
protein	126B	 4.41048	 1.40E-05	
Molecular	function:	protein	binding,	Biological	process:	electron	transport	chain,	protein	complex	assembly,	
macromolecular	complex	assembly,	Cellular	component:	mitochondrial	membrane,	cytoplasmic	part	
95:	
RASGRP1	
RAS	guanyl	releasing	
protein	1	 4.39238	 0.000123324	
Molecular	function:	protein	binding,	protein	homodimerisation	activity,	Biological	process:	macromolecule	metabolic	
process,	protein	metabolic	process,	phosphate-containing	compound	metabolic	process,	leukocyte	activation,	cell	
activation	involved	in	immune	response,	protein	complex	assembly,	macromolecular	complex	assembly,	immune	system	
process,	response	to	stress,	response	to	stimulus,	Cellular	component:	cytosol,	cytoplasmic	part	
96:	HCP5	
HLA	complex	P5	
(non-protein	
encoding)	 4.39231	 2.30E-05	 		
97:	CCNB2	 Cyclin	B2	 4.3901	 0.00128209	
Molecular	function:	protein	binding,	Biological	process:	mitotic	cell	cycle	process,	mitotic	nuclear	division,	cell	cycle	
phase	transition,	membrane	disassembly,	nuclear	envelope	organisation,	lymphocyte	homeostasis,	immune	system	
process,	cellular	component	disassembly,	Cellular	component:	nucleoplasm,	cytoskeletal	part,	microtubule	organising	
centre,	cytosol,	nucleus,	nuclear	part,	cytoplasmic	part	
98:	FLI1	
Fli-1	proto-oncogene,	
ETS	transcription	
factor	 4.38579	 1.90E-05	
Molecular	function:	macromolecular	complex	binding,	protein	binding,	nucleic	acid	binding,	Biological	process:	
macromolecule	metabolic	process,	nucleobase-containing	compound	metabolic	process,	Cellular	component:	nucleus	
99:	USO1	
USO1	vesicle	
transport	factor	 4.36513	 2.10E-05	
Molecular	function:	protein	binding,	nucleic	acid	binding,	Biological	process:	macromolecule	metabolic	process,	protein	
metabolic	process,	vesicle	coating,	protein	complex	assembly,	macromolecular	complex	assembly,	nitrogen	compound	
metabolic	process,	Cellular	component:	nucleolus,	cytosol,	nuclear	part,	cytoplasmic	part	
100:	GPR18	
G	protein-coupled	
receptor	18	 4.35971	 2.30E-06	 		
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1:	EBI2	
G	protein-coupled	
receptor	183	
(GPR183)	 22.8741	 1.49E-07	
Molecular	function:	signalling	receptor	activity,	Biological	process:	immune	system	process,	cell	activation	involved	in	
immune	response,	cytokine	production	involved	in	immune	response,	adaptive	immune	response,	leukocyte	activation,	
lymphocyte	activation,	lymphocyte	differentiation,	cell	differentiation,	regulation	of	biological	process,	positive	
regulation	of	cellular	process,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	metabolic	process,	
positive	regulation	of	immune	system	process,	positive	regulation	of	signalling,	regulation	of	cell	proliferation,	regulation	
of	cell	communication,	regulation	of	cell	activation,	regulation	of	leukocyte	activation,	regulation	of	macromolecule	
metabolic	process,	response	to	stimulus,	Cellular	component:	membrane	part,	intrinsic	component	of	membrane	
2:	GZMK	 Granzyme	K	 16.2852	 2.69E-06	 		
3:	CSDA	
Y-box	binding	protein	
3	(YBX3)	 11.6081	 5.46E-06	
Biological	process:	anatomical	structure	development,	regulation	of	biological	process,	positive	regulation	of	cellular	
process,	positive	regulation	of	developmental	process,	positive	regulation	of	metabolic	process,	negative	regulation	of	
developmental	process,	regulation	of	cell	communication,	regulation	of	cell	death,	negative	regulation	of	cellular	
process,	regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	
response	to	stimulus,	negative	regulation	of	signalling,	response	to	stimulus,	response	to	organic	substance	
4:	IL7R	
Interleukin	7	
receptor	 9.608	 0.00147383	
Molecular	function:	signalling	receptor	activity,	Biological	process:		immune	system	process,	immunoglobulin	
production,	adaptive	immune	response,	leukocyte	activation,	lymphocyte	activation,	lymphocyte	differentiation,	
anatomical	structure	morphogenesis,	anatomical	structure	development,		cell	differentiation,	regulation	of	biological	
process,	homeostatic	process,	positive	regulation	of	cellular	process,		positive	regulation	of	developmental	process,	
positive	regulation	of	metabolic	process,	positive	regulation	of	immune	system	process,	regulation	of	cell	differentiation,	
regulation	of	cell	adhesion,	regulation	of	cell	activation,	regulation	of	haemopoiesis,	negative	regulation	of	immune	
system	process,	regulation	of	leukocyte	activation,	regulation	of	immune	effector	process,	regulation	of	macromolecule	
metabolic	process,	negative	regulation	of	response	to	stimulus,	cell	adhesion,	response	to	stimulus,	cell	proliferation,	
Cellular	component:	membrane	part,	intrinsic	component	of	membrane,	side	of	membrane	
5:	HOXA5	 Homeobox	A5	 8.06554	 2.05E-05	
Biological	process:	immune	system	process,	anatomical	structure	morphogenesis,	anatomical	structure	development,	
cell	differentiation,	pattern	specification	process,	regulation	of	biological	process,	regulation	of	homeostatic	process,	
positive	regulation	of	cellular	process,	positive	regulation	of	developmental	process,	positive	regulation	of	metabolic	
process,	positive	regulation	of	immune	system	process,	regulation	of	cell	differentiation,	negative	regulation	of	
developmental	process,	regulation	of	cell	proliferation,	regulation	of	cell	death,	negative	regulation	of	cellular	process,	
regulation	of	haemopoiesis,	negative	regulation	of	immune	system	process,	regulation	of	macromolecule	metabolic	
process,	regulation	of	biosynthetic	process,	cell	motility	
6:	FOXC1	 Forkhead	box	C1	 7.30239	 0.000245601	
Biological	process:	immune	system	process,	anatomical	structure	morphogenesis,	anatomical	structure	development,	
cell	differentiation,	pattern	specification	process,	regulation	of	biological	process,	homeostatic	process,	positive	
regulation	of	cellular	process,	positive	regulation	of	developmental	process,	positive	regulation	of	metabolic	process,	
positive	regulation	of	immune	system	process,	regulation	of	cell	differentiation,	negative	regulation	of	developmental	
process,	regulation	of	cell	death,	negative	regulation	of	cellular	process,	regulation	of	haemopoiesis,	regulation	of	
macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	extracellular	structure	organisation,	cell	
proliferation,	cell	motility	
7:	HAPLN3	
Hyaluronan	and	
proteoglycan	link	
protein	3	 6.43253	 4.47E-05	 Biological	process:	anatomical	structure	development,	cell	adhesion	
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8:	PRDM8	 PR	domain	8	 6.42037	 9.20E-05	
Biological	process:	anatomical	structure	morphogenesis,	anatomical	structure	development,	regulation	of	biological	
process,	negative	regulation	of	cellular	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	
biosynthetic	process	
9:	AXIN2	 Axin	2	 6.38678	 3.20E-05	
Biological	process:	anatomical	structure	morphogenesis,	anatomical	structure	development,	cell	differentiation,	pattern	
specification	process,	regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	
developmental	process,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	
regulation	of	signalling,	regulation	of	cell	differentiation,	negative	regulation	of	developmental	process,	regulation	of	cell	
proliferation,	regulation	of	cell	communication,	regulation	of	cell	death,	negative	regulation	of	cellular	process,	
regulation	of	macromolecule	metabolic	process,	regulation	of	catalytic	activity,	regulation	of	biosynthetic	process,	
negative	regulation	of	response	to	stimulus,	negative	regulation	of	signalling,	regulation	of	transport,	response	to	
stimulus,	response	to	organic	substance,	cell	proliferation	
10:	FLNB	 Filamin	B	 6.37752	 4.42E-06	
Biological	process:	anatomical	structure	morphogenesis,	anatomical	structure	development,	cell	differentiation,	
regulation	of	biological	process,	Cellular	component:	membrane	part,	intrinsic	component	of	membrane	
11:	
PACSIN1	
Protein	kinase	C	and	
casein	kinase	
substrate	in	neurons	
1	 5.79543	 0.000410182	
Biological	process:	anatomical	structure	morphogenesis,	anatomical	structure	development,	cell	differentiation,	
regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	developmental	process,	
regulation	of	cell	differentiation,	negative	regulation	of	cellular	process,	regulation	of	transport,	Cellular	component:	
membrane	part,	membrane	region	
12:	HLA-
DMB	
Major	
histocompatibility	
complex,	class	II,	DM	
beta	 5.4804	 1.99E-05	
Biological	process:	immune	system	process,	leukocyte	activation,	lymphocyte	activation,	antigen	processing	and	
presentation	of	peptide	or	polysaccharide	antigen	via	MHC	class	II,	regulation	of	biological	process,	positive	regulation	of	
cellular	process,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	immune	system	process,	regulation	of	
cell	adhesion,	regulation	of	cell	proliferation,	regulation	of	cell	activation,	regulation	of	leukocyte	activation,	regulation	
of	immune	effector	process,	response	to	stimulus,	Cellular	component:	membrane	part,	intrinsic	component	of	
membrane	
13:	IRAK3	
Interleukin	1	
receptor	associated	
kinase	3	 4.85695	 0.000133243	
Biological	process:	immune	system	process,	cytokine	production	involved	in	immune	response,	regulation	of	biological	
process,	positive	regulation	of	cellular	process,	positive	regulation	of	developmental	process,	positive	regulation	of	
response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	regulation	of	immune	system	process,	regulation	
of	cytokine	production,	regulation	of	cell	communication,	negative	regulation	of	cellular	process,	negative	regulation	of	
immune	system	process,	regulation	of	immune	effector	process,	regulation	of	macromolecule	metabolic	process,	
regulation	of	catalytic	activity,	regulation	of	biosynthetic	process,	negative	regulation	of	response	to	stimulus,	negative	
regulation	of	signalling,	regulation	of	sequence-specific	DNA	binding	transcription	factor	activity,	response	to	stimulus,	
response	to	external	biotic	stimulus,	response	to	organic	substance,	response	to	endogenous	stimulus	
14:	COTL1	
Coactosin	like	F-actin	
binding	protein	1	 4.68917	 0.000118759	 Biological	process:	response	to	stimulus,	response	to	external	biotic	stimulus	
15:	LTB	 Lymphotoxin	beta	 4.60111	 9.34E-08	
Biological	process:	immune	system	process,	anatomical	structure	development,	regulation	of	biological	process,	positive	
regulation	of	cellular	process,	positive	regulation	of	metabolic	process,	regulation	of	cytokine	production,	regulation	of	
macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	response	to	stimulus,	Cellular	component:	
membrane	part,	intrinsic	component	of	membrane	
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16:	CD44	 CD44	molecule	 4.45991	 6.13E-07	
Molecular	function:	signalling	receptor	activity,	Biological	process:	immune	system	process,	anatomical	structure	
morphogenesis,	anatomical	structure	development,	regulation	of	biological	process,	positive	regulation	of	cellular	
process,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	regulation	of	
signalling,	regulation	of	cell	adhesion,	regulation	of	cell	communication,	regulation	of	cell	death,	negative	regulation	of	
cellular	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	catalytic	activity,	negative	regulation	of	
response	to	stimulus,	negative	regulation	of	signalling,	coagulation,	cell	adhesion,	response	to	stimulus,	response	to	
organic	substance,	response	to	growth	factor,	response	to	endogenous	stimulus,	extracellular	structure	organisation,	cell	
motility,	Cellular	component:	membrane	part,	intrinsic	component	of	membrane,	side	of	membrane,	membrane	region	
17:	
CABLES1	
Cdk5	and	Abl	enzyme	
subtrate	1	 4.44346	 0.00010817	 Biological	process:	regulation	of	biological	process,	coagulation	
18:	CCR7	
C-C	motif	chemokine	
receptor	7		 4.43789	 0.000384761	
Molecular	function:	signalling	receptor	activity,	Biological	process:	immune	system	process,	lymphocyte	migration,	
leukocyte	chemotaxis,	T	cell	selection,	leukocyte	activation,	lymphocyte	activation,	cell	differentiation,	regulation	of	
biological	process,	regulation	of	homeostatic	process,	homeostatic	process,	positive	regulation	of	cellular	process,	
positive	regulation	of	response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	regulation	of	immune	
system	process,	positive	regulation	of	signalling,	positive	regulation	of	locomotion,	regulation	of	cytokine	production,	
regulation	of	cell	adhesion,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	activation,	
negative	regulation	of	cellular	process,	regulation	of	leukocyte	activation,	regulation	of	leukocyte	migration,	regulation	
of	antigen	processing	and	presentation,	regulation	of	macromolecule	metabolic	process,	regulation	of	catalytic	activity,	
regulation	of	biosynthetic	process,	regulation	of	cell	motility,	regulation	of	chemotaxis,	regulation	of	transport,	response	
to	stimulus,	response	to	external	biotic	stimulus,	response	to	organic	substance,	response	to	endogenous	stimulus,	cell	
motility,	Cellular	component:	membrane	part,	intrinsic	component	of	membrane,	side	of	membrane	
19:	IGFBP4	
Insulin	like	growth	
factor	binding	
protein	4	 4.40699	 0.000112373	
Biological	process:	anatomical	structure	development,	regulation	of	biological	process,		positive	regulation	of	cellular	
process,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	regulation	of	
signalling,	regulation	of	cell	communication,	regulation	of	macromolecule	metabolic	process,	response	to	stimulus,	cell	
proliferation	
20:	COL9A2	 Collagen	type	IX	alpha	2	 4.38712	 1.04E-05	 Biological	process:	anatomical	structure	development,	extracellular	structure	organisation	
21:	IER3	
Immediate	early	
response	3	 4.37233	 0.00210597	
Biological	process:	anatomical	structure	morphogenesis,	regulation	of	biological	process,	positive	regulation	of	
metabolic	process,	regulation	of	cell	communication,	regulation	of	cell	death,	negative	regulation	of	cellular	process,	
regulation	of	macromolecule	metabolic	process,	negative	regulation	of	response	to	stimulus,	negative	regulation	of	
signalling,	regulation	of	transport,	response	to	stimulus,	response	to	external	biotic	stimulus,	Cellular	component:	
membrane	part,	intrinsic	component	of	membrane	
22:	NELL2	 Neural	EGFL	like	2	 4.13993	 9.06E-05	 Biological	process:	regulation	of	biological	process,	homeostatic	process	
23:	FES	
FES	proto-oncogene,	
tyrosine	kinase	 4.13025	 0.000609175	
Biological	process:	immune	system	process,	cell	activation	involved	in	immune	response,	leukocyte	activation,	
anatomical	structure	morphogenesis,	cell	differentiation,	regulation	of	biological	process,	positive	regulation	of	cellular	
process,	positive	regulation	of	developmental	process,	positive	regulation	of	immune	system	process,	regulation	of	cell	
differentiation,	regulation	of	cell	adhesion,		regulation	of	cell	proliferation,	regulation	of	cell	activation,	regulation	of	
haemopoiesis,	regulation	of	leukocyte	activation,	regulation	of	immune	effector	process,	regulation	of	cell	motility,	
regulation	of	transport,	cell	adhesion,	response	to	stimulus,	cell	proliferation,	Cellular	component:	membrane	part,	
intrinsic	component	of	membrane	
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24:	ADCY3	 Adenylate	cyclase	3	 4.03742	 4.95E-05	
Biological	process:	immune	system	process,	regulation	of	biological	process,	homeostatic	process,	positive	regulation	of	
cellular	process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	
catalytic	activity,	response	to	stimulus,	response	to	organic	substance,	response	to	endogenous	stimulus,	cell	motility,	
Cellular	component:	membrane	part,	intrinsic	component	of	membrane,	membrane	region,	membrane	raft	
25:	CXCR3	
C-X-C	motif	
chemokine	receptor	
3	 4.03192	 9.20E-06	
Molecular	function:	signalling	receptor	activity,	Biological	process:	immune	system	process,	lymphocyte	migration,	
leukocyte	chemotaxis,	anatomical	structure	morphogenesis,	regulation	of	biological	process,	regulation	of	homeostatic	
process,	homeostatic	process,	positive	regulation	of	cellular	process,	positive	regulation	of	developmental	process,	
positive	regulation	of	response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	regulation	of	signalling,	
positive	regulation	of	locomotion,	negative	regulation	of	developmental	process,	regulation	of	cell	proliferation,	
regulation	of	cell	communication,	regulation	of	cell	death,	negative	regulation	of	cellular	process,	regulation	of	leukocyte	
migration,	regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	regulation	of	cell	motility,	
regulation	of	chemotaxis,	regulation	of	transport,	cytokine	production,	cell	adhesion,	response	to	stimulus,	cell	motility,	
Cellular	component:	membrane	part,	intrinsic	component	of	membrane,	side	of	membrane	
26:	SELL	 Selectin	L	 3.95785	 0.00134396	
Biological	process:	immune	system	process,	regulation	of	biological	process,	coagulation,	cell	adhesion,	response	to	
stimulus,	response	to	organic	substance,	response	to	endogenous	stimulus,	cell	motility,	Cellular	component:	
membrane	part,	intrinsic	component	of	membrane,	side	of	membrane	
27:	MYC	
v-myc	avian	
myelocytomatosis	
viral	oncogene	
homolog	 3.89977	 0.000116108	
Biological	process:	immune	system	process,	anatomical	structure	morphogenesis,	cell	differentiation,	regulation	of	
biological	process,	regulation	of	homeostatic	process,	homeostatic	process,	positive	regulation	of	cellular	process,	
positive	regulation	of	developmental	process,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	
metabolic	process,	regulation	of	cell	differentiation,	negative	regulation	of	developmental	process,	regulation	of	cell	
proliferation,	regulation	of	cell	communication,	regulation	of	cell	death,	negative	regulation	of	cellular	process,	
regulation	of	haemopoiesis,	negative	regulation	of	immune	system	process,	regulation	of	macromolecule	metabolic	
process,	regulation	of	catalytic	activity,	regulation	of	biosynthetic	process,	negative	regulation	of	response	to	stimulus,	
negative	regulation	of	signalling,	response	to	stimulus,	response	to	organic	substance,	response	to	growth	factor	
28:	LEF1	
Lymphoid	enhancer-
binding	factor	1	 3.74101	 4.75E-05	
Molecular	function:	signalling	receptor	activity,	Biological	process:	immune	system	process,	cell	activation	involved	in	
immune	response,	leukocyte	activation,	lymphocyte	activation,	lymphocyte	differentiation,	anatomical	structure	
morphogenesis,	anatomical	structure	development,	cell	differentiation,	pattern	specification	process,	regulation	of	
biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	developmental	process,	positive	
regulation	of	metabolic	process,	positive	regulation	of	immune	system	process,	positive	regulation	of	locomotion,	
regulation	of	cytokine	production,	regulation	of	cell	differentiation,	negative	regulation	of	developmental	process,	
regulation	of	cell	adhesion,	regulation	of	cell	proliferation,	regulation	of	cell	communication,	regulation	of	cell	death,	
negative	regulation	of	cellular	process,	regulation	of	haemopoiesis,	regulation	of	macromolecule	metabolic	process,	
regulation	of	catalytic	activity,	regulation	of	biosynthetic	process,	negative	regulation	of	response	to	stimulus,	negative	
regulation	of	signalling,	regulation	of	cell	motility,	cell	adhesion,	response	to	stimulus,	response	to	organic	substance,	
cell	proliferation,	cell	motility	
29:	NFIX	 Nuclear	factor	I	X	 3.62485	 0.00148141	
Biological	process:	anatomical	structure	development,	cell	differentiation,	regulation	of	biological	process,	positive	
regulation	of	cellular	process,	positive	regulation	of	metabolic	process,	negative	regulation	of	cellular	process,	regulation	
of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process	
30:	FVT1	
3-ketodihydrosphing-
osine	reductase	(KDSR)	 3.61403	 5.07E-05	 Cellular	component:	membrane	part,	intrinsic	component	of	membrane	
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31:	
LOC440359	
Y-box	binding	protein	3	
pseudogene	1	(YBX3P1)	 3.58305	 0.000102672	 		
32:	SSBP2	
Single	stranded	DNA	
binding	protein	2	 3.54882	 1.37E-06	
Biological	process:	regulation	of	biological	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	
biosynthetic	process	
33:	
LOC339192	
Uncharacterised	
LOC339192	 3.53629	 0.00116119	 		
34:	BMP2	
Bone	morphogenetic	
protein	2	 3.48072	 0.00073021	
Biological	process:	anatomical	structure	morphogenesis,	anatomical	structure	development,	cell	differentiation,	pattern	
specification	process,	regulation	of	biological	process,	regulation	of	homeostatic	process,	positive	regulation	of	cellular	
process,	positive	regulation	of	developmental	process,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	
metabolic	process,	positive	regulation	of	signalling,	positive	regulation	of	locomotion,	regulation	of	cell	differentiation,	
negative	regulation	of	developmental	process,	regulation	of	cell	adhesion,	regulation	of	cell	proliferation,	regulation	of	
cell	communication,	regulation	of	cell	death,	negative	regulation	of	cellular	process,	regulation	of	macromolecule	
metabolic	process,	regulation	of	catalytic	activity,	regulation	of	biosynthetic	process,	negative	regulation	of	response	to	
stimulus,	negative	regulation	of	signalling,	regulation	of	cell	motility,	response	to	stimulus,	response	to	organic	
substance,	response	to	growth	factor,	response	to	endogenous	stimulus,	extracellular	structure	organisation,	cell	
proliferation,	Cellular	component:	membrane	part	
35:	PCDH21	
Cadherin	related	family	
member	1	 3.46481	 0.000104655	
Biological	process:	cell	adhesion,	Cellular	component:	membrane	part,	intrinsic	component	of	membrane,	membrane	
region	
36:	DLL1	
Delta-like	1	
(Drosophila)	 3.44976	 0.000121077	
Biological	process:	immune	system	process,	cell	activation	involved	in	immune	response,	leukocyte	activation,	
lymphocyte	activation,	lymphocyte	differentiation,	anatomical	structure	morphogenesis,	anatomical	structure	
development,	cell	differentiation,	pattern	specification	process,	regulation	of	biological	process,	positive	regulation	of	
cellular	process,	positive	regulation	of	developmental	process,	positive	regulation	of	response	to	stimulus,	positive	
regulation	of	metabolic	process,	positive	regulation	of	signalling,	regulation	of	cytokine	production,	regulation	of	cell	
differentiation,	negative	regulation	of	developmental	process,	regulation	of	cell	adhesion,	regulation	of	cell	proliferation,	
regulation	of	cell	communication,	regulation	of	cell	death,	negative	regulation	of	cellular	process,	regulation	of	
haemopoiesis,	negative	regulation	of	immune	system	process,	regulation	of	macromolecule	metabolic	process,	
regulation	of	biosynthetic	process,	regulation	of	transport,	Cellular	component:	membrane	part,	intrinsic	component	of	
membrane,	membrane	region,	membrane	raft	
37:	SYPL1	 Synaptophysin	like	1	 3.39172	 8.50E-05	 Cellular	component:	membrane	part,	intrinsic	component	of	membrane	
38:	
CCDC109B	
Coiled-coil	domain	
containing	109B	 3.37593	 1.14E-05	 Biological	process:	homeostatic	process,	Cellular	component:	membrane	part,	intrinsic	component	of	membrane	
39:	NFKBIZ	 NFKB	inhibitor	zeta	 3.29602	 0.00153028	
Biological	process:	regulation	of	biological	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	
biosynthetic	process,	response	to	stimulus	
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40:	PTK2	
Protein	tyrosine	
kinase	2	 3.28527	 4.50E-05	
Biological	process:	immune	system	process,	anatomical	structure	morphogenesis,	anatomical	structure	development,	
cell	differentiation,	regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	
response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	regulation	of	immune	system	process,	positive	
regulation	of	signalling,	positive	regulation	of	locomotion,	regulation	of	cell	differentiation,	negative	regulation	of	
developmental	process,	regulation	of	cell	adhesion,	regulation	of	cell	proliferation,	regulation	of	cell	communication,	
regulation	of	cell	death,	negative	regulation	of	cellular	process,	regulation	of	macromolecule	metabolic	process,	
regulation	of	catalytic	activity,	regulation	of	cell	motility,	coagulation,	cell	adhesion,	response	to	stimulus,	extracellular	
structure	organisation,	cell	motility,	Cellular	component:	membrane	part,	membrane	region	
41:	CRIP1	
Cysteine	rich	protein	
1	 3.18543	 0.00139478	
Biological	process:	immune	system	process,	anatomical	structure	morphogenesis,	anatomical	structure	development,	
regulation	of	biological	process,	regulation	of	macromolecule	metabolic	process,	response	to	stimulus,	response	to	
organic	substance,	cell	proliferation	
42:	
LOC643384	
unc-93	homolog	B4	
pseudogene	(C.	
elegans)	 3.15746	 9.47E-05	 		
43:	HOXA9	 Homeobox	A9	 3.15049	 0.000278868	
Biological	process:	immune	system	process,	anatomical	structure	morphogenesis,	anatomical	structure	development,	
cell	differentiation,	pattern	specification	process,	regulation	of	biological	process,	regulation	of	cell	differentiation,	
negative	regulation	of	developmental	process,	negative	regulation	of	cellular	process,	regulation	of	haemopoiesis,	
negative	regulation	of	immune	system	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	
biosynthetic	process	
44:	NOD2	
Nucleotide	binding	
oligomerisation	
domain	containing	2	 3.11356	 0.00819364	
Biological	process:	immune	system	process,	leukocyte	chemotaxis,	cytokine	production	involved	in	immune	response,	
immunoglobulin	production,	adaptive	immune	response,	leukocyte	activation,	lymphocyte	activation,	regulation	of	
biological	process,	homeostatic	process,	positive	regulation	of	cellular	process,	positive	regulation	of	response	to	
stimulus,	positive	regulation	of	metabolic	process,	positive	regulation	of	immune	system	process,	positive	regulation	of	
signalling,	regulation	of	cytokine	production,	regulation	of	cell	adhesion,	regulation	of	cell	proliferation,	regulation	of	cell	
communication,	regulation	of	cell	death,	regulation	of	cell	activation,	negative	regulation	of	cellular	process,	negative	
regulation	of	immune	system	process,	regulation	of	leukocyte	activation,	regulation	of	leukocyte	migration,	regulation	of	
antigen	processing	and	presentation,	regulation	of	immune	effector	process,	regulation	of	macromolecule	metabolic	
process,	regulation	of	catalytic	activity,	regulation	of	biosynthetic	process,	negative	regulation	of	response	to	stimulus,	
negative	regulation	of	signalling,	regulation	of	cell	motility,	regulation	of	chemotaxis,	regulation	of	transport,	regulation	
of	sequence-specific	DNA	binding	transcription	factor	activity,		cytokine	production,	response	to	stimulus,	response	to	
external	biotic	stimulus,	response	to	organic	substance,	response	to	endogenous	stimulus,	Cellular	component:	
membrane	part,	membrane	region	
45:	
DENND5A	
DENN	domain	
containing	5A	 3.09415	 2.36E-05	
Biological	process:	regulation	of	biological	process,	positive	regulation	of	metabolic	process,	regulation	of	catalytic	
activity,	response	to	stimulus,	Cellular	component:	membrane	part	
46:	IL18R1	
Interleukin	18	
receptor	1	 3.05681	 9.09E-05	
Molecular	function:	signalling	receptor	activity,	Biological	process:	immune	system	process,	cell	activation	involved	in	
immune	response,	leukocyte	activation,	lymphocyte	activation,	lymphocyte	differentiation,	cell	differentiation,	
regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	response	to	stimulus,	
positive	regulation	of	signalling,	regulation	of	cytokine	production,	regulation	of	cell	communication,	regulation	of	
transport,	cell	adhesion,	response	to	stimulus,	Cellular	component:	membrane	part,	intrinsic	component	of	membrane	
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47:	CXXC5	 CXXC	finger	protein	5	 3.05571	 0.00127327	
Biological	process:	regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	
response	to	stimulus,	positive	regulation	of	signalling,	regulation	of	cell	communication,	negative	regulation	of	cellular	
process,	regulation	of	macromolecule	metabolic	process,		regulation	of	biosynthetic	process	
48:	TCF4	 Transcription	factor	4	 3.03148	 0.000284287	
Biological	process:	cell	differentiation,	regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	
regulation	of	developmental	process,	positive	regulation	of	metabolic	process,	regulation	of	cell	differentiation,	negative	
regulation	of	cellular	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process	
49:	GPR183	
G	protein-coupled	
receptor	183	 2.97515	 9.70E-06	
Molecular	function:	signalling	receptor	activity,	Biological	process:	immune	system	process,	cell	activation	involved	in	
immune	response,	adaptive	immune	response,	leukocyte	activation,	lymphocyte	activation,	lymphocyte	differentiation,	
cell	differentiation,	regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	
response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	regulation	of	immune	system	process,	positive	
regulation	of	signalling,	regulation	of	cell	proliferation,	regulation	of	cell	communication,	regulation	of	cell	activation,	
regulation	of	leukocyte	activation,	regulation	of	macromolecule	metabolic	process,	response	to	stimulus,	Cellular	
component:	membrane	part,	intrinsic	component	of	membrane	
50:	CD2	 CD2	molecule	 2.96361	 0.00361787	
Biological	process:	immune	system	process,	leukocyte	activation,	lymphocyte	activation,	lymphocyte	differentiation,	cell	
differentiation,	regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	immune	
system	process,	regulation	of	cytokine	production,	regulation	of	cell	differentiation,	regulation	of	cell	adhesion,	
regulation	of	cell	activation,	regulation	of	haemopoiesis,	regulation	of	leukocyte	activation,	regulation	of	transport,	
coagulation,	cell	adhesion,	cell	motility,	Cellular	component:	membrane	part,	intrinsic	component	of	membrane,	side	of	
membrane	
51:	
TNFRSF11A	
Tumor	necrosis	
factor	receptor	
superfamily	member	
11a	 2.88774	 6.54E-05	
Molecular	function:	signalling	receptor	activity,	Biological	process:	immune	system	process,	leukocyte	chemotaxis,	
adaptive	immune	response,	anatomical	structure	development,	cell	differentiation,	regulation	of	biological	process,	
regulation	of	homeostatic	process,	homeostatic	process,	positive	regulation	of	cellular	process,	positive	regulation	of	
response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	regulation	of	signalling,	regulation	of	cell	
proliferation,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	macromolecule	metabolic	process,	
regulation	of	catalytic	activity,	regulation	of	biosynthetic	process,	regulation	of	transport,	regulation	of	sequence-specific	
DNA	binding	transcription	factor	activity,	response	to	stimulus,	response	to	external	biotic	stimulus,	response	to	organic	
substance,	cell	motility,	Cellular	component:	membrane	part,	intrinsic	component	of	membrane,	side	of	membrane	
52:	NBL1	
Neuroblastoma	1,	
DAN	family	BMP	
antagonist	 2.86103	 0.000594151	
Biological	process:	immune	system	process,	leukocyte	chemotaxis,	anatomical	structure	morphogenesis,	anatomical	
structure	development,	cell	differentiation,	pattern	specification	process,	regulation	of	biological	process,	positive	
regulation	of	cellular	process,	positive	regulation	of	developmental	process,	regulation	of	cell	differentiation,	regulation	
of	cell	communication,	negative	regulation	of	cellular	process,	negative	regulation	of	immune	system	process,	regulation	
of	leukocyte	migration,	regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	negative	
regulation	of	response	to	stimulus,	negative	regulation	of	signalling,	regulation	of	cell	motility,	regulation	of	chemotaxis	
53:	SPRY2	
Sprouty	RTK	
signalling	antagonist	
2	 2.85993	 0.000648007	
Biological	process:	anatomical	structure	morphogenesis,	cell	differentiation,	regulation	of	biological	process,	positive	
regulation	of	cellular	process,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	metabolic	process,	
positive	regulation	of	signalling,	regulation	of	cell	differentiation,	regulation	of	cell	proliferation,	regulation	of	cell	
communication,	regulation	of	cell	death,	negative	regulation	of	cellular	process,	regulation	of	macromolecule	metabolic	
process,	regulation	of	catalytic	activity,	negative	regulation	of	response	to	stimulus,	negative	regulation	of	signalling,	
Cellular	component:	membrane	part,	membrane	region	
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54:	
STARD10	
StAR	related	lipid	
transfer	domain	
containing	10	 2.85654	 0.000437673	
Biological	process:	regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	
response	to	stimulus,	positive	regulation	of	signalling,	regulation	of	cell	communication	
55:	CHPT1	
Choline	phospho-
transferase	1	 2.85023	 0.0010745	
Biological	process:	regulation	of	biological	process,	positive	regulation	of	cellular	process,	Cellular	component:	
membrane	part,	intrinsic	component	of	membrane	
56:	MFGE8	
Milk	fat	globule-EGF	
factor	8	protein	 2.83903	 2.32E-05	
Biological	process:	regulation	of	biological	process,	regulation	of	cell	proliferation,	regulation	of	transport,	cell	adhesion,	
response	to	stimulus,	response	to	organic	substance,	response	to	endogenous	stimulus,	Cellular	component:	membrane	
part,	side	of	membrane	
57:	HLA-
DMA	
Major	
histocompatibility	
complex,	class	II,	DM	
alpha	 2.75552	 0.000940876	
Biological	process:	immune	system	process,	adaptive	immune	response,	T	cell	selection,	leukocyte	activation,	
lymphocyte	activation,	lymphocyte	differentiation,	antigen	processing	and	presentation	of	peptide	or	polysaccharide	
antigen	via	MHC	class	II,	anatomical	structure	development,	cell	differentiation,	regulation	of	biological	process,	positive	
regulation	of	cellular	process,	positive	regulation	of	developmental	process,	positive	regulation	of	response	to	stimulus,	
positive	regulation	of	immune	system	process,	regulation	of	cell	differentiation,	regulation	of	cell	adhesion,	regulation	of	
cell	activation,	regulation	of	haemopoiesis,	regulation	of	leukocyte	activation,	response	to	stimulus,	Cellular	component:	
membrane	part,	intrinsic	component	of	membrane	
58:	EFHC2	
EF-hand	domain	
containing	2	 2.71765	 0.0039594	 		
59:	KIT	
KIT	proto-oncogene	
receptor	tyrosine	
kinase	 2.70867	 0.000602614	
Molecular	function:	signalling	receptor	activity,	Biological	process:	immune	system	process,	leukocyte	chemotaxis,	cell	
activation	involved	in	immune	response,	cytokine	production	involved	in	immune	response,	leukocyte	activation,	
lymphocyte	activation,	lymphocyte	differentiation,	anatomical	structure	morphogenesis,	anatomical	structure	
development,	cell	differentiation,	regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	
regulation	of	developmental	process,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	metabolic	
process,	positive	regulation	of	signalling,	positive	regulation	of	locomotion,	regulation	of	cell	differentiation,	regulation	
of	cell	proliferation,	regulation	of	cell	communication,	regulation	of	cell	death,	negative	regulation	of	cellular	process,	
regulation	of	macromolecule	metabolic	process,	regulation	of	catalytic	activity,	regulation	of	biosynthetic	process,	
regulation	of	cell	motility,	regulation	of	sequence-specific	DNA	binding	transcription	factor	activity,	cytokine	production,	
cell	adhesion,	response	to	stimulus,	response	to	organic	substance,	response	to	endogenous	stimulus,	lamellipodium	
organisation,	cell	proliferation,	cell	motility,	Cellular	component:	membrane	part,	intrinsic	component	of	membrane,	
side	of	membrane	
60:	CAPN12	 Calpain	12	 2.66966	 2.07E-05	 		
61:	SCML1	
Sex	comb	on	midleg-
like	1	(Drosophila)	 2.66087	 4.14E-05	
Biological	process:	anatomical	structure	morphogenesis,	regulation	of	biological	process,	regulation	of	macromolecule	
metabolic	process,	regulation	of	biosynthetic	process	
62:	
TMEM123	
Transmembrane	
protein	123	 2.5854	 0.0011517	 Cellular	component:	membrane	part,	intrinsic	component	of	membrane,	side	of	membrane	
63:	
FAM129A	
Family	with	sequence	
similarity	129	
member	A	 2.58504	 0.000144039	
Biological	process:	regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	
metabolic	process,	negative	regulation	of	cellular	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	
biosynthetic	process,	response	to	stimulus	
Appendix 3 C: Top 100 CD56bright vs. CD56dim upregulated genes with GO Function categories 
 
SYMBOL	/	
Probeset	ID	 Gene	description	 Fold-Change	 p-value	 GO	Function	categories	
 
	 266 
64:	KLF4	 Kruppel-like	factor	4	 2.58229	 0.00176608	
Biological	process:	anatomical	structure	morphogenesis,	anatomical	structure	development,	cell	differentiation,	
regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	metabolic	process,	
regulation	of	cytokine	production,	regulation	of	cell	differentiation,	negative	regulation	of	developmental	process,	
regulation	of	cell	adhesion,	regulation	of	cell	proliferation,	regulation	of	cell	communication,	regulation	of	cell	death,	
negative	regulation	of	cellular	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	catalytic	activity,	
regulation	of	biosynthetic	process,	negative	regulation	of	response	to	stimulus,	negative	regulation	of	signalling,	
regulation	of	cell	motility,		regulation	of	sequence-specific	DNA	binding	transcription	factor	activity,	response	to	
stimulus,	response	to	organic	substance,	response	to	growth	factor,	response	to	endogenous	stimulus	
65:	GNA15	
G	protein	subunit	
alpha	15	 2.50072	 0.00159194	
Biological	process:	regulation	of	biological	process,	homeostatic	process,	positive	regulation	of	metabolic	process,	
regulation	of	catalytic	activity,	coagulation,	Cellular	component:	membrane	part	
66:	XCL1	
X-C	motif	chemokine	
ligand	1	 2.46906	 9.65E-05	
Biological	process:	immune	system	process,	lymphocyte	migration,	leukocyte	chemotaxis,	cytokine	production	involved	
in	immune	response,	immunoglobulin	production,	adaptive	immune	response,	leukocyte	activation,	lymphocyte	
activation,	regulation	of	biological	process,	regulation	of	homeostatic	process,	homeostatic	process,	positive	regulation	
of	cellular	process,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	
regulation	of	immune	system	process,	positive	regulation	of	signalling,	positive	regulation	of	locomotion,	regulation	of	
cytokine	production,	regulation	of	cell	adhesion,	regulation	of	cell	proliferation,	regulation	of	cell	communication,	
regulation	of	cell	activation,	negative	regulation	of	cellular	process,	negative	regulation	of	immune	system	process,	
regulation	of	leukocyte	activation,	regulation	of	leukocyte	migration,	regulation	of	immune	effector	process,	regulation	
of	macromolecule	metabolic	process,	regulation	of	catalytic	activity,	regulation	of	biosynthetic	process,	negative	
regulation	of	response	to	stimulus,	regulation	of	cell	motility,	regulation	of	chemotaxis,	regulation	of	transport,	
regulation	of	sequence-specific	DNA	binding	transcription	factor	activity,	response	to	stimulus,	response	to	external	
biotic	stimulus,	response	to	organic	substance,	response	to	growth	factor,	response	to	endogenous	stimulus,	cell	motility	
67:	SPRY1	
Sprouty	RTK	
signalling	antagonist	
1	 2.44711	 0.00019	
Biological	process:	anatomical	structure	morphogenesis,	anatomical	structure	development,	regulation	of	biological	
process,	positive	regulation	of	developmental	process,	regulation	of	cell	proliferation,	regulation	of	cell	communication,	
negative	regulation	of	cellular	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	catalytic	activity,	
negative	regulation	of	response	to	stimulus,	negative	regulation	of	signalling	
68:	TAGLN2	 Transgelin	2	 2.43615	 0.00207062	 Biological	process:	cell	differentiation	
69:	SLC7A6	
Solute	carrier	family	
7	member	6	 2.41553	 0.00013377	
Biological	process:	immune	system	process,	coagulation,	cell	motility,	Cellular	component:	membrane	part,	intrinsic	
component	of	membrane,	membrane	region	
70:	ATP1B1	
ATPase	Na+/K+	
transporting	subunit	
beta	1	 2.40191	 0.000430593	
Biological	process:	immune	system	process,	regulation	of	biological	process,	homeostatic	process,	positive	regulation	of	
cellular	process,	positive	regulation	of	metabolic	process,	regulation	of	immune	effector	process,	regulation	of	
macromolecule	metabolic	process,	regulation	of	catalytic	activity,	regulation	of	transport,	coagulation,	cell	adhesion,	
response	to	stimulus,	cell	motility,	Cellular	component:	membrane	part,	membrane	region,	membrane	raft	
71:	FURIN	
Furin,	paired	basic	
amino	acid	cleaving	
enzyme	 2.39778	 0.0018894	
Biological	process:	regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	
response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	regulation	of	signalling,	positive	regulation	of	
locomotion,	regulation	of	cytokine	production,	regulation	of	cell	communication,	negative	regulation	of	cellular	process,	
regulation	of	macromolecule	metabolic	process,	regulation	of	catalytic	activity,	regulation	of	biosynthetic	process,	
regulation	of	cell	motility,	extracellular	structure	organisation,	cell	proliferation,	Cellular	component:	membrane	part,	
intrinsic	component	of	membrane,	membrane	region,	membrane	raft	
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72:	C8orf13	
Family	with	sequence	
similarity	167	member	
A	(FAM167A)	 2.39343	 0.000104967	 		
73:	ATP8B4	
ATPase	phospholipid	
transporting	8B4	
(putative)	 2.3779	 0.000677897	 Cellular	component:	membrane	part,	intrinsic	component	of	membrane	
74:	GPR68	
G	protein-coupled	
receptor	68	 2.37266	 1.19E-05	
Molecular	function:	signalling	receptor	activity,	Biological	process:	immune	system	process,	leukocyte	activation,	cell	
differentiation,	regulation	of	biological	process,	regulation	of	homeostatic	process,	positive	regulation	of	cellular	
process,	positive	regulation	of	developmental	process,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	
immune	system	process,	positive	regulation	of	signalling,	regulation	of	cell	differentiation,	negative	regulation	of	
developmental	process,	regulation	of	cell	communication,	negative	regulation	of	cellular	process,	regulation	of	
haemopoiesis,	negative	regulation	of	immune	system	process,	regulation	of	transport,	response	to	stimulus,	Cellular	
component:	membrane	part,	intrinsic	component	of	membrane	
75:	RARA	
Retinoic	acid	
receptor	alpha	 2.36061	 0.000220299	
Molecular	function:	signalling	receptor	activity,	Biological	process:	immune	system	process,	lymphocyte	activation,	
lymphocyte	differentiation,	anatomical	structure	morphogenesis,	anatomical	structure	development,	cell	differentiation,	
regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	developmental	process,	
positive	regulation	of	response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	regulation	of	immune	
system	process,	regulation	of	cytokine	production,	regulation	of	cell	differentiation,	negative	regulation	of	
developmental	process,	regulation	of	cell	adhesion,	regulation	of	cell	proliferation,	regulation	of	cell	communication,	
regulation	of	cell	death,	regulation	of	cell	activation,	negative	regulation	of	cellular	process,	regulation	of	haemopoiesis,	
negative	regulation	of	immune	system	process,	regulation	of	leukocyte	activation,	regulation	of	immune	effector	
process,	regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	response	to	stimulus,	
response	to	external	biotic	stimulus,	response	to	organic	substance,	response	to	endogenous	stimulus	
76:	ZFHX3	
Zinc	finger	homeobox	
3	 2.33693	 0.00024732	
Biological	process:	anatomical	structure	development,	cell	differentiation,	regulation	of	biological	process,	positive	
regulation	of	cellular	process,	positive	regulation	of	developmental	process,	positive	regulation	of	metabolic	process,	
regulation	of	cell	differentiation,	negative	regulation	of	developmental	process,	negative	regulation	of	cellular	process,	
regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	response	to	stimulus,	response	to	
organic	substance,	response	to	growth	factor,	response	to	endogenous	stimulus	
77:	CD83	 CD83	molecule	 2.32123	 0.000822096	
Biological	process:	immune	system	process,	leukocyte	activation,	lymphocyte	activation,	lymphocyte	differentiation,	cell	
differentiation,	regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	
developmental	process,	positive	regulation	of	immune	system	process,	regulation	of	cytokine	production,	regulation	of	
cell	differentiation,	regulation	of	cell	adhesion,	regulation	of	cell	activation,	regulation	of	haemopoiesis,	regulation	of	
leukocyte	activation,	response	to	stimulus,	response	to	organic	substance,	Cellular	component:	membrane	part,	intrinsic	
component	of	membrane,	side	of	membrane	
78:	
LOC729389	
Ribosomal	protein	S6	
pseudogene	25	
(RPS6P25)	 2.31959	 6.51E-05	 		
79:	FHL1	
Four	and	a	half	LIM	
domains	1	 2.29262	 3.55E-05	
Biological	process:	anatomical	structure	morphogenesis,	anatomical	structure	development,	cell	differentiation,	
regulation	of	biological	process,	regulation	of	homeostatic	process,	negative	regulation	of	cellular	process,	regulation	of	
transport	
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80:	ITGA5	
Integrin	subunit	
alpha	5	 2.28381	 0.000695723	
Biological	process:	immune	system	process,	anatomical	structure	morphogenesis,	cell	differentiation,	regulation	of	
biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	developmental	process,	positive	
regulation	of	response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	regulation	of	signalling,	positive	
regulation	of	locomotion,	regulation	of	cell	adhesion,	regulation	of	cell	communication,	regulation	of	cell	death,	negative	
regulation	of	cellular	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	cell	motility,	coagulation,	
cell	adhesion,	extracellular	structure	organisation,	cell	motility,	Cellular	component:	membrane	part,	intrinsic	
component	of	membrane,	side	of	membrane,	membrane	region	
81:	RUNX2	
Runt	related	
transcription	factor	2	 2.24688	 8.70E-05	
Biological	process:	immune	system	process,	leukocyte	activation,	lymphocyte	activation,	lymphocyte	differentiation,	
anatomical	structure	morphogenesis,	anatomical	structure	development,	cell	differentiation,	regulation	of	biological	
process,	positive	regulation	of	cellular	process,	positive	regulation	of	developmental	process,	positive	regulation	of	
metabolic	process,	regulation	of	cell	differentiation,	regulation	of	cell	proliferation,	regulation	of	cell	communication,	
negative	regulation	of	cellular	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	
process,	negative	regulation	of	response	to	stimulus,	negative	regulation	of	signalling,	cell	adhesion,	response	to	
stimulus,	response	to	organic	substance,	response	to	growth	factor,	response	to	endogenous	stimulus	
82:	RAB32	
RAB32,	member	RAS	
oncogene	family	 2.23958	 0.00081378	 Biological	process:	immune	system	process,	regulation	of	biological	process	
83:	C14orf4	
Interferon	regulatory	
factor	2	binding	
protein-like	(IRF2BPL)	 2.20896	 2.73E-05	
Biological	process:	regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	
metabolic	process,	negative	regulation	of	cellular	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	
biosynthetic	process	
84:	AHNAK	
AHNAK	
nucleoprotein	 2.20862	 0.0058199	
Biological	process:	regulation	of	biological	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	
transport,	Cellular	component:	membrane	part,	membrane	region,	membrane	raft	
85:	RASSF2	
Ras	association	
domain	family	
member	2	 2.20034	 0.00151173	
Biological	process:	immune	system	process,	anatomical	structure	development,	cell	differentiation,	regulation	of	
biological	process,	homeostatic	process,	positive	regulation	of	cellular	process,	positive	regulation	of	response	to	
stimulus,	positive	regulation	of	metabolic	process,	positive	regulation	of	signalling,	regulation	of	cell	differentiation,	
regulation	of	cell	communication,	regulation	of	cell	death,	negative	regulation	of	cellular	process,	regulation	of	
haemopoiesis,	regulation	of	macromolecule	metabolic	process,	regulation	of	catalytic	activity,	negative	regulation	of	
response	to	stimulus,	negative	regulation	of	signalling	
86:	HVCN1	
Hydrogen	voltage	
gated	channel	1	 2.18594	 0.000138057	
Biological	process:	regulation	of	biological	process,	regulation	of	transport,	response	to	stimulus,	Cellular	component:	
membrane	part,	intrinsic	component	of	membrane	
87:	IL12RB2	
Interleukin	12	
receptor	subunit	
beta	2	 2.18423	 0.00260226	
Molecular	function:	signalling	receptor	activity,	Biological	process:	regulation	of	biological	process,	positive	regulation	
of	cellular	process,	regulation	of	cytokine	production,	regulation	of	cell	proliferation,	cytokine	production,	response	to	
stimulus,	response	to	external	biotic	stimulus,	response	to	organic	substance,	Cellular	component:	membrane	part,	
intrinsic	component	of	membrane,	side	of	membrane	
88:	MAFF	
MAF	bZIP	
transcription	factor	F	 2.1738	 0.00329375	
Biological	process:	anatomical	structure	development,	cell	differentiation,	regulation	of	biological	process,	positive	
regulation	of	cellular	process,	positive	regulation	of	metabolic	process,	regulation	of	cell	differentiation,	regulation	of	
macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	coagulation	
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89:	EPHA4	 Eph	receptor	A4	 2.17038	 0.00109219	
Molecular	function:	signalling	receptor	activity,	Biological	process:	anatomical	structure	morphogenesis,		cell	
differentiation,	regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	regulation	of	
developmental	process,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	
regulation	of	signalling,	regulation	of	cell	differentiation,	negative	regulation	of	developmental	process,	regulation	of	cell	
communication,	negative	regulation	of	cellular	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	
catalytic	activity,	negative	regulation	of	response	to	stimulus,	cell	adhesion,	cell	motility,	Cellular	component:	
membrane	part,	intrinsic	component	of	membrane,	membrane	region	
90:	
GRAMD4	
GRAM	domain	
containing	4	 2.16998	 5.74E-05	 Cellular	component:	membrane	part,	intrinsic	component	of	membrane	
91:	
PPP1R9A	
Protein	phosphatase	
1,	regulatory	subunit	
9A	 2.16929	 0.00271116	
Biological	process:	anatomical	structure	morphogenesis,	cell	differentiation,	regulation	of	biological	process,	positive	
regulation	of	cellular	process,	positive	regulation	of	developmental	process,	positive	regulation	of	metabolic	process,	
regulation	of	cell	differentiation,	regulation	of	cell	communication,	negative	regulation	of	cellular	process,	regulation	of	
macromolecule	metabolic	process,	regulation	of	catalytic	activity,	negative	regulation	of	signalling,	regulation	of	
transport,	response	to	stimulus	
92:	SOX4	 SRY-box	4	 2.15864	 0.00217189	
Biological	process:	immune	system	process,	leukocyte	activation,	lymphocyte	activation,	lymphocyte	differentiation,	
anatomical	structure	morphogenesis,	anatomical	structure	development,	cell	differentiation,	regulation	of	biological	
process,	homeostatic	process,	positive	regulation	of	cellular	process,	positive	regulation	of	response	to	stimulus,	positive	
regulation	of	metabolic	process,	positive	regulation	of	signalling,	regulation	of	cell	proliferation,	regulation	of	cell	
communication,	regulation	of	cell	death,	negative	regulation	of	cellular	process,	regulation	of	macromolecule	metabolic	
process,	regulation	of	biosynthetic	process,	regulation	of	transport,	cell	adhesion,	response	to	stimulus,	response	to	
organic	substance,	cell	proliferation	
93:	
TMEM14B	
Transmembrane	
protein	14B	 2.13257	 0.00221477	 Cellular	component:	membrane	part,	intrinsic	component	of	membrane	
94:	
SLC44A1	
Solute	carrier	family	44	
member	1	 2.12597	 4.02E-06	 Cellular	component:	membrane	part,	intrinsic	component	of	membrane	
95:	
WHAMM	
WAS	protein	homolog	
associated	with	actin,	
Golgi	membranes	and	
microtubules	 2.12361	 0.000509171	 Biological	process:	regulation	of	biological	process,	positive	regulation	of	cellular	process,	lamellipodium	organisation	
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96:	CD74	
CD74	antigen	
(invariant	
polypeptide	of	major	
histocompatibility	
complex,	class	II	
antigen-associated)	 2.11691	 0.0018008	
Molecular	function:	signalling	receptor	activity,	Biological	process:	immune	system	process,	leukocyte	chemotaxis,	
cytokine	production	involved	in	immune	response,	adaptive	immune	response,	T	cell	selection,	leukocyte	activation,	
lymphocyte	activation,	lymphocyte	differentiation,	antigen	processing	and	presentation	of	peptide	or	polysaccharide	
antigen	via	MHC	class	II,	cell	differentiation,	regulation	of	biological	process,	regulation	of	homeostatic	process,	positive	
regulation	of	cellular	process,	positive	regulation	of	developmental	process,	positive	regulation	of	response	to	stimulus,	
positive	regulation	of	metabolic	process,	positive	regulation	of	immune	system	process,	positive	regulation	of	signalling,	
positive	regulation	of	locomotion,	regulation	of	cytokine	production,	regulation	of	cell	differentiation,	negative	
regulation	of	developmental	process,	regulation	of	cell	adhesion,	regulation	of	cell	proliferation,	regulation	of	cell	
communication,	regulation	of	cell	death,	regulation	of	cell	activation,	negative	regulation	of	cellular	process,	regulation	
of	haemopoiesis,	negative	regulation	of	immune	system	process,	regulation	of	leukocyte	activation,	regulation	of	
leukocyte	migration,	regulation	of	antigen	processing	and	presentation,	regulation	of	immune	effector	process,	
regulation	of	macromolecule	metabolic	process,	regulation	of	catalytic	activity,	negative	regulation	of	response	to	
stimulus,	negative	regulation	of	signalling,	regulation	of	cell	motility,	regulation	of	chemotaxis,	regulation	of	transport,	
coagulation,	response	to	stimulus,	cell	proliferation,	cell	motility,	Cellular	component:	membrane	part,	intrinsic	
component	of	membrane,	side	of	membrane	
97:	
TMEM14C	
Transmembrane	
protein	14C	 2.11572	 0.000242096	 Cellular	component:	membrane	part,	intrinsic	component	of	membrane	
98:	
UNC93B1	 unc-93	homolog	B1	 2.10986	 0.00066325	
Biological	process:	immune	system	process,	adaptive	immune	response,	antigen	processing	and	presentation	of	peptide	
or	polysaccharide	antigen	via	MHC	class	II,	regulation	of	biological	process,	positive	regulation	of	response	to	stimulus,	
positive	regulation	of	immune	system	process,	response	to	stimulus,	response	to	external	biotic	stimulus,		Cellular	
component:	membrane	part,	intrinsic	component	of	membrane	
99:	IFI44L	
Interferon	induced	
protein	44	like	 2.09205	 0.00122823	 Biological	process:	immune	system	process,	response	to	stimulus,	response	to	external	biotic	stimulus	
100:	S1PR1	
Sphingosine-1-
phosphate	receptor	1	 2.08572	 0.000425441	
Molecular	function:	signalling	receptor	activity,	Biological	process:	immune	system	process,	lymphocyte	migration,	
anatomical	structure	morphogenesis,	anatomical	structure	development,	cell	differentiation,	regulation	of	biological	
process,	regulation	of	homeostatic	process,	homeostatic	process,	positive	regulation	of	cellular	process,	positive	
regulation	of	response	to	stimulus,	positive	regulation	of	metabolic	process,	positive	regulation	of	locomotion,	
regulation	of	cell	adhesion,	regulation	of	cell	proliferation,	negative	regulation	of	cellular	process,	regulation	of	
macromolecule	metabolic	process,	regulation	of	catalytic	activity,	regulation	of	biosynthetic	process,	regulation	of	cell	
motility,	regulation	of	chemotaxis,	cell	adhesion,	lamellipodium	organisation,	cell	motility,	Cellular	component:	
membrane	part,	intrinsic	component	of	membrane,	side	of	membrane,	membrane	region,	membrane	raft	
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1:	
NR4A2	
Nuclear	receptor	
subfamily	4,	group	A,	
member	2	 -22.8372	 0.000102576	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity	sequence-specific	DNA	binding,	nucleic	acid	binding,	
protein	binding,	beta-catenin	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
metabolic	process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	
of	nitrogen	compound	metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	
positive	regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	negative	regulation	of	
signalling,	negative	regulation	of	response	to	stimulus,	regulation	of	signal	transduction,	regulation	of	catalytic	activity,	
cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	
process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	nucleic	acid	
metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	stress,	cellular	response	to	organic	substance,	
cellular	response	to	oxygen-containing	compound,	Cellular	component:	nucleus	
2:	RGS2	
Regulator	of	G-protein	
signalling	2	 -20.6308	 4.39E-06	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
metabolic	process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	
of	nitrogen	compound	metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	
positive	regulation	of	cellular	process,		regulation	of	cell	communication,	regulation	of	cellular	component	organisation,	
negative	regulation	of	signalling,	negative	regulation	of	response	to	stimulus,	regulation	of	signal	transduction,	
regulation	of	catalytic	activity,	regulation	of	transferase	activity,	Cellular	component:	nucleus	
3:	S1PR5	
Sphingosine-1-
phosphate	receptor	5	 -14.1049	 4.99E-05	 Biological	process:	regulation	of	biological	process,	regulation	of	cellular	process,	regulation	of	cell	differentiation	
4:	PTGDS	
Prostaglandin	D2	
synthase	 -11.1643	 0.00271371	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	cellular	
process,	regulation	of	cell	proliferation,	cellular	metabolic	process,	
5:	YES1	
YES	proto-oncogene	1,	
Src	family	tyrosine	
kinase	 -10.9395	 7.72E-06	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	regulation	of	biological	process,	positive	
regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,		regulation	of	nitrogen	compound	
metabolic	process,	regulation	of	biosynthetic	process,	positive	regulation	of	cellular	process,	regulation	of	cell	
proliferation,	positive	regulation	of	response	to	stimulus,	regulation	of	cell	activation,	regulation	of	immune	response,	
regulation	of	leukocyte	activation,	cellular	metabolic	process,	macromolecule	metabolic	process,	protein	metabolic	
process,	cellular	response	to	stimulus,	cellular	response	to	organic	substance,	cellular	response	to	oxygen-containing	
compound,	activation	of	immune	response,	immune	effector	process	
6:	TSC22D3	
TSC22	domain	family	
member	3	 -10.5937	 4.23E-05	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	
regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	negative	regulation	of	immune	system	
process,	negative	regulation	of	developmental	process,	Cellular	component:	nucleus	
7:	RBM38	
RNA	binding	motif	
protein	38	 -9.46466	 7.20E-07	
Molecular	function:	nucleic	acid	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	metabolic	
process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	negative	
regulation	of	cellular	process,	positive	regulation	of	cellular	process,	regulation	of	cell	death,	regulation	of	cell	
differentiation,	regulation	of	cell	proliferation,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	
metabolic	process,	nucleic	acid	metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	stress,	Cellular	
component:	nucleus	
8:	FKBP11	
FK506	binding	protein	
11	 -9.24978	 0.000191744	 Biological	process:	cellular	metabolic	process,	macromolecule	metabolic	process,	protein	metabolic	process	
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9:	ENC1	
Ectodermal-neural	
cortex	1	 -9.10488	 5.21E-05	
Molecular	function:		protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,		regulation	of	nitrogen	compound	metabolic	
process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	
regulation	of	cell	differentiation,	regulation	of	cellular	component	organisation,	cellular	metabolic	process,	
macromolecule	metabolic	process,	macromolecule	catabolic	process,	protein	metabolic	process,	protein	catabolic	
process,	Cellular	component:	nucleus	
10:	CENTG2	
ArfGAP	with	GTPase	
domain,	ankyrin	repeat	
and	PH	domain	1	
(AGAP1)	 -8.91218	 0.00027534	
Biological	process:	regulation	of	biological	process,	positive	regulation	of	metabolic	process,	regulation	of	cellular	
process,	regulation	of	catalytic	activity	
11:	PRSS23	 Protease,	serine	23	 -8.25571	 2.43E-05	 Biological	process:	macromolecule	metabolic	process,	protein	metabolic	process,	Cellular	component:	nucleus	
12:	SPON2	 Spondin	2	 -8.16032	 0.000213282	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	response	
to	stimulus,	regulation	of	immune	response,	regulation	of	cytokine	production,	cellular	response	to	stimulus,	cellular	
response	to	organic	substance,	cellular	response	to	oxygen-containing	compound,	cellular	response	to	biotic	stimulus,	
immune	effector	process,	
13:	GARNL4	
RAP1	GTPase	
activating	protein	2	
(RAP1GAP2)	 -7.564	 1.64E-05	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	metabolic	
process,	negative	regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	of	cell	differentiation,	
regulation	of	cellular	component	organisation,	negative	regulation	of	developmental	process,	regulation	of	signal	
transduction,	regulation	of	catalytic	activity	
14:	
LOC645381	
Transducin	like	
enhancer	of	split	1	
pseudogene	1	(TLE1P1)	 -7.42881	 4.40E-05	 		
15:	ATG2A	 Autophagy	related	2A	 -7.39844	 5.68E-07	 Molecular	function:	protein	binding	
16:	TKTL1	 Transketolase-like	1	 -7.37608	 3.11E-05	 Biological	process:	cellular	metabolic	process,	Cellular	component:	nucleus	
17:	CBX4	 Chromobox	4	 -7.36749	 9.24E-07	
Molecular	function:	nucleic	acid	binding,	enzyme	binding,	transcription	factor	activity-	transcription	factor	binding,	
protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	metabolic	process,	regulation	
of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	biosynthetic	
process,	negative	regulation	of	cellular	process,	regulation	of	cell	death,	cellular	metabolic	process,	macromolecule	
metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	
process,	cellular	nitrogen	compound	biosynthetic	process,	nucleic	acid	metabolic	process,	protein	metabolic	process,	
Cellular	component:	nucleus	
18:	
TP53INP2	
Tumor	protein	p53	
inducible	nuclear	
protein	2	 -7.29796	 2.01E-05	
Molecular	function:	protein	binding,	ubiquitin	binding,	Biological	process:	regulation	of	biological	process,	positive	
regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,		regulation	of	nitrogen	compound	
metabolic	process,	regulation	of	biosynthetic	process,	positive	regulation	of	cellular	process,	cellular	metabolic	process,	
macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	macromolecule	
catabolic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	nucleic	
acid	metabolic	process,	protein	metabolic	process,	Cellular	component:	nucleus	
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19:	
MGAT4A	
Mannosyl	(alpha-1,3-)-
glycoprotein	beta-1,4-
N-
acetylglucosaminyltran
sferase,	isozyme	A	 -7.18399	 3.93E-05	 Biological	process:	cellular	metabolic	process,	macromolecule	metabolic	process,	protein	metabolic	process	
20:	CASZ1	 Castor	zinc	finger	1	 -7.11192	 3.37E-06	
Molecular	function:	nucleic	acid	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	metabolic	
process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	
of	biosynthetic	process,	negative	regulation	of	cellular	process,	regulation	of	cell	differentiation,	negative	regulation	of	
developmental	process,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	
macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	
process,	nucleic	acid	metabolic	process	
21:	ZEB2	
Zinc	finger	E-box	
binding	homeobox	2	 -7.04125	 5.17E-05	
Molecular	function:	nucleic	acid	binding,	protein	binding,	SMAD	binding,	Biological	process:	regulation	of	biological	
process,	negative	regulation	of	metabolic	process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	
metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	biosynthetic	process,	negative	
regulation	of	cellular	process,	positive	regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	of	cell	
differentiation,	regulation	of	cellular	component	organisation,	positive	regulation	of	response	to	stimulus,	positive	
regulation	of	signalling,	regulation	of	response	to	stress,	regulation	of	signal	transduction,	regulation	of	catalytic	activity,	
regulation	of	transferase	activity,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	
macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	
process,	nucleic	acid	metabolic	process,	Cellular	component:	nucleus	
22:	IFNGR1	
Interferon	gamma	
receptor	1	 -6.96219	 0.000130933	
Molecular	function:		protein	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	cellular	process,	
regulation	of	cell	communication,	regulation	of	response	to	stress,	regulation	of	signal	transduction,	regulation	of	
immune	response,	
23:	
FAM53B	
Family	with	sequence	
similarity	53	member	B	 -6.87091	 4.93E-05	 		
24:	USP36	
Ubiquitin	specific	
peptidase	36	 -6.81931	 0.000599133	
Molecular	function:	nucleic	acid	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	metabolic	
process,	positive	regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	of	cellular	component	
organisation,	regulation	of	response	to	stress,	cellular	metabolic	process,	macromolecule	metabolic	process,	
macromolecule	catabolic	process,	protein	metabolic	process,	Cellular	component:	nucleus	
25:	KRT73	 Keratin	73	 -6.43615	 6.57E-06	 Molecular	function:	protein	binding,	Cellular	component:	nucleus	
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26:	IFNG	 Interferon,	gamma	 -6.40298	 0.00227162	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
metabolic	process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	
of	nitrogen	compound	metabolic	process,	regulation	of	biosynthetic	process,	regulation	of	vitamin	metabolic	process,	
negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	regulation	of	cell	communication,	
regulation	of	cell	death,	regulation	of	cell	differentiation,	regulation	of	cell	proliferation,	regulation	of	cellular	
component	organisation,	regulation	of	cell	activation,	negative	regulation	of	developmental	process,	positive	regulation	
of	response	to	stimulus,	positive	regulation	of	signalling,	regulation	of	response	to	stress,	regulation	of	signal	
transduction,	regulation	of	immune	response,	regulation	of	cytokine	production,	regulation	of	haemopoiesis,	regulation	
of	leukocyte	activation,	regulation	of	catalytic	activity,	cellular	response	to	stimulus,	cellular	response	to	stress,	cellular	
response	to	organic	substance,		cellular	response	to	oxygen-containing	compound,	cellular	response	to	biotic	stimulus,	
immune	effector	process,	
27:	FGFBP2	
Fibroblast	growth	
factor	binding	protein	
2	 -6.38691	 0.00225944	 Molecular	function:	protein	binding	
28:	
TNFAIP3	
TNF	alpha	induced	
protein	3	 -6.26505	 0.000214707	
Molecular	function:	nucleic	acid	binding,	protein	binding,	ubiquitin	binding,	enzyme	binding,	Biological	process:	
regulation	of	biological	process,	negative	regulation	of	metabolic	process,	positive	regulation	of	metabolic	process,	
regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	
biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	regulation	of	cell	
communication,	regulation	of	cell	death,	regulation	of	cell	proliferation,	regulation	of	cell	activation,	negative	regulation	
of	signalling,	negative	regulation	of	response	to	stimulus,	negative	regulation	of	immune	system	process,	positive	
regulation	of	response	to	stimulus,	regulation	of	signal	transduction,	regulation	of	immune	response,	regulation	of	
cytokine	production,		regulation	of	leukocyte	activation,	regulation	of	catalytic	activity,	regulation	of	transferase	activity,	
cellular	metabolic	process,	macromolecule	metabolic	process,	protein	metabolic	process,	cellular	response	to	stimulus,	
cellular	response	to	stress,	cellular	response	to	organic	substance,	cellular	response	to	oxygen-containing	compound,	
cellular	response	to	biotic	stimulus,	activation	of	immune	response,	innate	immune	response-activating	signal	
transduction,	Cellular	component:	nucleus	
29:	LITAF	
Lipopolysaccharide	
induced	TNF	factor	 -6.24573	 1.43E-05	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	metabolic	
process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	
of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	regulation	of	cell	
communication,	negative	regulation	of	signalling,	negative	regulation	of	response	to	stimulus,	positive	regulation	of	
response	to	stimulus,	positive	regulation	of	signalling,	regulation	of	response	to	stress,	regulation	of	signal	transduction,	
regulation	of	cytokine	production,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	
macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	
process,	nucleic	acid	metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	organic	substance,	cellular	
response	to	oxygen-containing	compound,	cellular	response	to	biotic	stimulus,	Cellular	component:	nucleus	
30:	TTC38	
Tetratricopeptide	
repeat	domain	38	 -6.0756	 3.32E-05	 		
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31:	TSPYL2	 TSPY-like	2	 -6.0544	 8.76E-06	
Molecular	function:	nucleic	acid	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	
regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	
of	cellular	component	organisation,	regulation	of	signal	transduction,	regulation	of	catalytic	activity,	regulation	of	
transferase	activity,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	
macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	
process,	nucleic	acid	metabolic	process,	protein	metabolic	process,	cellular	response	to	stress,	Cellular	component:	
nucleus	
32:	CEBPB	
CCAAT/enhancer	
binding	protein	beta	 -6.03796	 0.00278859	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity,	sequence-specific	DNA	binding,	nucleic	acid	binding,	
protein	binding,	enzyme	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	metabolic	
process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	
compound	metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	
regulation	of	cellular	process,	regulation	of	cell	death,	regulation	of	cell	differentiation,	regulation	of	cell	proliferation,	
regulation	of	cell	activation,	negative	regulation	of	immune	system	process,	regulation	of	cytokine	production,	
regulation	of	haemopoiesis,	regulation	of	leukocyte	activation,	cellular	metabolic	process,	macromolecule	metabolic	
process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	
nitrogen	compound	biosynthetic	process,	nucleic	acid	metabolic	process,	cellular	response	to	stimulus,	cellular	response	
to	organic	substance,	cellular	response	to	oxygen-containing	compound,	cellular	response	to	biotic	stimulus,	immune	
effector	process,	Cellular	component:	nucleus	
33:	AXUD1	
Cystein	and	serine	rich	
nuclear	protein	1	
(CSRNP1)	 -5.88495	 0.000534201	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity,	sequence-specific	DNA	binding,	nucleic	acid	binding,	
protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	metabolic	process,	regulation	
of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	biosynthetic	
process,	positive	regulation	of	cellular	process,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	
metabolic	process,	macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	
compound	biosynthetic	process,	nucleic	acid	metabolic	process,	Cellular	component:	nucleus	
34:	PAPD5	
PAP	associated	domain	
containing	5	 -5.86556	 1.15E-06	
Molecular	function:	nucleic	acid	binding,	Biological	process:	cellular	metabolic	process,	macromolecule	metabolic	
process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	macromolecule	catabolic	process,	aromatic	
compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	nucleic	acid	metabolic	process,		
35:	SIK1	 Salt	inducible	kinase	1	 -5.82807	 0.000485443	
Molecular	function:	protein	binding,	14-3-3	protein	binding,	enzyme	binding,	Biological	process:	regulation	of	biological	
process,	negative	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	
nitrogen	compound	metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	
positive	regulation	of	cellular	process,	regulation	of	cell	death,	regulation	of	cell	differentiation,	cellular	metabolic	
process,	macromolecule	metabolic	process,	protein	metabolic	process,	cellular	response	to	stress,	Cellular	component:	
nucleus	
36:	KIR2DL1	
Killer	cell	
immunoglobulin	like	
receptor,	two	Ig	
domains	and	long	
cytoplasmic	tail	1	 -5.76616	 0.000272508	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	cellular	process,	
regulation	of	immune	response,	
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37:	CD6	 CD6	molecule	 -5.72147	 0.00163171	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	cellular	
process,	regulation	of	cell	proliferation,	regulation	of	cell	activation,	positive	regulation	of	response	to	stimulus,	
regulation	of	response	to	stress,	regulation	of	cytokine	production,	regulation	of	leukocyte	activation,	
38:	
FLJ20699	
Hypothetical	protein	
FLJ20699	 -5.7033	 3.94E-05	 		
39:	KRT72	 Keratin	72	 -5.67577	 0.000138919	 Molecular	function:	protein	binding	
40:	VPS37B	
VPS37B,	ESCRT-I	
subunit	 -5.64907	 1.06E-05	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	cellular	
process,	regulation	of	cellular	component	organisation,	macromolecule	metabolic	process,	protein	metabolic	process,	
41:	SKP1	
S-phase	kinase-
associated	protein	1	 -5.56396	 1.85E-06	
Molecular	function:	protein	binding,	beta-catenin	binding,	Biological	process:	regulation	of	biological	process,	positive	
regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	positive	regulation	of	cellular	process,	
positive	regulation	of	response	to	stimulus,	regulation	of	response	to	stress,	regulation	of	immune	response,	regulation	
of	catalytic	activity,	regulation	of	transferase	activity,	cellular	metabolic	process,	macromolecule	metabolic	process,	
macromolecule	catabolic	process,	protein	metabolic	process,	protein	catabolic	process,	cellular	response	to	stimulus,	
cellular	response	to	stress,	activation	of	immune	response,	innate	immune	response-activating	signal	transduction,	
Cellular	component:	nucleus	
42:	CXCR4	
C-X-C	motif	chemokine	
receptor	4	 -5.43049	 9.47E-05	
Molecular	function:	protein	binding,	ubiquitin	binding,	enzyme	binding,	Biological	process:	regulation	of	biological	
process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	positive	regulation	of	
cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	differentiation,	positive	
regulation	of	response	to	stimulus,	positive	regulation	of	signalling,	regulation	of	signal	transduction,	regulation	of	
catalytic	activity,	regulation	of	transferase	activity,	cellular	response	to	stimulus,	cellular	response	to	organic	substance	
43:	GRASP	
GRP1	(general	receptor	
for	phosphoinositides	
1)-associated	scaffold	
protein	 -5.30277	 0.000332761	
Molecular	function:	enzyme	binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	
cellular	process,	
44:	PDGFRB	
Platelet	derived	
growth	factor	receptor	
beta	 -5.27544	 0.00101308	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	regulation	of	biological	process,	positive	
regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	
metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	
cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	proliferation,	regulation	of	
cellular	component	organisation,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	signalling,	regulation	
of	signal	transduction,	regulation	of	immune	response,	regulation	of	catalytic	activity,	regulation	of	transferase	activity,	
cellular	metabolic	process,	macromolecule	metabolic	process,	macromolecule	biosynthetic	process,	protein	metabolic	
process,	cellular	response	to	stimulus,	cellular	response	to	organic	substance,	Cellular	component:	nucleus	
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45:	RORA	
RAR	related	orphan	
receptor	A	 -5.25244	 2.52E-05	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity	sequence-specific	DNA	binding,	nucleic	acid	binding,	
protein	binding,	beta-catenin	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	
regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	
regulation	of	cell	communication,	regulation	of	cell	differentiation,	regulation	of	cell	activation,	negative	regulation	of	
signalling,	negative	regulation	of	response	to	stimulus,	negative	regulation	of	developmental	process,	regulation	of	
response	to	stress,	regulation	of	signal	transduction,	regulation	of	cytokine	production,	regulation	of	leukocyte	
activation,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	
biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	nucleic	
acid	metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	stress,	cellular	response	to	organic	substance,	
cellular	response	to	oxygen-containing	compound,	immune	effector	process,	Cellular	component:	nucleus	
46:	PDZD8	
PDZ	domain	containing	
8	 -5.17657	 1.08E-06	
Biological	process:	regulation	of	biological	process,	regulation	of	cellular	process,	regulation	of	cellular	component	
organisation,	
47:	ITPRIP	
Inositol	1,4,5-
triphosphate	receptor	
interacting	protein	 -5.16864	 1.42E-05	 		
48:	GRK5	
G	protein-coupled	
receptor	kinase	5	 -5.11813	 3.37E-06	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	regulation	of	biological	process,	negative	
regulation	of	cellular	process,	positive	regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	of	cell	
death,	regulation	of	cell	proliferation,	negative	regulation	of	signalling,	negative	regulation	of	response	to	stimulus,	
regulation	of	signal	transduction,	cellular	metabolic	process,	macromolecule	metabolic	process,	protein	metabolic	
process,	Cellular	component:	nucleus	
49:	FAM46C	
Family	with	sequence	
similarity	46	member	C	 -5.06949	 0.0014106	 Molecular	function:	protein	binding	
50:	CCL3	
C-C	motif	chemokine	
ligand	3	(MIP1A)	 -4.98915	 0.00117228	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
metabolic	process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	
of	nitrogen	compound	metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	
positive	regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	
differentiation,	regulation	of	cellular	component	organisation,	negative	regulation	of	immune	system	process,	negative	
regulation	of	developmental	process,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	signalling,	
regulation	of	response	to	stress,	regulation	of	signal	transduction,	regulation	of	cytokine	production,	regulation	of	
haemopoiesis,	regulation	of	catalytic	activity,	cellular	metabolic	process,	macromolecule	metabolic	process,	protein	
metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	organic	substance,	immune	effector	process,	
51:	MYLIP	
Myosin	regulatory	light	
chain	interacting	
protein	 -4.98539	 9.49E-05	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	metabolic	
process,	regulation	of	macromolecule	metabolic	process,	regulation	of	cellular	process,	cellular	metabolic	process,	
macromolecule	metabolic	process,	protein	metabolic	process,	
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52:	KLF9	 Kruppel-like	factor	9	 -4.95965	 2.48E-05	
Molecular	function:	nucleic	acid	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	metabolic	
process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	
of	biosynthetic	process,	negative	regulation	of	cellular	process,	regulation	of	cell	proliferation,	cellular	metabolic	
process,	macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	aromatic	
compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	nucleic	acid	metabolic	process,	
cellular	response	to	stimulus,	cellular	response	to	organic	substance,	cellular	response	to	oxygen-containing	compound,	
Cellular	component:	nucleus	
53:	DYNLL2	
Dynein	light	chain	LC8-
type	2	 -4.93551	 2.21E-08	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	cellular	
process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cellular	component	organisation,	
positive	regulation	of	response	to	stimulus,	positive	regulation	of	signalling,	regulation	of	signal	transduction,	cellular	
metabolic	process,	macromolecule	metabolic	process,	protein	metabolic	process,	Cellular	component:	nucleus	
54:	CEP78	
Centrosomal	protein	
78	 -4.85833	 1.06E-06	 		
55:	FOSL2	
FOS	like	2,	AP-1	
transcription	factor	
subunit	 -4.84719	 2.65E-05	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity,	sequence-specific	DNA	binding,	nucleic	acid	binding,	
protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	metabolic	process,	regulation	
of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	biosynthetic	
process,	positive	regulation	of	cellular	process,	regulation	of	cell	proliferation,	cellular	metabolic	process,	macromolecule	
metabolic	process,	RNA	metabolic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	
biosynthetic	process,	nucleic	acid	metabolic	process,	Cellular	component:	nucleus	
56:	
TNFRSF1B	
Tumor	necrosis	factor	
receptor	superfamily	
member	1B	 -4.84414	 6.47E-06	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:		regulation	of	biological	process,	positive	
regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	positive	regulation	of	cellular	process,	
regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	proliferation,	negative	regulation	of	
response	to	stimulus,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	signalling,	regulation	of	response	
to	stress,	regulation	of	signal	transduction,	macromolecule	biosynthetic	process,	cellular	response	to	stimulus,	cellular	
response	to	stress,	cellular	response	to	organic	substance,	cellular	response	to	oxygen-containing	compound,	cellular	
response	to	biotic	stimulus,	Cellular	component:	nucleus	
57:	CSNK1D	 Casein	kinase	1	delta	 -4.71518	 1.33E-05	
Molecular	function:	nucleic	acid	binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	
regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	positive	regulation	of	cellular	process,	
regulation	of	cell	communication,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	signalling,	regulation	
of	signal	transduction,	cellular	metabolic	process,	macromolecule	metabolic	process,	nucleic	acid	metabolic	process,	
protein	metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	stress,	cellular	response	to	organic	
substance,	Cellular	component:	nucleus	
58:	
C20orf111	
Oxidative	stress	
responsive	serine-rich	
1	(OSER1)	 -4.62266	 5.57E-07	 Biological	process:	cellular	response	to	stress,	cellular	response	to	oxygen-containing	compound,	
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59:	DUSP1	
Dual	specificity	
phosphatase	1	 -4.55328	 0.00115392	
Molecular	function:		protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	
regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	
regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cellular	component	organisation,	negative	
regulation	of	signalling,	negative	regulation	of	response	to	stimulus,	regulation	of	signal	transduction,	regulation	of	
catalytic	activity,	regulation	of	transferase	activity,	cellular	metabolic	process,	macromolecule	metabolic	process,	protein	
metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	organic	substance,	Cellular	component:	nucleus	
60:	GPR56	
Adhesion	G	protein-
coupled	receptor	G1	
(ADGRG1)	 -4.43599	 0.00293259	 		
61:	
HS.143408	
	cDNA	clone	
IMAGE:30332316	 -4.38505	 1.32E-05	 		
62:	IDS	 Iduronate	2-sulfatase	 -4.37555	 1.10E-05	 Biological	process:	cellular	metabolic	process,	macromolecule	catabolic	process,	
63:	
LOC641825	
Hypothetical	protein	
LOC641825	 -4.33639	 4.55E-05	 		
64:	
LOC54103	
Gamma-secretase	
activating	protein	
(GSAP)	 -4.29944	 0.000123193	 		
65:	CRY1	
Cryptochrome	
circadian	clock	1	 -4.29574	 6.89E-05	
Molecular	function:	nucleic	acid	binding,	protein	binding,	enzyme	binding,	ubiquitin	binding,	transcription	factor	
activity-	transcription	factor	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	
regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	regulation	of	cell	communication,	negative	
regulation	of	signalling,	negative	regulation	of	response	to	stimulus,	regulation	of	response	to	stress,	regulation	of	signal	
transduction,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	
biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	nucleic	
acid	metabolic	process,	protein	metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	stress,	Cellular	
component:	nucleus	
66:	RIPK2	
Receptor	interacting	
serine/threonine	
kinase	2	 -4.28315	 1.49E-06	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	metabolic	
process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	
of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	regulation	of	cell	
communication,	regulation	of	cell	death,	regulation	of	cell	differentiation,	regulation	of	cell	proliferation,	regulation	of	
cell	activation,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	signalling,	regulation	of	response	to	
stress,	regulation	of	signal	transduction,	regulation	of	immune	response,	regulation	of	cytokine	production,	regulation	of	
haemopoiesis,	regulation	of	leukocyte	activation,	regulation	of	catalytic	activity,	regulation	of	transferase	activity,	
cellular	metabolic	process,	macromolecule	metabolic	process,	protein	metabolic	process,	cellular	response	to	stimulus,	
cellular	response	to	stress,	cellular	response	to	organic	substance,	cellular	response	to	oxygen-containing	compound,	
cellular	response	to	biotic	stimulus,	activation	of	immune	response,	innate	immune	response-activating	signal	
transduction,	
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67:	LMTK2	
Lemur	tyrosine	kinase	
2	 -4.2608	 3.04E-05	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
metabolic	process,	regulation	of	catalytic	activity,	cellular	metabolic	process,	macromolecule	metabolic	process,	protein	
metabolic	process,	
68:	AKR1C3	
Aldo-keto	reductase	
family	1,	member	C3	 -4.24203	 0.0117979	
Biological	process:	regulation	of	biological	process,	negative	regulation	of	metabolic	process,	positive	regulation	of	
metabolic	process,	regulation	of	biosynthetic	process,	regulation	of	vitamin	metabolic	process,	negative	regulation	of	
cellular	process,	positive	regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	
regulation	of	cell	proliferation,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	signalling,	regulation	of	
signal	transduction,	cellular	metabolic	process,	macromolecule	metabolic	process,	cellular	response	to	stimulus,	cellular	
response	to	stress,	cellular	response	to	organic	substance,	cellular	response	to	oxygen-containing	compound,	Cellular	
component:	nucleus	
69:	ZFP36	
ZFP36	ring	finger	
protein	 -4.23717	 0.00023585	
Molecular	function:	nucleic	acid	binding,	protein	binding,	14-3-3	protein	binding,	enzyme	binding,	Biological	process:	
regulation	of	biological	process,	negative	regulation	of	metabolic	process,	positive	regulation	of	metabolic	process,	
regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	
biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	regulation	of	cell	
differentiation,	negative	regulation	of	response	to	stimulus,	negative	regulation	of	immune	system	process,	negative	
regulation	of	developmental	process,	regulation	of	response	to	stress,	regulation	of	cytokine	production,	regulation	of	
haemopoiesis,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	
catabolic	process,	nucleic	acid	metabolic	process,	Cellular	component:	nucleus	
70:	
LOC401321	
Long	intergenic	non-
protein	coding	RNA	
997	(LINC00997)	 -4.23554	 9.19E-05	 		
71:	MAF	
MAF	bZIP	transcription	
factor	 -4.23022	 1.91E-05	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity,	sequence-specific	DNA	binding,	nucleic	acid	binding,	
protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	metabolic	process,	positive	
regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	
metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	
cellular	process,	regulation	of	cell	differentiation,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	
metabolic	process,	macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	
compound	biosynthetic	process,	nucleic	acid	metabolic	process,	Cellular	component:	nucleus	
72:	IRS2	
Insulin	receptor	
substrate	2	 -4.2026	 0.000525941	
Molecular	function:	protein	binding,	14-3-3	protein	binding,	enzyme	binding,	Biological	process:	regulation	of	biological	
process,	negative	regulation	of	metabolic	process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	
metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	
cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	proliferation,	regulation	of	
cell	activation,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	signalling,	regulation	of	signal	
transduction,	regulation	of	immune	response,	regulation	of	leukocyte	activation,	regulation	of	catalytic	activity,	
regulation	of	transferase	activity,	cellular	metabolic	process,	macromolecule	metabolic	process,	protein	metabolic	
process,	cellular	response	to	stimulus,	cellular	response	to	organic	substance,	cellular	response	to	oxygen-containing	
compound,	
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73:	
LOC653171	
Similar	to	MAPK-
interacting	and	
spindle-stabilising	
protein	 -4.17584	 3.51E-05	 		
74:	RGS1	
Regulator	of	G-protein	
signalling	1	 -4.12889	 0.0190503	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	metabolic	
process,	negative	regulation	of	cellular	process,	regulation	of	cell	communication,	negative	regulation	of	signalling,	
negative	regulation	of	response	to	stimulus,	regulation	of	signal	transduction,	regulation	of	catalytic	activity,	Cellular	
component:	nucleus	
75:	EFHD2	
EF-hand	domain	family	
member	D2	 -4.11862	 1.89E-05	 		
76:	SBDS	
SBDS	ribosome	
assembly	guanine	
nucleotide	exchange	
factor	 -4.07864	 0.000116519	
Molecular	function:	nucleic	acid	binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	
regulation	of	cellular	process,	regulation	of	cellular	component	organisation,	cellular	metabolic	process,	macromolecule	
metabolic	process,	RNA	metabolic	process,	nucleic	acid	metabolic	process,	Cellular	component:	nucleus	
77:	
LOC100132
532	
Hypothetical	protein	
LOC100132532	 -4.07229	 3.10E-06	 		
78:	GNG2	
G	protein	subunit	
gamma	2	 -4.03382	 0.00139634	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	cellular	process,	
cellular	metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	organic	substance,	cellular	response	to	
oxygen-containing	compound,	
79:	
ANKRD9	
Ankyrin	repeat	domain	
9	 -4.01612	 0.000149612	 		
80:	
LOC729009	
Ferritin,	heavy	
polypeptide	1	
pseudogene	20	
(FTH1P20)	 -4.00527	 9.90E-05	 		
81:	
SNORD35B	
Small	nucleolar	RNA,	
C/D	box	35B	 -3.98344	 3.17E-05	 		
82:	RAD23B	
RAD23	homolog	B,	
nucleotide	excision	
repair	protein	 -3.97262	 2.58E-06	
Molecular	function:	nucleic	acid	binding,	protein	binding,	ubiquitin	binding,	Biological	process:	regulation	of	biological	
process,	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	cellular	process,	
cellular	metabolic	process,	macromolecule	metabolic	process,	macromolecule	catabolic	process,	nucleic	acid	metabolic	
process,	protein	metabolic	process,	protein	catabolic	process,	cellular	response	to	stimulus,	cellular	response	to	stress,	
Cellular	component:	nucleus	
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83:	DDIT4	
DNA	damage	inducible	
transcript	4	 -3.94258	 0.000179109	
Molecular	function:	protein	binding,	14-3-3	protein	binding,	Biological	process:	regulation	of	biological	process,	
negative	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	
compound	metabolic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	regulation	
of	cell	communication,	regulation	of	cell	death,	negative	regulation	of	signalling,	negative	regulation	of	response	to	
stimulus,	regulation	of	signal	transduction,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	
process,	macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	
biosynthetic	process,	nucleic	acid	metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	stress,	immune	
effector	process,	
84:	
SNORD68	
Small	nucleolar	RNA,	
C/D	box	68	 -3.88823	 3.17E-06	 		
85:	GZMB	 Granzyme	B	 -3.87638	 0.000653158	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	cellular	
process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cellular	component	organisation,	
positive	regulation	of	response	to	stimulus,	positive	regulation	of	signalling,	regulation	of	signal	transduction,	
macromolecule	metabolic	process,	protein	metabolic	process,		immune	effector	process,	Cellular	component:	nucleus	
86:	PMAIP1	
Phorbol-12-myristate-
13-acetate-induced	
protein	1	 -3.84674	 0.000835359	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	metabolic	
process,	regulation	of	macromolecule	metabolic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	
cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	proliferation,	regulation	of	
cellular	component	organisation,	positive	regulation	of	response	to	stimulus,	positive	regulation	of	signalling,	regulation	
of	response	to	stress,	regulation	of	signal	transduction,	regulation	of	catalytic	activity,	cellular	metabolic	process,	
macromolecule	metabolic	process,	macromolecule	catabolic	process,	protein	metabolic	process,	cellular	response	to	
stimulus,		cellular	response	to	stress,	immune	effector	process,	Cellular	component:	nucleus	
87:	ASCL2	
Achaete-scute	family	
bHLH	transcription	
factor	2	 -3.8115	 0.000134537	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity,	sequence-specific	DNA	binding,	nucleic	acid	binding,	
protein	binding,		Biological	process:	regulation	of	biological	process,	negative	regulation	of	metabolic	process,	regulation	
of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	biosynthetic	
process,	negative	regulation	of	cellular	process,	regulation	of	cell	differentiation,	regulation	of	cell	proliferation,	negative	
regulation	of	developmental	process,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	
process,	macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	
biosynthetic	process,	nucleic	acid	metabolic	process,	Cellular	component:	nucleus	
88:	TXNDC3	
NME/NM23	family	
member	8	 -3.80617	 0.00042157	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	cellular	
process,	regulation	of	cell	communication,	regulation	of	cell	death,		negative	regulation	of	signalling,	negative	regulation	
of	response	to	stimulus,	regulation	of	response	to	stress,	regulation	of	signal	transduction,	cellular	metabolic	process,	
aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	cellular	response	to	
stimulus,	cellular	response	to	stress,	cellular	response	to	oxygen-containing	compound,	
89:	
LOC387820	
DnaJ	heat	shock	
protein	family	(Hsp40)	
member	B7	
pseudogene	 -3.79525	 5.17E-06	 		
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90:	
FAM179A	
Family	with	sequence	
similarity	179	member	
A	 -3.79388	 5.06E-07	 		
91:	MIAT	
Myocardial	infarction	
associated	transcript	 -3.78145	 0.00178191	 		
92:	UAP1	
UDP-N-
acetylglucosamine	
pyrophosphorylase	 -3.78068	 1.33E-07	
Molecular	function:	protein	binding,	Biological	process:	cellular	metabolic	process,	macromolecule	metabolic	process,	
aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	protein	metabolic	process,	
93:	EIF1	
Eukaryotic	translation	
initiation	factor	1	 -3.77013	 8.42E-07	
Molecular	function:	nucleic	acid	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	metabolic	
process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	
of	biosynthetic	process,	regulation	of	cellular	process,	cellular	metabolic	process,	Cellular	component:	nucleus	
94:	
LOC731878	
Similar	to	MAPK-
interacting	and	
spindle-stabilising	
protein	 -3.76785	 2.87E-05	 		
95:	GTF3C1	
General	transcription	
factor	IIIC	subunit	1	 -3.72939	 0.000111718	
Molecular	function:	protein	binding,	Biological	process:	cellular	metabolic	process,	macromolecule	metabolic	process,	
RNA	metabolic	process,	macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	
compound	biosynthetic	process,	nucleic	acid	metabolic	process,	Cellular	component:	nucleus	
96:	RNF10	 Ring	finger	protein	10	 -3.72922	 5.78E-07	
Molecular	function:	nucleic	acid	binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	
regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	
metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	
cellular	process,	regulation	of	cell	differentiation,	regulation	of	cell	proliferation,	negative	regulation	of	developmental	
process,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	
biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	nucleic	
acid	metabolic	process,	protein	metabolic	process,	Cellular	component:	nucleus	
97:	
ZFAND2A	
Zinc	finger,	AN1-type	
domain	2A	 -3.69312	 7.12E-06	
Biological	process:	regulation	of	biological	process,	positive	regulation	of	metabolic	process,	regulation	of	
macromolecule	metabolic	process,	positive	regulation	of	cellular	process,	cellular	response	to	stimulus,	Cellular	
component:	nucleus	
98:	YPEL5	 Yippee	like	5	 -3.68677	 0.000482135	 		
99:	
RMND5A	
Required	for	meiotic	
nuclear	division	5	
homolog	A	 -3.66497	 1.55E-06	 Molecular	function:	protein	binding	
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100:	
ZC3H12A	
Zinc	finger	CCCH	type	
containing	12A	 -3.66218	 0.000466131	
Molecular	function:	nucleic	acid	binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	
regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	
metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	
cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	differentiation,	regulation	of	
cell	activation,	negative	regulation	of	signalling,	negative	regulation	of	response	to	stimulus,	negative	regulation	of	
immune	system	process,	regulation	of	response	to	stress,	regulation	of	signal	transduction,	regulation	of	cytokine	
production,	regulation	of	leukocyte	activation,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	
metabolic	process,	nucleic	acid	metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	organic	substance,	
cellular	response	to	oxygen-containing	compound,	cellular	response	to	biotic	stimulus,	Cellular	component:	nucleus	
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1:	TSC22D3	
TSC22	domain	family	
member	3	 -16.0053	 1.67E-05	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	cellular	
process,	regulation	of	metabolic	process,	regulation	of	developmental	process,	regulation	of	macromolecule	
metabolic	process,	regulation	of	biosynthetic	process,	regulation	of	nitrogen	compound	metabolic	process,	
negative	regulation	of	metabolic	process,	negative	regulation	of	cellular	process,	regulation	of	cell	death,	negative	
regulation	of	multicellular	organismal	process,	negative	regulation	of	immune	system	process,	negative	regulation	
of	developmental	process,	negative	regulation	of	homeostatic	process,	regulation	of	multicellular	organismal	
development,	Cellular	Component:	nucleus	
2:	NR4A2	
Nuclear	receptor	
subfamily	4,	group	A,	
member	2	 -15.3753	 0.000218455	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity	sequence-specific	DNA	binding,	nucleic	acid	
binding,	protein	binding,	beta-catenin	binding,	Biological	process:	regulation	of	biological	process,	negative	
regulation	of	metabolic	process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	
process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	biosynthetic	process,	negative	
regulation	of	cellular	process,	positive	regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	
of	cell	death,	negative	regulation	of	signalling,	negative	regulation	of	response	to	stimulus,	regulation	of	signal	
transduction,	regulation	of	catalytic	activity,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	
metabolic	process,	macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	
nitrogen	compound	biosynthetic	process,	nucleic	acid	metabolic	process,	cellular	response	to	stimulus,	cellular	
response	to	stress,	cellular	response	to	organic	substance,	cellular	response	to	oxygen-containing	compound,	
Cellular	component:	nucleus	
3:	TNFAIP3	
TNF	alpha	induced	
protein	3	 -11.9515	 3.91E-05	
Molecular	function:	nucleic	acid	binding,	protein	binding,	ubiquitin	binding,	enzyme	binding,	Biological	process:	
regulation	of	biological	process,	regulation	of	cellular	process,	regulation	of	metabolic	process,	regulation	of	
developmental	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	
regulation	of	nitrogen	compound	metabolic	process,	negative	regulation	of	metabolic	process,	positive	regulation	
of	metabolic	process,	regulation	of	catabolic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	
cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	negative	regulation	of	signalling,	
negative	regulation	of	response	to	stimulus,	negative	regulation	of	multicellular	organismal	process,	negative	
regulation	of	immune	system	process,	negative	regulation	of	homeostatic	process,	positive	regulation	of	
multicellular	organismal	process,	positive	regulation	of	response	to	stimulus,	regulation	of	signal	transduction,	
regulation	of	response	to	cytokine	stimulus,	regulation	of	cytokine	production,	regulation	of	multicellular	
organismal	development,	negative	regulation	of	sequence-specific	DNA	binding	transcription	factor	activity,	
negative	regulation	of	catalytic	activity,	regulation	of	transferase	activity,	cellular	macromolecule	metabolic	
process,	RNA	metabolic	process,	cellular	macromolecule	biosynthetic	process,	cellular	protein	metabolic	process,	
nucleobase-containing	compound	metabolic	process,	protein	modification	process,	proteolysis,	cellular	response	
to	stress,	cellular	response	to	organic	substance,	cellular	response	to	oxygen-containing	compound,	cellular	
response	to	biotic	stimulus,	innate	immune	response-activating	signal	transduction,	defense	response	to	virus,	
Cellular	component:	nucleus	
4:	RGS2	
Regulator	of	G-protein	
signalling	2	 -11.3949	 1.57E-05	
Molecular	function:	protein	binding,	Biological	process:	negative	regulation	of	biological	process,	positive	
regulation	of	biological	process,	negative	regulation	of	metabolic	process,	positive	regulation	of	metabolic	process,	
regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	
biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,		regulation	of	
cell	communication,	negative	regulation	of	signalling,	negative	regulation	of	response	to	stimulus,	regulation	of	
signal	transduction,	regulation	of	catalytic	activity,	regulation	of	transferase	activity,	Cellular	component:	nucleus	
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5:	SIK1	 Salt	inducible	kinase	1	 -10.3534	 0.000101987	
Molecular	function:	protein	binding,	14-3-3	protein	binding,	enzyme	binding,	Biological	process:	regulation	of	
biological	process,	negative	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	
regulation	of	nitrogen	compound	metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	
cellular	process,	positive	regulation	of	cellular	process,	regulation	of	cell	death,	regulation	of	cell	differentiation,	
cellular	metabolic	process,	macromolecule	metabolic	process,	protein	metabolic	process,	cellular	response	to	
stress,	Cellular	component:	nucleus	
6:	AXUD1	
Cystein	and	serine	rich	
nuclear	protein	1	
(CSRNP1)	 -9.30016	 0.000151313	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity,	sequence-specific	DNA	binding,	nucleic	acid	
binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	metabolic	
process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	
regulation	of	biosynthetic	process,	positive	regulation	of	cellular	process,	cellular	metabolic	process,	
macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	aromatic	
compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	nucleic	acid	metabolic	process,	
Cellular	component:	nucleus	
7:	RGS1	
Regulator	of	G-protein	
signalling	1	 -9.26186	 0.00246842	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	
metabolic	process,	negative	regulation	of	cellular	process,	regulation	of	cell	communication,	negative	regulation	of	
signalling,	negative	regulation	of	response	to	stimulus,	regulation	of	signal	transduction,	regulation	of	catalytic	
activity,	Cellular	component:	nucleus	
8:	RBM38	
RNA	binding	motif	
protein	38	 -7.335	 1.47E-06	
Molecular	function:	nucleic	acid	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	
process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	regulation	of	cell	death,	
regulation	of	cell	differentiation,	regulation	of	cell	proliferation,	cellular	metabolic	process,	macromolecule	
metabolic	process,	RNA	metabolic	process,	nucleic	acid	metabolic	process,	cellular	response	to	stimulus,	cellular	
response	to	stress,	Cellular	component:	nucleus	
9:	DUSP1	
Dual	specificity	
phosphatase	1	 -7.1498	 0.000285629	
Molecular	function:		protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	
process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	
process,	regulation	of	cell	communication,	regulation	of	cell	death,	negative	regulation	of	signalling,	negative	
regulation	of	response	to	stimulus,	regulation	of	signal	transduction,	regulation	of	catalytic	activity,	regulation	of	
transferase	activity,	cellular	metabolic	process,	macromolecule	metabolic	process,	protein	metabolic	process,	
cellular	response	to	stimulus,	cellular	response	to	organic	substance,	Cellular	component:	nucleus	
10:	ATG2A	 Autophagy	related	2A	 -6.78419	 7.38E-07	 Molecular	function:	protein	binding	
11:	GRASP	
GRP1	(general	receptor	
for	phosphoinositides	1)-
associated	scaffold	
protein	 -6.41601	 0.000183191	
Molecular	function:	enzyme	binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	
regulation	of	cellular	process	
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12:	NFKBIA	 NFKB	inhibitor	alpha	 -6.36754	 7.53E-05	
Molecular	function:	transcription	factor	binding,	enzyme	binding,	protein	binding,	Biological	process:	regulation	of	
biological	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	negative	
regulation	of	metabolic	process,	positive	regulation	of	metabolic	process,	regulation	of	developmental	process,	
regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	regulation	of	nitrogen	
compound	metabolic	process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	
differentiation,	regulation	of	cell	proliferation,	negative	regulation	of	signalling,	negative	regulation	of	response	to	
stimulus,	negative	regulation	of	immune	system	process,	negative	regulation	of	developmental	process,	positive	
regulation	of	response	to	stimulus,		regulation	of	signal	transduction,	regulation	of	cytokine	production,	regulation	
of	haemopoiesis,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	protein	metabolic	process,	cellular	
response	to	stress,	cellular	response	to	organic	substance,	innate	immune	response-activating	signal	transduction,	
Cellular	component:	nucleus	
13:	CBX4	 Chromobox	4	 -5.57854	 2.24E-06	
Molecular	function:	nucleic	acid	binding,	enzyme	binding,	transcription	factor	activity-	transcription	factor	binding,	
protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	metabolic	process,	
regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	
biosynthetic	process,	negative	regulation	of	cellular	process,	regulation	of	cell	death,	cellular	metabolic	process,	
macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	aromatic	
compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	nucleic	acid	metabolic	process,	
protein	metabolic	process,	Cellular	component:	nucleus	
14:	ZFP36	 ZFP36	ring	finger	protein	 -5.50893	 9.27E-05	
Molecular	function:	nucleic	acid	binding,	protein	binding,	14-3-3	protein	binding,	enzyme	binding,	Biological	
process:	regulation	of	biological	process,	negative	regulation	of	metabolic	process,	positive	regulation	of	metabolic	
process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	
regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	
regulation	of	cell	differentiation,	negative	regulation	of	response	to	stimulus,	negative	regulation	of	immune	
system	process,	negative	regulation	of	developmental	process,	regulation	of	response	to	stress,	regulation	of	
cytokine	production,	regulation	of	haemopoiesis,	cellular	metabolic	process,	macromolecule	metabolic	process,	
RNA	metabolic	process,	macromolecule	catabolic	process,	nucleic	acid	metabolic	process,	Cellular	component:	
nucleus	
15:	JUN	
Jun	proto-oncogene,	AP-
1	transcription	factor	
subunit	 -5.3929	 0.00221514	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity,	sequence-specific	DNA	binding,	nucleic	acid	
binding,	transcription	factor	binding,	protein	binding,	enzyme	binding,	transcription	cofactor	activity,	Biological	
process:	regulation	of	biological	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	
process,	negative	regulation	of	metabolic	process,	positive	regulation	of	metabolic	process,	regulation	of	
developmental	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process,		
regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	differentiation,		regulation	of	cell	cycle,	
regulation	of	cell	proliferation,	positive	regulation	of	response	to	stimulus,	regulation	of	signal	transduction,	
regulation	of	haemopoiesis,	macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	
biosynthetic	process,	protein	metabolic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	
compound	biosynthetic	process,	protein	modification	process,	cellular	response	to	stress,	cellular	response	to	
organic	substance,	innate	immune	response-activating	signal	transduction,	Cellular	component:	nucleus,	
nucleoplasm,	
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16:	NFKBIZ	 NFKB	inhibitor	zeta	 -5.21802	 0.000269487	
Molecular	function:	protein	binding,	transcription	factor	binding,	transcription	cofactor	activity,	Biological	
process:	regulation	of	biological	process,	regulation	of	cellular	process,	regulation	of	metabolic	process,	regulation	
of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	regulation	of	nitrogen	compound	
metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	
process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	Cellular	
component:	nucleus	
17:	HOXA5	 Homeobox	A5	 -5.20602	 7.90E-05	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity,	sequence-specific	DNA	binding,	nucleic	acid	
binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	cellular	
process,	positive	regulation	of	cellular	process,	positive	regulation	of	metabolic	process,	regulation	of	
developmental	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	
regulation	of	nitrogen	compound	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	
regulation	of	cell	death,	regulation	of	cell	differentiation,	regulation	of	cell	proliferation,	negative	regulation	of	
immune	system	process,	negative	regulation	of	developmental	process,	negative	regulation	of	homeostatic	
process,	regulation	of	haemopoiesis,	macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	
biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	
Cellular	component:	nucleus	
18:	PDZD8	 PDZ	domain	containing	8	 -5.10741	 1.14E-06	 Biological	process:	regulation	of	biological	process,	regulation	of	cellular	process	
19:	CXCR4	
C-X-C	motif	chemokine	
receptor	4	 -5.09515	 0.000117577	
Molecular	function:	protein	binding,	ubiquitin	binding,	enzyme	binding,	Biological	process:	regulation	of	biological	
process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	positive	
regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	
differentiation,	positive	regulation	of	response	to	stimulus,	regulation	of	signal	transduction,	regulation	of	catalytic	
activity,	regulation	of	transferase	activity,	cellular	response	to	stimulus,	cellular	response	to	organic	substance		
20:	ZC3H12A	
Zinc	finger	CCCH	type	
containing	12A	 -5.03063	 0.000139604	
Molecular	function:	nucleic	acid	binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	
positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	
compound	metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	
regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	
differentiation,	negative	regulation	of	signalling,	negative	regulation	of	response	to	stimulus,	negative	regulation	of	
immune	system	process,	regulation	of	response	to	stress,	regulation	of	signal	transduction,	regulation	of	cytokine	
production,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	nucleic	acid	
metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	organic	substance,	cellular	response	to	
oxygen-containing	compound,	cellular	response	to	biotic	stimulus,	Cellular	component:	nucleus	
21:	FAM46C	
Family	with	sequence	
similarity	46	member	C	 -4.92382	 0.00154817	 Molecular	function:	protein	binding	
22:	PMAIP1	
Phorbol-12-myristate-
13-acetate-induced	
protein	1	 -4.85128	 0.000355688	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,	negative	regulation	of	cellular	process,	positive	
regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	
proliferation,	positive	regulation	of	response	to	stimulus,	regulation	of	response	to	stress,	regulation	of	signal	
transduction,	regulation	of	catalytic	activity,	cellular	metabolic	process,	macromolecule	metabolic	process,	
macromolecule	catabolic	process,	protein	metabolic	process,	cellular	response	to	stimulus,		cellular	response	to	
stress,	immune	effector	process,	Cellular	component:	nucleus	
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23:	YES1	
YES	proto-oncogene	1,	
Src	family	tyrosine	
kinase	 -4.80422	 8.77E-05	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	regulation	of	biological	process,	positive	
regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,		regulation	of	nitrogen	
compound	metabolic	process,	regulation	of	biosynthetic	process,	positive	regulation	of	cellular	process,	regulation	
of	cell	proliferation,	positive	regulation	of	response	to	stimulus,	cellular	metabolic	process,	macromolecule	
metabolic	process,	protein	metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	organic	substance,	
cellular	response	to	oxygen-containing	compound,	activation	of	immune	response,	immune	effector	process,	
24:	
LOC654126	
Similar	to	leucine	rich	
repeat	containing	37B	 -4.69526	 8.65E-07	 		
25:	FOSL2	
FOS	like	2,	AP-1	
transcription	factor	
subunit	 -4.62659	 3.15E-05	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity,	sequence-specific	DNA	binding,	nucleic	acid	
binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	metabolic	
process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	
regulation	of	biosynthetic	process,	positive	regulation	of	cellular	process,	regulation	of	cell	proliferation,	cellular	
metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	aromatic	compound	biosynthetic	
process,	cellular	nitrogen	compound	biosynthetic	process,	nucleic	acid	metabolic	process,	Cellular	component:	
nucleus	
26:	FOXC1	 Forkhead	box	C1	 -4.61397	 0.00101051	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity,	sequence-specific	DNA	binding,	nucleic	acid	
binding,	transcription	factor	binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	
regulation	of	cellular	process,	positive	regulation	of	cellular	process,	positive	regulation	of	metabolic	process,	
regulation	of	developmental	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	
process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	cell	death,	regulation	of	cell	
differentiation,	regulation	of	cell	cycle,	negative	regulation	of	developmental	process,	regulation	of	haemopoiesis,	
macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	aromatic	
compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	Cellular	component:	nucleus,	
nucleoplasm	
27:	MYLIP	
Myosin	regulatory	light	
chain	interacting	protein	 -4.60867	 0.000125826	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	cellular	process,	cellular	
metabolic	process,	macromolecule	metabolic	process,	protein	metabolic	process,	
28:	HAPLN3	
Hyaluronan	and	
proteoglycan	link	protein	
3	 -4.53249	 0.000145419	 		
29:	MYADM	
Myeloid-associated	
differentiation	marker	 -4.51229	 0.00296597	
Biological	process:	regulation	of	biological	process,	negative	regulation	of	cellular	process,	positive	regulation	of	
cellular	process,	negative	regulation	of	metabolic	process,	regulation	of	developmental	process,	regulation	of	
macromolecule	metabolic	process,	regulation	of	cell	communication,	regulation	of	cell	differentiation,	negative	
regulation	of	signalling,	negative	regulation	of	response	to	stimulus,	regulation	of	signal	transduction,	protein	
metabolic	process	
30:	WHAMM	
WAS	protein	homolog	
associated	with	actin,	
Golgi	membranes	and	
microtubules	 -4.48632	 1.03E-05	
Molecular	function:	enzyme	binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	
regulation	of	cellular	process	
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31:	
LOC401321	
Long	intergenic	non-
protein	coding	RNA	997	
(LINC00997)	 -4.4222	 7.77E-05	 		
32:	
LOC650832	
Similar	to	mitogen-
activated	protein	kinase	
kinase	3	isoform	A	 -4.39858	 3.24E-06	 		
33:	YPEL5	 Yippee	like	5	 -4.34256	 0.000252862	 		
34:	GARNL4	
RAP1	GTPase	activating	
protein	2	(RAP1GAP2)	 -4.29705	 0.000107014	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	
metabolic	process,	negative	regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	of	cell	
differentiation,	negative	regulation	of	developmental	process,	regulation	of	signal	transduction,	regulation	of	
catalytic	activity,	
35:	USP36	
Ubiquitin	specific	
peptidase	36	 -4.27741	 0.00252929	
Molecular	function:	nucleic	acid	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	
metabolic	process,	positive	regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	of	response	
to	stress,	cellular	metabolic	process,	macromolecule	metabolic	process,	macromolecule	catabolic	process,	protein	
metabolic	process,	Cellular	component:	nucleus	
36:	MAFF	
MAF	bZIP	transcription	
factor	F	 -4.23608	 0.000122889	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity,	sequence-specific	DNA	binding,	nucleic	acid	
binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	cellular	process,	positive	
regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	
process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	multicellular	organismal	development,	
macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	aromatic	
compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	Cellular	component:	nucleus,	
nucleoplasm	
37:	RNF10	 Ring	finger	protein	10	 -4.22158	 3.39E-07	
Molecular	function:	nucleic	acid	binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	
positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	
compound	metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	
regulation	of	cellular	process,	regulation	of	cell	differentiation,	regulation	of	cell	proliferation,	negative	regulation	
of	developmental	process,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	
macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	
biosynthetic	process,	nucleic	acid	metabolic	process,	protein	metabolic	process,	Cellular	component:	nucleus	
38:	LITAF	
Lipopolysaccharide	
induced	TNF	factor	 -4.1971	 5.84E-05	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	metabolic	
process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	process,	
regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	
regulation	of	cell	communication,	negative	regulation	of	signalling,	negative	regulation	of	response	to	stimulus,	
positive	regulation	of	response	to	stimulus,	regulation	of	response	to	stress,	regulation	of	signal	transduction,	
regulation	of	cytokine	production,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	
process,	macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	
compound	biosynthetic	process,	nucleic	acid	metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	
organic	substance,	cellular	response	to	oxygen-containing	compound,	cellular	response	to	biotic	stimulus,	Cellular	
component:	nucleus	
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39:	PAPD5	
PAP	associated	domain	
containing	5	 -4.04664	 4.61E-06	
Molecular	function:	nucleic	acid	binding,	Biological	process:	cellular	metabolic	process,	macromolecule	metabolic	
process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	macromolecule	catabolic	process,	aromatic	
compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	nucleic	acid	metabolic	process,		
40:	DDIT4	
DNA	damage	inducible	
transcript	4	 -3.95875	 0.000176161	
Molecular	function:	protein	binding,	14-3-3	protein	binding,	Biological	process:	regulation	of	biological	process,	
negative	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	
compound	metabolic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	
regulation	of	cell	communication,	regulation	of	cell	death,	negative	regulation	of	signalling,	negative	regulation	of	
response	to	stimulus,	regulation	of	signal	transduction,	cellular	metabolic	process,	macromolecule	metabolic	
process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	
cellular	nitrogen	compound	biosynthetic	process,	nucleic	acid	metabolic	process,	cellular	response	to	stimulus,	
cellular	response	to	stress,	immune	effector	process,	
41:	SKP1	
S-phase	kinase-
associated	protein	1	 -3.85902	 7.59E-06	
Molecular	function:	protein	binding,	beta-catenin	binding,	Biological	process:	regulation	of	biological	process,	
positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	positive	regulation	of	
cellular	process,	positive	regulation	of	response	to	stimulus,	regulation	of	response	to	stress,	regulation	of	catalytic	
activity,	regulation	of	transferase	activity,	cellular	metabolic	process,	macromolecule	metabolic	process,	
macromolecule	catabolic	process,	protein	metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	
stress,	activation	of	immune	response,	innate	immune	response-activating	signal	transduction,	Cellular	
component:	nucleus	
42:	CASZ1	 Castor	zinc	finger	1	 -3.82539	 3.09E-05	
Molecular	function:	nucleic	acid	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,		regulation	of	nitrogen	compound	metabolic	
process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	regulation	of	cell	
differentiation,	negative	regulation	of	developmental	process,	cellular	metabolic	process,	macromolecule	
metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	
process,	cellular	nitrogen	compound	biosynthetic	process,	nucleic	acid	metabolic	process		
43:	EIF1	
Eukaryotic	translation	
initiation	factor	1	 -3.78498	 8.27E-07	
Molecular	function:	nucleic	acid	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	
process,	regulation	of	biosynthetic	process,	regulation	of	cellular	process,	cellular	metabolic	process,	Cellular	
component:	nucleus	
44:	IRS2	
Insulin	receptor	
substrate	2	 -3.75916	 0.000809721	
Molecular	function:	protein	binding,	14-3-3	protein	binding,	enzyme	binding,	Biological	process:	regulation	of	
biological	process,	negative	regulation	of	metabolic	process,	positive	regulation	of	metabolic	process,	regulation	of	
macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	
positive	regulation	of	cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	
proliferation,	positive	regulation	of	response	to	stimulus,	regulation	of	signal	transduction,	regulation	of	catalytic	
activity,	regulation	of	transferase	activity,	cellular	metabolic	process,	macromolecule	metabolic	process,	protein	
metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	organic	substance,	cellular	response	to	
oxygen-containing	compound,	
45:	
C20orf111	
Oxidative	stress	
responsive	serine-rich	1	
(OSER1)	 -3.75245	 1.33E-06	 Biological	process:	cellular	response	to	stress,	cellular	response	to	oxygen-containing	compound	
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46:	FURIN	
Furin,	paired	basic	amino	
acid	cleaving	enzyme	 -3.74826	 0.000209643	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	regulation	of	biological	process,	negative	
regulation	of	cellular	process,	positive	regulation	of	cellular	process,	negative	regulation	of	metabolic	process,	
positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	
biosynthetic	process,	regulation	of	catabolic	process,	regulation	of	cell	communication,	positive	regulation	of	
response	to	stimulus,	regulation	of	signal	transduction,	regulation	of	cytokine	production,	negative	regulation	of	
catalytic	activity,	macromolecule	metabolic	process,	protein	metabolic	process,	cellular	nitrogen	compound	
biosynthetic	process,	proteolysis	
47:	IDS	 Iduronate	2-sulfatase	 -3.70641	 2.19E-05	 Biological	process:	cellular	metabolic	process,	macromolecule	catabolic	process,	
48:	TP53INP2	
Tumour	protein	p53	
inducible	nuclear	protein	
2	 -3.69845	 0.00021617	
Molecular	function:	protein	binding,	ubiquitin	binding,	Biological	process:	regulation	of	biological	process,	positive	
regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,		regulation	of	nitrogen	
compound	metabolic	process,	regulation	of	biosynthetic	process,	positive	regulation	of	cellular	process,	cellular	
metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	
process,	macromolecule	catabolic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	
biosynthetic	process,	nucleic	acid	metabolic	process,	protein	metabolic	process,	Cellular	component:	nucleus	
49:	IRF1	
Interferon	regulatory	
factor	1	 -3.66622	 4.96E-05	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity,	sequence-specific	DNA	binding,	nucleic	acid	
binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	cellular	
process,	positive	regulation	of	cellular	process,	negative	regulation	of	metabolic	process,	positive	regulation	of	
metabolic	process,	regulation	of	developmental	process,	regulation	of	macromolecule	metabolic	process,	
regulation	of	biosynthetic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	cell	
communication,	regulation	of	cell	differentiation,	regulation	of	cell	cycle,	regulation	of	cell	proliferation,	negative	
regulation	of	immune	system	process,	negative	regulation	of	developmental	process,	positive	regulation	of	
multicellular	organismal	process,	regulation	of	signal	transduction,	regulation	of	cytokine	production,	regulation	of	
haemopoiesis,	macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	
aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	cellular	response	to	
organic	substance,	defense	response	to	virus,	Cellular	component:	nucleus,	nucleoplasm	
50:	PIM3	
Pim-3	proto-oncogene,	
serine/threonine	kinase	 -3.66599	 0.000544484	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	cycle,	negative	
regulation	of	signalling,	negative	regulation	of	response	to	stimulus,	negative	regulation	of	homeostatic	process,	
macromolecule	metabolic	process,	protein	metabolic	process	
51:	C9orf21	
AhpC/TSA	antioxidant	
enzyme	domain	
containing	1	(AAED1)	 -3.65493	 0.000174966	 		
52:	RBM39	
RNA	binding	motif	
protein	39	 -3.65468	 6.68E-06	
Molecular	function:	nucleic	acid	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	
process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	regulation	of	cell	death,	
regulation	of	cell	differentiation,	regulation	of	cell	proliferation,	cellular	metabolic	process,	macromolecule	
metabolic	process,	RNA	metabolic	process,	nucleic	acid	metabolic	process,	cellular	response	to	stimulus,	cellular	
response	to	stress,	Cellular	component:	nucleus	
53:	FBXO33	 F-box	protein	33	 -3.64207	 5.51E-05	
Molecular	function:	protein	binding,	Biological	process:	macromolecule	metabolic	process,	protein	metabolic	
process	
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54:	SBDS	
SBDS	ribosome	assembly	
guanine	nucleotide	
exchange	factor	 -3.64001	 0.000186826	
Molecular	function:	nucleic	acid	binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	
negative	regulation	of	cellular	process,	cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	
metabolic	process,	nucleic	acid	metabolic	process,	Cellular	component:	nucleus	
55:	DYNLL2	
Dynein	light	chain	LC8-
type	2	 -3.578	 8.48E-08	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	
cellular	process,	regulation	of	cell	communication,	regulation	of	cell	death,	positive	regulation	of	response	to	
stimulus,	regulation	of	signal	transduction,	cellular	metabolic	process,	macromolecule	metabolic	process,	protein	
metabolic	process,	Cellular	component:	nucleus	
56:	DUSP2	
Dual	specificity	
phosphatase	2	 -3.57411	 0.0006278	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	regulation	of	biological	process,	negative	
regulation	of	cellular	process,	negative	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	
process,	regulation	of	cell	communication,	negative	regulation	of	signalling,	negative	regulation	of	response	to	
stimulus,	regulation	of	signal	transduction,	negative	regulation	of	catalytic	activity,	regulation	of	transferase	
activity,	macromolecule	metabolic	process,	protein	metabolic	process,	Cellular	component:	nucleus	
57:	CCNL1	 Cyclin	L1	 -3.55931	 1.92E-06	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	regulation	of	biological	process,	positive	
regulation	of	cellular	process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	
process,	regulation	of	biosynthetic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	cell	
cycle,	regulation	of	transferase	activity,	macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	
biosynthetic	process,	protein	metabolic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	
compound	biosynthetic	process,	Cellular	component:	nucleus,	nucleoplasm	
58:	NINJ1	 Ninjurin	1	 -3.54765	 8.02E-06	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	cellular	
process,	positive	regulation	of	cellular	process	
59:	RLF	 Rearranged	L-myc	fusion	 -3.49517	 9.83E-06	
Molecular	function:	nucleic	acid	binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	
positive	regulation	of	cellular	process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	
metabolic	process,	regulation	of	biosynthetic	process,	regulation	of	nitrogen	compound	metabolic	process,	
macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	aromatic	
compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	Cellular	component:	nucleus	
60:	RIPK2	
Receptor	interacting	
serine/threonine	kinase	
2	 -3.48946	 3.66E-06	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	
process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	
process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	differentiation,	regulation	of	
cell	proliferation,	positive	regulation	of	response	to	stimulus,	regulation	of	response	to	stress,	regulation	of	signal	
transduction,	regulation	of	cytokine	production,	regulation	of	haemopoiesis,	regulation	of	catalytic	activity,	
regulation	of	transferase	activity,	cellular	metabolic	process,	macromolecule	metabolic	process,	protein	metabolic	
process,	cellular	response	to	stimulus,	cellular	response	to	stress,	cellular	response	to	organic	substance,	cellular	
response	to	oxygen-containing	compound,	cellular	response	to	biotic	stimulus,	activation	of	immune	response,	
innate	immune	response-activating	signal	transduction	
61:	SEC14L1	 SEC14	like	lipid	binding	1	 -3.44687	 0.000451156	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
cellular	process,	regulation	of	cell	communication,	negative	regulation	of	signalling,	negative	regulation	of	
response	to	stimulus,	negative	regulation	of	immune	system	process,	regulation	of	signal	transduction,	regulation	
of	cytokine	production,	defense	response	to	virus	
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62:	SNORD68	
Small	nucleolar	RNA,	C/D	
box	68	 -3.44679	 5.47E-06	 		
63:	STAM	
Signal	transducing	
adaptor	molecule	 -3.42863	 9.18E-05	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
cellular	process,	positive	regulation	of	cellular	process,	regulation	of	cell	communication,	negative	regulation	of	
signalling,	negative	regulation	of	response	to	stimulus,	positive	regulation	of	response	to	stimulus,	regulation	of	
signal	transduction	
64:	CD83	 CD83	molecule	 -3.34097	 0.000115027	
Biological	process:	regulation	of	biological	process,	positive	regulation	of	cellular	process,	regulation	of	
developmental	process,	regulation	of	cell	differentiation,	regulation	of	cytokine	production,	regulation	of	
haemopoiesis	
65:	TOB1	 Transducer	of	ERBB2,	1	 -3.34031	 0.00298786	
Molecular	function:	transcription	factor	binding,	enzyme	binding,	transcription	cofactor	activity,	protein	binding,	
Biological	process:	regulation	of	biological	process,	negative	regulation	of	cellular	process,	positive	regulation	of	
cellular	process,	negative	regulation	of	metabolic	process,	positive	regulation	of	metabolic	process,	regulation	of	
developmental	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	
regulation	of	nitrogen	compound	metabolic	process,		regulation	of	catabolic	process,	regulation	of	cell	
communication,	regulation	of	cell	differentiation,	regulation	of	cell	proliferation,	negative	regulation	of	signalling,	
negative	regulation	of	response	to	stimulus,	negative	regulation	of	developmental	process,	positive	regulation	of	
response	to	stimulus,	regulation	of	signal	transduction	Cellular	component:	nucleus	
66:	
LOC652637	
Similar	to	junction-
mediating	and	
regulatory	protein	 -3.32659	 1.64E-06	 		
67:	CEP78	 Centrosomal	protein	78	 -3.31322	 5.42E-06	 		
68:	MAP2K3	
Mitogen-activated	
protein	kinase	kinase	3	 -3.30843	 2.98E-07	
Molecular	function:	protein	binding,	enzyme	binding,	Biological	process:	regulation	of	biological	process,	positive	
regulation	of	cellular	process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	
process,	regulation	of	biosynthetic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	cell	
communication,	regulation	of	cell	death,	regulation	of	cell	cycle,	positive	regulation	of	response	to	stimulus,	
regulation	of	signal	transduction,	regulation	of	cytokine	production,	regulation	of	transferase	activity,	
macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	protein	metabolic	
process,	cellular	response	to	stress,	innate	immune	response-activating	signal	transduction,	Cellular	component:	
nucleoplasm	
69:	SNHG9	
Small	nucleolar	RNA	host	
gene	9	 -3.29234	 2.71E-07	 		
70:	SNIP1	
Smad	nuclear	interacting	
protein	1	 -3.29055	 5.15E-06	
Molecular	function:	nucleic	acid	binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	
positive	regulation	of	cellular	process,	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	
process,	regulation	of	biosynthetic	process,	regulation	of	nitrogen	compound	metabolic	process,	macromolecule	
metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	Cellular	component:	nucleoplasm	
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71:	IRAK3	
Interleukin	1	receptor	
associated	kinase	3	 -3.28698	 0.000632043	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
cellular	process,	positive	regulation	of	cellular	process,	negative	regulation	of	metabolic	process,	positive	
regulation	of	metabolic	process,	regulation	of	developmental	process,	regulation	of	macromolecule	metabolic	
process,	regulation	of	biosynthetic	process,	regulation	of	nitrogen	compound	metabolic	process,	regulation	of	
catabolic	process,	regulation	of	cell	communication,	negative	regulation	of	signalling,	negative	regulation	of	
response	to	stimulus,	negative	regulation	of	immune	system	process,	positive	regulation	of	response	to	stimulus,	
regulation	of	signal	transduction,	regulation	of	response	to	cytokine	stimulus,	regulation	of	cytokine	production,	
regulation	of	catalytic	activity,	regulation	of	transferase	activity,	macromolecule	metabolic	process,	RNA	metabolic	
process,	macromolecule	biosynthetic	process,	protein	metabolic	process,	innate	immune	response-activating	
signal	transduction,	Cellular	component:	nucleus	
72:	CHD1	
Chromodomain	helicase	
DNA	binding	protein	1	 -3.25847	 5.95E-06	
Molecular	function:	nucleic	acid	binding,	protein	binding,	Biological	process:	regulation	of	biological	process,	
positive	regulation	of	cellular	process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	
metabolic	process,	regulation	of	biosynthetic	process,	regulation	of	nitrogen	compound	metabolic	process,	
macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	aromatic	
compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	Cellular	component:	nucleus	
73:	CTRL	 Chymotrypsin	like	 -3.25574	 0.000467934	 Biological	process:	proteolysis	
74:	GPRIN3	 GPRIN	family	member	3	 -3.25527	 0.000119065	 		
75:	PTS	
6-
pyruvoyltetrahydropteri
n	synthase	 -3.25195	 0.000174978	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	cellular	
process,	regulation	of	metabolic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	
biosynthetic	process	
76:	
LOC399491	
Polycystic	kidney	disease	
1	(autosomal	dominant)	
pseudogene	 -3.24832	 0.000263201	 		
77:	KLF9	 Kruppel-like	factor	9	 -3.2275	 0.000146813	
Molecular	function:	nucleic	acid	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	
metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	nitrogen	compound	metabolic	
process,	regulation	of	biosynthetic	process,	negative	regulation	of	cellular	process,	regulation	of	cell	proliferation,	
cellular	metabolic	process,	macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	
process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	process,	nucleic	acid	
metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	organic	substance,	cellular	response	to	
oxygen-containing	compound,	Cellular	component:	nucleus	
78:	CSNK1D	 Casein	kinase	1	delta	 -3.20321	 6.92E-05	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	
cellular	process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	
regulation	of	catabolic	process,	regulation	of	cell	communication,	positive	regulation	of	response	to	stimulus,	
regulation	of	signal	transduction,	macromolecule	metabolic	process,	protein	metabolic	process,	proteolysis,	
cellular	response	to	stress,	cellular	response	to	organic	substance,	Cellular	component:	nucleus	
79:	
LOC285074	
Anaphase	promoting	
complex	subunit	1	
pseudogene	 -3.19215	 1.88E-07	 		
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80:	IER5	
Immediate	early	
response	5	 -3.18749	 0.000722341	 Molecular	function:	protein	binding		
81:	TRA2A	
Transformer	2	alpha	
homolog	 -3.17544	 1.08E-05	
Molecular	function:	nucleic	acid	binding,	Biological	process:	macromolecule	metabolic	process,	RNA	metabolic	
process,	Cellular	component:	nucleus,	nucleolus	
82:	PRR8	
RNA	binding	motif	
protein	33	(RBM33)	 -3.16492	 3.37E-05	 Molecular	function:	nucleic	acid	binding	
83:	RAD23B	
RAD23	homolog	B,	
nucleotide	excision	
repair	protein	 -3.14093	 7.74E-06	
Molecular	function:	nucleic	acid	binding,	protein	binding,	ubiquitin	binding,	Biological	process:	regulation	of	
biological	process,	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	
cellular	process,	cellular	metabolic	process,	macromolecule	metabolic	process,	macromolecule	catabolic	process,	
nucleic	acid	metabolic	process,	protein	metabolic	process,	cellular	response	to	stimulus,	cellular	response	to	stress,	
Cellular	component:	nucleus	
84:	SBDSP	
Shwachman-Bodian-
Diamond	syndrome	
pseudogene	1	 -3.13092	 2.08E-06	 		
85:	
LOC730167	
Similar	to	protein	
tyrosine	phosphatase	
4a1	 -3.10343	 0.00315574	 		
86:	EFHD2	
EF-hand	domain	family	
member	D2	 -3.10255	 6.83E-05	 		
87:	ZFAND2A	
Zinc	finger,	AN1-type	
domain	2A	 -3.0993	 1.65E-05	
Biological	process:	regulation	of	biological	process,	positive	regulation	of	metabolic	process,	regulation	of	
macromolecule	metabolic	process,	positive	regulation	of	cellular	process,	cellular	response	to	stimulus,	Cellular	
component:	nucleus	
88:	
LOC440093	
Similar	to	protein	
tyrosine	phosphatase	
4a1	 -3.09076	 2.84E-06	 		
89:	
LOC653171	
Similar	to	MAPK-
interacting	and	spindle-
stabilising	protein	 -3.08483	 0.000135664	 		
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90:	KLF4	 Kruppel-like	factor	4	 -3.07861	 0.000729318	
Molecular	function:	RNA	polymerase	II	transcription	factor	activity,	sequence-specific	DNA	binding,	nucleic	acid	
binding,	transcription	factor	binding,	protein	binding,	beta-catenin	binding,	enzyme	binding,	Biological	process:	
regulation	of	biological	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,	
negative	regulation	of	metabolic	process,	positive	regulation	of	metabolic	process,	regulation	of	developmental	
process,	regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	regulation	of	nitrogen	
compound	metabolic	process,	regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	cell	
differentiation,	regulation	of	cell	proliferation,	regulation	of	cellular	response	to	stress,	negative	regulation	of	
signalling,	negative	regulation	of	response	to	stimulus,	negative	regulation	of	developmental	process,	regulation	of	
signal	transduction,	regulation	of	response	to	cytokine	stimulus,	regulation	of	cytokine	production,	regulation	of	
catalytic	activity,	regulation	of	transferase	activity,	macromolecule	metabolic	process,	RNA	metabolic	process,	
macromolecule	biosynthetic	process,	protein	metabolic	process,	aromatic	compound	biosynthetic	process,	cellular	
nitrogen	compound	biosynthetic	process,	proteolysis,	cellular	response	to	stress,	cellular	response	to	organic	
substance,	cellular	response	to	oxygen-containing	compound,	Cellular	component:	nucleoplasm	
91:	VPS37B	 VPS37B,	ESCRT-I	subunit	 -3.07733	 0.000126295	
Molecular	function:	protein	binding,	Biological	process:	regulation	of	biological	process,	positive	regulation	of	
cellular	process,	macromolecule	metabolic	process,	protein	metabolic	process,	
92:	IKZF5	
IKAROS	family	zinc	finger	
5	 -3.07576	 1.12E-06	
Molecular	function:	nucleic	acid	binding,	Biological	process:	regulation	of	biological	process,	regulation	of	cellular	
process,	regulation	of	metabolic	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	
biosynthetic	process,	regulation	of	nitrogen	compound	metabolic	process,	macromolecule	metabolic	process,	RNA	
metabolic	process,	macromolecule	biosynthetic	process,	aromatic	compound	biosynthetic	process,	cellular	
nitrogen	compound	biosynthetic	process,	Cellular	component:	nucleus	
93:	NECAP1	
NECAP	endocytosis	
associated	1	 -3.0681	 1.07E-07	 		
94:	BCL3	 B-cell	CLL/lymphoma	3	 -3.02133	 5.40E-05	
Molecular	function:	nucleic	acid	binding,	transcription	factor	binding,	protein	binding,	Biological	process:	
regulation	of	biological	process,	negative	regulation	of	cellular	process,	positive	regulation	of	cellular	process,		
negative	regulation	of	metabolic	process,	positive	regulation	of	metabolic	process,	regulation	of	macromolecule	
metabolic	process,	regulation	of	biosynthetic	process,	regulation	of	nitrogen	compound	metabolic	process,	
regulation	of	cell	communication,	regulation	of	cell	death,	regulation	of	signal	transduction,	regulation	of	cytokine	
production,	macromolecule	metabolic	process,	RNA	metabolic	process,	macromolecule	biosynthetic	process,	
protein	metabolic	process,	aromatic	compound	biosynthetic	process,	cellular	nitrogen	compound	biosynthetic	
process,	cellular	response	to	stress,	Cellular	component:	nucleus,	nucleoplasm	
95:	NXT1	
Nuclear	transport	factor	
2	like	export	factor	1	 -2.99274	 0.00112511	 Molecular	function:	protein	binding,	enzyme	binding,	Cellular	component:	nucleus,	nucleoplasm		
96:	
LOC645381	
Transducin	like	enhancer	
of	split	1	pseudogene	1	
(TLE1P1)	 -2.98841	 0.00122748	 		
97:	
SNORD35B	
Small	nucleolar	RNA,	C/D	
box	35B	 -2.97787	 0.000121874	 		
98:	ZBED4	 Zinc	finger	BED-type	 -2.97112	 0.00122944	 Molecular	function:	nucleic	acid	binding,	protein	binding,	Cellular	component:	nucleus	
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containing	4	
99:	
LOC1001324
18	
Uncharacterised	
PRO1102-like	protein	
LOC100132418	 -2.95013	 1.62E-06	 		
100:	ZFP36L2	
ZFP36	ring	finger	
protein-like	2	 -2.94506	 3.11E-05	
Molecular	function:	nucleic	acid	binding,	Biological	process:	regulation	of	biological	process,	negative	regulation	of	
cellular	process,	positive	regulation	of	cellular	process,	positive	regulation	of	metabolic	process,	regulation	of	
developmental	process,	regulation	of	macromolecule	metabolic	process,	regulation	of	biosynthetic	process,	
regulation	of	nitrogen	compound	metabolic	process,	regulation	of	catabolic	process,		regulation	of	cell	
differentiation,	negative	regulation	of	developmental	process,	macromolecule	metabolic	process,	RNA	metabolic	
process,	macromolecule	biosynthetic	process,	macromolecule	catabolic	process,	Cellular	component:	nucleus	
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1:	AKR1C3	
Aldo-keto	reductase	family	
1,	member	C3	 -8.42743	 0.00189328	
Biological	process:	response	to	stimulus,	response	to	organic	substance,	response	to	organic	cyclic	compound,	
response	to	hormone,	response	to	stress,	response	to	endogenous	stimulus,	response	to	external	stimulus,	
Cellular	component:	extracellular	organelle,	extracellular	exosome	
2:	FGFBP2	
Fibroblast	growth	factor	
binding	protein	2	 -7.34799	 0.00156233	 		
3:	PTGDS	 Prostaglandin	D2	synthase	 -6.6952	 0.00835522	
Biological	process:	response	to	stimulus,	response	to	organic	substance,	response	to	organic	cyclic	compound,	
response	to	hormone,	response	to	endogenous	stimulus,	Cellular	component:	extracellular	organelle,	
extracellular	exosome,	membrane	part,	
4:	GNG2	
G	protein	subunit	gamma	
2	 -6.07676	 0.000355277	
Molecular	function:	Molecular	transducer	activity,	Biological	process:	response	to	stimulus,	response	to	organic	
substance,	response	to	lipid,	response	to	organic	cyclic	compound,	response	to	hormone,	response	to	
endogenous	stimulus,	Cellular	component:	extracellular	organelle,	extracellular	exosome,	membrane	part,	
5:	TKTL1	 Transketolase-like	1	 -6.03509	 5.71E-05	 		
6:	CD6	 CD6	molecule	 -5.64591	 0.00169664	
Molecular	function:	Molecular	transducer	activity,	cargo	receptor	activity,	Biological	process:	immune	system	
process,	innate	immune	response,	response	to	stimulus,	response	to	organic	substance,	response	to	lipid,	
response	to	molecule	of	bacterial	origin,	response	to	stress,	innate	immune	response,	response	to	external	
stimulus,	Cellular	component:	membrane	part,	intrinsic	component	of	plasma	membrane,	immunological	
synapse,	
7:	CENTG2	
ArfGAP	with	GTPase	
domain,	ankyrin	repeat	
and	PH	domain	1	 -5.34602	 0.00114705	 		
8:	CCL3	
C-C	motif	chemokine	
ligand	3	 -5.33458	 0.000947189	
Biological	process:	immune	system	process,	immune	effector	process,	cell	activation	involved	in	immune	
response,	leukocyte	degranulation,	leukocyte	activation,	myeloid	leukocyte	activation,	leukocyte	chemotaxis,	
response	to	stimulus,	response	to	organic	substance,	response	to	organic	cyclic	compound,	response	to	stress,	
cell	motility,	cell	migration	
9:	FAM53B	
Family	with	sequence	
similarity	53	member	B	 -5.17697	 0.000121422	 		
10:	S1PR5	
Sphingosine-1-phosphate	
receptor	5	 -5.10266	 0.000732485	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Cellular	component:	membrane	
part,	
11:	GRK5	
G	protein-coupled	
receptor	kinase	5	 -4.51338	 5.40E-06	 Biological	process:	response	to	stimulus,	
12:	CCL4L2	
C-C	motif	chemokine	
ligand	4	like	2	 -4.47391	 0.00187209	 Biological	process:	immune	system	process,	response	to	stimulus,	cell	motility,	cell	migration	
13:	KIR2DL1	
Killer	cell	immunoglobulin	
like	receptor,	two	Ig	
domains	and	long	
cytoplasmic	tail	1	 -4.46208	 0.000642982	
Molecular	function:	Molecular	transducer	activity,	Biological	process:	immune	system	process,	response	to	
stimulus,	Cellular	component:	membrane	part,		intrinsic	component	of	plasma	membrane,	
14:	PRSS23	 Protease,	serine	23	 -4.33914	 0.000191459	 	Cellular	component:	extracellular	organelle,	extracellular	exosome,	
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15:	SPON2	 Spondin	2	 -4.32986	 0.00146276	
Biological	process:	immune	system	process,	immune	effector	process,	innate	immune	response,	response	to	
stimulus,	response	to	organic	substance,	response	to	molecule	of	bacterial	origin,	response	to	stress,		response	
to	external	stimulus,	Cellular	component:	extracellular	organelle,	extracellular	exosome,	
16:	FKBP11	 FK506	binding	protein	11	 -4.2872	 0.00184582	 		
17:	KRT72	 Keratin	72	 -4.2801	 0.000370527	 	Cellular	component:	extracellular	organelle,	extracellular	exosome,	
18:	GPR56	
G	protein-coupled	
receptor	56	 -4.08502	 0.00386854	 		
19:	MIAT	
Myocardial	infarction	
associated	transcript	 -4.06009	 0.00136502	 		
20:	CX3CR1	
C-X3-C	motif	chemokine	
receptor	1	 -4.03803	 0.000335643	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Biological	process:	immune	
system	process,		immune	effector	process,	cell	activation	involved	in	immune	response,	leukocyte	activation,	
myeloid	leukocyte	activation,	leukocyte	chemotaxis,	response	to	stimulus,	response	to	organic	substance,	
response	to	lipid,	response	to	growth	factor,	response	to	molecule	of	bacterial	origin,	response	to	stress,	
response	to	endogenous	stimulus,	response	to	external	stimulus,	cell	motility,	cell	migration,	Cellular	
component:	membrane	part,		intrinsic	component	of	plasma	membrane,	
21:	KRT73	 Keratin	73	 -3.88722	 4.10E-05	 	Cellular	component:	extracellular	organelle,	extracellular	exosome,	
22:	ADRB2	 Adenoceptor	beta	2	 -3.77877	 0.000254862	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Biological	process:	response	to	
stimulus,	response	to	organic	substance,	response	to	lipid,	response	to	organic	cyclic	compound,	response	to	
hormone,	response	to	stress,	response	to	endogenous	stimulus,	Cellular	component:	membrane	part,	intrinsic	
component	of	plasma	membrane,	
23:	CCL3L1	
C-C	motif	chemokine	
ligand	3	like	1	 -3.70947	 0.00231452	
Biological	process:	immune	system	process,	leukocyte	chemotaxis,	response	to	stimulus,	response	to	organic	
substance,	response	to	stress,	cell	motility,	cell	migration	
24:	MAF	
MAF	bZIP	transcription	
factor	 -3.65509	 3.53E-05	 Biological	process:	cytokine	production	
25:	PDGFRB	
Platelet	derived	growth	
factor	receptor	beta	 -3.60235	 0.00376814	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Biological	process:	immune	
system	process,	innate	immune	response,	response	to	stimulus,	response	to	organic	substance,	response	to	lipid,	
response	to	organic	cyclic	compound,	response	to	hormone,	response	to	growth	factor,	response	to	stress,	
innate	immune	response,	response	to	endogenous	stimulus,	cell	motility,	cell	migration,	Cellular	component:	
extracellular	organelle,	extracellular	exosome,	membrane	part,		intrinsic	component	of	plasma	membrane,	
26:	KIR3DL1	
Killer	cell	immunoglobulin	
like	receptor,	three	Ig	
domains	and	long	
cytoplasmic	tail	1	 -3.55515	 0.00128778	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Biological	process:	immune	
system	process,	immune	effector	process,	innate	immune	response,	natural	killer	cell	mediated	immunity,	
response	to	stimulus,	response	to	stress,	innate	immune	response,	Cellular	component:	membrane	part,		
intrinsic	component	of	plasma	membrane,	
27:	TXNDC3	
NME/NM23	family	
member	8	 -3.45416	 0.000632683	 Biological	process:	response	to	stimulus,	response	to	stress,	cell	motility,	
28:	CST7	 Cystatin	F	 -3.44085	 0.00312376	 Biological	process:	immune	system	process,	response	to	stimulus,	
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29:	ENC1	
Ectodermal-neural	cortex	
1	 -3.37593	 0.00136669	 		
30:	KIR2DS5	
Killer	cell	immunoglobulin	
like	receptor,	two	Ig	
domains	and	short	
cytoplasmic	tail	5	 -3.27188	 0.00346026	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Biological	process:	immune	
system	process,	innate	immune	response,	response	to	stimulus,	response	to	stress,	innate	immune	response,	
Cellular	component:	membrane	part,		intrinsic	component	of	plasma	membrane,	
31:	KIR3DL2	
Killer	cell	immunoglobulin	
like	receptor,	three	Ig	
domains	and	long	
cytoplasmic	tail	2	 -3.2224	 0.000689487	
Biological	process:	response	to	stimulus,	response	to	stress,	Cellular	component:	membrane	part,	intrinsic	
component	of	plasma	membrane	
32:	
TNFRSF1B	
Tumor	necrosis	factor	
receptor	superfamily	
member	1b	 -3.22004	 3.68E-05	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Biological	process:	immune	
system	process,	response	to	stimulus,	response	to	organic	substance,	response	to	lipid,	response	to	growth	
factor,	response	to	molecule	of	bacterial	origin,	response	to	stress,	response	to	external	stimulus,	Cellular	
component:	membrane	part,	intrinsic	component	of	plasma	membrane,	membrane	raft	
33:	GTF3C1	
General	transcription	
factor	IIIC	subunit	1	 -3.1986	 0.00022331	 		
34:	SDCBP	 Syndecan	binding	protein	 -3.18186	 0.00087698	 	Cellular	component:	extracellular	organelle,	extracellular	exosome,	membrane	part,	membrane	raft	
35:	PLEKHF1	
Pleckstrin	homology	and	
FYVE	domain	containing	1	 -3.15503	 7.99E-05	 		
36:	MGAT4A	
Mannosyl	(alpha-1,3-)-
glycoprotein	beta-1,4-N-
acetylglucosaminyltransfer
ase,	isozyme	A	 -3.13404	 0.00081167	 	Cellular	component:	extracellular	organelle,	extracellular	exosome,	membrane	part,	
37:	PYHIN1	
Pyrin	and	HIN	domain	
family	member	1	 -3.10643	 0.000437402	 		
38:	LGALS1	
Lectin,	galactoside	binding	
soluble	1	 -3.03863	 0.00036478	
Molecular	function:	Molecular	transducer	activity,	Biological	process:	immune	system	process,	immune	effector	
process,	cell	activation	involved	in	immune	response,	leukocyte	activation,	response	to	stimulus,	response	to	
organic	substance,	response	to	organic	cyclic	compound,	response	to	stress,	Cellular	component:	extracellular	
organelle,	extracellular	exosome,	
39:	NFIL3	
Nuclear	factor,	interleukin	
3	regulated	 -3.02151	 0.000489746	
Biological	process:	immune	system	process,	leukocyte	chemotaxis,	response	to	stimulus,	response	to	organic	
substance	
40:	PDE4D	 Phosphodiesterase	4D	 -3.02116	 0.00146078	
Biological	process:	immune	system	process,	response	to	stimulus,	response	to	organic	substance,	response	to	
lipid,	response	to	organic	cyclic	compound,	response	to	molecule	of	bacterial	origin,	response	to	endogenous	
stimulus,	response	to	external	stimulus,	cell	motility,	cell	migration,	Cellular	component:	membrane	part	
41:	CTNNA1	 Catenin	alpha	1	 -3.00623	 0.000464655	
Biological	process:	response	to	stimulus,	response	to	organic	substance,	response	to	lipid,	response	to	organic	
cyclic	compound,	response	to	hormone,	response	to	stress,	response	to	endogenous	stimulus,	Cellular	
component:	membrane	part,	
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42:	HES6	
Hes	family	bHLH	
transcription	factor	6	 -2.96979	 0.00188912	 		
43:	ERRFI1	
ERBB	receptor	feedback	
inhibitor	1	 -2.9457	 0.000832955	
Biological	process:	response	to	stimulus,	response	to	organic	substance,	response	to	lipid,	response	to	organic	
cyclic	compound,	response	to	hormone,	response	to	growth	factor,	response	to	stress,	response	to	endogenous	
stimulus,	Cellular	component:	membrane	part,	
44:	BTBD11	 BTB	domain	containing	11	 -2.9201	 0.00149899	 Cellular	component:	membrane	part,	
45:	ANKRD9	 Ankyrin	repeat	domain	9	 -2.89904	 0.000645942	 		
46:	PRDM1	 PR	domain	1	 -2.89627	 0.00095776	 		
47:	ASCL2	
Achaete-scute	family	bHLH	
transcription	factor	2	 -2.88188	 0.000489341	 Biological	process:	response	to	stimulus,	response	to	stress,	
48:	LINGO2	
Leucine	rich	repeat	and	IG	
domain	containing	2	 -2.86004	 0.000705144	 Cellular	component:	membrane	part,	
49:	TMEM2	 Transmembrane	protein	2	 -2.84851	 0.000859612	
	Cellular	component:	extracellular	organelle,	extracellular	exosome,	membrane	part,	intrinsic	component	of	
plasma	membrane,	
50:	UAP1	
UDP-N-acetylglucosamine	
pyrophosphorylase	 -2.83317	 5.68E-07	 		
51:	NPC1	
NPC	intracellular	
cholesterol	transporter	1	 -2.81967	 0.00311562	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Biological	process:	response	to	
stimulus,	response	to	organic	substance,	response	to	lipid,	response	to	organic	cyclic	compound,	response	to	
hormone,	response	to	endogenous	stimulus,	Cellular	component:	extracellular	organelle,	extracellular	exosome,	
membrane	part,	membrane	raft	
52:	MTP18	
Mitochondrial	fission	
process	1	 -2.78728	 0.000363883	 		
53:	LDLR	
Low	density	lipoprotein	
receptor	 -2.78467	 5.82E-05	
Molecular	function:	Molecular	transducer	activity,	cargo	receptor	activity,	Biological	process:	response	to	
stimulus,	response	to	external	stimulus,	Cellular	component:	membrane	part,	intrinsic	component	of	plasma	
membrane,	
54:	SLC15A4	
Solute	carrier	family	15	
member	4	 -2.78364	 0.00144038	 Cellular	component:	membrane	part,	
55:	RASGRP1	
RAS	guanyl	releasing	
protein	1	 -2.75145	 0.000977571	
Biological	process:	immune	system	process,	immune	effector	process,	cell	activation	involved	in	immune	
response,	leukocyte	degranulation,	innate	immune	response,	leukocyte	activation,	myeloid	leukocyte	activation,	
response	to	stimulus,	response	to	stress,	innate	immune	response,	cytokine	production	Cellular	component:	
membrane	part,	
56:	IFNGR1	
Interferon	gamma	
receptor	1	 -2.75082	 0.00404058	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Biological	process:	response	to	
stimulus,	response	to	external	stimulus,	Cellular	component:	membrane	part,	intrinsic	component	of	plasma	
membrane,	
57:	TSPYL2	 TSPY-like	2	 -2.72938	 0.000245908	 Biological	process:	response	to	stimulus,	response	to	stress,	
58:	TTC38	
Tetratricopeptide	repeat	
domain	38	 -2.72283	 0.000871082	 	Cellular	component:	extracellular	organelle,	extracellular	exosome,	
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59:	PTGER2	 Prostaglandin	E	receptor	2	 -2.71661	 0.00226947	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Biological	process:	response	to	
stimulus,	response	to	organic	substance,	response	to	lipid,	response	to	organic	cyclic	compound,	response	to	
hormone,	response	to	molecule	of	bacterial	origin,	response	to	endogenous	stimulus,	response	to	external	
stimulus,	Cellular	component:	membrane	part,	intrinsic	component	of	plasma	membrane,	
60:	PLOD1	
Procollagen-lysine,2-
oxoglutarate	5-
dioxygenase	1	 -2.67529	 0.000136957	
Biological	process:	response	to	stimulus,	response	to	organic	substance,	response	to	hormone,	response	to	
stress,	response	to	endogenous	stimulus,	Cellular	component:	extracellular	organelle,	extracellular	exosome,	
membrane	part,	
61:	ABI3	 ABI	family	member	3	 -2.67077	 1.23E-05	 		
62:	TGFBR3	
Transforming	growth	
factor	beta	receptor	3	 -2.65849	 0.00299064	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Biological	process:	immune	
system	process,	response	to	stimulus,	response	to	organic	substance,	response	to	lipid,	response	to	hormone,	
response	to	stress,	response	to	endogenous	stimulus,	cell	motility,	cell	migration,	Cellular	component:	
extracellular	organelle,	extracellular	exosome,	membrane	part,	intrinsic	component	of	plasma	membrane,	
63:	PRSSL1	
Kallikrein	related	
peptidase	10	(KLK10)	 -2.6427	 0.000369836	 		
64:	
HS.534427	
Human	mRNA	for	T-cell	
specific	protein	 -2.62803	 0.00271564	 		
65:	SYNE2	
Spectrin	repeat	containing	
nuclear	envelope	protein	2	 -2.61909	 0.000124645	
Biological	process:	cell	motility,	cell	migration,		Cellular	component:	extracellular	organelle,	extracellular	
exosome,	membrane	part,	
66:	SLC2A8	
Solute	carrier	family	2	
member	8	 -2.5802	 0.000723838	
Biological	process:	response	to	stimulus,	response	to	stress,	Cellular	component:	membrane	part,	intrinsic	
component	of	plasma	membrane,	
67:	ZEB2	
Zinc	finger	E-box	binding	
homeobox	2	 -2.57385	 0.00259963	 Biological	process:	cell	motility,	cell	migration	
68:	MT2A	 Metallothionein	2A	 -2.5068	 0.00611898	 Biological	process:	response	to	stimulus,	
69:	IGF2R	
Insulin	like	growth	factor	2	
receptor	 -2.50114	 0.000263572	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Biological	process:	response	to	
stimulus,	response	to	organic	substance,	response	to	lipid,	Cellular	component:	extracellular	organelle,	
extracellular	exosome,	membrane	part,		intrinsic	component	of	plasma	membrane,	
70:	
LOC645381	
Transducin	like	enhancer	
of	split	1	pseudogene	1	
(TLE1P1)	 -2.48587	 0.00310879	 		
71:	ATP1B3	
ATPase	Na+/K+	
transporting	subunit	beta	
3	 -2.46777	 0.00364773	
Biological	process:	immune	system	process,	cell	motility,	cell	migration,	Cellular	component:	extracellular	
organelle,	extracellular	exosome,	membrane	part,	membrane	raft	
72:	FLJ20699	
Hypothetical	protein	
FLJ20699	 -2.45075	 0.00150348	 		
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73:	
HS.560343	
mRNA;	cDNA	
DKFZp686M2414	(from	
clone	DKFZp686M2414)	 -2.44053	 0.00108507	 		
74:	TPP1	 Tripeptidyl	peptidase	1	 -2.43162	 0.000766348	
Biological	process:	response	to	stimulus,	response	to	stress,	Cellular	component:	extracellular	organelle,	
extracellular	exosome,	
75:	TMEM71	
Transmembrane	protein	
71	 -2.43141	 0.000355031	 		
76:	PPP2R5C	
Protein	phosphatase	2	
regulatory	subunit	B',	
gamma	 -2.42453	 3.41E-06	 Biological	process:	response	to	stimulus,	response	to	stress,	Cellular	component:	membrane	part,	
77:	
HS.143408	
	cDNA	clone	
IMAGE:30332316	 -2.42287	 0.000244958	 		
78:	DBNDD2	
Dysbindin	domain	
containing	2	 -2.41478	 5.96E-05	 		
79:	NUAK1	 NUAK	family	kinase	1	 -2.40292	 0.000893803	 Biological	process:	response	to	stimulus,	response	to	stress,	
80:	GZMB	 Granzyme	B	 -2.3924	 0.00595711	
Biological	process:	immune	system	process,	immune	effector	process,	innate	immune	response,	natural	killer	
cell	mediated	immunity,	response	to	stimulus,	response	to	stress,	innate	immune	response,	Cellular	component:	
membrane	part,	immunological	synapse,	
81:	KIR2DL3	
Killer	cell	immunoglobulin	
like	receptor,	two	Ig	
domains	and	long	
cytoplasmic	tail	3	 -2.39065	 0.00309275	
Molecular	function:	Molecular	transducer	activity,	Biological	process:	immune	system	process,	response	to	
stimulus,	Cellular	component:	membrane	part,	intrinsic	component	of	plasma	membrane,	
82:	RORA	
RAR	related	orphan	
receptor	A	 -2.38738	 0.000911275	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Biological	process:	immune	
system	process,	immune	effector	process,	cell	activation	involved	in	immune	response,	leukocyte	activation,	
response	to	stimulus,	response	to	organic	substance,	response	to	organic	cyclic	compound,	response	to	stress,	
83:	RBPMS2	
RNA	binding	protein	with	
multiple	splicing	2	 -2.38542	 0.000958671	 		
84:	PRF1	 Perforin	1	 -2.38484	 0.000586113	
Biological	process:	immune	system	process,	immune	effector	process,	response	to	stimulus,	response	to	stress,	
response	to	external	stimulus,	Cellular	component:	membrane	part,	
85:	
LOC1001325
35	
Hypothetical	
LOC100132535	 -2.37148	 0.000602849	 		
86:	ADIPOR2	 Adiponectin	receptor	2	 -2.3612	 0.000183605	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Biological	process:	response	to	
stimulus,	response	to	external	stimulus,	Cellular	component:	membrane	part,	intrinsic	component	of	plasma	
membrane,	
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87:	MAPK1	
Mitogen-activated	protein	
kinase	1	 -2.35526	 0.00093939	
Molecular	function:	Molecular	transducer	activity,	Biological	process:	immune	system	process,	immune	effector	
process,	innate	immune	response,	response	to	stimulus,	response	to	organic	substance,	response	to	lipid,	
response	to	organic	cyclic	compound,	response	to	hormone,	response	to	growth	factor,	response	to	stress,	
innate	immune	response,	response	to	endogenous	stimulus,	Cellular	component:	extracellular	organelle,	
extracellular	exosome,	membrane	part,	membrane	raft	
88:	ENPP4	
Ectonucleotide	
pyrophosphatase/phosph
odiesterase	4	(putative)	 -2.31607	 0.00157071	 	Cellular	component:	extracellular	organelle,	extracellular	exosome,	membrane	part,	
89:	HDDC2	 HD	domain	containing	2	 -2.3095	 0.00398187	 	Cellular	component:	extracellular	organelle,	extracellular	exosome,	
90:	
LOC1001325
32	
Hypothetical	protein	
LOC100132532	 -2.29818	 6.46E-05	 		
91:	GIMAP4	
GTPase,	IMAP	family	
member	4	 -2.29144	 0.00466543	 		
92:	
HS.397465	
	mRNA;	cDNA	
DKFZp686F1546	(from	
clone	DKFZp686F1546)	 -2.27945	 0.00180265	 		
93:	YES1	
YES	proto-oncogene	1,	Src	
family	tyrosine	kinase	 -2.27706	 0.00278458	
Biological	process:	immune	system	process,	immune	effector	process,	innate	immune	response,	response	to	
stimulus,	response	to	organic	substance,	response	to	lipid,	response	to	growth	factor,	response	to	stress,		innate	
immune	response,	response	to	endogenous	stimulus,	cell	motility,	cell	migration,	Cellular	component:	
extracellular	organelle,	extracellular	exosome,	membrane	part,	
94:	PRKCQ	 Protein	kinase	C	theta	 -2.27528	 0.00711195	
Biological	process:	immune	system	process,	innate	immune	response,	response	to	stimulus,	response	to	organic	
substance,	response	to	organic	cyclic	compound,	response	to	hormone,	response	to	stress,	innate	immune	
response,	response	to	endogenous	stimulus,	response	to	external	stimulus,	cell	motility,	cell	migration,	Cellular	
component:	membrane	part,	immunological	synapse,	
95:	SLC5A6	
Solute	carrier	family	5	
member	6	 -2.27413	 0.000524134	 Cellular	component:	membrane	part,	intrinsic	component	of	plasma	membrane,	
96:	NUDT11	 Nudix	hydrolase	11	 -2.27137	 0.00140139	 		
97:	
LOC284757	 MIR646	host	gene	 -2.25564	 0.000816783	 		
98:	MT1A	 Metallothionein	1A	 -2.24512	 0.0100086	 Biological	process:	response	to	stimulus,	
99:	CRY1	
Cryptochrome	circadian	
clock	1	 -2.2439	 0.00169743	
Molecular	function:	Molecular	transducer	activity,	signalling	receptor	activity,	Biological	process:	response	to	
stimulus,	response	to	organic	substance,	response	to	hormone,	response	to	stress,	response	to	endogenous	
stimulus,	response	to	external	stimulus,	
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100:	ITK	 IL2	inducible	T-cell	kinase	 -2.23818	 0.00291465	
Biological	process:	immune	system	process,	innate	immune	response,	leukocyte	activation,	response	to	
stimulus,	response	to	stress,	innate	immune	response,	cytokine	production,	Cellular	component:	membrane	
part,	
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Appendix 4: DNA Microarray all up and 
downregulated genes 
 
A. IL-7 CD56bright vs. CD56dim upregulated genes (First 1000 genes only) 
B. IL-7 CD56bright vs. CD56bright upregulated genes (First 1000 genes only) 
C. CD56bright vs. CD56dim upregulated genes  
D. IL-7 CD56bright vs. CD56dim downregulated genes  
E. IL-7 CD56bright vs. CD56bright downregulated genes  
F. CD56bright vs. CD56dim downregulated genes  
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1	 LTB	 30.86	 7.36E-10	
	
45	 DPYSL2	 6.47	 2.18E-06	
	
89	 PRDM8	 5.13	 0.00019	
2	 KIT	 24.92	 7.26E-07	
	
46	 HMMR	 6.44	 5.28E-05	
	
90	 WDR40A	 5.11	 5.29E-06	
3	 GZMK	 23.83	 1.26E-06	
	
47	 STS-1	 6.37	 9.04E-07	
	
91	 EGR2	 5.11	 6.81E-05	
4	 MAL	 22.99	 8.91E-08	
	
48	 ACADM	 6.29	 2.40E-09	
	
92	 CABLES1	 5.09	 6.58E-05	
5	 CCR7	 19.10	 7.93E-06	
	
49	 PDE7B	 6.26	 0.00146	
	
93	 EGR1	 5.09	 0.00284	
6	 IL7R	 17.80	 0.00041	
	
50	 CEP55	 6.23	 0.00040	
	
94	 PAICS	 5.06	 6.64E-07	
7	 GPR68	 16.94	 1.04E-08	
	
51	 LPXN	 6.23	 4.59E-05	
	
95	 CYP1B1	 5.06	 0.00011	
8	 TOP2A	 16.47	 2.66E-05	
	
52	 MRPS6	 6.21	 8.18E-06	
	
96	 NCAPD2	 5.03	 0.00038	
9	 LEF1	 14.19	 8.01E-07	
	
53	 SSBP2	 6.20	 1.57E-07	
	
97	 NCAPG	 5.02	 0.00197	
10	 NELL2	 13.70	 2.62E-06	
	
54	 ST6GAL1	 6.12	 1.50E-05	
	
98	 CD27	 4.99	 0.00298	
11	 AMICA1	 12.70	 1.89E-06	
	
55	 CSDA	 6.11	 3.18E-05	
	
99	 MRPS31	 4.94	 4.61E-07	
12	 EBI2	 12.46	 5.36E-07	
	
56	 TST	 6.08	 4.03E-05	
	
100	 SPINK2	 4.93	 1.11E-05	
13	 ADCY3	 11.21	 2.02E-06	
	
57	 DNCL1	 6.06	 9.57E-06	
	
101	 PAFAH1B1	 4.92	 6.18E-05	
14	 HLA-DMB	 11.16	 2.58E-06	
	
58	 ZMIZ1	 6.06	 1.04E-06	
	
102	 AHI1	 4.91	 0.00063	
15	 MMP25	 10.72	 9.58E-08	
	
59	 ASXL2	 6.06	 1.70E-06	
	
103	 C5orf13	 4.89	 2.36E-05	
16	 CD2	 10.57	 5.71E-05	
	
60	 DENND5A	 5.99	 1.60E-06	
	
104	 HCP5	 4.88	 1.55E-05	
17	 DCAF7	 10.42	 6.94E-09	
	
61	 TMBIM4	 5.95	 6.77E-06	
	
105	 BCL2L13	 4.87	 0.00013	
18	 PCMT1	 10.41	 1.38E-05	
	
62	 TTF2	 5.89	 1.16E-06	
	
106	 PDCD6	 4.87	 5.05E-06	
19	 CDC20	 10.31	 3.99E-05	
	
63	 KIFC1	 5.81	 0.00043	
	
107	 TNFSF10	 4.87	 2.24E-05	
20	 RCBTB2	 9.85	 2.13E-06	
	
64	 ARPC5	 5.68	 1.68E-05	
	
108	 CPOX	 4.86	 2.18E-06	
21	 XCL1	 9.62	 4.55E-07	
	
65	 PCMTD1	 5.57	 2.21E-06	
	
109	 EPHA4	 4.86	 2.08E-05	
22	 DLL1	 9.38	 3.97E-06	
	
66	 VPS35	 5.57	 1.10E-07	
	
110	 CDCA7	 4.83	 5.75E-05	
23	 NUSAP1	 9.00	 0.00047	
	
67	 IGFBP4	 5.57	 4.90E-05	
	
111	 ZMYM6	 4.82	 1.16E-07	
24	 SELL	 8.80	 0.00011	
	
68	 GLS	 5.56	 1.18E-06	
	
112	 PTGDR	 4.81	 0.00012	
25	 RNF144	 8.34	 4.98E-08	
	
69	 CD44	 5.54	 2.74E-07	
	
113	 TUBB	 4.80	 0.00011	
26	 IL12RB2	 8.30	 1.08E-05	
	
70	 HS.137971	 5.48	 4.01E-05	
	
114	 HDHD2	 4.77	 4.63E-07	
27	 PRAGMIN	 8.28	 9.10E-07	
	
71	 TMEM123	 5.48	 4.67E-05	
	
115	 CCNB2	 4.76	 0.00097	
28	 CDCA5	 8.04	 0.00075	
	
72	 VIM	 5.45	 0.00037	
	
116	 FAM129A	 4.74	 8.49E-06	
29	 TYMS	 7.91	 0.00069	
	
73	 STAMBPL1	 5.44	 2.58E-06	
	
117	 C2orf42	 4.73	 1.40E-07	
30	 S100A11	 7.86	 3.25E-07	
	
74	 VPS36	 5.41	 2.58E-06	
	
118	 M6PR	 4.72	 2.79E-06	
31	 AARS	 7.75	 3.26E-07	
	
75	 ERMP1	 5.40	 2.32E-05	
	
119	 DAD1	 4.70	 0.00012	
32	 CXCR3	 7.67	 9.87E-07	
	
76	 HADH	 5.39	 1.77E-06	
	
120	 CDC45L	 4.69	 0.00336	
33	 E2F2	 7.39	 0.00092	
	
77	 FVT1	 5.38	 1.07E-05	
	
121	 COL9A2	 4.66	 8.23E-06	
34	 MYC	 7.17	 1.40E-05	
	
78	 DLGAP5	 5.35	 0.00063	
	
122	 GNPDA1	 4.64	 1.23E-05	
35	 RAB10	 7.10	 2.01E-07	
	
79	 ZNF512	 5.34	 8.48E-08	
	
123	 C10orf6	 4.59	 9.34E-05	
36	 ATP8B4	 7.08	 6.76E-06	
	
80	 CAPN12	 5.32	 9.13E-07	
	
124	 ANXA5	 4.57	 0.00042	
37	 TMEM14C	 6.95	 9.99E-07	
	
81	 TMEM14D	 5.29	 1.70E-05	
	
125	 UGDH	 4.56	 2.04E-07	
38	 NOD2	 6.92	 0.00058	
	
82	 DYNLL1	 5.28	 4.48E-06	
	
126	 C5orf51	 4.55	 1.40E-07	
39	 CAPG	 6.89	 1.04E-05	
	
83	 TMEM106B	 5.27	 7.65E-06	
	
127	 RALA	 4.55	 2.04E-06	
40	 RNF144A	 6.88	 7.96E-08	
	
84	 IL32	 5.27	 0.00557	
	
128	 GIMAP6	 4.54	 1.28E-07	
41	 LOC730278	 6.78	 1.27E-07	
	
85	 KRCC1	 5.25	 2.10E-07	
	
129	 LYRM7	 4.54	 1.88E-06	
42	 ASPM	 6.64	 0.00015	
	
86	 E2F3	 5.21	 4.59E-05	
	
130	 SEPT11	 4.54	 8.88E-07	
43	 PROSC	 6.52	 6.11E-08	
	
87	 SLC44A1	 5.16	 3.97E-08	
	
131	 LOC100129034	 4.53	 3.63E-07	
44	 KLRC1	 6.51	 0.00025	
	
88	 AXIN2	 5.15	 6.47E-05	
	
132	 DDX17	 4.49	 5.72E-06	
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133	 USO1	 4.46	 1.93E-05	
	
177	 UHRF1	 4.15	 0.000836	
	
221	 MGST2	 3.88	 2.62E-06	
134	 TMEM149	 4.46	 4.54E-06	
	
178	 GIMAP1	 4.14	 5.43E-05	
	
222	 FAM111A	 3.86	 0.00016	
135	 MITD1	 4.46	 1.23E-06	
	
179	 GINS2	 4.14	 0.00425	
	
223	 UBAC2	 3.86	 3.61E-06	
136	 HIBADH	 4.45	 7.30E-06	
	
180	 C3orf57	 4.13	 3.13E-06	
	
224	 IL18R1	 3.86	 3.09E-05	
137	 DNAJA3	 4.45	 0.00029	
	
181	 YWHAH	 4.12	 0.00032	
	
225	 SKAP2	 3.84	 3.96E-06	
138	 TMEM126B	 4.44	 1.36E-05	
	
182	 GIMAP4	 4.12	 0.00029	
	
226	 CD96	 3.84	 1.21E-07	
139	 MRPL51	 4.42	 2.42E-06	
	
183	 NSMCE1	 4.12	 5.60E-06	
	
227	 TMEM14B	 3.82	 0.00010	
140	 C9orf69	 4.39	 4.58E-09	
	
184	 NDUFAF3	 4.12	 2.11E-05	
	
228	 OBFC2A	 3.82	 2.99E-05	
141	 KLHL22	 4.37	 5.87E-07	
	
185	 AP1S2	 4.12	 1.24E-06	
	
229	 HLA-DMA	 3.81	 0.00021	
142	 C10orf33	 4.36	 5.03E-05	
	
186	 LFNG	 4.11	 8.08E-07	
	
230	 IL10RB	 3.81	 1.45E-05	
143	 OXR1	 4.34	 2.62E-06	
	
187	 TIAM1	 4.10	 2.80E-05	
	
231	 PYCARD	 3.81	 6.16E-06	
144	 WASPIP	 4.33	 8.30E-05	
	
188	 CHURC1	 4.10	 5.03E-06	
	
232	 NUCB2	 3.80	 4.29E-06	
145	 PAQR4	 4.33	 0.00041	
	
189	 FLI1	 4.09	 2.50E-05	
	
233	 TTC27	 3.80	 3.82E-07	
146	 KIF11	 4.33	 0.00081	
	
190	 PSMA5	 4.08	 9.05E-06	
	
234	 MPZL2	 3.80	 1.44E-05	
147	 ATIC	 4.32	 4.57E-06	
	
191	 C14orf173	 4.08	 0.00013	
	
235	 KLHL9	 3.79	 3.25E-05	
148	 SLC16A3	 4.32	 1.17E-06	
	
192	 CSTB	 4.07	 0.00010	
	
236	 CPNE3	 3.79	 5.46E-06	
149	 TALDO1	 4.30	 7.52E-06	
	
193	 P2RY5	 4.06	 1.35E-06	
	
237	 PDCD6IP	 3.78	 1.23E-06	
150	 FAM102A	 4.30	 1.91E-07	
	
194	 WDR61	 4.06	 9.88E-06	
	
238	 IQGAP1	 3.77	 1.27E-05	
151	 PARP1	 4.29	 2.70E-06	
	
195	 PRKAR1A	 4.06	 0.00054	
	
239	 RAB40C	 3.76	 9.42E-07	
152	 FLNB	 4.29	 1.81E-05	
	
196	 C20orf30	 4.03	 0.00207	
	
240	 PYCR2	 3.76	 5.44E-07	
153	 UBE2C	 4.28	 0.00075	
	
197	 DPP4	 4.03	 0.00097	
	
241	 LOC439949	 3.76	 2.67E-05	
154	 LOC642975	 4.28	 0.00270	
	
198	 ZNF573	 4.02	 1.33E-06	
	
242	 ASF1B	 3.76	 0.00013	
155	 C14orf106	 4.28	 3.82E-05	
	
199	 KIAA0748	 4.02	 2.55E-05	
	
243	 NR1H3	 3.75	 0.00019	
156	 ESD	 4.27	 3.07E-05	
	
200	 CCNA2	 4.01	 0.00053	
	
244	 SPHK2	 3.74	 8.34E-07	
157	 HJURP	 4.27	 0.00096	
	
201	 RAB38	 4.01	 3.85E-05	
	
245	 CENPK	 3.72	 0.00015	
158	 AURKB	 4.27	 0.00091	
	
202	 SLC7A1	 4.01	 0.00028	
	
246	 YWHAB	 3.72	 3.24E-06	
159	 TMEM5	 4.27	 1.17E-06	
	
203	 NDUFB5	 4.00	 1.11E-05	
	
247	 SNCA	 3.71	 6.75E-05	
160	 SNX10	 4.27	 0.00040	
	
204	 TMEM194A	 4.00	 1.21E-06	
	
248	 CCDC76	 3.71	 9.95E-07	
161	 MAT2A	 4.27	 1.44E-06	
	
205	 TUBA1C	 4.00	 0.00055	
	
249	 ESYT1	 3.71	 4.56E-06	
162	 UBAP2L	 4.27	 2.45E-07	
	
206	 ANKRD46	 4.00	 4.48E-06	
	
250	 UNC50	 3.71	 0.00014	
163	 CCDC56	 4.26	 1.46E-07	
	
207	 STAP1	 3.99	 5.03E-07	
	
251	 HVCN1	 3.70	 7.14E-06	
164	 ZNF559	 4.25	 1.92E-06	
	
208	 CKLF	 3.98	 1.60E-05	
	
252	 APBB1IP	 3.70	 3.06E-05	
165	 ENPP3	 4.25	 8.57E-05	
	
209	 CKAP2L	 3.98	 0.00117	
	
253	 CCR1	 3.70	 0.00104	
166	 IL1R1	 4.24	 9.37E-05	
	
210	 CBR4	 3.97	 1.42E-05	
	
254	 CCDC53	 3.70	 4.54E-07	
167	 HS.452445	 4.23	 7.24E-05	
	
211	 ELOVL6	 3.96	 1.45E-08	
	
255	 TRAK2	 3.69	 2.56E-06	
168	 PRDX1	 4.22	 1.77E-06	
	
212	 CKS1B	 3.96	 0.00064	
	
256	 HNRPA2B1	 3.69	 1.14E-05	
169	 EOMES	 4.22	 0.00039	
	
213	 TFCP2	 3.95	 5.70E-07	
	
257	 RASSF7	 3.68	 7.48E-07	
170	 COTL1	 4.22	 0.00018	
	
214	 CCDC109B	 3.94	 5.67E-06	
	
258	 VKORC1	 3.67	 1.22E-06	
171	 TMEM200A	 4.21	 0.00019	
	
215	 LOC285016	 3.94	 0.00038	
	
259	 ITM2C	 3.67	 0.00030	
172	 NOTCH1	 4.21	 5.27E-06	
	
216	 HSD17B4	 3.93	 5.64E-07	
	
260	 RBM14	 3.66	 6.88E-07	
173	 AKR7A2	 4.20	 7.92E-05	
	
217	 COMMD3	 3.92	 0.00036	
	
261	 KLHL6	 3.66	 1.03E-06	
174	 MTIF3	 4.18	 9.47E-07	
	
218	 CISD1	 3.92	 7.87E-07	
	
262	 PAPOLA	 3.66	 0.00070	
175	 METTL13	 4.18	 3.61E-08	
	
219	 TUBA1B	 3.90	 0.0003	
	
263	 LOC253039	 3.64	 0.00410	
176	 IMPA2	 4.15	 7.71E-05	
	
220	 PNPO	 3.89	 3.36E-06	
	
264	 RAB7A	 3.64	 3.15E-06	
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265	 FANCE	 3.63	 1.66E-06	
	
309	 GCNT1	 3.48	 3.11E-05	
	
353	 HSPH1	 3.29	 2.02E-05	
266	 DOCK8	 3.63	 0.00045	
	
310	 INPP4B	 3.48	 0.00039	
	
354	 CLNS1A	 3.29	 1.86E-05	
267	 SEL1L3	 3.63	 0.00142	
	
311	 FAM150B	 3.47	 0.00052	
	
355	 LOC100130633	 3.29	 6.71E-07	
268	 COQ5	 3.63	 6.29E-06	
	
312	 SYPL1	 3.47	 7.65E-05	
	
356	 OSTF1	 3.28	 0.00020	
269	 BRDG1	 3.62	 4.33E-06	
	
313	 SLC35B3	 3.47	 4.58E-06	
	
357	 STIL	 3.28	 0.00248	
270	 CLDND1	 3.62	 0.00253	
	
314	 KIF20A	 3.46	 0.00016	
	
358	 FUCA1	 3.28	 6.00E-05	
271	 KLHDC5	 3.61	 7.94E-07	
	
315	 TEX2	 3.45	 1.50E-07	
	
359	 RNF34	 3.27	 9.72E-06	
272	 C11orf75	 3.60	 3.81E-06	
	
316	 LOC100134304	 3.44	 7.39E-06	
	
360	 P15RS	 3.26	 4.39E-06	
273	 DBNL	 3.60	 0.00021	
	
317	 C1orf24	 3.43	 1.61E-05	
	
361	 CD47	 3.26	 0.0015663	
274	 STK39	 3.60	 5.93E-05	
	
318	 RGS10	 3.43	 5.37E-05	
	
362	 GRAMD4	 3.26	 4.97E-06	
275	 HS.294103	 3.59	 1.94E-06	
	
319	 GVIN1	 3.42	 0.00208	
	
363	 LOC113386	 3.26	 2.26E-05	
276	 FCER1G	 3.59	 0.00019	
	
320	 PREPL	 3.42	 4.26E-06	
	
364	 NDUFB3	 3.26	 9.00E-07	
277	 SMUG1	 3.59	 1.32E-06	
	
321	 ATXN2	 3.42	 1.93E-05	
	
365	 C16orf75	 3.25	 3.82E-05	
278	 RBM4B	 3.59	 5.92E-06	
	
322	 RAD51AP1	 3.41	 0.00274	
	
366	 OPTN	 3.24	 1.39E-05	
279	 MBP	 3.58	 0.00061	
	
323	 TMEM43	 3.41	 7.25E-05	
	
367	 RALBP1	 3.24	 3.00E-06	
280	 STT3A	 3.58	 0.00019	
	
324	 SLAMF6	 3.41	 0.00074	
	
368	 SERP2	 3.24	 0.00026	
281	 NIF3L1	 3.57	 1.70E-05	
	
325	 HSPA1A	 3.40	 0.00069	
	
369	 ASF1A	 3.24	 9.01E-06	
282	 NUP43	 3.57	 5.79E-07	
	
326	 TTC15	 3.40	 3.69E-06	
	
370	 PVRIG	 3.23	 0.00028	
283	 LOC729816	 3.57	 2.06E-05	
	
327	 SLFN5	 3.40	 2.08E-06	
	
371	 NEK2	 3.23	 0.00020	
284	 BIVM	 3.57	 4.74E-05	
	
328	 SDCCAG10	 3.39	 6.63E-07	
	
372	 LOC401397	 3.23	 8.39E-06	
285	 APEX2	 3.56	 9.22E-05	
	
329	 CSK	 3.39	 0.00017	
	
373	 TUBA1A	 3.23	 0.00082	
286	 HNRNPA0	 3.56	 5.21E-06	
	
330	 MTHFS	 3.38	 1.95E-05	
	
374	 ENPP1	 3.22	 4.45E-06	
287	 KIAA0907	 3.56	 8.58E-06	
	
331	 PRDX6	 3.38	 1.82E-06	
	
375	 PPT1	 3.22	 0.00132	
288	 WDR67	 3.55	 1.72E-05	
	
332	 DENND2D	 3.38	 0.00032	
	
376	 MTM1	 3.21	 2.65E-05	
289	 ZFHX3	 3.55	 2.55E-05	
	
333	 FAM120B	 3.37	 0.00027	
	
377	 EHBP1	 3.21	 1.65E-05	
290	 LOC339192	 3.55	 0.00115	
	
334	 TCFL5	 3.37	 2.66E-05	
	
378	 SMARCAL1	 3.21	 1.12E-05	
291	 GOPC	 3.54	 1.47E-06	
	
335	 CORO1A	 3.36	 4.02E-05	
	
379	 WDR18	 3.21	 0.00034	
292	 TNF	 3.52	 0.00238	
	
336	 HS.436134	 3.36	 0.00031	
	
380	 RNF20	 3.21	 0.00019	
293	 PSD4	 3.52	 0.00019	
	
337	 PDXK	 3.36	 3.68E-06	
	
381	 KLRAQ1	 3.20	 2.00E-05	
294	 C1orf162	 3.52	 2.41E-06	
	
338	 CENPJ	 3.36	 2.80E-05	
	
382	 ACVR1	 3.20	 1.11E-06	
295	 APEH	 3.52	 3.58E-06	
	
339	 CDKN3	 3.35	 0.00112	
	
383	 LARS	 3.19	 9.37E-06	
296	 CNDP2	 3.51	 2.88E-05	
	
340	 COPB2	 3.35	 1.76E-06	
	
384	 SLC37A4	 3.19	 3.44E-05	
297	 CD300A	 3.51	 0.00126	
	
341	 SPRY2	 3.35	 0.00030	
	
385	 GLB1	 3.19	 2.82E-08	
298	 ARMCX2	 3.51	 2.77E-05	
	
342	 LOC728532	 3.34	 3.41E-07	
	
386	 AFG3L2	 3.19	 0.00010	
299	 PAQR8	 3.51	 0.00029	
	
343	 LOC643384	 3.33	 7.31E-05	
	
387	 TM2D1	 3.18	 0.00016	
300	 SLC39A10	 3.51	 5.12E-05	
	
344	 LOC648868	 3.33	 0.00053	
	
388	 BUB1	 3.18	 0.00174	
301	 NUDT5	 3.51	 3.39E-05	
	
345	 AURKA	 3.32	 0.00043	
	
389	 BCDIN3D	 3.18	 4.39E-06	
302	 DYNC1I2	 3.51	 1.66E-05	
	
346	 ZNF302	 3.31	 5.07E-06	
	
390	 RNASEL	 3.18	 1.32E-06	
303	 TC2N	 3.50	 0.00139	
	
347	 CDC2	 3.31	 0.00134	
	
391	 ZDHHC16	 3.18	 4.16E-08	
304	 TRAPPC3	 3.50	 3.77E-05	
	
348	 CYSLTR1	 3.30	 7.77E-05	
	
392	 HSDL2	 3.17	 6.70E-05	
305	 CDK6	 3.50	 0.00034	
	
349	 REEP5	 3.30	 0.00326	
	
393	 TROAP	 3.17	 0.00045	
306	 AHCYL1	 3.49	 7.79E-05	
	
350	 B3GALT6	 3.30	 1.18E-06	
	
394	 ZSWIM1	 3.17	 3.95E-06	
307	 CENPF	 3.49	 0.00059	
	
351	 PDE6D	 3.30	 9.08E-06	
	
395	 BCL2	 3.16	 6.60E-05	
308	 PACSIN1	 3.49	 0.00244	
	
352	 LOC647000	 3.30	 0.00083	
	
396	 PHTF1	 3.16	 4.64E-06	
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397	 ARL2	 3.16	 0.00011	
	
441	 POLA1	 3.05	 1.72E-06	
	
485	 DNAL4	 2.97	 1.02E-06	
398	 FLJ14213	 3.15	 0.00037	
	
442	 SEC23IP	 3.05	 7.77E-06	
	
486	 RASSF2	 2.96	 0.00027	
399	 APOBEC3G	 3.15	 4.61E-05	
	
443	 MED20	 3.05	 0.00023	
	
487	 ZBTB46	 2.96	 0.00066	
400	 PTPN6	 3.14	 0.00016	
	
444	 CDCA8	 3.05	 0.00092	
	
488	 KIFAP3	 2.96	 1.26E-05	
401	 HS.356079	 3.14	 0.00012	
	
445	 TBCA	 3.04	 0.00121	
	
489	 CCDC128	 2.96	 1.39E-05	
402	 ARV1	 3.14	 6.42E-06	
	
446	 ZNF816A	 3.04	 2.77E-06	
	
490	 METTL5	 2.96	 2.19E-06	
403	 MUM1	 3.14	 2.32E-05	
	
447	 MELK	 3.04	 0.00270	
	
491	 LOC606724	 2.96	 4.62E-06	
404	 LOC124512	 3.14	 2.06E-05	
	
448	 MCM3	 3.04	 0.00025	
	
492	 DERA	 2.96	 1.59E-05	
405	 RACGAP1	 3.14	 0.00047	
	
449	 RXRA	 3.04	 0.00022	
	
493	 CCNF	 2.96	 0.00011	
406	 IFNAR1	 3.14	 3.98E-06	
	
450	 GALK1	 3.03	 3.59E-07	
	
494	 GTF2H5	 2.95	 8.80E-06	
407	 MLEC	 3.13	 5.62E-07	
	
451	 SLC25A43	 3.03	 2.17E-05	
	
495	 RGS19	 2.95	 0.00012	
408	 GPR18	 3.12	 1.04E-05	
	
452	 C21orf33	 3.03	 3.45E-06	
	
496	 MGAT3	 2.95	 0.00032	
409	 ELP3	 3.12	 1.98E-05	
	
453	 ZNF135	 3.03	 1.05E-06	
	
497	 ZBED5	 2.94	 6.83E-06	
410	 RBM12B	 3.12	 1.10E-05	
	
454	 EPRS	 3.02	 1.33E-05	
	
498	 ZBTB24	 2.94	 5.34E-06	
411	 ECT2	 3.12	 0.00121	
	
455	 PRKCA	 3.02	 2.27E-06	
	
499	 XPO1	 2.94	 1.77E-05	
412	 TPX2	 3.11	 0.00084	
	
456	 SAC3D1	 3.02	 0.00097	
	
500	 AIMP2	 2.93	 5.54E-07	
413	 C14orf135	 3.11	 3.23E-05	
	
457	 BCKDK	 3.02	 1.04E-06	
	
501	 GDI2	 2.93	 1.16E-05	
414	 GIMAP8	 3.11	 6.41E-06	
	
458	 NUP37	 3.02	 2.60E-06	
	
502	 RPUSD3	 2.92	 2.42E-05	
415	 PRDX3	 3.11	 1.83E-06	
	
459	 HOPX	 3.01	 0.00041	
	
503	 ZFYVE26	 2.92	 4.55E-05	
416	 ANTXR2	 3.11	 0.00160	
	
460	 NUPL2	 3.01	 3.09E-05	
	
504	 ENO1	 2.91	 2.62E-05	
417	 PRCP	 3.10	 0.00020	
	
461	 UFSP2	 3.01	 2.55E-06	
	
505	 KIAA0494	 2.91	 5.41E-05	
418	 GLE1	 3.10	 0.00017	
	
462	 GOLGA3	 3.00	 0.00023	
	
506	 GART	 2.91	 1.87E-08	
419	 RCSD1	 3.10	 4.25E-05	
	
463	 C6orf125	 3.00	 3.62E-06	
	
507	 CDC25B	 2.91	 2.38E-06	
420	 C14orf142	 3.10	 2.83E-05	
	
464	 GSN	 3.00	 1.27E-06	
	
508	 NEK1	 2.90	 5.42E-07	
421	 TACC3	 3.09	 0.00047	
	
465	 RASA1	 3.00	 4.22E-06	
	
509	 CKAP5	 2.90	 1.02E-05	
422	 GLIPR2	 3.09	 0.00043	
	
466	 IL16	 3.00	 3.44E-06	
	
510	 HS.125056	 2.90	 0.00054	
423	 PLP2	 3.09	 0.00119	
	
467	 PUS7	 2.99	 0.00013	
	
511	 PRELID1	 2.90	 8.46E-06	
424	 BZW2	 3.09	 4.12E-06	
	
468	 HSD17B12	 2.99	 6.30E-06	
	
512	 CSTF3	 2.90	 8.42E-07	
425	 ECHS1	 3.08	 7.01E-06	
	
469	 C11orf54	 2.99	 7.21E-08	
	
513	 C10orf104	 2.90	 0.00026	
426	 DKFZp761P0423	 3.08	 1.60E-05	
	
470	 C20orf72	 2.99	 0.00038	
	
514	 AIDA	 2.90	 7.11E-05	
427	 TBC1D2B	 3.08	 4.05E-05	
	
471	 ZNF252	 2.99	 5.22E-06	
	
515	 ABHD3	 2.89	 0.00026	
428	 SAMD9L	 3.08	 3.79E-06	
	
472	 DEXI	 2.99	 0.00043	
	
516	 C12orf35	 2.89	 0.00070	
429	 TNFAIP8	 3.08	 1.06E-06	
	
473	 TAF4	 2.99	 8.20E-06	
	
517	 YIF1A	 2.89	 2.81E-05	
430	 CDT1	 3.08	 0.00223	
	
474	 MAN1C1	 2.99	 0.00068	
	
518	 GLO1	 2.89	 0.00019	
431	 QDPR	 3.07	 0.00022	
	
475	 ZCCHC7	 2.99	 2.22E-05	
	
519	 THEM2	 2.89	 4.15E-05	
432	 IMPDH2	 3.07	 1.56E-05	
	
476	 C10orf137	 2.99	 6.69E-05	
	
520	 EPDR1	 2.89	 0.00019	
433	 CARD8	 3.07	 6.35E-05	
	
477	 DARS2	 2.98	 8.66E-06	
	
521	 ZC3H4	 2.89	 2.83E-05	
434	 CNPY2	 3.07	 2.80E-06	
	
478	 TMEM218	 2.98	 1.41E-06	
	
522	 PAPSS1	 2.88	 2.85E-05	
435	 IL4R	 3.06	 0.00080	
	
479	 TSPAN31	 2.98	 5.94E-05	
	
523	 CAT	 2.88	 2.72E-06	
436	 LARP4B	 3.06	 1.73E-05	
	
480	 LOC81691	 2.98	 0.00016	
	
524	 ASH2L	 2.88	 2.00E-05	
437	 CRIP1	 3.06	 0.00167	
	
481	 C9orf114	 2.98	 9.40E-07	
	
525	 MRPL14	 2.88	 2.02E-06	
438	 TXN	 3.06	 1.49E-05	
	
482	 RALB	 2.97	 2.03E-05	
	
526	 PSMB9	 2.88	 3.19E-05	
439	 FH	 3.06	 1.30E-05	
	
483	 PPP1R14B	 2.97	 1.38E-05	
	
527	 ARHGAP15	 2.88	 0.00015	
440	 ACTL6A	 3.05	 7.42E-06	
	
484	 LOC728715	 2.97	 0.00057	
	
528	 PEX11B	 2.88	 0.00071	
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529	 TMEM194	 2.88	 4.02E-05	
	
573	 C17orf62	 2.78	 6.65E-06	
	
617	 WDR92	 2.72	 7.72E-05	
530	 GPR132	 2.87	 4.27E-06	
	
574	 MNAT1	 2.78	 1.21E-07	
	
618	 CBL	 2.72	 0.00016	
531	 PRMT6	 2.86	 0.00022	
	
575	 GOLGA9P	 2.78	 5.13E-05	
	
619	 LMNB2	 2.72	 1.85E-05	
532	 KIAA0528	 2.86	 0.00028	
	
576	 ZCCHC9	 2.78	 7.72E-07	
	
620	 LOC440063	 2.72	 0.00011	
533	 FAR1	 2.86	 8.15E-05	
	
577	 PGM2	 2.77	 7.51E-06	
	
621	 ROBLD3	 2.72	 0.00023	
534	 TIA1	 2.86	 1.33E-05	
	
578	 NDUFA8	 2.77	 5.85E-08	
	
622	 SSU72	 2.72	 0.00098	
535	 C14orf109	 2.86	 1.06E-06	
	
579	 C13orf27	 2.77	 2.03E-05	
	
623	 SEPX1	 2.71	 4.48E-05	
536	 CMAS	 2.86	 1.91E-07	
	
580	 WDR51A	 2.77	 0.00021	
	
624	 EBNA1BP2	 2.71	 0.00017	
537	 EXOSC3	 2.86	 2.63E-05	
	
581	 HNRNPAB	 2.77	 3.58E-05	
	
625	 UBE2T	 2.71	 0.00152	
538	 GPR114	 2.86	 0.00066	
	
582	 HERC4	 2.77	 5.04E-06	
	
626	 NCK2	 2.71	 0.00024	
539	 CHM	 2.85	 2.92E-06	
	
583	 TMED10	 2.77	 7.55E-05	
	
627	 COMMD4	 2.71	 9.30E-06	
540	 AKR1A1	 2.85	 1.04E-06	
	
584	 LOC653344	 2.77	 0.00158	
	
628	 MCM2	 2.71	 0.00215	
541	 TMEM60	 2.85	 0.00020	
	
585	 DTL	 2.77	 0.00103	
	
629	 SDAD1	 2.71	 0.00045	
542	 CISH	 2.84	 0.00092	
	
586	 ZFYVE21	 2.76	 9.66E-06	
	
630	 INTS3	 2.71	 2.06E-06	
543	 SEC22B	 2.84	 2.64E-05	
	
587	 CDC2L5	 2.76	 9.57E-05	
	
631	 SH2D1A	 2.71	 0.00038	
544	 ZNF25	 2.83	 8.91E-06	
	
588	 USP47	 2.76	 0.00018	
	
632	 COQ9	 2.71	 1.28E-06	
545	 IPO11	 2.83	 4.61E-05	
	
589	 DPYD	 2.76	 0.00012	
	
633	 OMA1	 2.70	 1.30E-06	
546	 METTL3	 2.83	 7.14E-05	
	
590	 CHCHD4	 2.76	 2.93E-06	
	
634	 MMRN1	 2.70	 0.00038	
547	 APPBP2	 2.83	 3.22E-05	
	
591	 LAGE3	 2.76	 0.00012	
	
635	 CKS2	 2.70	 0.00164	
548	 BMP2	 2.83	 0.00188	
	
592	 SFRS7	 2.75	 2.15E-07	
	
636	 ME2	 2.70	 0.00018	
549	 TFB1M	 2.83	 1.85E-07	
	
593	 RPAP2	 2.75	 1.56E-05	
	
637	 LOC730432	 2.70	 0.00015	
550	 CCDC34	 2.82	 7.12E-05	
	
594	 TTC4	 2.75	 0.00022	
	
638	 BARD1	 2.70	 0.00146	
551	 FLJ39639	 2.82	 1.92E-05	
	
595	 RSU1	 2.75	 8.98E-05	
	
639	 NICN1	 2.70	 5.89E-05	
552	 NP	 2.82	 1.97E-05	
	
596	 ADSL	 2.75	 9.00E-06	
	
640	 SHMT2	 2.70	 0.00055	
553	 FAM127A	 2.82	 3.71E-05	
	
597	 UTP14C	 2.75	 2.64E-06	
	
641	 ZNF260	 2.70	 1.04E-05	
554	 PFAS	 2.82	 5.30E-05	
	
598	 HEBP1	 2.75	 1.33E-06	
	
642	 MGC16169	 2.70	 4.53E-05	
555	 PFKP	 2.82	 0.00188	
	
599	 LOC400657	 2.75	 7.04E-05	
	
643	 ZNF544	 2.69	 0.00012	
556	 ZNF439	 2.81	 2.23E-05	
	
600	 LOC100129828	 2.74	 7.67E-05	
	
644	 RB1	 2.69	 0.00122	
557	 MGST3	 2.81	 3.22E-06	
	
601	 SLC4A7	 2.74	 0.00010	
	
645	 KIAA1671	 2.69	 0.00012	
558	 AGAP8	 2.81	 0.00192	
	
602	 SOS1	 2.74	 1.03E-06	
	
646	 EXOC1	 2.69	 1.50E-06	
559	 ZNF285A	 2.81	 8.10E-05	
	
603	 LOC554203	 2.74	 9.16E-05	
	
647	 HTATIP2	 2.69	 0.00018	
560	 DUSP23	 2.80	 8.01E-05	
	
604	 WIBG	 2.74	 9.36E-06	
	
648	 INTS8	 2.69	 2.72E-05	
561	 STYXL1	 2.80	 4.29E-06	
	
605	 UST	 2.74	 1.16E-06	
	
649	 CRLS1	 2.69	 1.03E-05	
562	 COQ2	 2.80	 1.55E-06	
	
606	 CD53	 2.74	 7.38E-05	
	
650	 ZFP36L1	 2.69	 0.00023	
563	 KIF15	 2.80	 0.00073	
	
607	 GUCY1A3	 2.73	 0.00010	
	
651	 MFSD1	 2.69	 5.25E-06	
564	 C14orf167	 2.79	 5.77E-05	
	
608	 HADHB	 2.73	 4.63E-06	
	
652	 HS.516646	 2.68	 0.00024	
565	 ATP5H	 2.79	 5.78E-06	
	
609	 C1orf71	 2.73	 8.16E-05	
	
653	 KIAA0146	 2.68	 4.32E-07	
566	 ECHDC1	 2.79	 4.65E-06	
	
610	 HS.371609	 2.73	 0.00031	
	
654	 RNF145	 2.68	 6.57E-05	
567	 HPS3	 2.79	 2.69E-05	
	
611	 NQO1	 2.73	 0.00063	
	
655	 MRI1	 2.68	 7.45E-05	
568	 PSMG1	 2.79	 2.37E-05	
	
612	 ADO	 2.72	 3.63E-05	
	
656	 PLD6	 2.68	 0.00013	
569	 GNPAT	 2.79	 0.00016	
	
613	 ZNF146	 2.72	 4.07E-06	
	
657	 FAM50B	 2.68	 4.04E-05	
570	 KIAA1012	 2.79	 0.00053	
	
614	 IL27RA	 2.72	 0.00012	
	
658	 PDS5A	 2.68	 7.44E-05	
571	 HDDC3	 2.78	 2.06E-06	
	
615	 NFE2L3	 2.72	 9.67E-05	
	
659	 FANCI	 2.68	 0.00222	
572	 RAI1	 2.78	 5.94E-07	
	
616	 G3BP1	 2.72	 6.10E-06	
	
660	 MRPL24	 2.68	 1.50E-09	
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661	 ZNF75D	 2.68	 5.11E-05	
	
705	 LOC391811	 2.63	 0.00201	
	
749	 CDC16	 2.56	 2.19E-05	
662	 NCAM1	 2.68	 3.57E-06	
	
706	 TRAPPC6B	 2.63	 9.37E-06	
	
750	 FZD6	 2.56	 0.00038	
663	 TNFSF14	 2.67	 5.28E-07	
	
707	 TM9SF3	 2.63	 2.16E-06	
	
751	 POGK	 2.56	 9.00E-05	
664	 RPA3	 2.67	 1.43E-05	
	
708	 RMI1	 2.63	 6.71E-05	
	
752	 SNTB1	 2.56	 0.00575	
665	 SAP18	 2.67	 7.08E-08	
	
709	 SPG11	 2.63	 0.00043	
	
753	 LOC642755	 2.56	 0.00255	
666	 AKTIP	 2.67	 0.00372	
	
710	 MFSD3	 2.62	 3.50E-05	
	
754	 LOC730324	 2.56	 1.24E-06	
667	 ILK	 2.67	 3.41E-05	
	
711	 GTF2H1	 2.62	 8.16E-06	
	
755	 C6orf115	 2.56	 1.98E-06	
668	 GIMAP2	 2.67	 4.88E-05	
	
712	 SLC33A1	 2.62	 0.00018	
	
756	 NDUFAF1	 2.56	 0.00033	
669	 RSBN1L	 2.66	 1.40E-06	
	
713	 ZMYM1	 2.62	 1.28E-06	
	
757	 HIBCH	 2.56	 2.69E-06	
670	 PIK3CD	 2.66	 4.69E-06	
	
714	 PIGU	 2.62	 6.87E-06	
	
758	 ACYP1	 2.56	 1.03E-05	
671	 C6orf173	 2.66	 0.00452	
	
715	 C22orf36	 2.62	 4.86E-05	
	
759	 ATP5G1	 2.56	 5.24E-07	
672	 CBX5	 2.66	 0.00023	
	
716	 CDK2AP2	 2.62	 2.39E-05	
	
760	 SH2D3C	 2.56	 2.49E-06	
673	 RAB5B	 2.66	 9.80E-05	
	
717	 SFRS1	 2.62	 7.63E-07	
	
761	 SDHC	 2.55	 2.25E-06	
674	 CENPQ	 2.66	 2.51E-05	
	
718	 ATP6V1D	 2.62	 0.00080	
	
762	 SRPK1	 2.55	 8.46E-06	
675	 MCTS1	 2.66	 0.00012	
	
719	 ITGB7	 2.62	 0.00691	
	
763	 ANKIB1	 2.55	 1.60E-05	
676	 TIMM10	 2.66	 0.00087	
	
720	 RAB22A	 2.62	 6.35E-05	
	
764	 FLOT1	 2.55	 0.00016	
677	 STX3	 2.66	 0.00029	
	
721	 TIMELESS	 2.61	 0.00195	
	
765	 POLQ	 2.55	 0.00532	
678	 SPATS2L	 2.66	 5.64E-05	
	
722	 PTK2	 2.61	 0.00015	
	
766	 NUDT7	 2.55	 7.89E-05	
679	 ARHGAP25	 2.66	 6.65E-05	
	
723	 C14orf147	 2.61	 7.79E-06	
	
767	 C12orf29	 2.55	 1.68E-05	
680	 FES	 2.66	 0.00408	
	
724	 ECH1	 2.61	 5.44E-05	
	
768	 OAZ1	 2.55	 3.66E-05	
681	 RABEP1	 2.65	 7.34E-05	
	
725	 S1PR4	 2.61	 9.86E-07	
	
769	 TXNDC14	 2.54	 2.84E-06	
682	 TMEM79	 2.65	 2.05E-06	
	
726	 CEP110	 2.61	 1.28E-05	
	
770	 HS.372654	 2.54	 0.00013	
683	 C12orf32	 2.65	 2.09E-05	
	
727	 RAB3GAP1	 2.60	 0.00014	
	
771	 CCM2	 2.54	 0.00041	
684	 LOC100128252	 2.65	 0.00027	
	
728	 PHB	 2.60	 0.00034	
	
772	 PCDH21	 2.54	 0.00051	
685	 LTA4H	 2.65	 0.00019	
	
729	 COMMD10	 2.60	 4.93E-05	
	
773	 CPSF2	 2.54	 9.54E-06	
686	 ADARB1	 2.65	 5.96E-05	
	
730	 GPSM2	 2.60	 0.00144	
	
774	 TRAF3IP3	 2.53	 0.00023	
687	 HAGH	 2.65	 2.11E-05	
	
731	 PURB	 2.60	 7.36E-05	
	
775	 PSIP1	 2.53	 0.00024	
688	 C8orf55	 2.65	 7.97E-05	
	
732	 STK38	 2.59	 7.50E-06	
	
776	 ZNF621	 2.53	 1.10E-05	
689	 RPP40	 2.65	 1.84E-05	
	
733	 CCDC97	 2.59	 1.44E-06	
	
777	 MAPBPIP	 2.53	 0.00036	
690	 NAGK	 2.65	 3.35E-07	
	
734	 LOC653888	 2.58	 0.00438	
	
778	 C5orf53	 2.53	 3.99E-05	
691	 C16orf53	 2.64	 8.94E-08	
	
735	 KIAA1826	 2.58	 8.53E-05	
	
779	 KIAA0513	 2.53	 2.80E-05	
692	 PREB	 2.64	 7.96E-08	
	
736	 CMTM7	 2.58	 7.83E-05	
	
780	 DGUOK	 2.53	 1.60E-05	
693	 GSTO1	 2.64	 5.41E-06	
	
737	 PMS1	 2.58	 1.99E-06	
	
781	 OAS2	 2.53	 1.26E-05	
694	 TMEM141	 2.64	 2.97E-05	
	
738	 HS.354359	 2.58	 0.00022	
	
782	 CMC1	 2.52	 0.00014	
695	 SNX27	 2.64	 5.63E-06	
	
739	 BACH2	 2.58	 7.53E-05	
	
783	 SMARCAD1	 2.52	 6.63E-05	
696	 GOLGA5	 2.64	 7.55E-07	
	
740	 SUCLA2	 2.57	 2.66E-06	
	
784	 TNFAIP8L2	 2.52	 1.47E-06	
697	 DOCK10	 2.64	 0.00018	
	
741	 NOC3L	 2.57	 7.18E-07	
	
785	 ZNF175	 2.52	 7.34E-05	
698	 LOC729768	 2.63	 1.79E-05	
	
742	 CFDP1	 2.57	 0.00033	
	
786	 MRPS11	 2.52	 3.90E-07	
699	 SAE1	 2.63	 0.00025	
	
743	 ZNF583	 2.57	 2.02E-07	
	
787	 STRBP	 2.52	 6.31E-05	
700	 MRPL52	 2.63	 3.66E-05	
	
744	 TMEM204	 2.57	 8.22E-06	
	
788	 THOC7	 2.52	 0.00053	
701	 C1orf131	 2.63	 6.50E-05	
	
745	 HS.130036	 2.57	 5.39E-05	
	
789	 PPP3CB	 2.52	 0.00042	
702	 CLEC16A	 2.63	 6.04E-05	
	
746	 STAMBP	 2.57	 2.95E-06	
	
790	 ZNF322A	 2.52	 5.68E-06	
703	 TMEM30A	 2.63	 0.00045	
	
747	 ORC3L	 2.57	 1.67E-05	
	
791	 COMT	 2.52	 1.95E-05	
704	 ANLN	 2.63	 0.00276	
	
748	 SETDB2	 2.57	 0.00013	
	
792	 UBE2N	 2.51	 0.00051	
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793	 NEK6	 2.51	 3.01E-05	
	
837	 TMEM42	 2.47	 5.74E-05	
	
881	 UBE2V2	 2.42	 4.11E-07	
794	 BCAT2	 2.51	 1.46E-05	
	
838	 OIP5	 2.47	 0.00125	
	
882	 MIST	 2.42	 0.00137	
795	 RNF130	 2.51	 0.00028	
	
839	 DNAJC24	 2.47	 1.21E-06	
	
883	 RUNX2	 2.42	 5.33E-05	
796	 PARN	 2.51	 5.70E-05	
	
840	 FUT7	 2.47	 6.75E-05	
	
884	 LOC550643	 2.42	 5.76E-05	
797	 RAB32	 2.51	 0.00040	
	
841	 TRPV2	 2.46	 3.52E-05	
	
885	 TYW3	 2.41	 6.77E-06	
798	 DPAGT1	 2.51	 8.49E-06	
	
842	 ARHGEF6	 2.46	 1.40E-05	
	
886	 ACSS1	 2.41	 0.00108	
799	 PDSS2	 2.51	 2.94E-05	
	
843	 DEGS1	 2.46	 4.23E-07	
	
887	 LOC728006	 2.41	 1.63E-05	
800	 CASK	 2.51	 0.00014	
	
844	 CHN2	 2.46	 1.28E-05	
	
888	 EMILIN2	 2.41	 2.13E-06	
801	 CNN2	 2.51	 0.00011	
	
845	 C4orf34	 2.46	 4.11E-06	
	
889	 CKAP2	 2.41	 0.00102	
802	 CDC2L6	 2.51	 0.00013	
	
846	 SEC62	 2.46	 2.10E-06	
	
890	 MFNG	 2.41	 0.00392	
803	 TMCO3	 2.51	 0.00036	
	
847	 RPS6KA5	 2.46	 3.92E-07	
	
891	 HIRIP3	 2.41	 0.00010	
804	 RPL23AP53	 2.50	 0.00011	
	
848	 TARP	 2.45	 0.00027	
	
892	 RAPGEF6	 2.41	 5.04E-05	
805	 UBE3C	 2.50	 0.00026	
	
849	 DHX32	 2.45	 0.00081	
	
893	 EFHC2	 2.41	 0.00722	
806	 RAB33B	 2.50	 0.00028	
	
850	 NAB1	 2.45	 0.00019	
	
894	 FUT8	 2.41	 1.62E-08	
807	 RECK	 2.50	 2.47E-07	
	
851	 KIAA0391	 2.45	 5.22E-05	
	
895	 SLC1A5	 2.41	 0.00342	
808	 ACTR3	 2.50	 6.64E-05	
	
852	 CHD9	 2.45	 0.00045	
	
896	 TIGD5	 2.41	 0.00258	
809	 SLC35E3	 2.49	 3.09E-05	
	
853	 PRKAA1	 2.45	 0.00101	
	
897	 EMG1	 2.41	 1.84E-05	
810	 PRPSAP1	 2.49	 1.12E-06	
	
854	 GPR183	 2.45	 3.04E-05	
	
898	 SAMD3	 2.41	 0.00046	
811	 PRDX4	 2.49	 1.10E-05	
	
855	 CNOT6	 2.44	 0.00124	
	
899	 PUM2	 2.41	 0.00031	
812	 DARS	 2.49	 0.00047	
	
856	 RRM1	 2.44	 0.00387	
	
900	 SCYL3	 2.40	 2.32E-07	
813	 AP1M1	 2.49	 3.13E-05	
	
857	 ATOX1	 2.44	 8.09E-05	
	
901	 NUP133	 2.40	 2.90E-06	
814	 CTGLF3	 2.49	 0.00390	
	
858	 RPA2	 2.44	 0.00568	
	
902	 SRBD1	 2.40	 0.00018	
815	 PIGM	 2.49	 4.55E-07	
	
859	 SCOC	 2.44	 6.59E-05	
	
903	 HS.154336	 2.40	 1.66E-05	
816	 WDR6	 2.49	 4.48E-05	
	
860	 HS.489254	 2.44	 3.15E-06	
	
904	 LOC642590	 2.40	 1.59E-05	
817	 GRAMD1A	 2.49	 9.73E-05	
	
861	 FAIM3	 2.44	 0.00606	
	
905	 STRADB	 2.40	 4.74E-06	
818	 MKKS	 2.49	 1.37E-05	
	
862	 LOC728565	 2.44	 1.31E-06	
	
906	 FEN1	 2.40	 0.00193	
819	 LSM4	 2.49	 9.73E-06	
	
863	 ZRANB2	 2.44	 0.00025	
	
907	 CCDC99	 2.40	 0.00023	
820	 BANF1	 2.49	 4.78E-07	
	
864	 FLT3LG	 2.43	 0.00012	
	
908	 TRIP4	 2.40	 0.00024	
821	 ACTR2	 2.49	 0.00016	
	
865	 LARP4	 2.43	 0.00013	
	
909	 PLAC8	 2.39	 2.23E-05	
822	 RNASEH2A	 2.48	 4.40E-05	
	
866	 TTC31	 2.43	 1.25E-07	
	
910	 LOC442535	 2.39	 0.00135	
823	 PLCL2	 2.48	 0.00286	
	
867	 GOT1	 2.43	 8.15E-05	
	
911	 DECR1	 2.39	 0.00059	
824	 PPP1R11	 2.48	 0.00012	
	
868	 MAT2B	 2.43	 0.00030	
	
912	 C6orf108	 2.39	 2.05E-05	
825	 ZNF234	 2.48	 0.00200	
	
869	 LOC644128	 2.43	 1.59E-05	
	
913	 C20orf94	 2.39	 6.62E-05	
826	 MAPKAPK3	 2.48	 9.65E-05	
	
870	 PECI	 2.43	 0.00053	
	
914	 YIPF6	 2.39	 1.45E-07	
827	 LOC151162	 2.48	 0.00347	
	
871	 C1orf218	 2.43	 0.00155	
	
915	 PANK2	 2.39	 2.24E-05	
828	 OBFC1	 2.48	 9.16E-05	
	
872	 MPV17	 2.43	 1.10E-05	
	
916	 MZF1	 2.39	 7.15E-05	
829	 FLJ22795	 2.48	 0.00112	
	
873	 FAM179B	 2.43	 0.00046	
	
917	 APTX	 2.39	 5.55E-08	
830	 GRSF1	 2.48	 2.57E-05	
	
874	 BOP1	 2.43	 0.00089	
	
918	 APIP	 2.39	 2.91E-05	
831	 IPO8	 2.48	 0.00310	
	
875	 STAU2	 2.42	 0.00048	
	
919	 LGTN	 2.38	 6.36E-07	
832	 HS.572649	 2.47	 5.01E-05	
	
876	 MGEA5	 2.42	 0.00125	
	
920	 POLR3GL	 2.38	 0.00269	
833	 C19orf25	 2.47	 7.92E-05	
	
877	 KIF2C	 2.42	 0.00482	
	
921	 SLC1A4	 2.38	 0.00099	
834	 FAM113B	 2.47	 2.21E-05	
	
878	 LOC134997	 2.42	 0.00015	
	
922	 LASS6	 2.38	 0.00014	
835	 BSCL2	 2.47	 4.50E-06	
	
879	 XYLT1	 2.42	 0.00194	
	
923	 C12orf26	 2.38	 0.00013	
836	 TLN1	 2.47	 0.00044	
	
880	 TMEM4	 2.42	 0.00023	
	
924	 FGD3	 2.38	 1.81E-05	
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925	 TCF4	 2.38	 0.00107	
	
969	 IER3	 2.33	 0.02526	
926	 ZNF213	 2.38	 0.00017	
	
970	 PRPS2	 2.33	 0.00034	
927	 CECR5	 2.38	 4.71E-05	
	
971	 TRAPPC1	 2.33	 0.00013	
928	 UBQLN4	 2.38	 0.00015	
	
972	 MRPS28	 2.33	 2.34E-05	
929	 ZNF193	 2.37	 2.77E-05	
	
973	 NRD1	 2.33	 3.85E-05	
930	 ZC3HC1	 2.37	 1.13E-05	
	
974	 ANKRD17	 2.33	 2.05E-05	
931	 FHL1	 2.37	 2.80E-05	
	
975	 LYST	 2.33	 0.00039	
932	 HSZFP36	 2.37	 2.47E-05	
	
976	 P2RX4	 2.33	 0.00013	
933	 HMGN4	 2.37	 0.00016	
	
977	 TMEM165	 2.33	 3.17E-06	
934	 STXBP3	 2.37	 2.15E-05	
	
978	 NIPA1	 2.32	 0.00034	
935	 BAZ2B	 2.37	 0.00011	
	
979	 SLC5A3	 2.32	 0.00035	
936	 EXOC2	 2.37	 2.04E-06	
	
980	 CTSA	 2.32	 0.00014	
937	 EP400	 2.37	 3.59E-05	
	
981	 PPA1	 2.32	 0.00142	
938	 ACAP1	 2.37	 0.00024	
	
982	 GINS3	 2.32	 0.00348	
939	 TMEM140	 2.37	 7.32E-06	
	
983	 PPP1R10	 2.32	 5.81E-06	
940	 ACN9	 2.37	 2.38E-05	
	
984	 PRIM1	 2.32	 0.00117	
941	 FAHD2B	 2.36	 3.48E-05	
	
985	 SMS	 2.32	 6.21E-05	
942	 LOC374395	 2.36	 2.04E-05	
	
986	 PQLC3	 2.32	 0.00054	
943	 ST3GAL1	 2.36	 9.18E-06	
	
987	 CCNB1	 2.32	 0.00033	
944	 ACAT1	 2.36	 0.00094	
	
988	 SF3B3	 2.32	 1.79E-06	
945	 YEATS2	 2.36	 9.96E-07	
	
989	 LOC203547	 2.32	 1.01E-05	
946	 C9orf46	 2.36	 0.00010	
	
990	 HPRT1	 2.32	 0.00019	
947	 TRIM4	 2.36	 0.00232	
	
991	 PRPSAP2	 2.31	 2.24E-05	
948	 ALDH6A1	 2.36	 8.92E-06	
	
992	 ZNF217	 2.31	 7.43E-05	
949	 SMARCA4	 2.36	 2.28E-05	
	
993	 CCL1	 2.31	 0.00452	
950	 S1PR1	 2.36	 0.00018	
	
994	 GMPR2	 2.31	 1.69E-05	
951	 OGT	 2.35	 0.00070	
	
995	 RNF14	 2.31	 4.32E-05	
952	 C16orf33	 2.35	 0.00163	
	
996	 ARMC7	 2.31	 0.00011	
953	 HS.532698	 2.35	 6.29E-05	
	
997	 LOC653080	 2.31	 6.13E-07	
954	 ATP1B1	 2.35	 0.00049	
	
998	 INTS9	 2.31	 0.00028	
955	 GSTP1	 2.35	 0.00463	
	
999	 RNGTT	 2.31	 4.55E-06	
956	 C1orf93	 2.35	 0.00011	
	
1000	 Magmas	 2.31	 0.00024	
957	 ICAM2	 2.34	 7.71E-05	
	 	 	 	 	958	 CDK4	 2.34	 3.10E-05	
	 	 	 	 	959	 AP3B1	 2.34	 8.33E-05	
	 	 	 	 	960	 HPCAL1	 2.34	 0.00011	
	 	 	 	 	961	 LSM2	 2.34	 5.87E-05	
	 	 	 	 	962	 CYB5A	 2.34	 5.17E-05	
	 	 	 	 	963	 PLK4	 2.34	 0.00403	
	 	 	 	 	964	 STMN1	 2.34	 0.00412	
	 	 	 	 	965	 FAM20B	 2.34	 0.00013	
	 	 	 	 	966	 ATHL1	 2.34	 0.00093	
	 	 	 	 	967	 MTX2	 2.34	 5.38E-07	
	 	 	 	 	968	 KNTC1	 2.34	 0.00511	
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1	 RCBTB2	 14.90	 7.98E-07	
	
45	 STS-1	 5.64	 1.35E-06	
	
89	 TAF4	 4.49	 1.27E-06	
2	 AMICA1	 14.57	 1.38E-06	
	
46	 WASPIP	 5.59	 3.33E-05	
	
90	 HDHD2	 4.47	 5.94E-07	
3	 MAL	 12.97	 2.96E-07	
	
47	 FLJ14213	 5.55	 3.94E-05	
	
91	 PAFAH1B1	 4.46	 8.90E-05	
4	 TOP2A	 11.35	 6.03E-05	
	
48	 CSTB	 5.53	 3.27E-05	
	
92	 LOC642975	 4.42	 0.00242	
5	 PCMT1	 9.73	 1.64E-05	
	
49	 M6PR	 5.52	 1.58E-06	
	
93	 PECAM1	 4.41	 2.90E-07	
6	 DCAF7	 9.65	 8.49E-09	
	
50	 PRDX1	 5.52	 6.48E-07	
	
94	 TMEM126B	 4.41	 1.40E-05	
7	 GIMAP4	 9.44	 2.17E-05	
	
51	 EGR2	 5.48	 5.36E-05	
	
95	 RASGRP1	 4.39	 0.00012	
8	 CDC20	 9.37	 5.08E-05	
	
52	 PDE7B	 5.48	 0.00215	
	
96	 HCP5	 4.39	 2.30E-05	
9	 KIT	 9.20	 6.47E-06	
	
53	 PRKCA	 5.46	 1.79E-07	
	
97	 CCNB2	 4.39	 0.00128	
10	 RNF144	 8.63	 4.53E-08	
	
54	 EGR1	 5.42	 0.00236	
	
98	 FLI1	 4.39	 1.90E-05	
11	 DNCL1	 8.30	 3.73E-06	
	
55	 TMBIM4	 5.38	 9.52E-06	
	
99	 USO1	 4.37	 2.10E-05	
12	 AARS	 8.17	 2.80E-07	
	
56	 PTGDR	 5.31	 8.29E-05	
	
100	 GPR18	 4.36	 2.30E-06	
13	 LPXN	 8.07	 2.14E-05	
	
57	 DLGAP5	 5.25	 0.00067	
	
101	 LOC285016	 4.35	 0.00026	
14	 PRAGMIN	 7.99	 1.01E-06	
	
58	 C2orf42	 5.25	 9.55E-08	
	
102	 FAIM3	 4.35	 0.00048	
15	 IL32	 7.71	 0.00204	
	
59	 ZNF559	 5.20	 8.88E-07	
	
103	 NCAPD2	 4.34	 0.00063	
16	 RAB10	 7.65	 1.61E-07	
	
60	 MRPS6	 5.16	 1.52E-05	
	
104	 PSMA5	 4.33	 7.06E-06	
17	 MMP25	 7.27	 2.78E-07	
	
61	 ZNF512	 5.15	 9.64E-08	
	
105	 APOBEC3G	 4.33	 1.12E-05	
18	 DYNLL1	 7.25	 1.61E-06	
	
62	 VPS36	 5.12	 3.13E-06	
	
106	 CPOX	 4.32	 3.43E-06	
19	 S100A11	 7.19	 4.22E-07	
	
63	 GIMAP1	 5.10	 2.46E-05	
	
107	 LYRM7	 4.32	 2.29E-06	
20	 HMMR	 7.15	 3.86E-05	
	
64	 MRPL51	 5.03	 1.48E-06	
	
108	 C9orf69	 4.31	 4.90E-09	
21	 GPR68	 7.14	 9.20E-08	
	
65	 TMEM106B	 4.97	 9.43E-06	
	
109	 CX3CR1	 4.31	 0.00026	
22	 NUSAP1	 6.90	 0.00094	
	
66	 LOC439949	 4.97	 8.83E-06	
	
110	 TFCP2	 4.31	 3.99E-07	
23	 ARPC5	 6.88	 9.13E-06	
	
67	 KIFC1	 4.95	 0.00072	
	
111	 CCR7	 4.30	 0.00043	
24	 ST6GAL1	 6.84	 1.06E-05	
	
68	 CCDC56	 4.94	 8.14E-08	
	
112	 C20orf30	 4.29	 0.00166	
25	 P2RY5	 6.79	 2.13E-07	
	
69	 HS.452445	 4.89	 4.19E-05	
	
113	 TTF2	 4.29	 3.71E-06	
26	 GNPDA1	 6.77	 3.39E-06	
	
70	 C10orf6	 4.89	 7.41E-05	
	
114	 PDCD6	 4.27	 8.38E-06	
27	 CEP55	 6.76	 0.00032	
	
71	 ZMYM6	 4.89	 1.10E-07	
	
115	 TALDO1	 4.27	 7.74E-06	
28	 SLAMF6	 6.72	 6.46E-05	
	
72	 CHURC1	 4.86	 2.57E-06	
	
116	 KIAA0748	 4.26	 2.01E-05	
29	 LTB	 6.71	 2.50E-08	
	
73	 MITD1	 4.81	 9.16E-07	
	
117	 YWHAB	 4.26	 1.82E-06	
30	 RNF144A	 6.69	 8.70E-08	
	
74	 UGDH	 4.80	 1.67E-07	
	
118	 MBP	 4.26	 0.00030	
31	 PROSC	 6.67	 5.67E-08	
	
75	 APBB1IP	 4.74	 1.12E-05	
	
119	 SLC7A1	 4.23	 0.00022	
32	 ACADM	 6.57	 2.09E-09	
	
76	 TST	 4.72	 9.52E-05	
	
120	 CBR4	 4.23	 1.08E-05	
33	 LOC730278	 6.57	 1.40E-07	
	
77	 VKORC1	 4.72	 4.31E-07	
	
121	 PARP1	 4.21	 2.90E-06	
34	 ASXL2	 6.41	 1.41E-06	
	
78	 LGALS1	 4.68	 5.82E-05	
	
122	 HSPA1A	 4.21	 0.00029	
35	 DAD1	 6.40	 4.23E-05	
	
79	 MTIF3	 4.62	 6.31E-07	
	
123	 MAPK1	 4.21	 5.41E-05	
36	 TYMS	 6.38	 0.00122	
	
80	 HS.137971	 4.61	 7.44E-05	
	
124	 TMEM149	 4.19	 5.80E-06	
37	 GLS	 5.96	 9.32E-07	
	
81	 MRPS31	 4.61	 6.03E-07	
	
125	 MCM3	 4.19	 6.17E-05	
38	 ASPM	 5.94	 0.00021	
	
82	 METTL13	 4.57	 2.50E-08	
	
126	 WDR61	 4.18	 8.75E-06	
39	 WDR40A	 5.91	 3.20E-06	
	
83	 HADH	 4.57	 3.24E-06	
	
127	 HS.436134	 4.16	 0.00012	
40	 CYP1B1	 5.83	 6.77E-05	
	
84	 NDUFAF3	 4.57	 1.39E-05	
	
128	 NDUFA8	 4.16	 7.93E-09	
41	 VPS35	 5.79	 9.62E-08	
	
85	 GLO1	 4.56	 2.54E-05	
	
129	 ITGB7	 4.16	 0.00100	
42	 KRCC1	 5.73	 1.55E-07	
	
86	 CAPG	 4.50	 4.39E-05	
	
130	 BCL2	 4.16	 1.95E-05	
43	 C5orf51	 5.66	 6.28E-08	
	
87	 DNAJA3	 4.50	 0.00028	
	
131	 HIBADH	 4.12	 9.95E-06	
44	 PCMTD1	 5.66	 2.09E-06	
	
88	 PRDX6	 4.50	 5.27E-07	
	
132	 AKR7A2	 4.12	 8.54E-05	
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133	 PAICS	 4.11	 1.50E-06	
	
177	 BCDIN3D	 3.85	 1.77E-06	
	
221	 FCER1G	 3.68	 0.00017	
134	 EOMES	 4.10	 0.00044	
	
178	 AHI1	 3.85	 0.00152	
	
222	 ANXA5	 3.68	 0.00096	
135	 TMEM200A	 4.09	 0.00021	
	
179	 PDE6D	 3.84	 4.49E-06	
	
223	 SNCA	 3.68	 7.05E-05	
136	 UBAP2L	 4.09	 2.92E-07	
	
180	 STK39	 3.84	 4.47E-05	
	
224	 RGS10	 3.68	 3.93E-05	
137	 PTPN6	 4.09	 5.01E-05	
	
181	 SAMD9L	 3.83	 1.34E-06	
	
225	 EXOSC3	 3.67	 7.52E-06	
138	 LOC648868	 4.08	 0.00022	
	
182	 LOC401397	 3.82	 3.81E-06	
	
226	 TRAF3IP3	 3.67	 3.38E-05	
139	 CDCA5	 4.07	 0.00542	
	
183	 IL1R1	 3.82	 0.00014	
	
227	 PREPL	 3.67	 3.05E-06	
140	 PRKAR1A	 4.07	 0.00053	
	
184	 FAM150B	 3.81	 0.00035	
	
228	 DYNC1I2	 3.67	 1.36E-05	
141	 PNPO	 4.06	 2.80E-06	
	
185	 ASF1B	 3.81	 0.00012	
	
229	 B3GALT6	 3.67	 7.19E-07	
142	 HSD17B4	 4.06	 4.92E-07	
	
186	 IL12RB2	 3.80	 0.00015	
	
230	 KIF20A	 3.66	 0.00013	
143	 OSTF1	 4.05	 7.91E-05	
	
187	 RBM14	 3.80	 5.86E-07	
	
231	 RCSD1	 3.66	 1.92E-05	
144	 RBM4B	 4.04	 3.53E-06	
	
188	 CPNE3	 3.80	 5.44E-06	
	
232	 AIMP2	 3.66	 1.83E-07	
145	 CD27	 4.03	 0.00588	
	
189	 ZMIZ1	 3.80	 6.15E-06	
	
233	 UHRF1	 3.66	 0.00135	
146	 SDCCAG10	 4.03	 3.03E-07	
	
190	 LEF1	 3.79	 4.48E-05	
	
234	 CCR1	 3.66	 0.00109	
147	 DPYSL2	 4.03	 1.22E-05	
	
191	 HS.371609	 3.79	 6.41E-05	
	
235	 STT3A	 3.65	 0.00018	
148	 COQ5	 4.03	 3.98E-06	
	
192	 GOPC	 3.79	 1.08E-06	
	
236	 ZNF252	 3.64	 1.96E-06	
149	 RAB7A	 4.02	 2.03E-06	
	
193	 SLFN5	 3.79	 1.25E-06	
	
237	 CISD1	 3.64	 1.09E-06	
150	 APEH	 4.02	 1.98E-06	
	
194	 CKS1B	 3.78	 0.00076	
	
238	 METTL3	 3.63	 2.11E-05	
151	 PYCARD	 4.01	 4.94E-06	
	
195	 GINS2	 3.78	 0.00579	
	
239	 ENPP3	 3.63	 0.00016	
152	 KIF11	 4.01	 0.00108	
	
196	 TMEM194A	 3.78	 1.55E-06	
	
240	 HNRNPA0	 3.63	 4.81E-06	
153	 NDUFB3	 4.01	 3.44E-07	
	
197	 MPZL2	 3.78	 1.47E-05	
	
241	 C12orf35	 3.62	 0.00025	
154	 RAB38	 4.00	 3.88E-05	
	
198	 RPA3	 3.77	 2.44E-06	
	
242	 AURKA	 3.62	 0.00029	
155	 ICAM2	 3.99	 4.64E-06	
	
199	 UBE2C	 3.77	 0.00122	
	
243	 LFNG	 3.61	 1.42E-06	
156	 NIF3L1	 3.99	 1.05E-05	
	
200	 CD96	 3.75	 1.33E-07	
	
244	 ESYT1	 3.61	 5.12E-06	
157	 ARL2	 3.99	 3.97E-05	
	
201	 C14orf142	 3.75	 1.14E-05	
	
245	 GVIN1	 3.61	 0.00168	
158	 PAQR4	 3.98	 0.00056	
	
202	 PRDX3	 3.75	 7.44E-07	
	
246	 MGST2	 3.61	 3.62E-06	
159	 ARV1	 3.97	 2.16E-06	
	
203	 ANKRD46	 3.75	 5.93E-06	
	
247	 GLIPR2	 3.60	 0.00022	
160	 ZNF573	 3.95	 1.43E-06	
	
204	 CCDC76	 3.74	 9.56E-07	
	
248	 CDCA7	 3.60	 0.00018	
161	 ZNF302	 3.95	 2.26E-06	
	
205	 SLC35B3	 3.74	 3.24E-06	
	
249	 IQGAP1	 3.60	 1.55E-05	
162	 TTC27	 3.95	 3.21E-07	
	
206	 TMEM60	 3.74	 5.47E-05	
	
250	 HNRPA2B1	 3.60	 1.27E-05	
163	 FANCE	 3.94	 1.16E-06	
	
207	 CCNA2	 3.73	 0.00070	
	
251	 E2F2	 3.60	 0.00824	
164	 PTGER2	 3.93	 0.00044	
	
208	 BCKDK	 3.73	 3.71E-07	
	
252	 SH2D1A	 3.60	 9.47E-05	
165	 NCAPG	 3.92	 0.00448	
	
209	 C1orf162	 3.72	 1.86E-06	
	
253	 LOC729816	 3.59	 2.01E-05	
166	 KLHL9	 3.91	 2.87E-05	
	
210	 FAM111A	 3.72	 0.00019	
	
254	 AURKB	 3.58	 0.00178	
167	 PRKCQ	 3.91	 0.00057	
	
211	 HS.554324	 3.72	 0.00020	
	
255	 TEX2	 3.57	 1.28E-07	
168	 MAT2A	 3.91	 2.09E-06	
	
212	 PYCR2	 3.71	 5.75E-07	
	
256	 ZC3H4	 3.57	 9.74E-06	
169	 IL16	 3.90	 9.80E-07	
	
213	 UNC50	 3.71	 0.00014	
	
257	 ZBED5	 3.57	 2.57E-06	
170	 XCL1	 3.90	 9.20E-06	
	
214	 GALK1	 3.71	 1.33E-07	
	
258	 RASSF7	 3.57	 8.58E-07	
171	 GLE1	 3.89	 6.15E-05	
	
215	 PDCD6IP	 3.70	 1.36E-06	
	
259	 TSPAN31	 3.57	 2.47E-05	
172	 NDUFB5	 3.88	 1.26E-05	
	
216	 STAMBPL1	 3.69	 1.18E-05	
	
260	 CD2	 3.57	 0.00165	
173	 AHCYL1	 3.88	 4.89E-05	
	
217	 POLR3GL	 3.69	 0.00032	
	
261	 COQ2	 3.56	 4.46E-07	
174	 TM2D1	 3.88	 6.62E-05	
	
218	 LOC113386	 3.69	 1.27E-05	
	
262	 DPP4	 3.55	 0.00158	
175	 C3orf57	 3.88	 4.11E-06	
	
219	 RPA2	 3.68	 0.00085	
	
263	 HS.294103	 3.54	 2.07E-06	
176	 FAM120B	 3.86	 0.00015	
	
220	 DENND2D	 3.68	 0.00022	
	
264	 LOC728532	 3.54	 2.56E-07	
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265	 WDR67	 3.54	 1.76E-05	
	
309	 ACTL6A	 3.41	 4.28E-06	
	
353	 RNF20	 3.27	 0.00017	
266	 RAB40C	 3.53	 1.26E-06	
	
310	 TUBB	 3.40	 0.00045	
	
354	
DKFZp761P04
23	 3.26	 1.20E-05	
267	 RNASEL	 3.53	 7.86E-07	
	
311	 PAQR8	 3.40	 0.00034	
	
355	 DEXI	 3.26	 0.00028	
268	 OBFC2A	 3.53	 4.23E-05	
	
312	 GCNT1	 3.40	 3.49E-05	
	
356	 TCFL5	 3.26	 3.14E-05	
269	 CLDND2	 3.53	 4.89E-06	
	
313	 TMED10	 3.40	 2.66E-05	
	
357	 PRF1	 3.25	 0.00011	
270	 GZMA	 3.52	 0.00255	
	
314	 RAB5B	 3.39	 2.77E-05	
	
358	 NUPL2	 3.25	 2.11E-05	
271	 ERMP1	 3.52	 0.00012	
	
315	 ATP6V0E1	 3.39	 7.06E-05	
	
359	 CENPF	 3.25	 0.00081	
272	 SNTB1	 3.51	 0.00139	
	
316	 CKAP5	 3.39	 4.62E-06	
	
360	 MGC16169	 3.24	 1.69E-05	
273	 REEP5	 3.51	 0.00257	
	
317	 ECHDC1	 3.38	 1.71E-06	
	
361	 SLC46A3	 3.24	 7.16E-06	
274	 SKAP2	 3.50	 6.01E-06	
	
318	 PPT1	 3.38	 0.00108	
	
362	 TNFAIP8	 3.24	 8.19E-07	
275	 ZFYVE21	 3.50	 2.84E-06	
	
319	 SAC3D1	 3.37	 0.00059	
	
363	 HTATIP2	 3.24	 6.73E-05	
276	 NUP43	 3.49	 6.43E-07	
	
320	 AP1S2	 3.37	 3.05E-06	
	
364	 SNX10	 3.24	 0.00123	
277	 ZDHHC16	 3.49	 2.59E-08	
	
321	 TTC15	 3.37	 3.83E-06	
	
365	 RSU1	 3.24	 3.84E-05	
278	 LOC100129034	 3.49	 1.12E-06	
	
322	 ZNF146	 3.36	 1.32E-06	
	
366	 ZNF816A	 3.23	 2.02E-06	
279	 NUDT5	 3.49	 3.47E-05	
	
323	 VIM	 3.36	 0.00215	
	
367	 SPINK2	 3.23	 6.51E-05	
280	 ELOVL6	 3.49	 2.59E-08	
	
324	 SLC25A43	 3.35	 1.31E-05	
	
368	 GIMAP8	 3.23	 5.30E-06	
281	 C14orf109	 3.49	 3.77E-07	
	
325	 GLB1	 3.34	 2.23E-08	
	
369	 STX3	 3.23	 0.00011	
282	 TRAK2	 3.49	 3.33E-06	
	
326	 GIMAP6	 3.34	 4.94E-07	
	
370	 LOC124512	 3.22	 1.81E-05	
283	 TBCA	 3.49	 0.00066	
	
327	 IFNAR1	 3.34	 2.91E-06	
	
371	 LOC642755	 3.22	 0.00083	
284	 C5orf13	 3.48	 9.32E-05	
	
328	 CDC45L	 3.34	 0.01061	
	
372	 TMEM5	 3.22	 4.19E-06	
285	 CDKN3	 3.48	 0.00096	
	
329	 SAMD9	 3.34	 2.36E-05	
	
373	 PRMT6	 3.22	 0.00012	
286	 CENPK	 3.48	 0.00020	
	
330	 TMEM30A	 3.34	 0.00013	
	
374	 SOCS2	 3.22	 7.14E-05	
287	 SMUG1	 3.48	 1.53E-06	
	
331	 SAP18	 3.33	 2.09E-08	
	
375	 KLHDC5	 3.22	 1.39E-06	
288	 LARS	 3.47	 6.23E-06	
	
332	 C11orf75	 3.33	 5.50E-06	
	
376	 SLAMF7	 3.21	 1.46E-05	
289	 HPS3	 3.47	 8.83E-06	
	
333	 TRAPPC3	 3.33	 4.76E-05	
	
377	 SETDB2	 3.21	 3.86E-05	
290	 PVRIG	 3.47	 0.00020	
	
334	 RPS27L	 3.32	 9.51E-05	
	
378	 ELP3	 3.21	 1.71E-05	
291	 OXR1	 3.45	 7.10E-06	
	
335	 FAM102A	 3.32	 6.10E-07	
	
379	 P15RS	 3.21	 4.77E-06	
292	 IFI16	 3.45	 0.00019	
	
336	 C16orf75	 3.32	 3.48E-05	
	
380	 BIVM	 3.21	 7.80E-05	
293	 DBNL	 3.45	 0.00026	
	
337	 NELL2	 3.31	 0.00024	
	
381	 SPG11	 3.20	 0.00015	
294	 FAM113B	 3.44	 3.56E-06	
	
338	 KIAA0907	 3.31	 1.21E-05	
	
382	 GPR114	 3.20	 0.00038	
295	 CD53	 3.44	 2.27E-05	
	
339	 NUP37	 3.31	 1.62E-06	
	
383	 HJURP	 3.20	 0.00297	
296	 SEPT11	 3.44	 2.94E-06	
	
340	 TROAP	 3.30	 0.00037	
	
384	 BTN3A2	 3.20	 8.52E-05	
297	 LOC400657	 3.44	 2.23E-05	
	
341	 ADRB2	 3.30	 0.00046	
	
385	 TMEM218	 3.20	 9.76E-07	
298	 ROBLD3	 3.44	 7.08E-05	
	
342	 DDX17	 3.30	 2.17E-05	
	
386	 HSDL2	 3.19	 6.48E-05	
299	 RPUSD3	 3.43	 1.07E-05	
	
343	 PCID2	 3.30	 3.57E-05	
	
387	 BUB1	 3.18	 0.00173	
300	 CCDC53	 3.43	 6.43E-07	
	
344	 GOLGA3	 3.29	 0.00015	
	
388	 TM9SF3	 3.18	 7.36E-07	
301	 ASF1A	 3.43	 6.79E-06	
	
345	 UTP14C	 3.29	 1.01E-06	
	
389	 C14orf106	 3.18	 0.00014	
302	 DNAL4	 3.43	 4.87E-07	
	
346	 TMEM14C	 3.28	 1.76E-05	
	
390	 NEK2	 3.18	 0.00022	
303	 SSU72	 3.43	 0.00032	
	
347	 METTL5	 3.27	 1.30E-06	
	
391	 C14orf167	 3.17	 2.97E-05	
304	 MGST3	 3.42	 1.17E-06	
	
348	 YWHAH	 3.27	 0.00084	
	
392	 SLC37A4	 3.17	 3.57E-05	
305	 GIMAP7	 3.42	 9.10E-05	
	
349	 FAR1	 3.27	 4.11E-05	
	
393	 OAS2	 3.17	 3.48E-06	
306	 LOC253039	 3.41	 0.00525	
	
350	 C14orf135	 3.27	 2.54E-05	
	
394	 C9orf114	 3.17	 6.77E-07	
307	 LOC100130633	 3.41	 5.63E-07	
	
351	 RALBP1	 3.27	 2.86E-06	
	
395	 EHBP1	 3.16	 1.81E-05	
308	 CISH	 3.41	 0.00039	
	
352	 IMPA2	 3.27	 0.00022	
	
396	 MGAT3	 3.15	 0.00023	
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397	 TPX2	 3.14	 0.00080	
	
441	 G3BP1	 3.04	 3.30E-06	
	
485	 SEC22B	 2.94	 2.18E-05	
398	 DOCK8	 3.14	 0.00085	
	
442	 C17orf62	 3.04	 4.08E-06	
	
486	 TRIP4	 2.93	 7.61E-05	
399	 SLC16A3	 3.13	 5.05E-06	
	
443	 TNFAIP8L2	 3.04	 4.99E-07	
	
487	 CHMP4A	 2.93	 0.00026	
400	 MAT2B	 3.13	 7.29E-05	
	
444	 SOS1	 3.03	 5.85E-07	
	
488	 UBE2V2	 2.93	 1.28E-07	
401	 HS.572649	 3.13	 1.32E-05	
	
445	 GDI2	 3.03	 9.64E-06	
	
489	 ZCCHC7	 2.93	 2.49E-05	
402	 ATP5H	 3.13	 3.12E-06	
	
446	 HSPH1	 3.02	 3.11E-05	
	
490	 CSTF3	 2.92	 8.07E-07	
403	 MRPL24	 3.13	 6.24E-10	
	
447	 CKAP2L	 3.02	 0.00360	
	
491	 HMGN4	 2.92	 4.60E-05	
404	 OAZ1	 3.12	 1.16E-05	
	
448	 SPHK2	 3.02	 2.37E-06	
	
492	 ARHGAP25	 2.92	 3.91E-05	
405	 YIF1A	 3.12	 1.88E-05	
	
449	 ZNF285A	 3.02	 5.52E-05	
	
493	 GOLGA5	 2.92	 4.19E-07	
406	 TIGD7	 3.12	 4.02E-06	
	
450	 SLC33A1	 3.01	 8.64E-05	
	
494	 ZNF583	 2.92	 9.59E-08	
407	 C20orf72	 3.12	 0.00031	
	
451	 PPP1R11	 3.01	 3.89E-05	
	
495	 COMMD3	 2.92	 0.00133	
408	 GNPAT	 3.12	 9.26E-05	
	
452	 EPDR1	 3.01	 0.00015	
	
496	 PRELID1	 2.92	 8.18E-06	
409	 FLJ39639	 3.11	 1.14E-05	
	
453	 HS.534427	 3.00	 0.00141	
	
497	 NUDT7	 2.91	 3.67E-05	
410	 MTHFS	 3.11	 2.95E-05	
	
454	 POLA1	 3.00	 1.88E-06	
	
498	 FH	 2.91	 1.68E-05	
411	 DECR1	 3.11	 0.00014	
	
455	 IL10RB	 3.00	 4.55E-05	
	
499	 HPCAL1	 2.91	 3.00E-05	
412	 CCNF	 3.10	 8.77E-05	
	
456	 HDDC3	 3.00	 1.36E-06	
	
500	 TFB1M	 2.91	 1.57E-07	
413	 DARS2	 3.10	 6.99E-06	
	
457	 ACVR1	 2.99	 1.57E-06	
	
501	 GTF2H5	 2.91	 9.52E-06	
414	 CARD8	 3.10	 5.98E-05	
	
458	 NP	 2.99	 1.43E-05	
	
502	 ZNF135	 2.91	 1.31E-06	
415	 KLHL6	 3.10	 2.30E-06	
	
459	 KLHL22	 2.99	 3.40E-06	
	
503	 NEK1	 2.91	 5.35E-07	
416	 CCDC128	 3.10	 1.09E-05	
	
460	 LOC653888	 2.99	 0.00218	
	
504	 CECR1	 2.91	 0.00019	
417	 ZNF25	 3.10	 5.49E-06	
	
461	 WDR51A	 2.98	 0.00014	
	
505	 LAT2	 2.91	 0.00011	
418	 MED20	 3.10	 0.00021	
	
462	 TMEM194	 2.98	 3.30E-05	
	
506	 EBNA1BP2	 2.90	 0.00011	
419	 KIAA1671	 3.10	 5.51E-05	
	
463	 PUS7	 2.98	 0.00014	
	
507	 LOC648638	 2.90	 1.60E-06	
420	 SNX27	 3.10	 2.28E-06	
	
464	 ATP8B4	 2.98	 0.00019	
	
508	 PRCP	 2.90	 0.00029	
421	 UFSP2	 3.10	 2.19E-06	
	
465	 CCDC90B	 2.98	 7.93E-06	
	
509	 TMEM79	 2.89	 1.23E-06	
422	 PFKP	 3.10	 0.00119	
	
466	 TACC3	 2.97	 0.00057	
	
510	 HNRNPAB	 2.89	 2.83E-05	
423	 AOAH	 3.10	 0.00114	
	
467	 HS.354359	 2.97	 0.00010	
	
511	 ARMET	 2.89	 1.09E-05	
424	 KLRC1	 3.10	 0.00354	
	
468	 TUBA1C	 2.97	 0.00194	
	
512	 KLRAQ1	 2.89	 3.40E-05	
425	 CCDC92	 3.09	 0.00015	
	
469	 CANX	 2.97	 5.77E-05	
	
513	 NSMCE1	 2.89	 2.98E-05	
426	 HAGH	 3.09	 9.02E-06	
	
470	 GOLGA9P	 2.97	 3.60E-05	
	
514	 UBE3C	 2.89	 0.00012	
427	 SDHC	 3.08	 7.60E-07	
	
471	 WIBG	 2.96	 6.05E-06	
	
515	 SEC23IP	 2.89	 1.03E-05	
428	 ATP6V1D	 3.08	 0.00034	
	
472	 CD58	 2.96	 8.63E-05	
	
516	 CCDC97	 2.89	 7.47E-07	
429	 RNF34	 3.08	 1.32E-05	
	
473	 HIBCH	 2.96	 1.15E-06	
	
517	 AKR1A1	 2.89	 9.72E-07	
430	 C6orf125	 3.08	 3.16E-06	
	
474	 BCL2L13	 2.96	 0.00099	
	
518	 THEM2	 2.89	 4.17E-05	
431	 RINL	 3.08	 3.99E-07	
	
475	 CDC2L6	 2.96	 5.13E-05	
	
519	 STYXL1	 2.88	 3.63E-06	
432	 FASLG	 3.08	 0.00175	
	
476	 TIAM1	 2.96	 0.00013	
	
520	 PARN	 2.88	 2.55E-05	
433	 CDC2	 3.06	 0.00188	
	
477	 APPBP2	 2.96	 2.55E-05	
	
521	 C10orf104	 2.88	 0.00027	
434	 PSMB9	 3.06	 2.31E-05	
	
478	 CDK2AP2	 2.95	 1.20E-05	
	
522	 ZNF439	 2.87	 1.99E-05	
435	 RALA	 3.06	 1.21E-05	
	
479	 QDPR	 2.95	 0.00026	
	
523	 CNPY2	 2.87	 4.00E-06	
436	 ATIC	 3.05	 2.23E-05	
	
480	 LOC440063	 2.95	 6.99E-05	
	
524	 RXRA	 2.87	 0.00029	
437	 COMT	 3.05	 6.46E-06	
	
481	 C12orf32	 2.95	 1.14E-05	
	
525	 C11orf54	 2.87	 9.15E-08	
438	 SEL1L3	 3.05	 0.00294	
	
482	 LOC100134304	 2.95	 1.61E-05	
	
526	 C16orf53	 2.87	 5.56E-08	
439	 NQO1	 3.05	 0.00036	
	
483	 MAPBPIP	 2.94	 0.00016	
	
527	 SFRS1	 2.87	 4.48E-07	
440	 RACGAP1	 3.04	 0.00055	
	
484	 RABEP1	 2.94	 4.13E-05	
	
528	 RSBN1L	 2.86	 9.20E-07	
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529	 TNF	 2.86	 0.00572	
	
573	 PAPOLA	 2.78	 0.00237	
	
617	 DLL1	 2.72	 0.00040	
530	 TRIP13	 2.86	 0.00057	
	
574	 TARP	 2.78	 0.00013	
	
618	 RAD51AP1	 2.72	 0.00721	
531	 SHMT2	 2.86	 0.00041	
	
575	 UBAC2	 2.78	 1.83E-05	
	
619	 C13orf27	 2.71	 2.29E-05	
532	 PSD4	 2.86	 0.00051	
	
576	 KIAA0146	 2.78	 3.50E-07	
	
620	 TMEM49	 2.71	 1.92E-06	
533	 HIRIP3	 2.86	 3.72E-05	
	
577	 LOC134997	 2.78	 6.82E-05	
	
621	 RBM12B	 2.71	 2.36E-05	
534	 C9orf46	 2.85	 3.28E-05	
	
578	 SEC62	 2.78	 9.84E-07	
	
622	 MELK	 2.71	 0.00460	
535	 C10orf137	 2.85	 8.51E-05	
	
579	 EMG1	 2.78	 7.60E-06	
	
623	 RAB22A	 2.71	 5.19E-05	
536	 GIMAP2	 2.85	 3.34E-05	
	
580	 TIMM10	 2.78	 0.00068	
	
624	 ACTR2	 2.71	 0.00010	
537	 ZCCHC9	 2.85	 6.64E-07	
	
581	 RPA1	 2.78	 1.70E-06	
	
625	 MKKS	 2.71	 8.16E-06	
538	 MTSS1	 2.85	 0.00336	
	
582	 TRIM4	 2.78	 0.00095	
	
626	 LOC647037	 2.70	 5.28E-08	
539	 COPB2	 2.85	 4.14E-06	
	
583	 ADCY3	 2.78	 0.00029	
	
627	 DERA	 2.70	 2.62E-05	
540	 WDR92	 2.84	 6.06E-05	
	
584	 CENPQ	 2.77	 1.98E-05	
	
628	 COQ9	 2.70	 1.30E-06	
541	 HEXB	 2.84	 0.00019	
	
585	 CCDC34	 2.77	 7.90E-05	
	
629	 TLN1	 2.70	 0.00026	
542	 WDR18	 2.84	 0.00062	
	
586	 DIMT1L	 2.77	 1.90E-06	
	
630	 C1orf71	 2.70	 8.72E-05	
543	 MRFAP1L1	 2.83	 0.00014	
	
587	 ACTA2	 2.77	 1.59E-05	
	
631	 TRPV2	 2.70	 2.04E-05	
544	 FAM50B	 2.83	 2.96E-05	
	
588	 C6orf115	 2.77	 1.24E-06	
	
632	 CCM2	 2.69	 0.00029	
545	 CFDP1	 2.83	 0.00020	
	
589	 FIG4	 2.76	 3.87E-06	
	
633	 SRBD1	 2.69	 8.96E-05	
546	 PGM2	 2.83	 6.71E-06	
	
590	 C1orf59	 2.76	 0.00047	
	
634	 PPP1R10	 2.69	 2.24E-06	
547	 MFSD1	 2.83	 3.89E-06	
	
591	 FANCI	 2.76	 0.00191	
	
635	 ZFP3	 2.69	 9.35E-06	
548	 FADD	 2.83	 0.00011	
	
592	 ZNF621	 2.76	 6.56E-06	
	
636	 RNASEH2A	 2.69	 2.71E-05	
549	 CLNS1A	 2.83	 4.09E-05	
	
593	 KIAA1826	 2.76	 5.82E-05	
	
637	 TAPBPL	 2.69	 0.00064	
550	 CDT1	 2.82	 0.00331	
	
594	 PDCD5	 2.76	 0.00050	
	
638	 CBL	 2.69	 0.00016	
551	 PPP3CB	 2.82	 0.00022	
	
595	 PTTG1	 2.76	 0.00096	
	
639	 FNBP1	 2.69	 0.00265	
552	 SMARCAL1	 2.82	 2.24E-05	
	
596	 PQLC3	 2.76	 0.00019	
	
640	 KIFAP3	 2.69	 2.17E-05	
553	 CMAS	 2.82	 2.08E-07	
	
597	 NIPA1	 2.76	 0.00012	
	
641	 TNFRSF1A	 2.69	 5.24E-06	
554	 CTSC	 2.82	 1.60E-06	
	
598	 BCL11B	 2.75	 0.00015	
	
642	 LOC100129828	 2.69	 8.62E-05	
555	 NUP133	 2.81	 1.09E-06	
	
599	 TMEM141	 2.75	 2.31E-05	
	
643	 LOC644936	 2.69	 0.00052	
556	 HOPX	 2.81	 0.00058	
	
600	 EPRS	 2.75	 2.21E-05	
	
644	 EMILIN2	 2.69	 1.08E-06	
557	 PTTG3P	 2.81	 0.00097	
	
601	 MYBL1	 2.75	 0.00040	
	
645	 E2F3	 2.68	 0.00079	
558	 CCDC99	 2.81	 9.23E-05	
	
602	 RPP40	 2.75	 1.46E-05	
	
646	 ZNF234	 2.68	 0.00131	
559	 FKSG30	 2.81	 0.00012	
	
603	 ABHD3	 2.74	 0.00034	
	
647	 C21orf33	 2.68	 6.78E-06	
560	 MRPL52	 2.81	 2.52E-05	
	
604	 CYB5B	 2.74	 0.00014	
	
648	 ZNF260	 2.68	 1.07E-05	
561	 GSTO1	 2.81	 3.77E-06	
	
605	 PRPSAP1	 2.74	 6.30E-07	
	
649	 ADO	 2.68	 3.98E-05	
562	 ACN9	 2.81	 8.32E-06	
	
606	 STK38	 2.74	 5.38E-06	
	
650	 GSN	 2.68	 2.42E-06	
563	 IL27RA	 2.81	 0.00010	
	
607	 PMS1	 2.74	 1.40E-06	
	
651	 ANXA2P1	 2.68	 0.00126	
564	 TNFSF10	 2.81	 0.00025	
	
608	 ACAT1	 2.73	 0.00040	
	
652	 ZC3HC1	 2.67	 5.32E-06	
565	 RECK	 2.80	 1.23E-07	
	
609	 ZNF213	 2.73	 7.18E-05	
	
653	 RB1	 2.67	 0.00127	
566	 ZFP90	 2.80	 3.18E-06	
	
610	 SLC9A3R1	 2.73	 4.68E-05	
	
654	 GIMAP5	 2.67	 3.16E-05	
567	 MRPS11	 2.80	 2.06E-07	
	
611	 AP1M1	 2.73	 1.81E-05	
	
655	 CDCA8	 2.67	 0.00177	
568	 ZBTB24	 2.79	 7.07E-06	
	
612	 BANF1	 2.73	 2.70E-07	
	
656	 NICN1	 2.67	 6.31E-05	
569	 CENPJ	 2.79	 7.23E-05	
	
613	 STIL	 2.73	 0.00560	
	
657	 SLC39A10	 2.66	 0.00021	
570	 TUBA1B	 2.79	 0.00116	
	
614	 FEN1	 2.72	 0.00097	
	
658	 MPV17	 2.66	 6.22E-06	
571	 HERC4	 2.79	 4.87E-06	
	
615	 PREB	 2.72	 6.62E-08	
	
659	 HS.372654	 2.66	 0.00010	
572	 CUL4A	 2.79	 1.14E-05	
	
616	 TCTEX1D2	 2.72	 9.11E-05	
	
660	 OSTM1	 2.66	 1.39E-06	
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661	 RMI1	 2.66	 6.28E-05	
	
705	 C10orf33	 2.59	 0.00057	
	
749	 C5orf53	 2.55	 3.79E-05	
662	 DTL	 2.66	 0.00128	
	
706	 CHCHD4	 2.59	 4.23E-06	
	
750	 CARHSP1	 2.55	 0.00021	
663	 ECT2	 2.65	 0.00263	
	
707	 BCAT2	 2.59	 1.21E-05	
	
751	 WDR1	 2.55	 1.88E-05	
664	 PREP	 2.65	 2.52E-07	
	
708	 JAKMIP2	 2.59	 0.00215	
	
752	 TMEM43	 2.55	 0.00033	
665	 ZNF75D	 2.65	 5.40E-05	
	
709	 LOC730432	 2.59	 0.00018	
	
753	 TMEM4	 2.54	 0.00017	
666	 CPSF2	 2.65	 7.24E-06	
	
710	 DUSP23	 2.59	 0.00013	
	
754	 ACTR3	 2.54	 5.96E-05	
667	 TRAPPC6B	 2.65	 9.00E-06	
	
711	 GMPR2	 2.59	 8.08E-06	
	
755	 HEATR5B	 2.54	 9.46E-05	
668	 PIGU	 2.64	 6.51E-06	
	
712	 C7orf70	 2.59	 2.55E-06	
	
756	 TTC39C	 2.54	 2.93E-05	
669	 RPAP2	 2.64	 1.98E-05	
	
713	 GTF2H1	 2.58	 8.95E-06	
	
757	 C19orf25	 2.54	 6.72E-05	
670	 CORO1A	 2.64	 0.00014	
	
714	 ACYP1	 2.58	 9.73E-06	
	
758	 PDS5A	 2.54	 0.00010	
671	 PEPD	 2.63	 0.00114	
	
715	 PIGK	 2.58	 0.00035	
	
759	 SKAP1	 2.54	 0.00177	
672	 ASH2L	 2.63	 3.35E-05	
	
716	 DCTPP1	 2.58	 1.47E-06	
	
760	 PAPSS1	 2.54	 5.96E-05	
673	 LOC554203	 2.63	 0.00011	
	
717	 SFT2D1	 2.58	 0.00241	
	
761	 POLA2	 2.54	 0.00039	
674	 C1orf131	 2.63	 6.49E-05	
	
718	 PRIM1	 2.58	 0.00063	
	
762	 MCTS1	 2.54	 0.00016	
675	 LOC730324	 2.63	 1.05E-06	
	
719	 TNFSF12	 2.58	 2.21E-05	
	
763	 RNGTT	 2.54	 2.43E-06	
676	 ZNF322A	 2.63	 4.32E-06	
	
720	 ORC3L	 2.58	 1.63E-05	
	
764	 ME2	 2.53	 0.00026	
677	 AIDA	 2.63	 0.00012	
	
721	 NDUFAF1	 2.58	 0.00032	
	
765	 PSMB2	 2.53	 0.00058	
678	 ZMYM1	 2.63	 1.26E-06	
	
722	 INTS9	 2.57	 0.00014	
	
766	 SFRS7	 2.53	 3.60E-07	
679	 GOT1	 2.63	 5.04E-05	
	
723	 ORAOV1	 2.57	 5.95E-05	
	
767	 TMEM42	 2.53	 4.90E-05	
680	 C1orf123	 2.63	 2.57E-05	
	
724	 CHN2	 2.57	 9.60E-06	
	
768	 GRSF1	 2.52	 2.30E-05	
681	 UBE2T	 2.63	 0.00179	
	
725	 ASB1	 2.57	 0.00322	
	
769	 KIAA0391	 2.52	 4.38E-05	
682	 PHTF1	 2.63	 1.29E-05	
	
726	 DGUOK	 2.57	 1.44E-05	
	
770	 MMRN1	 2.52	 0.00057	
683	 TMEM14D	 2.63	 0.00037	
	
727	 RPL23AP53	 2.57	 9.78E-05	
	
771	 LOC391811	 2.52	 0.00252	
684	 ANXA4	 2.62	 0.00022	
	
728	 SEPX1	 2.57	 6.20E-05	
	
772	 MRPS28	 2.52	 1.41E-05	
685	 ATXN2	 2.62	 7.78E-05	
	
729	 POTEF	 2.57	 5.02E-05	
	
773	 KIF21A	 2.52	 0.00030	
686	 STAMBP	 2.62	 2.66E-06	
	
730	 HS.489254	 2.57	 2.25E-06	
	
774	 NDRG3	 2.51	 2.65E-06	
687	 SNAPIN	 2.62	 2.43E-05	
	
731	 PDSS2	 2.57	 2.54E-05	
	
775	 LACTB2	 2.51	 6.36E-06	
688	 ZNF175	 2.61	 5.97E-05	
	
732	 COPS7A	 2.57	 5.31E-06	
	
776	 MCM2	 2.51	 0.00319	
689	 LOC439953	 2.61	 5.88E-05	
	
733	 C17orf44	 2.56	 1.14E-06	
	
777	 TRIM68	 2.51	 1.06E-05	
690	 COMMD4	 2.61	 1.16E-05	
	
734	 STX2	 2.56	 4.43E-05	
	
778	 KIAA0513	 2.51	 2.94E-05	
691	 ZSWIM1	 2.61	 1.16E-05	
	
735	 SMARCA2	 2.56	 9.65E-05	
	
779	 RRM1	 2.51	 0.00338	
692	 TMCO1	 2.61	 7.94E-05	
	
736	 NOC3L	 2.56	 7.37E-07	
	
780	 AP4E1	 2.51	 3.71E-05	
693	 C14orf159	 2.61	 1.59E-05	
	
737	 SLC35A1	 2.56	 9.70E-09	
	
781	 ACO1	 2.51	 6.68E-06	
694	 PLEKHA9	 2.61	 8.65E-06	
	
738	 CCL1	 2.56	 0.00261	
	
782	 FAM120AOS	 2.51	 6.15E-06	
695	 OPTN	 2.60	 4.55E-05	
	
739	 C1GALT1C1	 2.56	 7.94E-07	
	
783	 HS.130036	 2.50	 6.36E-05	
696	 MLEC	 2.60	 1.61E-06	
	
740	 KIAA0494	 2.56	 0.00011	
	
784	 OBFC1	 2.50	 8.62E-05	
697	 CEP110	 2.60	 1.29E-05	
	
741	 NCBP1	 2.55	 6.63E-06	
	
785	 HS.154336	 2.50	 1.27E-05	
698	 DPYD	 2.60	 0.00017	
	
742	 FTSJD1	 2.55	 6.69E-05	
	
786	 ANKRD17	 2.50	 1.29E-05	
699	 C14orf147	 2.60	 7.99E-06	
	
743	 TMEM71	 2.55	 0.00026	
	
787	 OIP5	 2.50	 0.00115	
700	 BOLA3	 2.60	 9.22E-06	
	
744	 TC2N	 2.55	 0.00580	
	
788	 KIF15	 2.50	 0.00133	
701	 PTPRCAP	 2.60	 8.49E-05	
	
745	 HEBP1	 2.55	 2.09E-06	
	
789	 INTS3	 2.50	 3.37E-06	
702	 TERF2	 2.59	 5.48E-06	
	
746	 MSRB2	 2.55	 4.94E-06	
	
790	 CD99L2	 2.50	 1.85E-05	
703	 NEK6	 2.59	 2.48E-05	
	
747	 RNF14	 2.55	 2.26E-05	
	
791	 ATP5G1	 2.50	 6.10E-07	
704	 HS.356079	 2.59	 0.00033	
	
748	 SLC1A5	 2.55	 0.00250	
	
792	 CHM	 2.50	 6.46E-06	
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793	 CSNK2A2	 2.50	 0.000153	
	
837	 HADHB	 2.45	 9.02E-06	
	
881	 LOC339804	 2.41	 0.00111	
794	 LOC729768	 2.50	 2.51E-05	
	
838	 BET1	 2.45	 0.000146	
	
882	 TMEM14A	 2.40	 0.00154	
795	 PHB	 2.50	 0.000427	
	
839	 AP3B1	 2.45	 6.26E-05	
	
883	 C14orf173	 2.40	 0.00165	
796	 SH2D1B	 2.49	 0.002924	
	
840	 ZNF518B	 2.45	 1.27E-05	
	
884	 NR1H3	 2.40	 0.00172	
797	 CSRNP2	 2.49	 1.96E-06	
	
841	 DHX32	 2.44	 0.000830	
	
885	 DPAGT1	 2.40	 1.12E-05	
798	 LOC728715	 2.49	 0.001446	
	
842	 PRDX5	 2.44	 6.65E-05	
	
886	 C10orf57	 2.40	 4.55E-06	
799	 DUSP18	 2.49	 1.78E-05	
	
843	 GPSM2	 2.44	 0.002020	
	
887	 C12orf26	 2.40	 0.00012	
800	 C3orf75	 2.49	 5.70E-07	
	
844	 ATM	 2.44	 0.000500	
	
888	 BIRC5	 2.40	 0.00397	
801	 NEDD8	 2.49	 0.000661	
	
845	 LOC100132717	 2.44	 1.92E-05	
	
889	 MFNG	 2.40	 0.00401	
802	 WIPF1	 2.49	 0.000472	
	
846	 C16orf33	 2.44	 0.001325	
	
890	 C9orf95	 2.40	 0.00042	
803	 CKAP2	 2.49	 0.000846	
	
847	 RNF167	 2.43	 0.000271	
	
891	 TTC1	 2.40	 2.94E-05	
804	 MRPL46	 2.49	 8.08E-05	
	
848	 TMCO3	 2.43	 0.000428	
	
892	 POLQ	 2.40	 0.00725	
805	 ARHGEF6	 2.49	 1.31E-05	
	
849	 GART	 2.43	 5.63E-08	
	
893	 ENPP1	 2.40	 2.42E-05	
806	 TIMELESS	 2.49	 0.002554	
	
850	 PLP2	 2.43	 0.003937	
	
894	 ZNF75A	 2.40	 0.00028	
807	 ZNF318	 2.49	 1.07E-05	
	
851	 ZNF544	 2.43	 0.000223	
	
895	 SMYD4	 2.40	 2.85E-06	
808	 HS.571502	 2.49	 0.000141	
	
852	 SLC44A1	 2.43	 1.54E-06	
	
896	 ITGAL	 2.40	 0.00010	
809	 SMARCAD1	 2.48	 7.34E-05	
	
853	 MPHOSPH8	 2.43	 0.000179	
	
897	 EVI2A	 2.40	 0.00090	
810	 CDC7	 2.48	 4.21E-05	
	
854	 PPM1M	 2.43	 0.000983	
	
898	 RNF170	 2.39	 2.26E-06	
811	 APIP	 2.48	 2.26E-05	
	
855	 CLEC16A	 2.43	 9.89E-05	
	
899	 BATF	 2.39	 0.00020	
812	 FAM127A	 2.48	 7.92E-05	
	
856	 TMEM140	 2.43	 6.18E-06	
	
900	 ZNF680	 2.39	 6.54E-06	
813	 AGA	 2.48	 0.000660	
	
857	 FAHD2B	 2.43	 2.94E-05	
	
901	 ZFYVE26	 2.39	 0.00015	
814	 C10orf88	 2.48	 0.000001	
	
858	 CNDP2	 2.42	 0.000209	
	
902	 HS.572538	 2.39	 7.69E-06	
815	 C6orf130	 2.48	 0.000250	
	
859	 GPR132	 2.42	 1.19E-05	
	
903	 TMEM204	 2.39	 1.33E-05	
816	 MIB1	 2.48	 0.000115	
	
860	 FAM64A	 2.42	 0.000634	
	
904	 ICT1	 2.39	 1.24E-05	
817	 PLEK	 2.48	 8.73E-07	
	
861	 CYSLTR1	 2.42	 0.000416	
	
905	 APTX	 2.39	 5.56E-08	
818	 GPR172A	 2.47	 1.50E-05	
	
862	 ZNF33B	 2.42	 0.000200	
	
906	 FAM96A	 2.39	 5.07E-05	
819	 C22orf25	 2.47	 1.31E-05	
	
863	 SDAD1	 2.42	 0.000853	
	
907	 LOC100132457	 2.38	 9.80E-05	
820	 COG6	 2.47	 2.99E-05	
	
864	 HS.483906	 2.42	 7.21E-06	
	
908	 NMT1	 2.38	 0.00052	
821	 RALB	 2.47	 6.02E-05	
	
865	 LARP4B	 2.42	 6.70E-05	
	
909	 STAU2	 2.38	 0.00053	
822	 C16orf30	 2.47	 9.15E-06	
	
866	 CAT	 2.42	 7.86E-06	
	
910	 ARCN1	 2.38	 0.00085	
823	 ALDOC	 2.46	 0.000907	
	
867	 LOC728431	 2.42	 5.12E-05	
	
911	 ARL6IP6	 2.38	 0.00010	
824	 VPS45	 2.46	 3.36E-06	
	
868	 STXBP3	 2.42	 1.88E-05	
	
912	 LYPLAL1	 2.38	 3.75E-06	
825	 TBL1X	 2.46	 7.53E-05	
	
869	 FAM149B1	 2.42	 0.000167	
	
913	 ANLN	 2.38	 0.00467	
826	 TMEM184C	 2.46	 1.86E-05	
	
870	 PLK4	 2.42	 0.003353	
	
914	 COG2	 2.38	 9.13E-05	
827	 C20orf43	 2.46	 1.51E-06	
	
871	 SPATS2L	 2.42	 0.000101	
	
915	 PTPLB	 2.38	 0.00012	
828	 CNOT6	 2.46	 0.001205	
	
872	 LAGE3	 2.41	 0.000252	
	
916	 C4orf34	 2.38	 5.12E-06	
829	 PWWP2A	 2.46	 3.62E-06	
	
873	 INTS8	 2.41	 5.27E-05	
	
917	 NRD1	 2.38	 3.35E-05	
830	 SKA2	 2.46	 4.34E-05	
	
874	 PECI	 2.41	 0.000546	
	
918	 LOC374395	 2.38	 1.95E-05	
831	 LOC644128	 2.46	 1.48E-05	
	
875	 GABARAPL2	 2.41	 1.70E-05	
	
919	 LOC100130707	 2.38	 4.30E-07	
832	 TXNDC9	 2.46	 0.000469	
	
876	 EVL	 2.41	 0.000175	
	
920	 GINS3	 2.38	 0.00305	
833	 LOC442535	 2.46	 0.001162	
	
877	 STAT6	 2.41	 0.000271	
	
921	 ACSL5	 2.37	 2.47E-07	
834	 C6orf173	 2.45	 0.006793	
	
878	 LOC128192	 2.41	 0.000158	
	
922	 ZADH2	 2.37	 2.34E-06	
835	 PSMB5	 2.45	 2.56E-05	
	
879	 PCTP	 2.41	 0.000114	
	
923	 IBTK	 2.37	 1.23E-05	
836	 PLAC8	 2.45	 1.92E-05	
	
880	 PRKAA1	 2.41	 0.001115	
	
924	 LOC392285	 2.37	 0.00183	
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925	 LOC728565	 2.37	 1.58E-06	
	
969	 CHMP5	 2.33	 1.39E-05	
926	 PIP3-E	 2.37	 1.94E-05	
	
970	 AASDH	 2.33	 1.76E-05	
927	 FBXO6	 2.37	 0.00234	
	
971	 TMEM209	 2.33	 0.00111	
928	 ALG6	 2.37	 9.59E-05	
	
972	 NCR3	 2.33	 0.00026	
929	 IPO8	 2.37	 0.00394	
	
973	 CCPG1	 2.33	 1.02E-05	
930	 CKS2	 2.37	 0.00334	
	
974	 CCT7	 2.33	 2.17E-07	
931	 KRTCAP2	 2.37	 1.71E-05	
	
975	 ZNF613	 2.33	 5.13E-06	
932	 TTC31	 2.37	 1.50E-07	
	
976	 CYBRD1	 2.33	 0.00091	
933	 TXN	 2.36	 6.73E-05	
	
977	 DCAKD	 2.33	 8.28E-05	
934	 PPP2CB	 2.36	 6.67E-05	
	
978	 MAPKAPK3	 2.32	 0.00015	
935	 POLG2	 2.36	 0.00042	
	
979	 MTIF2	 2.32	 3.39E-06	
936	 CAPN1	 2.36	 0.00019	
	
980	 SAE1	 2.32	 0.00053	
937	 ZNF480	 2.36	 1.92E-05	
	
981	 CCDC14	 2.32	 0.00223	
938	 ADSL	 2.36	 2.35E-05	
	
982	 ITGB3BP	 2.32	 0.00069	
939	 UBXN2B	 2.36	 8.56E-06	
	
983	 TM7SF3	 2.32	 8.18E-05	
940	 ATOX1	 2.35	 0.00010	
	
984	 ANTXR2	 2.32	 0.00681	
941	 PANK2	 2.35	 2.46E-05	
	
985	 GTF2E1	 2.32	 0.00008	
942	 PEA15	 2.35	 0.00093	
	
986	 STMN3	 2.32	 0.00087	
943	 IMMT	 2.35	 0.00026	
	
987	 NOP10	 2.32	 7.17E-05	
944	 C8orf55	 2.35	 0.00017	
	
988	 KIAA1012	 2.32	 0.00150	
945	 PSMD4	 2.35	 8.10E-08	
	
989	 HS.24119	 2.32	 4.81E-06	
946	 MRPL50	 2.35	 0.00101	
	
990	 PIGM	 2.32	 7.40E-07	
947	 ZKSCAN4	 2.35	 5.99E-06	
	
991	 CENPA	 2.32	 0.00266	
948	 CRIPT	 2.35	 0.00030	
	
992	 POP5	 2.32	 1.11E-07	
949	 SLC35A5	 2.35	 6.20E-05	
	
993	 C9orf64	 2.31	 3.56E-07	
950	 MNAT1	 2.35	 3.57E-07	
	
994	 SRPK1	 2.31	 1.61E-05	
951	 CD47	 2.34	 0.00762	
	
995	 FIBP	 2.31	 2.26E-05	
952	 RAB33B	 2.34	 0.00042	
	
996	 C2orf44	 2.31	 8.82E-05	
953	 NDC80	 2.34	 0.00234	
	
997	 HS.7572	 2.31	 0.00012	
954	 NUDT18	 2.34	 0.00048	
	
998	 PEX11B	 2.31	 0.00235	
955	 RANBP1	 2.34	 1.19E-05	
	
999	 ZFP36L1	 2.31	 0.00056	
956	 TXLNA	 2.34	 5.41E-06	
	
1000	 LOC606724	 2.31	 2.10E-05	
957	 C11orf10	 2.34	 7.03E-05	
	 	 	 	 	958	 EPS15	 2.34	 6.73E-06	
	 	 	 	 	959	 NUDCD3	 2.34	 9.52E-07	
	 	 	 	 	960	 C17orf95	 2.34	 3.99E-08	
	 	 	 	 	961	 LOC727803	 2.34	 9.84E-05	
	 	 	 	 	962	 ZSWIM7	 2.34	 0.00057	
	 	 	 	 	963	 PSMG1	 2.34	 7.03E-05	
	 	 	 	 	964	 ARMCX2	 2.34	 0.00026	
	 	 	 	 	965	 NDUFAF2	 2.33	 1.53E-05	
	 	 	 	 	966	 TTL	 2.33	 4.26E-05	
	 	 	 	 	967	 MCEE	 2.33	 0.00033	
	 	 	 	 	968	 RABEPK	 2.33	 0.00025	
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1	 EBI2	 22.87	 1.49E-07	
	
45	 DENND5A	 3.09	 2.36E-05	
	
89	 EPHA4	 2.17	 0.00109	
2	 GZMK	 16.29	 2.69E-06	
	
46	 IL18R1	 3.06	 9.09E-05	
	
90	 GRAMD4	 2.17	 5.74E-05	
3	 CSDA	 11.61	 5.46E-06	
	
47	 CXXC5	 3.06	 0.00127	
	
91	 PPP1R9A	 2.17	 0.00271	
4	 IL7R	 9.61	 0.00147	
	
48	 TCF4	 3.03	 0.00028	
	
92	 SOX4	 2.16	 0.00217	
5	 HOXA5	 8.07	 2.05E-05	
	
49	 GPR183	 2.98	 9.70E-06	
	
93	 TMEM14B	 2.13	 0.00221	
6	 FOXC1	 7.30	 0.00025	
	
50	 CD2	 2.96	 0.00362	
	
94	 SLC44A1	 2.13	 4.02E-06	
7	 HAPLN3	 6.43	 4.47E-05	
	
51	 TNFRSF11A	 2.89	 6.54E-05	
	
95	 WHAMM	 2.12	 0.00051	
8	 PRDM8	 6.42	 9.20E-05	
	
52	 NBL1	 2.86	 0.00059	
	
96	 CD74	 2.12	 0.00180	
9	 AXIN2	 6.39	 3.20E-05	
	
53	 SPRY2	 2.86	 0.00065	
	
97	 TMEM14C	 2.12	 0.00024	
10	 FLNB	 6.38	 4.42E-06	
	
54	 STARD10	 2.86	 0.00044	
	
98	 UNC93B1	 2.11	 0.00066	
11	 PACSIN1	 5.80	 0.00041	
	
55	 CHPT1	 2.85	 0.00107	
	
99	 IFI44L	 2.09	 0.00123	
12	 HLA-DMB	 5.48	 1.99E-05	
	
56	 MFGE8	 2.84	 2.32E-05	
	
100	 S1PR1	 2.09	 0.00043	
13	 IRAK3	 4.86	 0.00013	
	
57	 HLA-DMA	 2.76	 0.00094	
	
101	 C1orf24	 2.08	 0.00031	
14	 COTL1	 4.69	 0.00012	
	
58	 EFHC2	 2.72	 0.00396	
	
102	 MTM1	 2.08	 0.00037	
15	 LTB	 4.60	 9.34E-08	
	
59	 KIT	 2.71	 0.00060	
	
103	 EFCAB4A	 2.07	 0.00312	
16	 CD44	 4.46	 6.13E-07	
	
60	 CAPN12	 2.67	 2.07E-05	
	
104	 CRIP2	 2.07	 0.00109	
17	 CABLES1	 4.44	 0.00011	
	
61	 SCML1	 2.66	 4.14E-05	
	
105	 SH3BP4	 2.07	 0.00013	
18	 CCR7	 4.44	 0.00038	
	
62	 TMEM123	 2.59	 0.00115	
	
106	 ATHL1	 2.06	 0.00212	
19	 IGFBP4	 4.41	 0.00011	
	
63	 FAM129A	 2.59	 0.00014	
	
107	 HS.91389	 2.06	 0.00012	
20	 COL9A2	 4.39	 1.04E-05	
	
64	 KLF4	 2.58	 0.00177	
	
108	 NINJ1	 2.06	 0.00020	
21	 IER3	 4.37	 0.00211	
	
65	 GNA15	 2.50	 0.00159	
	
109	 PIM2	 2.05	 0.00211	
22	 NELL2	 4.14	 9.06E-05	
	
66	 XCL1	 2.47	 9.65E-05	
	
110	 IL10RA	 2.05	 0.00073	
23	 FES	 4.13	 0.00061	
	
67	 SPRY1	 2.45	 0.00019	
	
111	 GOLPH4	 2.04	 0.00135	
24	 ADCY3	 4.04	 4.95E-05	
	
68	 TAGLN2	 2.44	 0.00207	
	
112	 TRAF5	 2.03	 6.30E-06	
25	 CXCR3	 4.03	 9.20E-06	
	
69	 SLC7A6	 2.42	 0.00013	
	
113	 TMEM14D	 2.02	 0.00200	
26	 SELL	 3.96	 0.00134	
	
70	 ATP1B1	 2.40	 0.00043	
	
114	 IFI44	 2.01	 0.00110	
27	 MYC	 3.90	 0.00012	
	
71	 FURIN	 2.40	 0.00189	
	
115	 IMMP2L	 2.01	 0.00021	
28	 LEF1	 3.74	 4.75E-05	
	
72	 C8orf13	 2.39	 0.00010	
	 	 	 	 	29	 NFIX	 3.62	 0.00148	
	
73	 ATP8B4	 2.38	 0.00068	
	 	 	 	 	30	 FVT1	 3.61	 5.07E-05	
	
74	 GPR68	 2.37	 1.19E-05	
	 	 	 	 	31	 LOC440359	 3.58	 0.00010	
	
75	 RARA	 2.36	 0.00022	
	 	 	 	 	32	 SSBP2	 3.55	 1.37E-06	
	
76	 ZFHX3	 2.34	 0.00025	
	 	 	 	 	33	 LOC339192	 3.54	 0.00116	
	
77	 CD83	 2.32	 0.00082	
	 	 	 	 	34	 BMP2	 3.48	 0.00073	
	
78	 LOC729389	 2.32	 6.51E-05	
	 	 	 	 	35	 PCDH21	 3.46	 0.00010	
	
79	 FHL1	 2.29	 3.55E-05	
	 	 	 	 	36	 DLL1	 3.45	 0.00012	
	
80	 ITGA5	 2.28	 0.00070	
	 	 	 	 	37	 SYPL1	 3.39	 8.50E-05	
	
81	 RUNX2	 2.25	 8.70E-05	
	 	 	 	 	38	 CCDC109B	 3.38	 1.14E-05	
	
82	 RAB32	 2.24	 0.00081	
	 	 	 	 	39	 NFKBIZ	 3.30	 0.00153	
	
83	 C14orf4	 2.21	 2.73E-05	
	 	 	 	 	40	 PTK2	 3.29	 4.50E-05	
	
84	 AHNAK	 2.21	 0.00582	
	 	 	 	 	41	 CRIP1	 3.19	 0.00139	
	
85	 RASSF2	 2.20	 0.00151	
	 	 	 	 	42	 LOC643384	 3.16	 9.47E-05	
	
86	 HVCN1	 2.19	 0.00014	
	 	 	 	 	43	 HOXA9	 3.15	 0.00028	
	
87	 IL12RB2	 2.18	 0.00260	
	 	 	 	 	44	 NOD2	 3.11	 0.00819	
	
88	 MAFF	 2.17	 0.00329	
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1	 NR4A2	 -22.84	 0.00010	
	
45	 RORA	 -5.25	 2.52E-05	
	
89	 LOC387820	 -3.80	 5.17E-06	
2	 RGS2	 -20.63	 4.39E-06	
	
46	 PDZD8	 -5.18	 1.08E-06	
	
90	 FAM179A	 -3.79	 5.06E-07	
3	 S1PR5	 -14.10	 4.99E-05	
	
47	 ITPRIP	 -5.17	 1.42E-05	
	
91	 MIAT	 -3.78	 0.00178	
4	 PTGDS	 -11.16	 0.00271	
	
48	 GRK5	 -5.12	 3.37E-06	
	
92	 UAP1	 -3.78	 1.33E-07	
5	 YES1	 -10.94	 7.72E-06	
	
49	 FAM46C	 -5.07	 0.00141	
	
93	 EIF1	 -3.77	 8.42E-07	
6	 TSC22D3	 -10.59	 4.23E-05	
	
50	 CCL3	 -4.99	 0.00117	
	
94	 LOC731878	 -3.77	 2.87E-05	
7	 RBM38	 -9.46	 7.20E-07	
	
51	 MYLIP	 -4.99	 9.49E-05	
	
95	 GTF3C1	 -3.73	 0.00011	
8	 FKBP11	 -9.25	 0.00019	
	
52	 KLF9	 -4.96	 2.48E-05	
	
96	 RNF10	 -3.73	 5.78E-07	
9	 ENC1	 -9.10	 5.21E-05	
	
53	 DYNLL2	 -4.94	 2.21E-08	
	
97	 ZFAND2A	 -3.69	 7.12E-06	
10	 CENTG2	 -8.91	 0.00028	
	
54	 CEP78	 -4.86	 1.06E-06	
	
98	 YPEL5	 -3.69	 0.00048	
11	 PRSS23	 -8.26	 2.43E-05	
	
55	 FOSL2	 -4.85	 2.65E-05	
	
99	 RMND5A	 -3.66	 1.55E-06	
12	 SPON2	 -8.16	 0.00021	
	
56	 TNFRSF1B	 -4.84	 6.47E-06	
	
100	 ZC3H12A	 -3.66	 0.00047	
13	 GARNL4	 -7.56	 1.64E-05	
	
57	 CSNK1D	 -4.72	 1.33E-05	
	
101	 LOC389293	 -3.65	 7.48E-05	
14	 LOC645381	 -7.43	 4.40E-05	
	
58	 C20orf111	 -4.62	 5.57E-07	
	
102	 PDE4D	 -3.65	 0.00064	
15	 ATG2A	 -7.40	 5.68E-07	
	
59	 DUSP1	 -4.55	 0.00115	
	
103	 CHD1	 -3.65	 3.49E-06	
16	 TKTL1	 -7.38	 3.11E-05	
	
60	 GPR56	 -4.44	 0.00293	
	
104	 SNIP1	 -3.60	 3.36E-06	
17	 CBX4	 -7.37	 9.24E-07	
	
61	 HS.143408	 -4.39	 1.32E-05	
	
105	 ERN1	 -3.60	 6.67E-05	
18	 TP53INP2	 -7.30	 2.01E-05	
	
62	 IDS	 -4.38	 1.10E-05	
	
106	 RRN3P2	 -3.59	 2.04E-05	
19	 MGAT4A	 -7.18	 3.93E-05	
	
63	 LOC641825	 -4.34	 4.55E-05	
	
107	 NUDT11	 -3.59	 0.00013	
20	 CASZ1	 -7.11	 3.37E-06	
	
64	 LOC54103	 -4.30	 0.00012	
	
108	 BTBD11	 -3.59	 0.00059	
21	 ZEB2	 -7.04	 5.17E-05	
	
65	 CRY1	 -4.30	 6.89E-05	
	
109	 FTHL8	 -3.59	 0.00012	
22	 IFNGR1	 -6.96	 0.00013	
	
66	 RIPK2	 -4.28	 1.49E-06	
	
110	 LOC654126	 -3.59	 2.68E-06	
23	 FAM53B	 -6.87	 4.93E-05	
	
67	 LMTK2	 -4.26	 3.04E-05	
	
111	 FTHL7	 -3.57	 0.00010	
24	 USP36	 -6.82	 0.00060	
	
68	 AKR1C3	 -4.24	 0.01180	
	
112	 PRR8	 -3.52	 2.02E-05	
25	 KRT73	 -6.44	 6.57E-06	
	
69	 ZFP36	 -4.24	 0.00024	
	
113	 MT2A	 -3.52	 0.00131	
26	 IFNG	 -6.40	 0.00227	
	
70	 LOC401321	 -4.24	 9.19E-05	
	
114	 LOC399491	 -3.51	 0.00019	
27	 FGFBP2	 -6.39	 0.00226	
	
71	 MAF	 -4.23	 1.91E-05	
	
115	 FTHL16	 -3.50	 8.30E-05	
28	 TNFAIP3	 -6.27	 0.00021	
	
72	 IRS2	 -4.20	 0.00053	
	
116	 SNHG9	 -3.50	 2.01E-07	
29	 LITAF	 -6.25	 1.43E-05	
	
73	 LOC653171	 -4.18	 3.51E-05	
	
117	 CCL3L1	 -3.50	 0.00290	
30	 TTC38	 -6.08	 3.32E-05	
	
74	 RGS1	 -4.13	 0.01905	
	
118	 NFKBIA	 -3.50	 0.00065	
31	 TSPYL2	 -6.05	 8.76E-06	
	
75	 EFHD2	 -4.12	 1.89E-05	
	
119	 RBM39	 -3.48	 8.36E-06	
32	 CEBPB	 -6.04	 0.00279	
	
76	 SBDS	 -4.08	 0.00012	
	
120	 LOC728098	 -3.48	 3.78E-06	
33	 AXUD1	 -5.88	 0.00053	
	
77	 LOC100132532	 -4.07	 3.10E-06	
	
121	 PTS	 -3.46	 0.00013	
34	 PAPD5	 -5.87	 1.15E-06	
	
78	 GNG2	 -4.03	 0.00140	
	
122	 FTHL12	 -3.40	 6.09E-05	
35	 SIK1	 -5.83	 0.00049	
	
79	 ANKRD9	 -4.02	 0.00015	
	
123	 LOC650832	 -3.40	 9.89E-06	
36	 KIR2DL1	 -5.77	 0.00027	
	
80	 LOC729009	 -4.01	 9.90E-05	
	
124	 LOC285074	 -3.40	 1.37E-07	
37	 CD6	 -5.72	 0.00163	
	
81	 SNORD35B	 -3.98	 3.17E-05	
	
125	 MT1A	 -3.39	 0.00138	
38	 FLJ20699	 -5.70	 3.94E-05	
	
82	 RAD23B	 -3.97	 2.58E-06	
	
126	 LOC730167	 -3.39	 0.00218	
39	 KRT72	 -5.68	 0.00014	
	
83	 DDIT4	 -3.94	 0.00018	
	
127	 SBDSP	 -3.38	 1.41E-06	
40	 VPS37B	 -5.65	 1.06E-05	
	
84	 SNORD68	 -3.89	 3.17E-06	
	
128	 C9orf21	 -3.37	 0.00025	
41	 SKP1	 -5.56	 1.85E-06	
	
85	 GZMB	 -3.88	 0.00065	
	
129	 C20orf24	 -3.35	 0.00017	
42	 CXCR4	 -5.43	 9.47E-05	
	
86	 PMAIP1	 -3.85	 0.00084	
	
130	 DBNDD2	 -3.35	 9.61E-06	
43	 GRASP	 -5.30	 0.00033	
	
87	 ASCL2	 -3.81	 0.00013	
	
131	 NECAP1	 -3.35	 6.84E-08	
44	 PDGFRB	 -5.28	 0.00101	
	
88	 TXNDC3	 -3.81	 0.00042	
	
132	 ISCA1L	 -3.34	 3.22E-05	
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133	 ARIH1	 -3.30	 4.89E-05	
	
177	 FTHL11	 -2.93	 3.62E-05	
	
221	 LOC388796	 -2.64	 0.00030	
134	 RLF	 -3.30	 1.29E-05	
	
178	 USP3	 -2.90	 6.06E-06	
	
222	 SNORA45	 -2.64	 0.00012	
135	 KIR3DL1	 -3.30	 0.00176	
	
179	 CCNH	 -2.89	 0.00071	
	
223	 CIR1	 -2.64	 3.70E-06	
136	 LOC648980	 -3.30	 0.00021	
	
180	 LOC649431	 -2.89	 8.28E-06	
	
224	 MMP23B	 -2.64	 0.00072	
137	 DUSP5	 -3.29	 0.00166	
	
181	 CIRBP	 -2.89	 2.41E-05	
	
225	 DNAJC3	 -2.64	 0.00142	
138	 ARNTL	 -3.28	 3.14E-06	
	
182	 LRMP	 -2.88	 0.00013	
	
226	 AMD1	 -2.63	 2.68E-06	
139	 SAT1	 -3.28	 1.55E-05	
	
183	 GGA2	 -2.88	 1.17E-06	
	
227	 JMJD1C	 -2.63	 3.70E-06	
140	 RNF166	 -3.27	 9.39E-06	
	
184	 USP30	 -2.86	 2.13E-05	
	
228	 IQSEC1	 -2.62	 3.25E-06	
141	 LYN	 -3.26	 1.45E-05	
	
185	 DDIT3	 -2.86	 0.00075	
	
229	 CAMK2N1	 -2.62	 0.00348	
142	 ERRFI1	 -3.26	 0.00052	
	
186	 LOC440093	 -2.85	 4.38E-06	
	
230	 TFDP2	 -2.62	 7.32E-06	
143	 RUNX3	 -3.26	 4.18E-05	
	
187	 REM2	 -2.85	 6.23E-05	
	
231	 PNO1	 -2.61	 2.98E-05	
144	 CLK1	 -3.25	 6.51E-05	
	
188	 POLB	 -2.85	 1.24E-06	
	
232	 SNORD56	 -2.61	 3.08E-05	
145	 PPP2R5C	 -3.25	 6.29E-07	
	
189	 MRPL10	 -2.85	 0.00235	
	
233	 TOB1	 -2.60	 0.00885	
146	 HNRNPC	 -3.24	 5.18E-06	
	
190	 HS.92308	 -2.84	 1.80E-05	
	
234	 FEM1B	 -2.60	 3.80E-06	
147	 IKZF5	 -3.22	 8.78E-07	
	
191	 PPP1R16B	 -2.84	 2.38E-05	
	
235	 ZNF207	 -2.59	 1.67E-05	
148	 SPOCK2	 -3.22	 0.00053	
	
192	 ULK1	 -2.83	 2.82E-06	
	
236	 C20orf45	 -2.58	 3.30E-05	
149	 KIR2DS5	 -3.21	 0.00376	
	
193	 CTRL	 -2.83	 0.00092	
	
237	 BRD1	 -2.58	 1.43E-05	
150	 EXOSC6	 -3.21	 0.00028	
	
194	 SDCBP	 -2.83	 0.00154	
	
238	 CAPN5	 -2.56	 0.00038	
151	 LOC643167	 -3.19	 8.32E-05	
	
195	 JOSD1	 -2.82	 2.13E-05	
	
239	 TIGA1	 -2.56	 1.59E-05	
152	 FAM46A	 -3.19	 5.15E-06	
	
196	 DRD3	 -2.81	 0.00274	
	
240	 NAP1L5	 -2.56	 1.59E-05	
153	 LOC100133163	 -3.18	 0.00026	
	
197	 NFIL3	 -2.81	 0.00071	
	
241	 FAM53C	 -2.56	 0.00037	
154	 PRSSL1	 -3.17	 0.00014	
	
198	 TMEM170A	 -2.81	 0.00030	
	
242	 GFPT1	 -2.56	 1.20E-05	
155	 RBPMS2	 -3.17	 0.00021	
	
199	 ARFGEF2	 -2.80	 3.27E-05	
	
243	 CD247	 -2.56	 9.64E-07	
156	 SYTL3	 -3.17	 2.11E-05	
	
200	 SLC35A3	 -2.79	 0.00018	
	
244	 CLCF1	 -2.55	 0.00013	
157	 SLC15A4	 -3.14	 0.00081	
	
201	 SYNE2	 -2.79	 8.80E-05	
	
245	 LOC144438	 -2.55	 1.01E-05	
158	 CCNL1	 -3.14	 3.55E-06	
	
202	 SUPV3L1	 -2.76	 1.09E-05	
	
246	 MADD	 -2.55	 2.27E-06	
159	 PARP15	 -3.14	 8.25E-05	
	
203	 SLC2A8	 -2.76	 0.00051	
	
247	 STK17B	 -2.54	 0.00091	
160	 FTHL3	 -3.10	 0.00021	
	
204	 LOC440280	 -2.75	 0.00019	
	
248	 LOC284757	 -2.54	 0.00040	
161	 DDX39	 -3.10	 5.45E-05	
	
205	 RP5-1022P6.2	 -2.75	 1.31E-05	
	
249	 CRTC2	 -2.53	 5.56E-05	
162	 FBXO33	 -3.09	 0.00012	
	
206	 AVPI1	 -2.75	 0.00023	
	
250	 BNIP3L	 -2.53	 4.47E-05	
163	 MGC16384	 -3.08	 0.00029	
	
207	 SNORD21	 -2.74	 8.28E-05	
	
251	 GNA13	 -2.53	 9.51E-06	
164	 KIR3DX1	 -3.07	 0.00160	
	
208	 LINGO2	 -2.74	 0.00088	
	
252	 IRF1	 -2.52	 0.00033	
165	 LOC100132418	 -3.06	 1.32E-06	
	
209	 LOC100132535	 -2.74	 0.00026	
	
253	 ATG16L1	 -2.52	 8.67E-05	
166	 NR1D2	 -3.06	 7.84E-06	
	
210	 PER1	 -2.73	 0.00214	
	
254	 SNRPA1	 -2.52	 6.28E-05	
167	 FTHL2	 -3.05	 1.12E-05	
	
211	 MOAP1	 -2.73	 0.00020	
	
255	 ASB7	 -2.52	 1.06E-06	
168	 PDZD4	 -3.03	 4.27E-05	
	
212	 ADNP2	 -2.72	 2.44E-05	
	
256	 HIAT1	 -2.52	 7.53E-05	
169	 HSF2	 -3.01	 5.87E-07	
	
213	 UHRF1BP1L	 -2.71	 8.43E-06	
	
257	 SNORD36A	 -2.51	 5.55E-05	
170	 FTH1	 -3.00	 7.21E-05	
	
214	 C12orf41	 -2.71	 5.28E-06	
	
258	 PRNP	 -2.51	 0.00062	
171	 PELI1	 -3.00	 0.00013	
	
215	 FBXL11	 -2.69	 1.32E-05	
	
259	 COQ10B	 -2.51	 0.00014	
172	 PRDM1	 -3.00	 0.00081	
	
216	 MAP2K3	 -2.67	 9.65E-07	
	
260	 SLC5A6	 -2.51	 0.00028	
173	 ZBTB44	 -2.96	 4.34E-05	
	
217	 PGRMC2	 -2.66	 2.21E-05	
	
261	 MLL5	 -2.50	 5.77E-07	
174	 NUAK1	 -2.94	 0.00029	
	
218	 NCRNA00219	 -2.65	 0.00012	
	
262	 JUN	 -2.49	 0.03249	
175	 BTG3	 -2.93	 0.00033	
	
219	 SNHG1	 -2.65	 2.36E-06	
	
263	 FEM1C	 -2.49	 4.08E-05	
176	 MAPRE2	 -2.93	 2.42E-05	
	
220	 HES6	 -2.64	 0.00331	
	
264	 FCRL6	 -2.49	 0.00228	
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265	 LGR6	 -2.48	 1.21E-05	
	
309	 SNORD11	 -2.34	 0.00016	
	
353	 SYAP1	 -2.25	 0.000325	
266	 PIGT	 -2.48	 3.16E-06	
	
310	 STAG3L4	 -2.34	 5.95E-05	
	
354	 CCDC49	 -2.24	 0.000795	
267	 JMY	 -2.48	 6.13E-06	
	
311	 ZNF331	 -2.34	 3.25E-05	
	
355	 LOC732425	 -2.24	 8.28E-05	
268	 MEF2D	 -2.47	 3.17E-05	
	
312	 CCDC93	 -2.34	 0.00148	
	
356	 ZFP36L2	 -2.24	 0.000164	
269	 KIR3DL2	 -2.47	 0.00262	
	
313	 HIST2H2AA4	 -2.34	 0.00086	
	
357	 ALG9	 -2.24	 6.58E-05	
270	 TCEB3	 -2.47	 7.86E-08	
	
314	 ZNF317	 -2.34	 2.33E-05	
	
358	 ZNF800	 -2.24	 9.49E-05	
271	 RAB8B	 -2.46	 0.00035	
	
315	 CACNA2D2	 -2.33	 2.09E-06	
	
359	 RBM15	 -2.23	 7.92E-05	
272	 ST3GAL4	 -2.45	 1.57E-06	
	
316	 ETF1	 -2.33	 0.00025	
	
360	 TOMM20	 -2.23	 0.000101	
273	 SEC14L1	 -2.45	 0.00245	
	
317	 MARCKSL1	 -2.33	 0.00084	
	
361	 FBXO7	 -2.23	 4.88E-06	
274	 PHF1	 -2.44	 8.48E-06	
	
318	 RIOK3	 -2.33	 0.00150	
	
362	 CMIP	 -2.22	 0.001489	
275	 SERTAD3	 -2.44	 0.00051	
	
319	 SNORA67	 -2.32	 0.00160	
	
363	 C3orf38	 -2.22	 4.27E-05	
276	 OSBPL7	 -2.44	 8.23E-05	
	
320	 SAP30L	 -2.32	 0.00089	
	
364	 CCDC59	 -2.21	 0.000286	
277	 DUSP2	 -2.43	 0.00392	
	
321	 TUFT1	 -2.32	 0.00159	
	
365	 KIR2DS4	 -2.21	 0.001355	
278	 RP9	 -2.43	 1.35E-05	
	
322	 LOC652864	 -2.32	 5.77E-06	
	
366	 GADD45B	 -2.21	 0.004220	
279	 MTP18	 -2.43	 0.00078	
	
323	 KIAA0194	 -2.31	 0.00019	
	
367	 TSEN54	 -2.21	 5.59E-06	
280	 GK5	 -2.43	 0.00295	
	
324	 FBXO32	 -2.31	 7.93E-07	
	
368	 PER2	 -2.21	 0.000197	
281	 PLIN2	 -2.43	 0.00176	
	
325	 TBC1D15	 -2.31	 0.00024	
	
369	 DHX8	 -2.20	 1.95E-06	
282	 NGDN	 -2.43	 2.60E-06	
	
326	 TMEM55B	 -2.31	 4.16E-06	
	
370	 WDR26	 -2.20	 0.001518	
283	 ISCA1	 -2.42	 2.44E-05	
	
327	 CTNNA1	 -2.31	 0.00197	
	
371	 SNORD25	 -2.20	 0.000156	
284	 SNORD36C	 -2.42	 1.41E-05	
	
328	 FLJ43663	 -2.30	 0.00048	
	
372	 DNAJB6	 -2.20	 0.001048	
285	 HS.537779	 -2.42	 8.88E-05	
	
329	 DYRK1A	 -2.30	 1.53E-05	
	
373	 SLC30A1	 -2.20	 6.40E-05	
286	 SPTY2D1	 -2.42	 0.00331	
	
330	 ELF1	 -2.29	 0.00011	
	
374	 LOC653052	 -2.20	 4.00E-05	
287	 UPP1	 -2.41	 0.00016	
	
331	 TRA2A	 -2.29	 7.30E-05	
	
375	 YOD1	 -2.19	 6.59E-06	
288	 SNORD38A	 -2.41	 3.67E-05	
	
332	 HS.37648	 -2.29	 0.00037	
	
376	 RBM18	 -2.19	 0.000502	
289	 EAF1	 -2.40	 0.00116	
	
333	 MED10	 -2.29	 1.98E-07	
	
377	 GPRIN3	 -2.19	 0.001099	
290	 STRAP	 -2.40	 2.34E-05	
	
334	 PSMA7	 -2.29	 2.64E-05	
	
378	 RAB2A	 -2.19	 2.15E-05	
291	 PELI2	 -2.40	 3.59E-06	
	
335	 ELL2	 -2.29	 0.00020	
	
379	 BRWD1	 -2.19	 1.47E-05	
292	 UBXN6	 -2.40	 1.72E-05	
	
336	 MAP1LC3B	 -2.28	 4.18E-05	
	
380	 SNORD34	 -2.19	 9.60E-05	
293	 CNOT2	 -2.39	 3.73E-05	
	
337	 TMEM183B	 -2.28	 2.52E-05	
	
381	 DDX24	 -2.19	 3.07E-06	
294	 SOD2	 -2.39	 4.70E-05	
	
338	 PXN	 -2.28	 2.47E-05	
	
382	 KLRB1	 -2.19	 0.00052	
295	 LOC100129267	 -2.39	 4.99E-06	
	
339	 SMAD7	 -2.28	 0.00687	
	
383	 CIB1	 -2.18	 7.61E-06	
296	 WBP11	 -2.38	 1.35E-05	
	
340	 PAFAH2	 -2.28	 0.00019	
	
384	 HNRPH1	 -2.18	 0.00138	
297	 C9orf91	 -2.37	 0.00288	
	
341	 TMEM183A	 -2.27	 7.48E-07	
	
385	 AXIN1	 -2.18	 0.00286	
298	 C15orf24	 -2.37	 2.26E-06	
	
342	 STAM	 -2.27	 0.00087	
	
386	 LSM14A	 -2.18	 5.38E-05	
299	 GFI1	 -2.36	 2.47E-05	
	
343	 HNRNPH1	 -2.27	 0.00049	
	
387	 C16orf87	 -2.18	 4.69E-05	
300	 FLJ33590	 -2.36	 0.00049	
	
344	 MOBKL3	 -2.26	 5.11E-05	
	
388	 KIAA1109	 -2.17	 5.53E-05	
301	 DOK2	 -2.36	 5.81E-05	
	
345	 SNORD3D	 -2.26	 0.00153	
	
389	 TSN	 -2.17	 2.57E-05	
302	 DAB2	 -2.36	 6.42E-05	
	
346	 CEBPZ	 -2.26	 0.00024	
	
390	 MIDN	 -2.17	 0.00017	
303	 CLP1	 -2.35	 4.77E-05	
	
347	 LOC652481	 -2.26	 1.87E-05	
	
391	 C14orf138	 -2.16	 0.00010	
304	 JMJD1A	 -2.35	 0.00025	
	
348	 JUND	 -2.26	 3.64E-05	
	
392	 SNORA34	 -2.16	 0.00010	
305	 DCP1A	 -2.35	 3.27E-07	
	
349	 FASTKD5	 -2.26	 5.63E-05	
	
393	 INSIG1	 -2.16	 0.00090	
306	 C20orf7	 -2.35	 2.21E-05	
	
350	 PSME4	 -2.26	 0.00012	
	
394	 SNORD31	 -2.16	 9.65E-05	
307	 AKAP8	 -2.35	 0.00012	
	
351	 C1orf55	 -2.25	 0.00066	
	
395	 ZNF467	 -2.16	 0.00029	
308	 H2AFV	 -2.35	 1.95E-05	
	
352	 ZBED4	 -2.25	 0.00533	
	
396	 BCL3	 -2.16	 0.00041	
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397	 CRY2	 -2.16	 0.003995	
	
441	 BUD31	 -2.07	 0.00041	
	
485	 LOC100131360	 -2.00	 2.05E-06	
398	 USP42	 -2.16	 2.88E-05	
	
442	 KLF2	 -2.07	 0.00172	
	 	 	 	 	399	 LOC731605	 -2.16	 0.000448	
	
443	 CAMLG	 -2.07	 0.00010	
	 	 	 	 	400	 ALKBH5	 -2.15	 4.67E-06	
	
444	 PIK3R1	 -2.07	 7.54E-05	
	 	 	 	 	401	 REC8	 -2.15	 0.004765	
	
445	 INPP5K	 -2.07	 6.16E-06	
	 	 	 	 	402	 CCNK	 -2.15	 1.13E-05	
	
446	 ZC3H15	 -2.07	 0.00248	
	 	 	 	 	403	 ZNF821	 -2.15	 2.92E-05	
	
447	 POMP	 -2.07	 1.86E-05	
	 	 	 	 	404	 FAM108A2	 -2.15	 9.73E-05	
	
448	 STAU1	 -2.07	 2.99E-05	
	 	 	 	 	405	 BAG3	 -2.15	 0.000425	
	
449	 ZNF91	 -2.07	 0.00318	
	 	 	 	 	406	 UTX	 -2.14	 0.002093	
	
450	 SIRT2	 -2.06	 0.00034	
	 	 	 	 	407	 SLC2A14	 -2.14	 0.002641	
	
451	 PPP6C	 -2.06	 3.41E-05	
	 	 	 	 	408	 CCL4L2	 -2.13	 0.037067	
	
452	 SNORA4	 -2.06	 0.00191	
	 	 	 	 	409	 ZBTB16	 -2.13	 0.001166	
	
453	 ABI3	 -2.05	 7.37E-05	
	 	 	 	 	410	 ADIPOR1	 -2.13	 3.68E-05	
	
454	 RAPGEF2	 -2.05	 0.00133	
	 	 	 	 	411	 HS.493947	 -2.12	 0.001883	
	
455	 PIGA	 -2.05	 1.13E-05	
	 	 	 	 	412	 UBE2D3	 -2.12	 1.63E-05	
	
456	 PRKCH	 -2.05	 8.26E-05	
	 	 	 	 	413	 DNAJB1	 -2.12	 0.002847	
	
457	 DDA1	 -2.05	 0.00016	
	 	 	 	 	414	 HSPA14	 -2.12	 1.56E-05	
	
458	 SNORA63	 -2.05	 0.00039	
	 	 	 	 	415	 USPL1	 -2.12	 6.81E-05	
	
459	 CTRC	 -2.05	 0.00090	
	 	 	 	 	416	 SETD1A	 -2.12	 0.000120	
	
460	 KIAA2010	 -2.04	 5.31E-06	
	 	 	 	 	417	 MED13	 -2.12	 1.14E-06	
	
461	 HECA	 -2.04	 5.80E-05	
	 	 	 	 	418	 H3F3B	 -2.12	 0.001316	
	
462	 ZNF256	 -2.04	 0.00221	
	 	 	 	 	419	 C6orf136	 -2.12	 7.69E-06	
	
463	 RNF115	 -2.04	 0.00041	
	 	 	 	 	420	 C18orf8	 -2.12	 3.62E-05	
	
464	 NRBP1	 -2.04	 0.00044	
	 	 	 	 	421	 CGRRF1	 -2.11	 1.37E-06	
	
465	 GTPBP1	 -2.03	 0.00138	
	 	 	 	 	422	 SNORD48	 -2.11	 4.73E-05	
	
466	 ARPC5L	 -2.03	 0.00052	
	 	 	 	 	423	 SERTAD2	 -2.11	 6.91E-05	
	
467	 LOC146517	 -2.03	 5.08E-05	
	 	 	 	 	424	 WHAMM	 -2.11	 0.00053	
	
468	 MNT	 -2.03	 6.22E-05	
	 	 	 	 	425	 KIAA0174	 -2.11	 1.18E-05	
	
469	 LOC729495	 -2.03	 4.90E-05	
	 	 	 	 	426	 RSRC2	 -2.11	 0.00016	
	
470	 HS.121525	 -2.03	 0.00094	
	 	 	 	 	427	 LOC648470	 -2.11	 0.00168	
	
471	 DEDD2	 -2.03	 8.33E-05	
	 	 	 	 	428	 ATP1B3	 -2.10	 0.00903	
	
472	 SNORA33	 -2.03	 0.00038	
	 	 	 	 	429	 EMD	 -2.10	 0.00251	
	
473	 EIF1B	 -2.02	 0.00030	
	 	 	 	 	430	 CBLL1	 -2.09	 0.00054	
	
474	 WWP2	 -2.02	 4.99E-07	
	 	 	 	 	431	 MAX	 -2.09	 2.97E-05	
	
475	 LOC728533	 -2.02	 1.39E-05	
	 	 	 	 	432	 RNU4-1	 -2.09	 0.00177	
	
476	 RASA2	 -2.02	 0.00135	
	 	 	 	 	433	 PALLD	 -2.09	 0.00191	
	
477	 FEZ1	 -2.01	 0.00250	
	 	 	 	 	434	 JUNB	 -2.09	 0.00170	
	
478	 LOC441150	 -2.01	 7.93E-05	
	 	 	 	 	435	 IRF4	 -2.09	 0.00103	
	
479	 THUMPD2	 -2.01	 3.18E-05	
	 	 	 	 	436	 HIST2H2AA3	 -2.09	 0.00634	
	
480	 LOC643035	 -2.01	 0.00060	
	 	 	 	 	437	 WDR45L	 -2.08	 8.94E-05	
	
481	 PLEKHA2	 -2.01	 0.00026	
	 	 	 	 	438	 DEDD	 -2.08	 8.06E-06	
	
482	 HS.554203	 -2.01	 0.00192	
	 	 	 	 	439	 ITK	 -2.07	 0.00471	
	
483	 USP19	 -2.01	 0.00019	
	 	 	 	 	440	 TMEM2	 -2.07	 0.00525	
	
484	 KIAA0831	 -2.00	 7.25E-05	
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1	 TSC22D3	 -16.01	 1.67E-05	
	
45	 C20orf111	 -3.75	 1.33E-06	
	
89	 LOC653171	 -3.08	 0.00014	
2	 NR4A2	 -15.38	 0.00022	
	
46	 FURIN	 -3.75	 0.00021	
	
90	 KLF4	 -3.08	 0.00073	
3	 TNFAIP3	 -11.95	 3.91E-05	
	
47	 IDS	 -3.71	 2.19E-05	
	
91	 VPS37B	 -3.08	 0.00013	
4	 RGS2	 -11.39	 1.57E-05	
	
48	 TP53INP2	 -3.70	 0.00022	
	
92	 IKZF5	 -3.08	 1.12E-06	
5	 SIK1	 -10.35	 0.00010	
	
49	 IRF1	 -3.67	 4.96E-05	
	
93	 NECAP1	 -3.07	 1.07E-07	
6	 AXUD1	 -9.30	 0.00015	
	
50	 PIM3	 -3.67	 0.00054	
	
94	 BCL3	 -3.02	 5.40E-05	
7	 RGS1	 -9.26	 0.00247	
	
51	 C9orf21	 -3.65	 0.00017	
	
95	 NXT1	 -2.99	 0.00113	
8	 RBM38	 -7.34	 1.47E-06	
	
52	 RBM39	 -3.65	 6.68E-06	
	
96	 LOC645381	 -2.99	 0.00123	
9	 DUSP1	 -7.15	 0.00029	
	
53	 FBXO33	 -3.64	 5.51E-05	
	
97	 SNORD35B	 -2.98	 0.00012	
10	 ATG2A	 -6.78	 7.38E-07	
	
54	 SBDS	 -3.64	 0.00019	
	
98	 ZBED4	 -2.97	 0.00123	
11	 GRASP	 -6.42	 0.00018	
	
55	 DYNLL2	 -3.58	 8.48E-08	
	
99	 LOC100132418	 -2.95	 1.62E-06	
12	 NFKBIA	 -6.37	 7.53E-05	
	
56	 DUSP2	 -3.57	 0.00063	
	
100	 ZFP36L2	 -2.95	 3.11E-05	
13	 CBX4	 -5.58	 2.24E-06	
	
57	 CCNL1	 -3.56	 1.92E-06	
	
101	 SLC25A36	 -2.94	 9.56E-06	
14	 ZFP36	 -5.51	 9.27E-05	
	
58	 NINJ1	 -3.55	 8.02E-06	
	
102	 BEX2	 -2.93	 0.00036	
15	 JUN	 -5.39	 0.00222	
	
59	 RLF	 -3.50	 9.83E-06	
	
103	 FAM46A	 -2.89	 8.65E-06	
16	 NFKBIZ	 -5.22	 0.00027	
	
60	 RIPK2	 -3.49	 3.66E-06	
	
104	 RUNX3	 -2.87	 8.00E-05	
17	 HOXA5	 -5.21	 7.90E-05	
	
61	 SEC14L1	 -3.45	 0.00045	
	
105	 SYTL3	 -2.87	 3.56E-05	
18	 PDZD8	 -5.11	 1.14E-06	
	
62	 SNORD68	 -3.45	 5.47E-06	
	
106	 HIAT1	 -2.85	 3.64E-05	
19	 CXCR4	 -5.10	 0.00012	
	
63	 STAM	 -3.43	 9.18E-05	
	
107	 LOC54103	 -2.84	 0.00076	
20	 ZC3H12A	 -5.03	 0.00014	
	
64	 CD83	 -3.34	 0.00012	
	
108	 RRN3P2	 -2.84	 6.53E-05	
21	 FAM46C	 -4.92	 0.00155	
	
65	 TOB1	 -3.34	 0.00299	
	
109	 LOC641825	 -2.83	 0.00031	
22	 PMAIP1	 -4.85	 0.00036	
	
66	 LOC652637	 -3.33	 1.64E-06	
	
110	 MIDN	 -2.82	 3.11E-05	
23	 YES1	 -4.80	 8.77E-05	
	
67	 CEP78	 -3.31	 5.42E-06	
	
111	 LOC731878	 -2.79	 0.00012	
24	 LOC654126	 -4.70	 8.65E-07	
	
68	 MAP2K3	 -3.31	 2.98E-07	
	
112	 LOC387820	 -2.78	 2.44E-05	
25	 FOSL2	 -4.63	 3.15E-05	
	
69	 SNHG9	 -3.29	 2.71E-07	
	
113	 CLK1	 -2.78	 0.00015	
26	 FOXC1	 -4.61	 0.00101	
	
70	 SNIP1	 -3.29	 5.15E-06	
	
114	 FBXL11	 -2.77	 1.09E-05	
27	 MYLIP	 -4.61	 0.00013	
	
71	 IRAK3	 -3.29	 0.00063	
	
115	 EXOSC6	 -2.77	 0.00058	
28	 HAPLN3	 -4.53	 0.00015	
	
72	 CHD1	 -3.26	 5.95E-06	
	
116	 REC8	 -2.77	 0.00114	
29	 MYADM	 -4.51	 0.00297	
	
73	 CTRL	 -3.26	 0.00047	
	
117	 S1PR5	 -2.76	 0.00759	
30	 WHAMM	 -4.49	 1.03E-05	
	
74	 GPRIN3	 -3.26	 0.00012	
	
118	 ARIH1	 -2.76	 0.00012	
31	 LOC401321	 -4.42	 7.77E-05	
	
75	 PTS	 -3.25	 0.00017	
	
119	 SNORA45	 -2.75	 9.64E-05	
32	 LOC650832	 -4.40	 3.24E-06	
	
76	 LOC399491	 -3.25	 0.00026	
	
120	 NFIX	 -2.74	 0.00494	
33	 YPEL5	 -4.34	 0.00025	
	
77	 KLF9	 -3.23	 0.00015	
	
121	 ZEB2	 -2.74	 0.00190	
34	 GARNL4	 -4.30	 0.00011	
	
78	 CSNK1D	 -3.20	 6.92E-05	
	
122	 LOC100133163	 -2.73	 0.00055	
35	 USP36	 -4.28	 0.00253	
	
79	 LOC285074	 -3.19	 1.88E-07	
	
123	 C20orf7	 -2.73	 8.59E-06	
36	 MAFF	 -4.24	 0.00012	
	
80	 IER5	 -3.19	 0.00072	
	
124	 C12orf41	 -2.72	 5.19E-06	
37	 RNF10	 -4.22	 3.39E-07	
	
81	 TRA2A	 -3.18	 1.08E-05	
	
125	 CIRBP	 -2.71	 3.42E-05	
38	 LITAF	 -4.20	 5.84E-05	
	
82	 PRR8	 -3.16	 3.37E-05	
	
126	 SNORA67	 -2.71	 0.00067	
39	 PAPD5	 -4.05	 4.61E-06	
	
83	 RAD23B	 -3.14	 7.74E-06	
	
127	 CRTC2	 -2.70	 3.78E-05	
40	 DDIT4	 -3.96	 0.00018	
	
84	 SBDSP	 -3.13	 2.08E-06	
	
128	 ENC1	 -2.70	 0.00379	
41	 SKP1	 -3.86	 7.59E-06	
	
85	 LOC730167	 -3.10	 0.00316	
	
129	 CIR1	 -2.68	 3.35E-06	
42	 CASZ1	 -3.83	 3.09E-05	
	
86	 EFHD2	 -3.10	 6.83E-05	
	
130	 TIGA1	 -2.68	 1.20E-05	
43	 EIF1	 -3.78	 8.27E-07	
	
87	 ZFAND2A	 -3.10	 1.65E-05	
	
131	 GADD45B	 -2.68	 0.00143	
44	 IRS2	 -3.76	 0.00081	
	
88	 LOC440093	 -3.09	 2.84E-06	
	
132	 PER1	 -2.66	 0.00244	
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133	 JMJD1C	 -2.65	 3.53E-06	
	
177	 DRD3	 -2.46	 0.00531	
	
221	 ELF2	 -2.26	 0.00032	
134	 ITPRIP	 -2.65	 0.00028	
	
178	 RIOK3	 -2.45	 0.00111	
	
222	 ZNF256	 -2.26	 0.00112	
135	 LOC648980	 -2.64	 0.00064	
	
179	 H3F3B	 -2.44	 0.00052	
	
223	 SNHG1	 -2.26	 6.69E-06	
136	 KLF11	 -2.63	 0.00052	
	
180	 HS.283402	 -2.44	 5.50E-05	
	
224	 PHF17	 -2.25	 7.27E-05	
137	 NCRNA00219	 -2.63	 0.00013	
	
181	 ZNF395	 -2.43	 0.00055	
	
225	 ZBTB10	 -2.25	 0.00136	
138	 RP5-1022P6.2	 -2.61	 1.77E-05	
	
182	 CRY2	 -2.43	 0.00200	
	
226	 LOC144438	 -2.25	 2.33E-05	
139	 PHF1	 -2.61	 5.60E-06	
	
183	 SMAD7	 -2.42	 0.00488	
	
227	 UTX	 -2.24	 0.00159	
140	 OGFRL1	 -2.60	 2.64E-05	
	
184	 ITCH	 -2.42	 0.00049	
	
228	 LOC100129267	 -2.23	 7.91E-06	
141	 SLC35A3	 -2.60	 0.00026	
	
185	 BHLHB2	 -2.41	 0.00092	
	
229	 TTC38	 -2.23	 0.00271	
142	 PELI1	 -2.60	 0.00029	
	
186	 ADNP2	 -2.40	 5.27E-05	
	
230	 IFFO2	 -2.23	 0.00148	
143	 SERTAD2	 -2.60	 1.71E-05	
	
187	 NARG1L	 -2.40	 3.50E-05	
	
231	 RNF19B	 -2.23	 0.00019	
144	 LOC728098	 -2.59	 1.82E-05	
	
188	 BTG3	 -2.40	 0.00099	
	
232	 DEDD2	 -2.23	 4.09E-05	
145	 USP3	 -2.59	 1.16E-05	
	
189	 SNORD38A	 -2.39	 3.79E-05	
	
233	 AMD1	 -2.23	 8.11E-06	
146	 ASB7	 -2.58	 9.16E-07	
	
190	 HSF2	 -2.39	 2.35E-06	
	
234	 MCL1	 -2.22	 7.09E-05	
147	 LMTK2	 -2.57	 0.00034	
	
191	 WDR48	 -2.39	 0.00025	
	
235	 CLP1	 -2.22	 7.12E-05	
148	 UHRF1BP1L	 -2.56	 1.18E-05	
	
192	 HNRNPC	 -2.38	 3.01E-05	
	
236	 TSPYL2	 -2.22	 0.00086	
149	 CD97	 -2.56	 0.00037	
	
193	 HS.554203	 -2.36	 0.00064	
	
237	 SPTY2D1	 -2.21	 0.00555	
150	 WHAMML1	 -2.56	 3.17E-05	
	
194	 JUND	 -2.36	 2.68E-05	
	
238	 KIAA0831	 -2.21	 3.46E-05	
151	 DDIT3	 -2.55	 0.00135	
	
195	 LOC729389	 -2.35	 5.91E-05	
	
239	 RBM15	 -2.20	 8.76E-05	
152	 B4GALT1	 -2.55	 0.00032	
	
196	 NR1D2	 -2.34	 3.83E-05	
	
240	 CHPT1	 -2.20	 0.00444	
153	 THUMPD2	 -2.55	 5.88E-06	
	
197	 LOC731605	 -2.34	 0.00026	
	
241	 RORA	 -2.20	 0.00152	
154	 DUSP5	 -2.54	 0.00544	
	
198	 FTHL7	 -2.34	 0.00094	
	
242	 ETF1	 -2.20	 0.00038	
155	 PPTC7	 -2.54	 4.89E-05	
	
199	 TMEM170A	 -2.34	 0.00084	
	
243	 C16orf87	 -2.20	 4.42E-05	
156	 IFNGR1	 -2.53	 0.00606	
	
200	 FEM1B	 -2.34	 7.61E-06	
	
244	 AVPI1	 -2.19	 0.00089	
157	 RMND5A	 -2.53	 1.12E-05	
	
201	 WBP11	 -2.34	 1.53E-05	
	
245	 RNF166	 -2.19	 0.00010	
158	 LOC643167	 -2.52	 0.00029	
	
202	 TMEM137	 -2.33	 0.00127	
	
246	 MADD	 -2.19	 6.35E-06	
159	 MLL5	 -2.52	 5.58E-07	
	
203	 DNAJA1	 -2.33	 0.00046	
	
247	 LOC653157	 -2.19	 0.00025	
160	 BRD1	 -2.51	 1.69E-05	
	
204	 STK17B	 -2.33	 0.00151	
	
248	 USPL1	 -2.19	 5.38E-05	
161	 C8orf13	 -2.51	 7.87E-05	
	
205	 LOC388796	 -2.33	 0.00065	
	
249	 C16orf80	 -2.18	 0.00064	
162	 IFI44L	 -2.50	 0.00039	
	
206	 RNF126	 -2.33	 7.07E-05	
	
250	 FEM1C	 -2.18	 9.97E-05	
163	 CRIP2	 -2.50	 0.00032	
	
207	 FLJ20699	 -2.33	 0.00203	
	
251	 AKAP8	 -2.18	 0.00020	
164	 SGK269	 -2.50	 6.70E-06	
	
208	 NFKB1	 -2.32	 3.40E-06	
	
252	 COQ10B	 -2.17	 0.00035	
165	 LUZP1	 -2.49	 0.00028	
	
209	 CCDC49	 -2.31	 0.00065	
	
253	 ZNF281	 -2.17	 0.00028	
166	 JUNB	 -2.49	 0.00055	
	
210	 C14orf4	 -2.30	 2.05E-05	
	
254	 CNOT2	 -2.17	 7.29E-05	
167	 MEF2D	 -2.48	 3.10E-05	
	
211	 MAPKAPK2	 -2.30	 6.42E-06	
	
255	 FKBP11	 -2.16	 0.03137	
168	 HS.92308	 -2.48	 4.01E-05	
	
212	 LOC650128	 -2.30	 0.00017	
	
256	 RELB	 -2.16	 4.90E-05	
169	 SNORD36C	 -2.47	 1.21E-05	
	
213	 SNORD21	 -2.30	 0.00024	
	
257	 KLF2	 -2.15	 0.00134	
170	 SAT1	 -2.47	 7.41E-05	
	
214	 SNORD36A	 -2.29	 0.00010	
	
258	 USP30	 -2.15	 0.00013	
171	 TXNDC11	 -2.47	 5.72E-07	
	
215	 BNIP3L	 -2.29	 8.43E-05	
	
259	 LOC649431	 -2.14	 5.55E-05	
172	 ARFGEF2	 -2.47	 6.98E-05	
	
216	 SNORD11	 -2.29	 0.00019	
	
260	 GFI1	 -2.14	 4.97E-05	
173	 SNRPA1	 -2.46	 7.16E-05	
	
217	 MGAT4A	 -2.29	 0.00409	
	
261	 MAX	 -2.14	 2.51E-05	
174	 DCP1A	 -2.46	 2.38E-07	
	
218	 ARL4A	 -2.29	 0.00215	
	
262	 C9orf91	 -2.14	 0.00526	
175	 ZBTB44	 -2.46	 0.00012	
	
219	 LOC729009	 -2.27	 0.00169	
	
263	 LOC644935	 -2.14	 0.00175	
176	 ULK1	 -2.46	 6.68E-06	
	
220	 FTHL12	 -2.27	 0.00057	
	
264	 GFPT1	 -2.13	 4.13E-05	
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265	 FTHL16	 -2.13	 0.00129	
	
309	 ELK4	 -2.04	 4.70E-07	
266	 HIST2H2AA3	 -2.13	 0.00559	
	
310	 SETD1A	 -2.03	 0.00016	
267	 RHOH	 -2.13	 0.00012	
	
311	 FTH1	 -2.03	 0.00081	
268	 DNAJB9	 -2.13	 0.00028	
	
312	 C9orf164	 -2.03	 0.00118	
269	 CCDC59	 -2.12	 0.00038	
	
313	 PPP1R16B	 -2.03	 0.00022	
270	 ETV3	 -2.12	 0.00035	
	
314	 MED10	 -2.03	 5.12E-07	
271	 C18orf8	 -2.12	 3.52E-05	
	
315	 SF1	 -2.03	 1.86E-05	
272	 WDR26	 -2.12	 0.00197	
	
316	 NGDN	 -2.03	 9.88E-06	
273	 JOSD1	 -2.12	 0.00013	
	
317	 DDX3X	 -2.02	 0.00161	
274	 JMJD1A	 -2.12	 0.00052	
	
318	 FAM179A	 -2.02	 2.18E-05	
275	 ISCA1L	 -2.11	 0.00047	
	
319	 CGRRF1	 -2.02	 2.02E-06	
276	 ARID4A	 -2.11	 0.00016	
	
320	 MOBKL3	 -2.02	 0.00012	
277	 GNA15	 -2.10	 0.00446	
	
321	 PGRMC2	 -2.02	 0.00015	
278	 CORO7	 -2.10	 0.00053	
	
322	 TBC1D15	 -2.01	 0.00065	
279	 ZRANB1	 -2.10	 0.00020	
	
323	 CCNT1	 -2.01	 0.00140	
280	 ZBTB43	 -2.10	 0.00244	
	
324	 TMEM62	 -2.01	 0.00026	
281	 TCEB3	 -2.10	 2.55E-07	
	
325	 ARNTL	 -2.01	 6.83E-05	
282	 HIST2H2AA4	 -2.09	 0.00177	
	
326	 PELI2	 -2.01	 1.34E-05	
283	 ZNF800	 -2.09	 0.00015	
	 	 	 	 	284	 C6orf136	 -2.09	 8.44E-06	
	 	 	 	 	285	 MKNK2	 -2.09	 0.00019	
	 	 	 	 	286	 LYN	 -2.09	 0.00021	
	 	 	 	 	287	 RHBDD2	 -2.09	 2.34E-05	
	 	 	 	 	288	 FBRS	 -2.09	 8.56E-06	
	 	 	 	 	289	 RAPGEF2	 -2.08	 0.00120	
	 	 	 	 	290	 RSRC2	 -2.08	 0.00017	
	 	 	 	 	291	 RP9	 -2.08	 4.14E-05	
	 	 	 	 	292	 LOC389293	 -2.08	 0.00167	
	 	 	 	 	293	 ZNF207	 -2.08	 7.54E-05	
	 	 	 	 	294	 FTHL8	 -2.07	 0.00239	
	 	 	 	 	295	 LOC653884	 -2.07	 5.96E-05	
	 	 	 	 	296	 KDM5B	 -2.06	 0.00060	
	 	 	 	 	297	 ZNF484	 -2.06	 3.99E-05	
	 	 	 	 	298	 FBXO7	 -2.06	 8.98E-06	
	 	 	 	 	299	 C19orf22	 -2.06	 1.05E-05	
	 	 	 	 	300	 PRR7	 -2.05	 0.00011	
	 	 	 	 	301	 BCLAF1	 -2.05	 0.00056	
	 	 	 	 	302	 C20orf45	 -2.05	 0.00016	
	 	 	 	 	303	 SPRY1	 -2.05	 0.00064	
	 	 	 	 	304	 MAPRE2	 -2.05	 0.00024	
	 	 	 	 	305	 DDX39	 -2.04	 0.00069	
	 	 	 	 	306	 ZNF317	 -2.04	 6.24E-05	
	 	 	 	 	307	 RNF115	 -2.04	 0.00040	
	 	 	 	 	308	 PNO1	 -2.04	 0.00016	
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1	 AKR1C3	 -8.43	 0.00189	
	
45	 ANKRD9	 -2.90	 0.00065	
	
89	 HDDC2	 -2.31	 0.00398	
2	 FGFBP2	 -7.35	 0.00156	
	
46	 PRDM1	 -2.90	 0.00096	
	
90	 LOC100132532	 -2.30	 6.46E-05	
3	 PTGDS	 -6.70	 0.00836	
	
47	 ASCL2	 -2.88	 0.00049	
	
91	 GIMAP4	 -2.29	 0.00467	
4	 GNG2	 -6.08	 0.00036	
	
48	 LINGO2	 -2.86	 0.00071	
	
92	 HS.397465	 -2.28	 0.00180	
5	 TKTL1	 -6.04	 5.71E-05	
	
49	 TMEM2	 -2.85	 0.00086	
	
93	 YES1	 -2.28	 0.00278	
6	 CD6	 -5.65	 0.00170	
	
50	 UAP1	 -2.83	 5.68E-07	
	
94	 PRKCQ	 -2.28	 0.00711	
7	 CENTG2	 -5.35	 0.00115	
	
51	 NPC1	 -2.82	 0.00312	
	
95	 SLC5A6	 -2.27	 0.00052	
8	 CCL3	 -5.33	 0.00095	
	
52	 MTP18	 -2.79	 0.00036	
	
96	 NUDT11	 -2.27	 0.00140	
9	 FAM53B	 -5.18	 0.00012	
	
53	 LDLR	 -2.78	 5.82E-05	
	
97	 LOC284757	 -2.26	 0.00082	
10	 S1PR5	 -5.10	 0.00073	
	
54	 SLC15A4	 -2.78	 0.00144	
	
98	 MT1A	 -2.25	 0.01001	
11	 GRK5	 -4.51	 5.40E-06	
	
55	 RASGRP1	 -2.75	 0.00098	
	
99	 CRY1	 -2.24	 0.00170	
12	 CCL4L2	 -4.47	 0.00187	
	
56	 IFNGR1	 -2.75	 0.00404	
	
100	 ITK	 -2.24	 0.00291	
13	 KIR2DL1	 -4.46	 0.00064	
	
57	 TSPYL2	 -2.73	 0.00025	
	
101	 CAMK2N1	 -2.24	 0.00811	
14	 PRSS23	 -4.34	 0.00019	
	
58	 TTC38	 -2.72	 0.00087	
	
102	 LIPA	 -2.23	 0.00386	
15	 SPON2	 -4.33	 0.00146	
	
59	 PTGER2	 -2.72	 0.00227	
	
103	 CHD7	 -2.23	 4.32E-05	
16	 FKBP11	 -4.29	 0.00185	
	
60	 PLOD1	 -2.68	 0.00014	
	
104	 DAB2	 -2.22	 9.69E-05	
17	 KRT72	 -4.28	 0.00037	
	
61	 ABI3	 -2.67	 1.23E-05	
	
105	 SLC2A1	 -2.21	 9.37E-05	
18	 GPR56	 -4.09	 0.00387	
	
62	 TGFBR3	 -2.66	 0.00299	
	
106	 GNS	 -2.21	 9.89E-05	
19	 MIAT	 -4.06	 0.00137	
	
63	 PRSSL1	 -2.64	 0.00037	
	
107	 UPP1	 -2.19	 0.00030	
20	 CX3CR1	 -4.04	 0.00034	
	
64	 HS.534427	 -2.63	 0.00272	
	
108	 SLC25A4	 -2.18	 5.69E-05	
21	 KRT73	 -3.89	 4.10E-05	
	
65	 SYNE2	 -2.62	 0.00012	
	
109	 MRPL10	 -2.18	 0.00951	
22	 ADRB2	 -3.78	 0.00025	
	
66	 SLC2A8	 -2.58	 0.00072	
	
110	 HS.554324	 -2.17	 0.00317	
23	 CCL3L1	 -3.71	 0.00231	
	
67	 ZEB2	 -2.57	 0.00260	
	
111	 ARHGEF3	 -2.16	 0.00021	
24	 MAF	 -3.66	 3.53E-05	
	
68	 MT2A	 -2.51	 0.00612	
	
112	 LMNB1	 -2.14	 0.00069	
25	 PDGFRB	 -3.60	 0.00377	
	
69	 IGF2R	 -2.50	 0.00026	
	
113	 LOC387882	 -2.14	 0.00322	
26	 KIR3DL1	 -3.56	 0.00129	
	
70	 LOC645381	 -2.49	 0.00311	
	
114	 MYBL1	 -2.13	 0.001841	
27	 TXNDC3	 -3.45	 0.00063	
	
71	 ATP1B3	 -2.47	 0.00365	
	
115	 TNFRSF1A	 -2.13	 2.48E-05	
28	 CST7	 -3.44	 0.00312	
	
72	 FLJ20699	 -2.45	 0.00150	
	
116	 TBL1X	 -2.13	 0.000201	
29	 ENC1	 -3.38	 0.00137	
	
73	 HS.560343	 -2.44	 0.00109	
	
117	 LGR6	 -2.12	 3.62E-05	
30	 KIR2DS5	 -3.27	 0.00346	
	
74	 TPP1	 -2.43	 0.00077	
	
118	 FAM108A2	 -2.12	 0.000107	
31	 KIR3DL2	 -3.22	 0.00069	
	
75	 TMEM71	 -2.43	 0.00036	
	
119	 CAPN5	 -2.12	 0.001276	
32	 TNFRSF1B	 -3.22	 3.68E-05	
	
76	 PPP2R5C	 -2.42	 3.41E-06	
	
120	 IFI16	 -2.11	 0.002744	
33	 GTF3C1	 -3.20	 0.00022	
	
77	 HS.143408	 -2.42	 0.00024	
	
121	 EVI2B	 -2.11	 9.10E-05	
34	 SDCBP	 -3.18	 0.00088	
	
78	 DBNDD2	 -2.41	 5.96E-05	
	
122	 TGFBR2	 -2.11	 0.000121	
35	 PLEKHF1	 -3.16	 7.99E-05	
	
79	 NUAK1	 -2.40	 0.00089	
	
123	 NENF	 -2.09	 0.004398	
36	 MGAT4A	 -3.13	 0.00081	
	
80	 GZMB	 -2.39	 0.00596	
	
124	 GLRX	 -2.07	 0.000123	
37	 PYHIN1	 -3.11	 0.00044	
	
81	 KIR2DL3	 -2.39	 0.00309	
	
125	 PCNT	 -2.06	 0.003770	
38	 LGALS1	 -3.04	 0.00036	
	
82	 RORA	 -2.39	 0.00091	
	
126	 FCRL6	 -2.05	 0.007161	
39	 NFIL3	 -3.02	 0.00049	
	
83	 RBPMS2	 -2.39	 0.00096	
	
127	 BCL11B	 -2.05	 0.001000	
40	 PDE4D	 -3.02	 0.00146	
	
84	 PRF1	 -2.38	 0.00059	
	
128	 LOC729495	 -2.04	 4.73E-05	
41	 CTNNA1	 -3.01	 0.00046	
	
85	 LOC100132535	 -2.37	 0.00060	
	
129	 NME4	 -2.03	 0.000864	
42	 HES6	 -2.97	 0.00189	
	
86	 ADIPOR2	 -2.36	 0.00018	
	
130	 ARAP3	 -2.03	 0.002289	
43	 ERRFI1	 -2.95	 0.00083	
	
87	 MAPK1	 -2.36	 0.00094	
	
131	 SYNGR1	 -2.02	 0.000314	
44	 BTBD11	 -2.92	 0.00150	
	
88	 ENPP4	 -2.32	 0.00157	
	
132	 ST3GAL4	 -2.01	 6.78E-06	
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133	 PLIN2	 -2.01	 0.005697	
134	 TMEM206	 -2.01	 0.001087	
135	 PECAM1	 -2.01	 2.48E-05	
136	 HS.19339	 -2.00	 0.002856	
137	 C20orf24	 -2.00	 0.003207	
138	 ERN1	 -2.00	 0.001863	
 
